

## National Direct Plus Drug List

### Drug list — Five Tier Drug Plan

Your prescription benefit comes with a drug list, which is also called a formulary. This list is made up of brand-name and generic prescription drugs approved by the U.S. Food & Drug Administration (FDA).

Here are a few things to remember about the list:

- You and your doctor can use it as a guide to choose drugs that are best for you. Drugs that aren't on this list may not be covered by your plan and may cost you more out of pocket.
- Your coverage has limitations and exclusions, which means there are certain rules about what's covered by your plan and what isn't. To find out more, view your Certificate/Evidence of Coverage or your Summary Plan Description by logging in at [anthem.com](http://anthem.com) and go to **My Plan ->Benefits-> Plan Documents**.
- To help you see how the drug list works with your drug benefit, we've included some frequently asked questions (FAQ) about how the list is set up and what to do if a drug you take isn't on it.
- This booklet is updated on a quarterly basis. To view the most up-to-date list of drugs for your plan - including drugs that have been added, generic drugs and more - log in at [anthem.com/pharmacyinformation](http://anthem.com/pharmacyinformation).

If you have questions about your pharmacy benefits, we're here to help. Just call us at the Pharmacy Member Services number on your ID card.



## And Its Affiliate HealthKeepers, Inc.

### National Direct Plus Drug List

#### What is a drug list?

The drug list, also called a formulary, is a list of prescription medicines your plan covers. It includes hundreds of brand-name and generic drugs approved by the U.S. Food & Drug Administration (FDA).

#### Is this a complete listing of all covered drugs?

Yes, this is a complete listing of all the drugs on the drug list. But, it's possible a drug(s) on this list may not be covered, depending on your plan's design. Your coverage has limitations and exclusions, which means there are certain conditions that determine what's covered by your plan and what isn't. To find out more, read your Certificate/Evidence of Coverage or your Summary Plan Description, which you got when you signed up for your plan.

#### How can I find a drug on the list?

The drugs are listed in alphabetical order based on the name of their drug class, also called therapeutic class. You can search the PDF drug list by:

- Drug name, using Ctrl + F on your keyboard, then type in the name of the drug you're looking for.
- Drug class, using the categories listed in alphabetical order.

The Notes column will tell you if you need preapproval before you can take the drug (called prior authorization or PA), or if you need to try other drugs first for your treatment (called step therapy or ST).

#### When I search the list, I see that each drug is on a tier. What are the tiers for?

The drug list is set up in tiers or levels. We place drugs on different tiers based on how well they work to improve health, whether there are over-the-counter (OTC) options and their costs compared to other drugs used for the same type of treatment. Your share of the drug cost will depend on what tier a drug is on. The lower the tier, the lower your share of the cost. Here's a breakdown of the tiers in your plan:

- Tier 1 drugs have the lowest cost share for you. These are usually generic drugs that offer the best value compared to other drugs that treat the same conditions. Some plans split Tier 1 into Tier 1a and Tier 1b:
  - Tier 1a drugs have the lowest cost share. These are often generic drugs that offer the greatest value compared to others that treat the same conditions.
  - Tier 1b drugs have a low cost share. These are typically generic drugs that offer the greatest value compared to others that treat the same conditions.
- Tier 2 drugs have a higher cost share than Tier 1. They may be preferred brand drugs, based on how well they work and their cost compared to other drugs used for the same type of treatment. Some are generic drugs that may cost more because they're newer to the market.
- Tier 3 drugs have the highest cost share. They often include non-preferred brand and generic drugs. They may cost more than drugs on lower tiers that are used to treat the same condition. Tier 3 may also include drugs that were recently approved by the FDA or specialty drugs that are used to treat serious, long-term health conditions and that may need special handling.
- Tier 4 drugs have the highest cost share and usually include specialty brand and generic drugs. They may cost more than drugs on lower tiers that are used to treat the same condition. Tier 4 may also include drugs recently approved by the FDA or specialty drugs used to treat serious, long-term health conditions and that may need special handling.
- Tier 5 drugs have the highest cost share. Drugs in this tier are non-preferred specialty brand and generic drugs. Tier 5 may also include drugs recently approved by the FDA or specialty drugs used to treat serious, long-term health conditions and that may need special handling.



## And Its Affiliate HealthKeepers, Inc.

### How will I know if my drug is covered and how much will it cost?

You can go online and with the [Price a Medication](#) tool, get pharmacy-specific drug coverage details and pricing from a number of local retail pharmacies in your zip code.

### If my medicine isn't on the drug list, what are my options?

Here are a few things to think about:

- If you want to take a drug that's not on the drug list, you may have to pay the full cost for it.
- You can also talk to your doctor or pharmacist to see if there's another drug covered by your plan that will work just as well, or if generic or OTC drugs are an option. Only you and your doctor can decide what drugs are right for you.
- You can search for generic drugs at [anthem.com](#). OTC drugs aren't shown on the list.
- If a drug you're taking isn't covered, your doctor can ask us to review the coverage. This process is called preapproval or prior authorization. Your doctor can get the process started by calling the Member Services number on the back of your member ID card or by downloading a prior authorization form from our website and submitting it. If your request is approved, the amount you pay for the drug will depend on your plan's benefit.
- If the contraceptive you are taking is not on the formulary, your doctor can contact us if it is medically necessary because the preferred contraceptives are inappropriate for you, and we will waive your cost share.

### Who decides what drugs are on the list?

The drugs on the list are reviewed through our Pharmacy and Therapeutics (P&T) process. In this process, a group of independent doctors, pharmacists and other health care professionals decides which drugs we include on our lists. This group meets regularly to look at new and existing drugs and recommends drugs based on how safe they are, how well they work and the value they offer our members.

### What's the difference between brand-name and generic drugs?

A brand-name drug is FDA-approved and usually available from only one manufacturer. It may be protected by a patent, which means it can only be made or sold by the company that has the patent.

A generic drug is also FDA-approved and has the same active ingredients as the brand-name drug. But a generic drug is usually available only after the patent on the brand-name drug ends. It may look different, but a generic drug works the same as the brand-name drug.

### Does the drug list change, and how will I know if it does?

Drugs on our list are reviewed on a regular basis. Sometimes, drugs are added, removed or moved to a different tier. We'll let you know if a drug you take is taken off the list and, in some cases, if a drug you take is moved to a higher tier.

You can always check the drug list to make sure medicines you take are still on it. You'll find the most up-to-date drug list when you log in at [anthem.com](#).

### Does my plan cover preventive drugs?

We cover preventive care drugs with zero cost share in compliance with the Affordable Care Act (ACA). We also include drugs recently approved by the FDA or specialty drugs used to treat serious, long-term health conditions and that may need special handling.

## Key terms

Here are some terms and notes you'll find on the drug list.

Brand name drugs are in UPPER CASE, bold type.

Generic drugs are in lower case, plain type.

**\$0** = preventive drugs. For some members, this product may be covered at 100% with \$0 cost share with a prescription from your provider if specified criteria are met.

**AL** = age limits. Some drugs require a prior authorization if your age does not meet drug manufacturer, Food and Drug Administration (FDA), or clinical recommendations.

**BE** = benefit exclusion. This drug may not be covered depending on your plans design. To find out if your drug is covered, log into your member portal or use the Sydney app to [Price a Medication](#) and refer to your plan documents.

**DO** = dose optimization. Usually, this means you may have to switch from taking a drug twice a day to taking it once a day at a higher strength.

**LD** = limited distribution. These drugs are available only through certain pharmacies or wholesalers, depending on what the manufacturer decides.

**PA** = prior authorization. You may need to get benefits approved before certain prescriptions can be filled.

**QL** = quantity limits. There are limits on the amount of medicine covered within a certain amount of time.

**SP** = specialty drugs. Specialty drugs are used to treat difficult, long-term conditions. You may need to get this drug through a specialty pharmacy.

**ST** = step therapy. You may need to use another recommended drug first before a prescribed drug is covered.

## Online Pharmacy Resources

Find your closest network pharmacy, get the most up-to-date coverage information on your drug list including details about pricing your medication, brands and generics, dosage/strength options, and much more — when you log in at [anthem.com](http://anthem.com).

A note about opioid analgesics: In response to the opioid epidemic, the U.S. Food and Drug Administration (FDA) encouraged the development of painkillers that prevent misuse. You may pay less for these types of opioids in certain states.

Drug(s) may be excluded from the list based on your plan's benefit design.

Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans, Inc. Independent licensee of the Blue Cross and Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

# National Direct Plus Drug List

## Five-Tier

### Table of Contents

|   |    |
|---|----|
| *ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS* | 7  |
| *ALLERGENIC EXTRACTS/BIOLOGICALS MISC*          | 9  |
| *AMEBICIDES*                                    | 9  |
| *AMINOGLYCOSIDES*                               | 9  |
| *ANALGESICS - ANTI-INFLAMMATORY*                | 10 |
| *ANALGESICS - NONNARCOTIC*                      | 12 |
| *ANALGESICS - OPIOID*                           | 13 |
| *ANDROGENS-ANABOLIC*                            | 15 |
| *ANORECTAL AND RELATED PRODUCTS*                | 16 |
| *ANTHELMINTICS*                                 | 16 |
| *ANTIANGINAL AGENTS*                            | 16 |
| *ANTIANKXIETY AGENTS*                           | 16 |
| *ANTIARRHYTHMICS*                               | 17 |
| *ANTIASTHMATIC AND BRONCHODILATOR AGENTS*       | 17 |
| *ANTICOAGULANTS*                                | 20 |
| *ANTICONVULSANTS*                               | 21 |
| *ANTIDEPRESSANTS*                               | 23 |
| *ANTIDIABETICS*                                 | 25 |
| *ANTIDIARRHEAL/PROBIOTIC AGENTS*                | 28 |
| *ANTIDOTES AND SPECIFIC ANTAGONISTS*            | 28 |
| *ANTIEMETICS*                                   | 29 |
| *ANTIFUNGALS*                                   | 30 |
| *ANTIHISTAMINES*                                | 31 |
| *ANTIHYPERLIPIDEMICS*                           | 32 |
| *ANTIHYPERTENSIVES*                             | 33 |
| *ANTI-INFECTIVE AGENTS - MISC.*                 | 35 |
| *ANTIMALARIALS*                                 | 37 |
| *ANTIMYASTHENIC/CHOLINERGIC AGENTS*             | 37 |
| *ANTIMYCOBACTERIAL AGENTS*                      | 38 |
| *ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES*      | 38 |
| *ANTIPARKINSON AND RELATED THERAPY AGENTS*      | 51 |
| *ANTIPSYCHOTICS/ANTIMANIC AGENTS*               | 53 |
| *ANTISEPTICS & DISINFECTANTS*                   | 55 |
| *ANTIVIRALS*                                    | 55 |
| *BETA BLOCKERS*                                 | 58 |
| *CALCIUM CHANNEL BLOCKERS*                      | 59 |
| *CARDIOTONICS*                                  | 60 |
| *CARDIOVASCULAR AGENTS - MISC.*                 | 61 |
| *CEPHALOSPORINS*                                | 63 |
| *CONTRACEPTIVES*                                | 64 |
| *CORTICOSTEROIDS*                               | 68 |
| *COUGH/COLD/ALLERGY*                            | 69 |
| *DERMATOLOGICALS*                               | 70 |
| *DIAGNOSTIC PRODUCTS*                           | 77 |
| *DIGESTIVE AIDS*                                | 77 |
| *DIURETICS*                                     | 78 |
| *ENDOCRINE AND METABOLIC AGENTS - MISC.*        | 79 |
| *ESTROGENS*                                     | 84 |
| *FLUOROQUINOLONES*                              | 85 |
| *GASTROINTESTINAL AGENTS - MISC.*               | 85 |
| *GENERAL ANESTHETICS*                           | 88 |
| *GENTOURINARY AGENTS - MISCELLANEOUS*           | 88 |
| *GOUT AGENTS*                                   | 89 |
| *HEMATOLOGICAL AGENTS - MISC.*                  | 89 |
| *HEMATOPOIETIC AGENTS*                          | 94 |
| *HEMOSTATICS*                                   | 96 |
| *HYPNOTICS/SEDATIVES/SLEEP DISORDER AGENTS*     | 97 |
| *LAXATIVES*                                     | 98 |

|  |     |
|--|-----|
| <b>*LOCAL ANESTHETICS-PARENTERAL*</b> .....                      | 99  |
| <b>*MACROLIDES*</b> .....  | 100 |
| <b>*MEDICAL DEVICES AND SUPPLIES*</b> .....                      | 100 |
| <b>*MIGRAINE PRODUCTS*</b> .....                                 | 114 |
| <b>*MINERALS &amp; ELECTROLYTES*</b> .....                       | 115 |
| <b>*MISCELLANEOUS THERAPEUTIC CLASSES*</b> .....                 | 117 |
| <b>*MOUTH/THROAT/DENTAL AGENTS*</b> .....                        | 119 |
| <b>*MULTIVITAMINS*</b> .....                                     | 120 |
| <b>*MUSCULOSKELETAL THERAPY AGENTS*</b> .....                    | 126 |
| <b>*NASAL AGENTS - SYSTEMIC AND TOPICAL*</b> .....               | 127 |
| <b>*NEUROMUSCULAR AGENTS*</b> .....                              | 127 |
| <b>*NUTRIENTS*</b> .....   | 128 |
| <b>*OPHTHALMIC AGENTS*</b> .....                                 | 129 |
| <b>*OTIC AGENTS*</b> .....                                       | 135 |
| <b>*OXYTOCICS*</b> .....   | 135 |
| <b>*PASSIVE IMMUNIZING AND TREATMENT AGENTS*</b> .....           | 135 |
| <b>*PENICILLINS*</b> .....                                       | 137 |
| <b>*PROGESTINS*</b> .....  | 138 |
| <b>*PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.*</b> ..... | 138 |
| <b>*RESPIRATORY AGENTS - MISC.*</b> .....                        | 142 |
| <b>*SULFONAMIDES*</b> .....                                      | 143 |
| <b>*TETRACYCLINES*</b> .....                                     | 143 |
| <b>*THYROID AGENTS*</b> .....                                    | 144 |
| <b>*TOXOIDS*</b> .....   | 144 |
| <b>*ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS*</b> .....       | 145 |
| <b>*URINARY ANTISPASMODICS*</b> .....                            | 146 |
| <b>*VACCINES*</b> .....  | 146 |
| <b>*VAGINAL AND RELATED PRODUCTS*</b> .....                      | 149 |
| <b>*VASOPRESSORS*</b> .....                                      | 150 |
| <b>*VITAMINS*</b> .....  | 150 |

Five-Tier

CURRENT AS OF 4/1/2026

| Drug Name   | Tier     | Notes  |
|---|----------|--------|
| <b>*ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANT S*</b>                               |          |        |
| <b>*ADHD AGENT - SELECTIVE ALPHA ADRENERGIC AGONISTS***</b>                           |          |        |
| clonidine hcl er oral tablet extended release 12 hour                                 | 1 or 1b* | PA     |
| guanfacine hcl er oral tablet extended release 24 hour                                | 1 or 1b* | PA     |
| <b>*ADHD AGENT - SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR***</b>                   |          |        |
| atomoxetine hcl oral capsule  | 1 or 1b* | PA     |
| <b>*AMPHETAMINE MIXTURES***</b>   |          |        |
| amphetamine-dextroamphet er oral capsule extended release 24 hour 10 mg, 15 mg, 5 mg  | 1 or 1b* | PA; DO |
| amphetamine-dextroamphet er oral capsule extended release 24 hour 20 mg, 25 mg, 30 mg | 1 or 1b* | PA; QL |
| amphetamine-dextroamphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 5 mg, 7.5 mg         | 1 or 1b* | PA; DO |
| amphetamine-dextroamphetamine oral tablet 20 mg, 30 mg                                | 1 or 1b* | PA; QL |
| amphet-dextroamphet 3-bead er oral capsule extended release 24 hour                   | 1 or 1b* | PA; QL |
| <b>*AMPHETAMINES***</b>   |          |        |
| amphetamine sulfate oral tablet 10 mg   | 1 or 1b* | QL     |
| amphetamine sulfate oral tablet 5 mg  | 1 or 1b* | DO     |
| dextroamphetamine sulfate er oral capsule extended release 24 hour 10 mg, 15 mg       | 1 or 1b* | PA; QL |

| Drug Name  | Tier     | Notes      |
|--|----------|------------|
| dextroamphetamine sulfate er oral capsule extended release 24 hour 5 mg  | 1 or 1b* | PA; DO     |
| dextroamphetamine sulfate oral solution                                  | 1 or 1b* | PA; QL     |
| dextroamphetamine sulfate oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 7.5 mg | 1 or 1b* | PA; QL     |
| dextroamphetamine sulfate oral tablet 2.5 mg, 5 mg                       | 1 or 1b* | PA; DO     |
| lisdexamphetamine dimesylate oral capsule 10 mg, 20 mg, 30 mg            | 1 or 1b* | PA; DO     |
| lisdexamphetamine dimesylate oral capsule 40 mg, 50 mg, 60 mg, 70 mg     | 1 or 1b* | PA; QL     |
| lisdexamphetamine dimesylate oral tablet chewable 10 mg, 20 mg, 30 mg    | 1 or 1b* | PA; DO     |
| lisdexamphetamine dimesylate oral tablet chewable 40 mg, 50 mg, 60 mg    | 1 or 1b* | PA; QL     |
| procentra oral solution  | 1 or 1b* | PA; QL     |
| zenzedi oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 7.5 mg                   | 1 or 1b* | PA; QL     |
| zenzedi oral tablet 2.5 mg, 5 mg   | 1 or 1b* | PA; DO     |
| <b>*ANALEPTICS***</b>  |          |            |
| caffeine citrate oral solution   | 1 or 1b* |            |
| <b>DOPRAM INTRAVENOUS SOLUTION</b>                                       | 3        |            |
| <b>*ANOREXIANTS NON-AMPHETAMINE***</b>                                   |          |            |
| benzphetamine hcl oral tablet 50 mg                                      | 1 or 1b* | PA; BE; QL |
| diethylpropion hcl er oral tablet extended release 24 hour               | 1 or 1b* | PA; BE; QL |
| diethylpropion hcl oral tablet   | 1 or 1b* | PA; BE; QL |
| <b>LOMAIRA ORAL TABLET</b>   | 1 or 1b* | PA; BE; QL |
| <b>PHENDIMETRAZINE TARTRATE ER ORAL CAPSULE EXTENDED RELEASE 24 HOUR</b> | 3        | PA; BE; QL |
| phendimetrazine tartrate oral tablet                                     | 1 or 1b* | PA; BE; QL |
| phentermine hcl oral capsule   | 1 or 1b* | PA; BE; QL |
| phentermine hcl oral tablet  | 1 or 1b* | PA; BE; QL |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| <b>*ANTI-OBESITY - GIP &amp; GLP-1 RECEPTOR AGONISTS***</b>                               |          |                |
| ZEPBOUND SUBCUTANEOUS SOLUTION AUTO-INJECTOR  | 2        | PA; BE; QL     |
| <b>*ANTI-OBESITY - GLP-1 RECEPTOR AGONISTS***</b>   |          |                |
| liraglutide -weight management subcutaneous solution pen-injector                         | 1 or 1b* | PA; BE; QL     |
| WEGOVY ORAL TABLET  | 2        | PA; BE; QL     |
| WEGOVY SUBCUTANEOUS SOLUTION AUTO-INJECTOR  | 2        | PA; BE; QL     |
| <b>*DOPAMINE AND NOREPINEPHRINE REUPTAKE INHIBITORS (DNRIS)***</b>                        |          |                |
| SUNOSI ORAL TABLET 150 MG   | 3        | PA; QL         |
| SUNOSI ORAL TABLET 75 MG  | 3        | PA; DO         |
| <b>*HISTAMINE H3-RECEPTOR ANTAGONIST/INVERSE AGONISTS***</b>                              |          |                |
| WAKIX ORAL TABLET 17.8 MG   | 4        | PA; LD; QL; SP |
| WAKIX ORAL TABLET 4.45 MG   | 4        | PA; LD; DO; SP |
| <b>*LIPASE INHIBITORS***</b>  |          |                |
| orlistat oral capsule   | 1 or 1b* | PA; BE; QL     |
| <b>*STIMULANT COMBINATIONS***</b>   |          |                |
| AZSTARYS ORAL CAPSULE   | 3        | PA; QL         |
| <b>*STIMULANTS - MISC.***</b>   |          |                |
| armodafinil oral tablet   | 1 or 1b* | PA; QL         |
| dexmethylphenidate hcl er oral capsule extended release 24 hour 10 mg, 15 mg, 20 mg, 5 mg | 1 or 1b* | PA; DO         |

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| dexmethylphenidate hcl er oral capsule extended release 24 hour 25 mg, 30 mg, 35 mg, 40 mg   | 1 or 1b* | PA; QL |
| dexmethylphenidate hcl oral tablet 10 mg   | 1 or 1b* | PA; QL |
| dexmethylphenidate hcl oral tablet 2.5 mg, 5 mg  | 1 or 1b* | PA; DO |
| methylphenidate hcl er (cd) oral capsule extended release 10 mg, 20 mg, 30 mg                | 1 or 1b* | PA; DO |
| methylphenidate hcl er (cd) oral capsule extended release 40 mg, 50 mg, 60 mg                | 1 or 1b* | PA; QL |
| methylphenidate hcl er (1a) oral capsule extended release 24 hour 10 mg, 20 mg               | 1 or 1b* | PA; DO |
| methylphenidate hcl er (1a) oral capsule extended release 24 hour 30 mg, 40 mg, 60 mg        | 1 or 1b* | PA; QL |
| methylphenidate hcl er (osm) oral tablet extended release 18 mg, 27 mg                       | 1 or 1b* | PA; DO |
| methylphenidate hcl er (osm) oral tablet extended release 36 mg, 45 mg, 54 mg, 63 mg         | 1 or 1b* | PA; QL |
| <b>METHYLPHENIDATE HCL ER (OSM) ORAL TABLET EXTENDED RELEASE 72 MG</b>                       | 1 or 1b* | PA; QL |
| methylphenidate hcl er (xr) oral capsule extended release 24 hour 10 mg, 15 mg, 20 mg, 30 mg | 1 or 1b* | PA; DO |
| methylphenidate hcl er (xr) oral capsule extended release 24 hour 40 mg, 50 mg, 60 mg        | 1 or 1b* | PA; QL |
| methylphenidate hcl er oral tablet extended release 10 mg                                    | 1 or 1b* | PA; DO |
| methylphenidate hcl er oral tablet extended release 20 mg                                    | 1 or 1b* | PA; QL |
| methylphenidate hcl er oral tablet extended release 24 hour                                  | 1 or 1b* | PA; DO |
| methylphenidate hcl oral solution  | 1 or 1b* | PA; QL |
| methylphenidate hcl oral tablet 10 mg, 5 mg  | 1 or 1b* | PA; DO |
| methylphenidate hcl oral tablet 20 mg  | 1 or 1b* | PA; QL |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes      |
|--|----------|------------|
| methylphenidate hcl oral tablet chewable 10 mg         | 1 or 1b* | PA; QL     |
| methylphenidate hcl oral tablet chewable 2.5 mg        | 1 or 1b* | ST; DO     |
| methylphenidate hcl oral tablet chewable 5 mg          | 1 or 1b* | PA; DO     |
| methylphenidate transdermal patch 10 mg/9hr, 15 mg/9hr | 1 or 1b* | ST; DO     |
| methylphenidate transdermal patch 20 mg/9hr, 30 mg/9hr | 1 or 1b* | ST; QL     |
| modafinil oral tablet 100 mg                           | 1 or 1b* | PA; DO     |
| modafinil oral tablet 200 mg                           | 1 or 1b* | PA; QL     |
| <b>*ALLERGENIC EXTRACTS/BIOLOGICALS MISC*</b>          |          |            |
| <b>*ALLERGENIC EXTRACTS***</b>                         |          |            |
| GRASTEK SUBLINGUAL TABLET SUBLINGUAL                   | 3        | PA; QL     |
| PALFORZIA (1 MG DAILY DOSE) ORAL                       | 5        | PA; LD; QL |
| PALFORZIA (12 MG DAILY DOSE) ORAL                      | 5        | PA; LD; QL |
| PALFORZIA (120 MG DAILY DOSE) ORAL                     | 5        | PA; LD; QL |
| PALFORZIA (160 MG DAILY DOSE) ORAL                     | 5        | PA; LD; QL |
| PALFORZIA (20 MG DAILY DOSE) ORAL                      | 5        | PA; LD; QL |
| PALFORZIA (200 MG DAILY DOSE) ORAL                     | 5        | PA; LD; QL |
| PALFORZIA (240 MG DAILY DOSE) ORAL                     | 5        | PA; LD; QL |
| PALFORZIA (3 MG DAILY DOSE) ORAL                       | 5        | PA; LD; QL |
| PALFORZIA (300 MG MAINTENANCE) ORAL PACKET             | 5        | PA; LD; QL |
| PALFORZIA (300 MG TITRATION) ORAL PACKET               | 5        | PA; LD; QL |
| PALFORZIA (40 MG DAILY DOSE) ORAL                      | 5        | PA; LD; QL |
| PALFORZIA (6 MG DAILY DOSE) ORAL                       | 5        | PA; LD; QL |
| PALFORZIA (80 MG DAILY DOSE) ORAL                      | 5        | PA; LD; QL |
| PALFORZIA INITIAL DOSE 1-3YRS ORAL                     | 5        | PA; LD; QL |

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| PALFORZIA INITIAL DOSE 4-17YRS ORAL   | 5        | PA; LD; QL |
| PALFORZIA INITIAL ESCALATION ORAL   | 5        | PA; LD; QL |
| RAGWITEK SUBLINGUAL TABLET SUBLINGUAL   | 3        | PA; QL     |
| <b>*MIXED ALLERGENIC EXTRACTS***</b>  |          |            |
| ODACTRA SUBLINGUAL TABLET SUBLINGUAL  | 3        | PA; QL     |
| ORALAIR SUBLINGUAL TABLET SUBLINGUAL  | 3        | PA; LD; QL |
| <b>*AMEBICIDES*</b>   |          |            |
| <b>*AMEBICIDES***</b>   |          |            |
| SOLOSEC ORAL PACKET   | 3        | PA; QL     |
| <b>*AMINOGLYCOSIDES*</b>  |          |            |
| <b>*AMINOGLYCOSIDES**</b>   |          |            |
| *   |          |            |
| amikacin sulfate injection solution 1 gm/4ml, 500 mg/2ml  | 1 or 1b* |            |
| ARIKAYCE INHALATION SUSPENSION  | 5        | PA; LD; QL |
| gentamicin in saline intravenous solution 0.8-0.9 mg/ml-%, 1-0.9 mg/ml-%, 1.2-0.9 mg/ml-%, 1.6-0.9 mg/ml-%, 2-0.9 mg/ml-% | 1 or 1b* |            |
| gentamicin sulfate injection solution   | 1 or 1b* |            |
| HUMATIN ORAL CAPSULE  | 3        | PA         |
| neomycin sulfate oral tablet  | 1 or 1a* |            |
| streptomycin sulfate intramuscular solution reconstituted   | 1 or 1b* |            |
| TOBI PODHALER INHALATION CAPSULE  | 5        | LD; QL; SP |
| tobramycin inhalation nebulization solution   | 4        | QL; SP     |
| tobramycin sulfate injection solution 1.2 gm/30ml, 10 mg/ml, 80 mg/2ml  | 1 or 1b* | QL         |
| tobramycin sulfate injection solution reconstituted   | 1 or 1b* | QL         |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier | Notes      |
|---|------|------------|
| ZEMDRI INTRAVENOUS SOLUTION   | 3    |            |
| <b>*ANALGESICS - ANTI-INFLAMMATORY*</b>   |      |            |
| <b>*ANTIRHEUMATIC - JANUS KINASE (JAK) INHIBITORS***</b>  |      |            |
| RINVOQ LQ ORAL SOLUTION   | 4    | PA; QL; SP |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HOUR   | 4    | PA; QL; SP |
| XELJANZ ORAL SOLUTION   | 4    | PA; QL; SP |
| XELJANZ ORAL TABLET   | 4    | PA; QL; SP |
| XELJANZ XR ORAL TABLET EXTENDED RELEASE 24 HOUR   | 4    | PA; QL; SP |
| <b>*ANTIRHEUMATIC ANTIMETABOLITES***</b>  |      |            |
| RASUVO SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.2ML, 12.5 MG/0.25ML, 15 MG/0.3ML, 17.5 MG/0.35ML, 20 MG/0.4ML, 22.5 MG/0.45ML, 25 MG/0.5ML, 30 MG/0.6ML, 7.5 MG/0.15ML | 4    | PA; QL; SP |
| <b>*ANTI-TNF-ALPHA - MONOCLONAL ANTIBODIES***</b>   |      |            |
| HUMIRA (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT   | 4    | PA; QL; SP |
| HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML  | 4    | PA; QL; SP |
| HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT 80 MG/0.8ML  | 4    | PA; QL; SP |

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| HUMIRA-PSORIASIS/UEVIT STARTER SUBCUTANEOUS AUTO-INJECTOR KIT | 4        | PA; QL; SP     |
| SIMLANDI (1 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT               | 4        | PA; QL; SP     |
| SIMLANDI (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT               | 4        | PA; QL; SP     |
| SIMLANDI (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT       | 4        | PA; QL; SP     |
| SIMPONI ARIA INTRAVENOUS SOLUTION                             | 4        | PA; SP         |
| <b>*CYCLOOXYGENASE 2 (COX-2) INHIBITORS***</b>                |          |                |
| celecoxib oral capsule  | 1 or 1b* | QL             |
| <b>*GOLD COMPOUNDS***</b>                                     |          |                |
| auranofin oral capsule  | 2        | QL             |
| RIDAURA ORAL CAPSULE  | 2        | QL             |
| <b>*INTERLEUKIN-1 BLOCKERS***</b>                             |          |                |
| ARCALYST SUBCUTANEOUS SOLUTION RECONSTITUTED                  | 5        | PA; LD; QL; SP |
| <b>*INTERLEUKIN-1BETA BLOCKERS***</b>                         |          |                |
| ILARIS SUBCUTANEOUS SOLUTION                                  | 5        | PA; LD; QL; SP |
| <b>*NONSTEROIDAL ANTI-INFLAMMATORY AGENT COMBINATIONS***</b>  |          |                |
| COMBOGESIC INTRAVENOUS SOLUTION                               | 3        |                |
| diclofenac-misoprostol oral tablet delayed release            | 1 or 1b* | QL             |
| ZYNRELEF INJECTION SOLUTION 400-12 MG/14ML                    | 3        |                |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes |
|---|----------|-------|
| <b>*NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (NSAIDS)***</b>     |          |       |
| <b>CALDOLOR INTRAVENOUS SOLUTION 800 MG/200ML, 800 MG/8ML</b> | 3        |       |
| diclofenac potassium oral tablet 50 mg                        | 1 or 1b* | QL    |
| diclofenac sodium er oral tablet extended release 24 hour     | 1 or 1b* | QL    |
| diclofenac sodium oral tablet delayed release                 | 1 or 1b* | QL    |
| etodolac er oral tablet extended release 24 hour              | 1 or 1b* | QL    |
| etodolac oral capsule   | 1 or 1b* | QL    |
| etodolac oral tablet  | 1 or 1b* | QL    |
| flurbiprofen oral tablet                                      | 1 or 1b* | QL    |
| ibu oral tablet   | 1 or 1a* | QL    |
| ibuprofen lysine intravenous solution                         | 1 or 1b* |       |
| ibuprofen oral suspension                                     | 1 or 1a* | QL    |
| ibuprofen oral tablet 400 mg, 600 mg, 800 mg                  | 1 or 1a* | QL    |
| indomethacin er oral capsule extended release                 | 1 or 1b* | QL    |
| indomethacin oral capsule 25 mg, 50 mg                        | 1 or 1b* | QL    |
| indomethacin sodium intravenous solution reconstituted        | 3        |       |
| ketoprofen er oral capsule extended release 24 hour           | 1 or 1b* | QL    |
| <b>KETOROLAC TROMETHAMINE +RFID INJECTION SOLUTION</b>        | 1 or 1b* | QL    |
| ketorolac tromethamine injection solution 15 mg/ml            | 1 or 1b* | QL    |
| <b>KETOROLAC TROMETHAMINE INJECTION SOLUTION 30 MG/ML</b>     | 1 or 1b* | QL    |
| ketorolac tromethamine intramuscular solution 60 mg/2ml       | 1 or 1b* | QL    |
| ketorolac tromethamine oral tablet                            | 1 or 1a* | QL    |

| Drug Name  | Tier     | Notes      |
|--|----------|------------|
| meclofenamate sodium oral capsule                              | 1 or 1b* | QL         |
| mefenamic acid oral capsule                                    | 1 or 1b* | QL         |
| meloxicam oral tablet  | 1 or 1b* | QL         |
| nabumetone oral tablet   | 1 or 1b* | QL         |
| naproxen dr oral tablet delayed release 500 mg                 | 1 or 1b* |            |
| naproxen oral tablet   | 1 or 1b* | QL         |
| naproxen oral tablet delayed release                           | 1 or 1b* |            |
| naproxen sodium oral tablet 275 mg, 550 mg                     | 1 or 1b* | QL         |
| oxaprozin oral tablet  | 1 or 1b* | QL         |
| piroxicam oral capsule   | 1 or 1b* | QL         |
| sulindac oral tablet   | 1 or 1b* | QL         |
| tolmetin sodium oral capsule                                   | 1 or 1b* | ST; QL     |
| <b>*PHOSPHODIESTERASE 4 (PDE4) INHIBITORS***</b>               |          |            |
| <b>OTEZLA ORAL TABLET</b>                                      | 4        | PA; QL; SP |
| <b>OTEZLA ORAL TABLET THERAPY PACK</b>                         | 4        | PA; QL; SP |
| <b>OTEZLA XR ORAL TABLET EXTENDED RELEASE 24 HOUR</b>          | 4        | PA; QL; SP |
| <b>OTEZLA/OTEZLA XR INITIATION PK ORAL TABLET THERAPY PACK</b> | 4        | PA; QL; SP |
| <b>*PYRIMIDINE SYNTHESIS INHIBITORS***</b>                     |          |            |
| leflunomide oral tablet  | 1 or 1b* | QL         |
| <b>*SELECTIVE COSTIMULATION MODULATORS***</b>                  |          |            |
| <b>ORENCIA CLICKJECT SUBCUTANEOUS SOLUTION AUTO-INJECTOR</b>   | 4        | PA; QL; SP |
| <b>ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE</b>         | 4        | PA; QL; SP |
| <b>*SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR AGENTS***</b>       |          |            |
| <b>ENBREL MINI SUBCUTANEOUS SOLUTION CARTRIDGE</b>             | 4        | PA; QL; SP |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes      |
|--|----------|------------|
| ENBREL<br>SUBCUTANEOUS<br>SOLUTION 25 MG/0.5ML                                 | 4        | PA; QL; SP |
| ENBREL<br>SUBCUTANEOUS<br>SOLUTION PREFILLED<br>SYRINGE                        | 4        | PA; QL; SP |
| ENBREL SURECLICK<br>SUBCUTANEOUS<br>SOLUTION AUTO-<br>INJECTOR                 | 4        | PA; QL; SP |
| <b>*ANALGESICS -<br/>NONNARCOTIC*</b>  |          |            |
| <b>*ANALGESICS -<br/>SELECTIVE NAV1.8<br/>SODIUM CHANNEL<br/>INHIBITORS***</b> |          |            |
| JOURNAVX ORAL<br>TABLET  | 3        | QL         |
| <b>*ANALGESICS<br/>OTHER***</b>  |          |            |
| acetaminophen intravenous<br>solution  | 1 or 1b* |            |
| <b>*ANALGESICS-<br/>SEDATIVES***</b>   |          |            |
| bac (butalbital-acetamin-<br>caff) oral tablet                                 | 1 or 1b* | QL         |
| butalbital-acetaminophen<br>oral capsule                                       | 1 or 1b* | QL         |
| butalbital-acetaminophen<br>oral tablet 50-325 mg                              | 1 or 1b* | QL         |
| butalbital-apap-caffeine oral<br>capsule 50-300-40 mg                          | 1 or 1b* | QL         |
| butalbital-apap-caffeine oral<br>tablet 50-325-40 mg                           | 1 or 1b* | QL         |
| butalbital-aspirin-caffeine<br>oral capsule                                    | 1 or 1b* | QL         |
| tencon oral tablet 50-325 mg   | 1 or 1b* | QL         |
| <b>*SALICYLATES***</b>   |          |            |
| aspirin 81 oral tablet<br>chewable   | 1 or 1a* | \$0        |
| aspirin 81 oral tablet delayed<br>release                                      | 1 or 1a* | \$0        |
| aspirin adult low dose oral<br>tablet delayed release                          | 1 or 1a* | \$0        |
| aspirin adult low strength<br>oral tablet delayed release                      | 1 or 1a* | \$0        |
| aspirin childrens oral tablet<br>chewable                                      | 1 or 1a* | \$0        |

| Drug Name   | Tier     | Notes |
|---|----------|-------|
| aspirin ec adult low dose oral<br>tablet delayed release      | 1 or 1a* | \$0   |
| aspirin ec low dose oral<br>tablet delayed release            | 1 or 1a* | \$0   |
| aspirin ec low strength oral<br>tablet delayed release        | 1 or 1a* | \$0   |
| aspirin low dose oral tablet<br>chewable                      | 1 or 1a* | \$0   |
| aspirin low dose oral tablet<br>delayed release               | 1 or 1a* | \$0   |
| aspirin oral tablet chewable                                  | 1 or 1a* | \$0   |
| aspirin oral tablet delayed<br>release 81 mg                  | 1 or 1a* | \$0   |
| aspirin regimen oral tablet<br>delayed release                | 1 or 1a* | \$0   |
| bayer aspirin ec low dose<br>oral tablet delayed release      | 1 or 1a* | \$0   |
| bayer low dose oral tablet<br>chewable                        | 1 or 1a* | \$0   |
| bayer low dose oral tablet<br>delayed release                 | 1 or 1a* | \$0   |
| childrens aspirin oral tablet<br>chewable                     | 1 or 1a* | \$0   |
| cvs aspirin adult low dose<br>oral tablet chewable            | 1 or 1a* | \$0   |
| cvs aspirin adult low strength<br>oral tablet delayed release | 1 or 1a* | \$0   |
| cvs aspirin ec oral tablet<br>delayed release 81 mg           | 1 or 1a* | \$0   |
| cvs aspirin low dose oral<br>tablet delayed release           | 1 or 1a* | \$0   |
| cvs aspirin low strength oral<br>tablet delayed release       | 1 or 1a* | \$0   |
| diflunisal oral tablet  | 1 or 1b* | QL    |
| ecotrin low strength oral<br>tablet delayed release           | 1 or 1a* | \$0   |
| eq aspirin adult low dose oral<br>tablet delayed release      | 1 or 1a* | \$0   |
| eq aspirin low dose oral<br>tablet chewable                   | 1 or 1a* | \$0   |
| eq aspirin low dose oral<br>tablet delayed release            | 1 or 1a* | \$0   |
| eql aspirin low dose oral<br>tablet chewable                  | 1 or 1a* | \$0   |
| eql aspirin low dose oral<br>tablet delayed release           | 1 or 1a* | \$0   |
| ft aspirin low dose oral tablet<br>delayed release            | 1 or 1a* | \$0   |
| ft aspirin oral tablet chewable                               | 1 or 1a* | \$0   |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| gnp adult aspirin low strength oral tablet chewable    | 1 or 1a* | \$0    |
| gnp aspirin low dose oral tablet delayed release       | 1 or 1a* | \$0    |
| gnp aspirin oral tablet delayed release 81 mg          | 1 or 1a* | \$0    |
| goodsense aspirin low dose oral tablet delayed release | 1 or 1a* | \$0    |
| goodsense aspirin oral tablet chewable                 | 1 or 1a* | \$0    |
| h-e-b aspirin oral tablet delayed release              | 1 or 1a* | \$0    |
| kls aspirin low dose oral tablet delayed release       | 1 or 1a* | \$0    |
| kp aspirin oral tablet delayed release                 | 1 or 1a* | \$0    |
| mm aspirin oral tablet delayed release                 | 1 or 1a* | \$0    |
| qc aspirin low dose oral tablet chewable               | 1 or 1a* | \$0    |
| qc aspirin low dose oral tablet delayed release        | 1 or 1a* | \$0    |
| qc childrens aspirin oral tablet chewable              | 1 or 1a* | \$0    |
| sb childrens aspirin oral tablet chewable              | 1 or 1a* | \$0    |
| sb low dose asa ec oral tablet delayed release         | 1 or 1a* | \$0    |
| st joseph aspirin oral tablet delayed release          | 1 or 1a* | \$0    |
| st joseph low dose oral tablet chewable                | 1 or 1a* | \$0    |
| st joseph low dose oral tablet delayed release         | 1 or 1a* | \$0    |
| <b>*ANALGESICS - OPIOID*</b>                           |          |        |
| <b>*CODEINE COMBINATIONS***</b>                        |          |        |
| acetaminophen-codeine oral solution                    | 1 or 1a* | AL; QL |
| acetaminophen-codeine oral tablet                      | 1 or 1a* | AL; QL |
| ascomp-codeine oral capsule                            | 1 or 1b* | AL; QL |
| butalbital-apap-caff-cod oral capsule                  | 1 or 1b* | AL; QL |
| butalbital-asa-caff-codeine oral capsule               | 1 or 1b* | AL; QL |

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| <b>*DIHYDROCODEINE COMBINATIONS***</b>   |          |        |
| apap-caff-dihydrocodeine oral capsule  | 1 or 1b* | QL     |
| trezix oral capsule 320.5-30-16 mg   | 1 or 1b* | QL     |
| <b>*HYDROCODONE COMBINATIONS***</b>  |          |        |
| hydrocodone-acetaminophen oral solution 2.5-108 mg/5ml, 5-217 mg/10ml, 7.5-325 mg/15ml                             | 1 or 1b* | QL     |
| hydrocodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 2.5-325 mg, 5-300 mg, 5-325 mg, 7.5-300 mg, 7.5-325 mg | 1 or 1b* | QL     |
| hydrocodone-ibuprofen oral tablet 10-200 mg, 5-200 mg, 7.5-200 mg  | 1 or 1b* | QL     |
| <b>*OPIOID AGONISTS***</b>   |          |        |
| <b>CODEINE SULFATE ORAL TABLET 15 MG, 60 MG</b>  | 3        | AL; QL |
| codeine sulfate oral tablet 30 mg  | 1 or 1b* | AL; QL |
| <b>DEMEROL INJECTION SOLUTION 75 MG/ML</b>   | 3        |        |
| <b>DISKETS ORAL TABLET SOLUBLE</b>   | 3        | PA; QL |
| <b>DSUVIA SUBLINGUAL TABLET SUBLINGUAL</b>   | 3        |        |
| <b>FENTANYL CITRATE (PF) INJECTION SOLUTION 100 MCG/2ML, 250 MCG/5ML</b>   | 1 or 1b* |        |
| fentanyl citrate (pf) injection solution 1000 mcg/20ml, 2500 mcg/50ml, 500 mcg/10ml                                | 1 or 1b* |        |
| fentanyl citrate (pf) injection solution prefilled syringe 25 mcg/0.5ml  | 3        |        |
| fentanyl transdermal patch 72 hour   | 1 or 1b* | PA; QL |
| hydrocodone bitartrate er oral tablet er 24 hour abuse-deterrent   | 1 or 1b* | PA; QL |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| hydromorphone hcl er oral tablet extended release 24 hour                  | 1 or 1b* | PA; QL |
| hydromorphone hcl injection solution 0.25 mg/0.5ml                         | 3        |        |
| hydromorphone hcl injection solution 4 mg/ml                               | 1 or 1b* |        |
| hydromorphone hcl oral liquid  | 1 or 1b* | QL     |
| hydromorphone hcl oral tablet  | 1 or 1b* | QL     |
| <b>HYDROMORPHONE HCL PF INJECTION SOLUTION 1 MG/ML, 2 MG/ML, 4 MG/ML</b>   | 3        |        |
| hydromorphone hcl pf injection solution 50 mg/5ml, 500 mg/50ml             | 1 or 1b* |        |
| levorphanol tartrate oral tablet 3 mg                                      | 1 or 1b* | PA; QL |
| meperidine hcl injection solution 100 mg/ml, 25 mg/ml, 50 mg/ml            | 1 or 1b* |        |
| meperidine hcl oral solution   | 1 or 1b* | QL     |
| meperidine hcl oral tablet 50 mg   | 1 or 1b* | QL     |
| methadone hcl intensol oral concentrate                                    | 1 or 1b* | PA; QL |
| methadone hcl oral concentrate   | 1 or 1b* | PA; QL |
| methadone hcl oral solution  | 1 or 1b* | PA; QL |
| methadone hcl oral tablet  | 1 or 1b* | PA; QL |
| methadone hcl oral tablet soluble  | 1 or 1b* | PA; QL |
| methadose oral tablet soluble  | 1 or 1b* | PA; QL |
| mitigo injection solution  | 1 or 1b* |        |
| morphine sulfate (concentrate) oral solution 100 mg/5ml                    | 1 or 1b* | QL     |
| morphine sulfate (pf) injection solution 0.5 mg/ml, 1 mg/ml                | 1 or 1b* |        |
| <b>MORPHINE SULFATE (PF) INJECTION SOLUTION 10 MG/ML, 2 MG/ML, 4 MG/ML</b> | 3        |        |

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| <b>MORPHINE SULFATE (PF) INTRAVENOUS SOLUTION 1 MG/ML, 10 MG/ML, 2 MG/ML, 4 MG/ML</b>                      | 3        |        |
| morphine sulfate er beads oral capsule extended release 24 hour  | 1 or 1b* | PA; QL |
| morphine sulfate er oral capsule extended release 24 hour 10 mg, 100 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg | 1 or 1b* | PA; QL |
| morphine sulfate er oral tablet extended release   | 1 or 1b* | PA; QL |
| <b>MORPHINE SULFATE INJECTION SOLUTION 2 MG/ML, 4 MG/ML</b>  | 3        |        |
| morphine sulfate intravenous solution 10 mg/ml, 2 mg/ml, 4 mg/ml, 8 mg/ml                                  | 1 or 1b* |        |
| morphine sulfate intravenous solution 50 mg/ml   | 3        |        |
| morphine sulfate oral solution   | 1 or 1b* | QL     |
| morphine sulfate oral tablet   | 1 or 1b* | QL     |
| <b>OLINVIK INTRAVENOUS SOLUTION 1 MG/ML, 2 MG/2ML</b>  | 3        |        |
| oxycodone hcl oral capsule   | 1 or 1b* | QL     |
| oxycodone hcl oral concentrate 100 mg/5ml  | 1 or 1b* | QL     |
| oxycodone hcl oral solution  | 1 or 1b* | QL     |
| oxycodone hcl oral tablet  | 1 or 1b* | QL     |
| oxycodone hcl oral tablet abuse-deterrent  | 3        | PA; QL |
| oxymorphone hcl er oral tablet extended release 12 hour  | 1 or 1b* | PA; QL |
| oxymorphone hcl oral tablet  | 1 or 1b* | QL     |
| remifentanil hcl intravenous solution reconstituted  | 1 or 1b* |        |
| <b>ROXYBOND ORAL TABLET ABUSE-DETERRENT</b>  | 3        | PA; QL |
| <b>SUFENTANIL CITRATE INTRAVENOUS SOLUTION 50 MCG/ML</b>   | 1 or 1b* |        |
| tapentadol hcl oral tablet   | 1 or 1b* | QL     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| tramadol hcl (er biphasic)<br>oral capsule extended release<br>24 hour 100 mg, 200 mg, 300<br>mg | 1 or 1b* | PA; QL |
| tramadol hcl (er biphasic)<br>oral tablet extended release<br>24 hour                            | 1 or 1b* | PA; QL |
| tramadol hcl er oral tablet<br>extended release 24 hour  | 1 or 1b* | PA; QL |
| tramadol hcl oral tablet 100<br>mg, 50 mg  | 1 or 1b* | AL; QL |
| tramadol hcl oral tablet 25<br>mg  | 1 or 1b* | PA; QL |
| <b>XYVONA ORAL TABLET<br/>3 MG</b>   | 1 or 1b* | PA; QL |
| <b>*OPIOID<br/>COMBINATIONS***</b>   |          |        |
| endocet oral tablet 10-325<br>mg, 2.5-325 mg, 5-325 mg,<br>7.5-325 mg                            | 1 or 1b* | QL     |
| <b>OXYCODONE-<br/>ACETAMINOPHEN<br/>ORAL SOLUTION 5-325<br/>MG/5ML</b>                           | 1 or 1b* | QL     |
| oxycodone-acetaminophen<br>oral tablet 10-325 mg, 2.5-<br>325 mg, 5-325 mg, 7.5-325<br>mg        | 1 or 1b* | QL     |
| <b>*OPIOID PARTIAL<br/>AGONISTS***</b>   |          |        |
| <b>BELBUCA BUCCAL<br/>FILM</b>   | 3        | PA; QL |
| <b>BRIXADI (WEEKLY)<br/>SUBCUTANEOUS<br/>SOLUTION PREFILLED<br/>SYRINGE</b>                      | 5        | LD; QL |
| <b>BRIXADI<br/>SUBCUTANEOUS<br/>SOLUTION PREFILLED<br/>SYRINGE</b>                               | 5        | LD; QL |
| buprenorphine hcl injection<br>solution 0.3 mg/ml  | 1 or 1b* |        |
| buprenorphine hcl sublingual<br>tablet sublingual  | 1 or 1b* | QL     |
| buprenorphine hcl-naloxone<br>hcl sublingual film  | 1 or 1b* | QL     |
| buprenorphine hcl-naloxone<br>hcl sublingual tablet<br>sublingual                                | 1 or 1b* | QL     |
| buprenorphine transdermal<br>patch weekly  | 1 or 1b* | PA; QL |

| Drug Name   | Tier     | Notes  |
|---|----------|--------|
| butorphanol tartrate injection<br>solution  | 1 or 1b* |        |
| butorphanol tartrate nasal<br>solution  | 1 or 1b* | QL     |
| nalbuphine hcl injection<br>solution  | 1 or 1b* | QL     |
| pentazocine-naloxone hcl<br>oral tablet   | 1 or 1b* | QL     |
| <b>SUBLOCADE<br/>SUBCUTANEOUS<br/>SOLUTION PREFILLED<br/>SYRINGE</b>  | 5        | LD; QL |
| <b>ZUBSOLV SUBLINGUAL<br/>TABLET SUBLINGUAL</b>   | 2        | QL     |
| <b>*TRAMADOL<br/>COMBINATIONS***</b>  |          |        |
| tramadol-acetaminophen oral<br>tablet   | 1 or 1b* | AL; QL |
| <b>*ANDROGENS-<br/>ANABOLIC*</b>  |          |        |
| <b>*ANDROGENS***</b>  |          |        |
| danazol oral capsule  | 1 or 1b* | QL     |
| <b>DEPO-TESTOSTERONE<br/>INTRAMUSCULAR<br/>SOLUTION</b>   | 1 or 1b* | PA     |
| <b>JATENZO ORAL<br/>CAPSULE</b>   | 3        | PA; QL |
| <b>NATESTO NASAL GEL</b>  | 3        | PA; QL |
| <b>TESTOPEL IMPLANT<br/>PELLET</b>  | 3        | PA; LD |
| testosterone cypionate<br>intramuscular solution 100<br>mg/ml, 200 mg/ml  | 1 or 1b* | PA     |
| testosterone enanthate<br>intramuscular solution  | 1 or 1b* | PA     |
| testosterone transdermal gel<br>1.62 %, 12.5 mg/act (1%),<br>20.25 mg/1.25gm (1.62%),<br>20.25 mg/act (1.62%), 25<br>mg/2.5gm (1%), 40.5<br>mg/2.5gm (1.62%), 50<br>mg/5gm (1%) | 1 or 1b* | PA; QL |
| testosterone transdermal<br>solution  | 1 or 1b* | PA; QL |
| <b>XYOSTED<br/>SUBCUTANEOUS<br/>SOLUTION AUTO-<br/>INJECTOR</b>   | 3        | PA     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| <b>*ANORECTAL AND RELATED PRODUCTS*</b>            |          |        |
| <b>*INTRARECTAL STEROIDS***</b>                    |          |        |
| budesonide rectal foam                             | 1 or 1b* | QL     |
| <b>CORTIFOAM EXTERNAL FOAM</b>                     | 3        | QL     |
| hydrocortisone rectal enema                        | 1 or 1b* |        |
| <b>*NITRATE VASODILATING AGENTS***</b>             |          |        |
| nitroglycerin rectal ointment                      | 1 or 1b* | QL     |
| <b>*RECTAL ANESTHETIC/STEROIDS ***</b>             |          |        |
| <b>ANALPRAM HC EXTERNAL LOTION</b>                 | 3        |        |
| hydrocortisone ace-pramoxine external cream 1-1 %  | 1 or 1b* |        |
| <b>PROCTOFOAM HC EXTERNAL FOAM</b>                 | 3        |        |
| <b>*RECTAL STEROIDS***</b>                         |          |        |
| hydrocortisone (perianal) external cream           | 1 or 1b* |        |
| <b>PROCTOCORT EXTERNAL CREAM</b>                   | 1 or 1b* |        |
| procto-med hc external cream                       | 1 or 1b* |        |
| proctosol hc external cream                        | 1 or 1b* |        |
| proctozone-hc external cream                       | 1 or 1b* |        |
| <b>*ANTHELMINTICS*</b>                             |          |        |
| <b>*ANTHELMINTICS***</b>                           |          |        |
| albendazole oral tablet                            | 1 or 1b* | PA; QL |
| <b>BENZNIDAZOLE ORAL TABLET</b>                    | 3        |        |
| <b>EMVERM ORAL TABLET CHEWABLE</b>                 | 3        |        |
| ivermectin oral tablet                             | 1 or 1b* | QL     |
| praziquantel oral tablet                           | 1 or 1b* |        |
| <b>*ANTIANGINAL AGENTS*</b>                        |          |        |
| <b>*ANTIANGINALS-OTHER***</b>                      |          |        |
| ranolazine er oral tablet extended release 12 hour | 1 or 1b* | QL     |

| Drug Name   | Tier     | Notes |
|---|----------|-------|
| <b>*NITRATES***</b>   |          |       |
| isosorbide dinitrate oral tablet                                | 1 or 1b* |       |
| isosorbide mononitrate er oral tablet extended release 24 hour  | 1 or 1b* |       |
| isosorbide mononitrate oral tablet                              | 3        |       |
| <b>NITRO-BID TRANSDERMAL OINTMENT</b>                           | 3        |       |
| <b>NITRO-DUR TRANSDERMAL PATCH 24 HOUR 0.3 MG/HR, 0.8 MG/HR</b> | 2        |       |
| nitroglycerin in d5w intravenous solution                       | 3        |       |
| <b>NITROGLYCERIN INTRAVENOUS SOLUTION</b>                       | 3        |       |
| nitroglycerin sublingual tablet sublingual                      | 1 or 1b* |       |
| nitroglycerin transdermal patch 24 hour                         | 1 or 1b* |       |
| nitroglycerin translingual solution                             | 1 or 1b* |       |
| <b>*ANTIANGIETY AGENTS*</b>                                     |          |       |
| <b>*ANTIANGIETY AGENTS - MISC.***</b>                           |          |       |
| bupirone hcl oral tablet  | 1 or 1b* |       |
| droperidol injection solution                                   | 1 or 1b* |       |
| hydroxyzine hcl intramuscular solution                          | 1 or 1b* |       |
| hydroxyzine hcl oral syrup 10 mg/5ml                            | 1 or 1b* |       |
| hydroxyzine hcl oral tablet                                     | 1 or 1b* |       |
| hydroxyzine pamoate oral capsule                                | 1 or 1a* |       |
| meprobamate oral tablet   | 3        |       |
| <b>*BENZODIAZEPINES***</b>                                      |          |       |
| alprazolam er oral tablet extended release 24 hour              | 1 or 1b* | QL    |
| <b>ALPRAZOLAM INTENSOL ORAL CONCENTRATE</b>                     | 3        | QL    |
| alprazolam oral tablet  | 1 or 1b* | QL    |
| alprazolam oral tablet dispersible                              | 1 or 1b* | QL    |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes |
|---|----------|-------|
| alprazolam xr oral tablet extended release 24 hour      | 1 or 1b* | QL    |
| chlordiazepoxide hcl oral capsule                       | 1 or 1b* | QL    |
| clorazepate dipotassium oral tablet                     | 1 or 1b* | QL    |
| diazepam injection solution 10 mg/2ml                   | 1 or 1a* |       |
| diazepam intensol oral concentrate                      | 1 or 1a* | QL    |
| diazepam oral concentrate                               | 1 or 1a* | QL    |
| diazepam oral solution 5 mg/5ml                         | 1 or 1a* |       |
| diazepam oral tablet                                    | 1 or 1a* | QL    |
| lorazepam injection solution 4 mg/ml                    | 1 or 1b* |       |
| lorazepam intensol oral concentrate                     | 1 or 1b* | QL    |
| lorazepam oral concentrate 2 mg/ml                      | 1 or 1b* | QL    |
| lorazepam oral tablet                                   | 1 or 1b* | QL    |
| oxazepam oral capsule                                   | 1 or 1b* | QL    |
| <b>*ANTIARRHYTHMICS*</b>                                |          |       |
| <b>*ANTIARRHYTHMICS - MISC.***</b>                      |          |       |
| adenosine intravenous solution 12 mg/4ml, 6 mg/2ml      | 1 or 1b* |       |
| <b>*ANTIARRHYTHMICS TYPE I-A***</b>                     |          |       |
| disopyramide phosphate oral capsule                     | 1 or 1b* |       |
| <b>NORPACE CR ORAL CAPSULE EXTENDED RELEASE 12 HOUR</b> | 2        |       |
| procainamide hcl injection solution                     | 1 or 1b* |       |
| quinidine gluconate er oral tablet extended release     | 1 or 1b* |       |
| quinidine sulfate oral tablet                           | 1 or 1a* |       |
| <b>*ANTIARRHYTHMICS TYPE I-B***</b>                     |          |       |
| <b>LIDOCAINE HCL (CARDIAC) PF INTRAVENOUS SOLUTION</b>  | 3        |       |

| Drug Name   | Tier     | Notes |
|---|----------|-------|
| <b>LIDOCAINE HCL (CARDIAC) PF INTRAVENOUS SOLUTION PREFILLED SYRINGE 100 MG/5ML</b>           | 1 or 1b* |       |
| lidocaine hcl (cardiac) pf intravenous solution prefilled syringe 50 mg/5ml                   | 1 or 1b* |       |
| lidocaine in d5w intravenous solution 4-5 mg/ml-%, 8-5 mg/ml-%                                | 1 or 1b* |       |
| mexiletine hcl oral capsule   | 1 or 1b* |       |
| <b>*ANTIARRHYTHMICS TYPE I-C***</b>   |          |       |
| flecainide acetate oral tablet  | 1 or 1b* | QL    |
| propafenone hcl er oral capsule extended release 12 hour                                      | 1 or 1b* |       |
| propafenone hcl oral tablet   | 1 or 1b* |       |
| <b>*ANTIARRHYTHMICS TYPE III***</b>   |          |       |
| amiodarone hcl intravenous solution   | 1 or 1b* |       |
| amiodarone hcl oral tablet 100 mg, 400 mg   | 1 or 1b* |       |
| amiodarone hcl oral tablet 200 mg   | 1 or 1b* | QL    |
| dofetilide oral capsule   | 1 or 1b* |       |
| ibutilide fumarate intravenous solution   | 1 or 1b* |       |
| <b>MULTAQ ORAL TABLET</b>   | 3        | QL    |
| <b>NEXTERONE INTRAVENOUS SOLUTION</b>   | 3        |       |
| pacerone oral tablet 100 mg   | 1 or 1b* |       |
| pacerone oral tablet 200 mg   | 1 or 1b* | QL    |
| <b>*ANTIASTHMATIC AND BRONCHODILATOR AGENTS*</b>  |          |       |
| <b>*ADRENERGIC COMBINATIONS***</b>  |          |       |
| <b>AIRSUPRA INHALATION AEROSOL</b>  | 2        | QL    |
| <b>BREO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-25 MCG/ACT, 200-25 MCG/ACT</b> | 1 or 1b* | QL    |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| <b>BREO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 50-25 MCG/INH</b>                                     | 2        | QL             |
| <b>BREYNA INHALATION AEROSOL</b>   | 1 or 1b* | QL             |
| <b>BREZTRI AEROSPHERE INHALATION AEROSOL</b>   | 2        | QL             |
| budesonide-formoterol fumarate inhalation aerosol  | 1 or 1b* | QL             |
| <b>COMBIVENT RESPIMAT INHALATION AEROSOL SOLUTION</b>  | 2        | QL             |
| fluticasone-salmeterol inhalation aerosol  | 1 or 1b* | QL             |
| fluticasone-salmeterol inhalation aerosol powder breath activated 100-50 mcg/act, 250-50 mcg/act, 500-50 mcg/act | 1 or 1b* | QL             |
| ipratropium-albuterol inhalation solution 0.5-2.5 (3) mg/3ml   | 1 or 1b* | QL             |
| <b>STIOLTO RESPIMAT INHALATION AEROSOL SOLUTION 2.5-2.5 MCG/ACT</b>  | 2        | QL             |
| <b>TRELEGY ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-62.5-25 MCG/ACT, 200-62.5-25 MCG/ACT</b>       | 2        | QL             |
| umeclidinium-vilanterol inhalation aerosol powder breath activated   | 1 or 1b* | QL             |
| wixela inhub inhalation aerosol powder breath activated 100-50 mcg/act, 250-50 mcg/act, 500-50 mcg/act           | 1 or 1b* | QL             |
| <b>*ANTI-IGE MONOCLONAL ANTIBODIES***</b>  |          |                |
| <b>XOLAIR SUBCUTANEOUS SOLUTION AUTO-INJECTOR</b>  | 4        | PA; LD; QL; SP |
| <b>XOLAIR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE</b>  | 4        | PA; LD; QL; SP |

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| <b>XOLAIR SUBCUTANEOUS SOLUTION RECONSTITUTED</b>  | 4        | PA; LD; QL; SP |
| <b>*ANTI-INFLAMMATORY AGENTS***</b>  |          |                |
| cromolyn sodium inhalation nebulization solution   | 1 or 1b* |                |
| <b>*BETA ADRENERGICS***</b>  |          |                |
| albuterol sulfate hfa inhalation aerosol solution 108 (90 base) mcg/act  | 1 or 1b* | QL             |
| albuterol sulfate inhalation nebulization solution (2.5 mg/3ml) 0.083%, 0.63 mg/3ml, 1.25 mg/3ml, 2.5 mg/0.5ml | 1 or 1b* | QL             |
| <b>ALBUTEROL SULFATE INHALATION NEBULIZATION SOLUTION (5 MG/ML) 0.5%</b>                                       | 1 or 1b* | QL             |
| albuterol sulfate oral syrup   | 1 or 1b* |                |
| albuterol sulfate oral tablet  | 1 or 1b* |                |
| arformoterol tartrate inhalation nebulization solution   | 1 or 1b* | QL             |
| formoterol fumarate inhalation nebulization solution   | 1 or 1b* | QL             |
| isoproterenol hcl injection solution   | 1 or 1b* |                |
| levalbuterol hcl inhalation nebulization solution 0.31 mg/3ml, 0.63 mg/3ml, 1.25 mg/0.5ml, 1.25 mg/3ml         | 1 or 1b* | QL             |
| levalbuterol tartrate inhalation aerosol   | 1 or 1b* | ST; QL         |
| <b>PROAIR RESPICLICK INHALATION AEROSOL POWDER BREATH ACTIVATED</b>  | 2        | QL             |
| <b>SEREVENT DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 50 MCG/ACT</b>                                   | 2        | QL             |
| <b>STRIVERDI RESPIMAT INHALATION AEROSOL SOLUTION</b>  | 3        | QL             |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| terbutaline sulfate injection solution  | 1 or 1b* |                |
| terbutaline sulfate oral tablet   | 1 or 1b* |                |
| <b>*BRONCHODILATORS - ANTICHOLINERGICS***</b>                                 |          |                |
| <b>ATROVENT HFA INHALATION AEROSOL SOLUTION</b>                               | 2        | QL             |
| ipratropium bromide inhalation solution                                       | 1 or 1b* | QL             |
| <b>SPIRIVA RESPIMAT INHALATION AEROSOL SOLUTION 1.25 MCG/ACT, 2.5 MCG/ACT</b> | 2        | QL             |
| tiotropium bromide inhalation capsule   | 1 or 1b* | QL             |
| <b>YUPELRI INHALATION SOLUTION</b>  | 3        | ST; QL         |
| <b>*INTERLEUKIN-5 ANTAGONISTS (IGG1 KAPPA)***</b>                             |          |                |
| <b>FASENRA PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR</b>                        | 4        | PA; LD; QL; SP |
| <b>FASENRA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE</b>                        | 4        | PA; LD; QL; SP |
| <b>NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR</b>                             | 4        | PA; LD; QL; SP |
| <b>NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE</b>                         | 4        | PA; LD; QL; SP |
| <b>NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED</b>                             | 4        | PA; LD; QL; SP |
| <b>*INTERLEUKIN-5 ANTAGONISTS (IGG4 KAPPA)***</b>                             |          |                |
| <b>CINQAIR INTRAVENOUS SOLUTION</b>   | 5        | PA; LD; SP     |
| <b>*LEUKOTRIENE RECEPTOR ANTAGONISTS***</b>                                   |          |                |
| montelukast sodium oral packet  | 1 or 1b* | QL             |

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| montelukast sodium oral tablet   | 1 or 1b* | QL             |
| montelukast sodium oral tablet chewable                                  | 1 or 1b* | QL             |
| zafirlukast oral tablet  | 1 or 1b* | QL             |
| <b>*PHOSPHODIESTERASE 3 &amp; 4 (PDE3 &amp; PDE4) INHIBITORS***</b>      |          |                |
| <b>OHTUVAYRE INHALATION SUSPENSION</b>                                   | 5        | PA; LD; QL; SP |
| <b>*SELECTIVE PHOSPHODIESTERASE 4 (PDE4) INHIBITORS***</b>               |          |                |
| roflumilast oral tablet  | 1 or 1b* | QL             |
| <b>*STEROID INHALANTS***</b>   |          |                |
| budesonide inhalation suspension   | 1 or 1b* | QL             |
| fluticasone furoate ellipta inhalation aerosol powder breath activated   | 1 or 1b* | QL             |
| fluticasone propionate diskus inhalation aerosol powder breath activated | 2        | QL             |
| fluticasone propionate hfa inhalation aerosol                            | 2        | QL             |
| <b>PULMICORT FLEXHALER INHALATION AEROSOL POWDER BREATH ACTIVATED</b>    | 2        | QL             |
| <b>QVAR REDHALER INHALATION AEROSOL BREATH ACTIVATED</b>                 | 2        | QL             |
| <b>*THYMIC STROMAL LYMPHOPOIETIN (TSLP) ANTAGONISTS***</b>               |          |                |
| <b>TEZSPIRE SUBCUTANEOUS SOLUTION AUTO-INJECTOR</b>                      | 4        | PA; LD; QL; SP |
| <b>TEZSPIRE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE</b>                  | 4        | PA; LD; QL; SP |
| <b>*XANTHINES***</b>   |          |                |
| aminophylline intravenous solution                                       | 3        |                |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes |
|---|----------|-------|
| <b>ELIXOPHYLLIN ORAL ELIXIR</b>                                     | 1 or 1b* | QL    |
| <b>THEO-24 ORAL CAPSULE EXTENDED RELEASE 24 HOUR</b>                | 2        | QL    |
| theophylline er oral tablet extended release 12 hour 100 mg, 200 mg | 1 or 1b* |       |
| theophylline er oral tablet extended release 12 hour 300 mg, 450 mg | 1 or 1b* | QL    |
| theophylline er oral tablet extended release 24 hour                | 1 or 1b* | QL    |
| theophylline oral elixir  | 1 or 1b* | QL    |
| theophylline oral solution  | 1 or 1b* | QL    |
| <b>*ANTICOAGULANTS*</b>   |          |       |
| <b>*COUMARIN ANTICOAGULANTS***</b>                                  |          |       |
| jantoven oral tablet  | 1 or 1a* |       |
| warfarin sodium oral tablet   | 1 or 1a* |       |
| <b>*DIRECT FACTOR XA INHIBITORS***</b>                              |          |       |
| <b>ELIQUIS (1.5 MG PACK) ORAL TABLET SOLUBLE</b>                    | 2        | QL    |
| <b>ELIQUIS (2 MG PACK) ORAL TABLET SOLUBLE</b>                      | 2        | QL    |
| <b>ELIQUIS DVT/PE STARTER PACK ORAL TABLET THERAPY PACK</b>         | 2        | QL    |
| <b>ELIQUIS ORAL CAPSULE SPRINKLE</b>                                | 2        | QL    |
| <b>ELIQUIS ORAL TABLET</b>  | 2        | QL    |
| <b>ELIQUIS ORAL TABLET SOLUBLE</b>                                  | 2        | QL    |
| rivaroxaban oral suspension reconstituted                           | 1 or 1b* | QL    |
| rivaroxaban oral tablet   | 1 or 1b* | QL    |
| <b>XARELTO ORAL SUSPENSION RECONSTITUTED</b>                        | 2        | QL    |
| <b>XARELTO ORAL TABLET</b>  | 2        | QL    |
| <b>XARELTO STARTER PACK ORAL TABLET THERAPY PACK</b>                | 2        | QL    |

| Drug Name   | Tier     | Notes |
|---|----------|-------|
| <b>*HEPARINS AND HEPARINOID-LIKE AGENTS***</b>  |          |       |
| bd heparin posiflush intravenous solution   | 1 or 1b* |       |
| <b>HEPARIN (PORCINE) IN NACL INTRAVENOUS SOLUTION 12500-0.45 UT/250ML-%, 25000-0.45 UT/250ML-%, 25000-0.45 UT/500ML-%</b> | 3        |       |
| heparin na (pork) lock flsh pf intravenous solution 1 unit/ml, 10 unit/ml   | 1 or 1b* |       |
| heparin na (pork) lock flsh pf intravenous solution 100 unit/ml   | 3        |       |
| <b>HEPARIN SOD (PORCINE) IN D5W INTRAVENOUS SOLUTION 100 UNIT/ML, 25000-5 UT/500ML-%</b>                                  | 3        |       |
| heparin sod (porcine) in d5w intravenous solution 40-5 unit/ml-%  | 1 or 1b* |       |
| heparin sod (pork) lock flush intravenous solution 10 unit/ml, 100 unit/ml  | 3        |       |
| heparin sodium (porcine) +rfid injection solution   | 1 or 1b* |       |
| heparin sodium (porcine) injection solution 1000 unit/ml, 10000 unit/ml, 20000 unit/ml, 5000 unit/ml                      | 1 or 1b* |       |
| <b>HEPARIN SODIUM (PORCINE) INJECTION SOLUTION PREFILLED SYRINGE</b>  | 3        |       |
| heparin sodium (porcine) pf injection solution 1000 unit/ml, 5000 unit/0.5ml  | 1 or 1b* |       |
| <b>HEPARIN SODIUM (PORCINE) PF INJECTION SOLUTION 5000 UNIT/ML</b>  | 3        |       |
| <b>*LOW MOLECULAR WEIGHT HEPARINS***</b>  |          |       |
| enoxaparin sodium injection solution 300 mg/3ml   | 1 or 1b* | QL    |
| enoxaparin sodium injection solution prefilled syringe  | 1 or 1b* | QL    |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes |
|--|----------|-------|
| <b>FRAGMIN<br/>SUBCUTANEOUS<br/>SOLUTION 10000<br/>UNIT/4ML, 95000<br/>UNIT/3.8ML</b>      | 3        | QL    |
| <b>FRAGMIN<br/>SUBCUTANEOUS<br/>SOLUTION PREFILLED<br/>SYRINGE</b>                         | 3        | QL    |
| <b>*SYNTHETIC<br/>HEPARINOID-LIKE<br/>AGENTS***</b>  |          |       |
| fondaparinux sodium<br>subcutaneous solution   | 1 or 1b* | QL    |
| <b>*THROMBIN<br/>INHIBITORS - HIRUDIN<br/>TYPE***</b>                                      |          |       |
| bivalirudin trifluoroacetate<br>intravenous solution                                       | 1 or 1b* |       |
| bivalirudin trifluoroacetate<br>intravenous solution<br>reconstituted                      | 1 or 1b* |       |
| <b>*THROMBIN<br/>INHIBITORS -<br/>SELECTIVE DIRECT &amp;<br/>REVERSIBLE***</b>             |          |       |
| <b>ARGATROBAN IN<br/>SODIUM CHLORIDE<br/>INTRAVENOUS<br/>SOLUTION 50-0.9<br/>MG/50ML-%</b> | 3        |       |
| <b>ARGATROBAN<br/>INTRAVENOUS<br/>SOLUTION 250<br/>MG/2.5ML</b>                            | 3        |       |
| <b>*ANTICONVULSANTS*</b>   |          |       |
| <b>*AMPA GLUTAMATE<br/>RECEPTOR<br/>ANTAGONISTS***</b>                                     |          |       |
| perampanel oral suspension   | 1 or 1b* | QL    |
| perampanel oral tablet   | 1 or 1b* | QL    |
| <b>*ANTICONVULSANTS -<br/>BENZODIAZEPINES***</b>   |          |       |
| clobazam oral suspension 2.5<br>mg/ml  | 1 or 1b* | QL    |
| clobazam oral tablet   | 1 or 1b* | QL    |
| clonazepam oral tablet   | 1 or 1b* | QL    |
| clonazepam oral tablet<br>dispersible  | 1 or 1b* | QL    |
| diazepam rectal gel  | 1 or 1b* | QL    |

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| midazolam intramuscular<br>solution auto-injector               | 3        | QL         |
| <b>SYMPAZAN ORAL FILM</b>                                       | 3        | QL         |
| <b>*ANTICONVULSANTS -<br/>MISC.***</b>                          |          |            |
| brivaracetam intravenous<br>solution                            | 1 or 1b* |            |
| brivaracetam oral solution                                      | 1 or 1b* | QL         |
| brivaracetam oral tablet  | 1 or 1b* | QL         |
| carbamazepine er oral<br>capsule extended release 12<br>hour    | 1 or 1b* | QL         |
| carbamazepine er oral tablet<br>extended release 12 hour        | 1 or 1b* | QL         |
| carbamazepine oral<br>suspension                                | 1 or 1b* | QL         |
| carbamazepine oral tablet                                       | 1 or 1b* | QL         |
| carbamazepine oral tablet<br>chewable                           | 1 or 1b* | QL         |
| <b>DIACOMIT ORAL<br/>CAPSULE 250 MG</b>                         | 5        | PA; LD; DO |
| <b>DIACOMIT ORAL<br/>CAPSULE 500 MG</b>                         | 5        | PA; LD; QL |
| <b>DIACOMIT ORAL<br/>PACKET 250 MG</b>                          | 5        | PA; LD; DO |
| <b>DIACOMIT ORAL<br/>PACKET 500 MG</b>                          | 5        | PA; LD; QL |
| <b>ELEPSIA XR ORAL<br/>TABLET EXTENDED<br/>RELEASE 24 HOUR</b>  | 3        | QL         |
| <b>EPIDIOLEX ORAL<br/>SOLUTION</b>                              | 5        | PA; LD; SP |
| eslicarbazepine acetate oral<br>tablet 200 mg, 400 mg           | 1 or 1b* | DO         |
| eslicarbazepine acetate oral<br>tablet 600 mg, 800 mg           | 1 or 1b* | QL         |
| <b>FINTEPLA ORAL<br/>SOLUTION</b>                               | 5        | PA; LD; QL |
| gabapentin oral capsule   | 1 or 1b* | DO         |
| gabapentin oral solution  | 1 or 1b* | QL         |
| gabapentin oral tablet 600<br>mg, 800 mg                        | 1 or 1b* | QL         |
| lacosamide intravenous<br>solution                              | 1 or 1b* |            |
| lacosamide oral solution 10<br>mg/ml, 100 mg/10ml, 50<br>mg/5ml | 1 or 1b* | QL         |
| lacosamide oral tablet  | 1 or 1b* | QL         |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes |
|---|----------|-------|
| lamotrigine er oral tablet extended release 24 hour 100 mg, 25 mg, 50 mg              | 1 or 1b* | DO    |
| lamotrigine er oral tablet extended release 24 hour 200 mg, 250 mg, 300 mg            | 1 or 1b* | QL    |
| lamotrigine oral kit 21 x 25 mg & 7 x 50 mg, 25 & 50 & 100 mg, 42 x 50 mg & 14x100 mg | 1 or 1b* | QL    |
| lamotrigine oral tablet   | 1 or 1b* | DO    |
| lamotrigine oral tablet chewable  | 1 or 1b* | QL    |
| lamotrigine oral tablet dispersible 100 mg, 200 mg, 25 mg                             | 1 or 1b* | QL    |
| lamotrigine oral tablet dispersible 50 mg   | 1 or 1b* | DO    |
| lamotrigine starter kit-blue oral kit   | 1 or 1b* | QL    |
| lamotrigine starter kit-green oral kit  | 1 or 1b* | QL    |
| lamotrigine starter kit-orange oral kit   | 1 or 1b* | QL    |
| levetiracetam er oral tablet extended release 24 hour                                 | 1 or 1b* | QL    |
| levetiracetam intravenous solution  | 1 or 1b* |       |
| levetiracetam oral solution   | 1 or 1b* | QL    |
| levetiracetam oral tablet 1000 mg   | 1 or 1b* | QL    |
| levetiracetam oral tablet 250 mg, 500 mg, 750 mg                                      | 1 or 1b* | DO    |
| levetiracetam oral tablet disintegrating soluble 250 mg                               | 1 or 1b* | QL    |
| levetiracetam oral tablet disintegrating soluble 500 mg                               | 3        | QL    |
| oxcarbazepine er oral tablet extended release 24 hour 150 mg, 300 mg                  | 1 or 1b* | DO    |
| oxcarbazepine er oral tablet extended release 24 hour 600 mg                          | 1 or 1b* | QL    |
| oxcarbazepine oral suspension   | 1 or 1b* | QL    |
| oxcarbazepine oral tablet   | 1 or 1b* | QL    |
| pregabalin oral capsule   | 1 or 1b* | QL    |
| pregabalin oral solution  | 1 or 1b* | QL    |

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| primidone oral tablet  | 1 or 1b* | QL     |
| roweepra oral tablet 500 mg  | 1 or 1b* | DO     |
| rufinamide oral suspension 40 mg/ml  | 1 or 1b* | QL     |
| rufinamide oral tablet 200 mg  | 1 or 1b* | DO     |
| rufinamide oral tablet 400 mg  | 1 or 1b* | QL     |
| subvenite oral tablet  | 1 or 1b* | DO     |
| subvenite starter kit-blue oral kit  | 1 or 1b* | QL     |
| subvenite starter kit-green oral kit   | 1 or 1b* | QL     |
| subvenite starter kit-orange oral kit  | 1 or 1b* | QL     |
| topiramate er oral capsule er 24 hour sprinkle 100 mg, 150 mg, 200 mg, 50 mg | 1 or 1b* | QL     |
| topiramate er oral capsule er 24 hour sprinkle 25 mg                         | 1 or 1b* | DO     |
| topiramate er oral capsule extended release 24 hour 100 mg, 200 mg, 50 mg    | 1 or 1b* | QL     |
| topiramate er oral capsule extended release 24 hour 25 mg                    | 1 or 1b* | DO     |
| topiramate oral capsule sprinkle 15 mg, 25 mg                                | 1 or 1b* | QL     |
| topiramate oral tablet 100 mg, 25 mg, 50 mg                                  | 1 or 1b* | DO     |
| topiramate oral tablet 200 mg  | 1 or 1b* | QL     |
| zonisamide oral capsule  | 1 or 1b* | QL     |
| <b>ZTALMY ORAL SUSPENSION</b>  | 5        | LD; QL |
| <b>*CARBAMATES***</b>  |          |        |
| felbamate oral suspension  | 1 or 1b* | QL     |
| felbamate oral tablet  | 1 or 1b* | QL     |
| <b>XCOPRI (250 MG DAILY DOSE) ORAL TABLET THERAPY PACK 100 &amp; 150 MG</b>  | 3        | QL     |
| <b>XCOPRI (350 MG DAILY DOSE) ORAL TABLET THERAPY PACK</b>                   | 3        | QL     |
| <b>XCOPRI ORAL TABLET</b>  | 3        | QL     |
| <b>XCOPRI ORAL TABLET THERAPY PACK</b>                                       | 3        | QL     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes  |
|---|----------|--------|
| <b>*GABA MODULATORS***</b>                                  |          |        |
| tiagabine hcl oral tablet                                   | 1 or 1b* | QL     |
| vigabatrin oral packet                                      | 1 or 1b* | QL; SP |
| vigabatrin oral tablet                                      | 1 or 1b* | LD; QL |
| vigadrone oral packet                                       | 1 or 1b* | LD; QL |
| <b>VIGADRONE ORAL TABLET</b>                                | 1 or 1b* | LD; QL |
| <b>VIGAFYDE ORAL SOLUTION</b>                               | 5        | LD; QL |
| <b>*HYDANTOINS***</b>                                       |          |        |
| <b>DILANTIN ORAL CAPSULE 30 MG</b>                          | 2        |        |
| fosphenytoin sodium injection solution                      | 1 or 1b* |        |
| <b>PHENYTEK ORAL CAPSULE</b>                                | 1 or 1b* |        |
| phenytoin infatabs oral tablet chewable                     | 1 or 1b* |        |
| phenytoin oral suspension 125 mg/5ml                        | 1 or 1b* |        |
| phenytoin oral tablet chewable                              | 1 or 1b* |        |
| phenytoin sodium extended oral capsule                      | 1 or 1b* |        |
| phenytoin sodium injection solution                         | 1 or 1b* |        |
| <b>*SUCCINIMIDES***</b>                                     |          |        |
| ethosuximide oral capsule                                   | 1 or 1b* | QL     |
| ethosuximide oral solution                                  | 1 or 1b* | QL     |
| methsuximide oral capsule                                   | 1 or 1b* | QL     |
| <b>*VALPROIC ACID***</b>                                    |          |        |
| divalproex sodium er oral tablet extended release 24 hour   | 1 or 1b* | QL     |
| divalproex sodium oral capsule delayed release sprinkle     | 1 or 1b* | QL     |
| divalproex sodium oral tablet delayed release               | 1 or 1b* | QL     |
| valproate sodium intravenous solution 100 mg/ml, 500 mg/5ml | 1 or 1b* |        |
| valproic acid oral capsule                                  | 1 or 1b* | QL     |
| valproic acid oral solution                                 | 1 or 1b* |        |

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| <b>*ANTIDEPRESSANTS*</b>  |          |            |
| <b>*ALPHA-2 RECEPTOR ANTAGONISTS (TETRACYCLICS)***</b>                    |          |            |
| mirtazapine oral tablet   | 1 or 1b* |            |
| mirtazapine oral tablet dispersible                                       | 1 or 1b* |            |
| <b>*ANTIDEPRESSANTS - MISC.***</b>  |          |            |
| <b>APLENZIN ORAL TABLET EXTENDED RELEASE 24 HOUR 174 MG</b>               | 3        | ST; DO     |
| <b>APLENZIN ORAL TABLET EXTENDED RELEASE 24 HOUR 348 MG, 522 MG</b>       | 3        | ST; QL     |
| bupropion hcl er (sr) oral tablet extended release 12 hour 100 mg         | 1 or 1b* | DO         |
| bupropion hcl er (sr) oral tablet extended release 12 hour 150 mg, 200 mg | 1 or 1b* | QL         |
| bupropion hcl er (xl) oral tablet extended release 24 hour                | 1 or 1b* | QL         |
| bupropion hcl oral tablet 100 mg  | 1 or 1b* | QL         |
| bupropion hcl oral tablet 75 mg   | 1 or 1b* | DO         |
| <b>*GABA RECEPTOR MODULATOR - NEUROACTIVE STEROID***</b>                  |          |            |
| <b>ZURZUVAE ORAL CAPSULE</b>  | 5        | PA; LD; QL |
| <b>*MONOAMINE OXIDASE INHIBITORS (MAOIS)***</b>                           |          |            |
| <b>EMSAM TRANSDERMAL PATCH 24 HOUR 12 MG/24HR, 9 MG/24HR</b>              | 3        | QL         |
| <b>EMSAM TRANSDERMAL PATCH 24 HOUR 6 MG/24HR</b>                          | 3        | DO         |
| <b>MARPLAN ORAL TABLET</b>  | 3        | QL         |
| phenelzine sulfate oral tablet  | 1 or 1b* | QL         |
| tranylcypromine sulfate oral tablet                                       | 1 or 1b* | QL         |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| <b>*N-METHYL-D-ASPARTIC ACID (NMDA) RECEPTOR ANTAGONISTS***</b> |          |            |
| SPRAVATO (56 MG DOSE) NASAL SOLUTION THERAPY PACK               | 5        | PA; LD; QL |
| SPRAVATO (84 MG DOSE) NASAL SOLUTION THERAPY PACK               | 5        | PA; LD; QL |
| <b>*SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)***</b>      |          |            |
| citalopram hydrobromide oral solution                           | 1 or 1b* |            |
| citalopram hydrobromide oral tablet                             | 1 or 1b* |            |
| escitalopram oxalate oral solution 5 mg/5ml                     | 1 or 1b* |            |
| escitalopram oxalate oral tablet                                | 1 or 1b* |            |
| fluoxetine hcl oral capsule                                     | 1 or 1b* |            |
| fluoxetine hcl oral capsule delayed release                     | 1 or 1b* |            |
| fluoxetine hcl oral solution                                    | 1 or 1b* |            |
| fluoxetine hcl oral tablet 10 mg, 20 mg                         | 1 or 1b* |            |
| fluvoxamine maleate er oral capsule extended release 24 hour    | 1 or 1b* |            |
| fluvoxamine maleate oral tablet                                 | 1 or 1b* |            |
| paroxetine hcl er oral tablet extended release 24 hour          | 1 or 1b* |            |
| paroxetine hcl oral suspension                                  | 1 or 1b* |            |
| paroxetine hcl oral tablet                                      | 1 or 1b* |            |
| sertraline hcl oral concentrate                                 | 1 or 1b* |            |
| sertraline hcl oral tablet                                      | 1 or 1b* |            |
| <b>*SEROTONIN MODULATORS***</b>                                 |          |            |
| nefazodone hcl oral tablet 100 mg, 50 mg                        | 1 or 1b* | DO         |
| nefazodone hcl oral tablet 150 mg, 200 mg, 250 mg               | 1 or 1b* | QL         |
| trazodone hcl oral tablet 100 mg, 150 mg, 50 mg                 | 1 or 1a* | DO         |

| Drug Name   | Tier     | Notes |
|---|----------|-------|
| trazodone hcl oral tablet 300 mg  | 1 or 1a* | QL    |
| <b>TRINTELLIX ORAL TABLET 10 MG, 5 MG</b>                                     | 2        | DO    |
| <b>TRINTELLIX ORAL TABLET 20 MG</b>   | 2        | QL    |
| vilazodone hcl oral tablet 10 mg, 20 mg                                       | 1 or 1b* | DO    |
| vilazodone hcl oral tablet 40 mg  | 1 or 1b* | QL    |
| <b>*SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)***</b>               |          |       |
| desvenlafaxine succinate er oral tablet extended release 24 hour 100 mg       | 1 or 1b* | QL    |
| desvenlafaxine succinate er oral tablet extended release 24 hour 25 mg, 50 mg | 1 or 1b* | DO    |
| duloxetine hcl oral capsule delayed release particles                         | 1 or 1b* | QL    |
| venlafaxine hcl er oral capsule extended release 24 hour                      | 1 or 1b* | QL    |
| venlafaxine hcl er oral tablet extended release 24 hour 225 mg                | 1 or 1b* | QL    |
| venlafaxine hcl oral tablet   | 1 or 1b* | QL    |
| <b>*TRICYCLIC AGENTS***</b>   |          |       |
| amitriptyline hcl oral tablet 10 mg, 25 mg, 50 mg, 75 mg                      | 1 or 1a* | DO    |
| amitriptyline hcl oral tablet 100 mg, 150 mg                                  | 1 or 1a* | QL    |
| amoxapine oral tablet 100 mg, 150 mg  | 1 or 1b* | QL    |
| amoxapine oral tablet 25 mg, 50 mg  | 1 or 1b* | DO    |
| clomipramine hcl oral capsule 25 mg   | 1 or 1b* | DO    |
| clomipramine hcl oral capsule 50 mg, 75 mg                                    | 1 or 1b* | QL    |
| desipramine hcl oral tablet 10 mg, 25 mg, 50 mg, 75 mg                        | 1 or 1b* | DO    |
| desipramine hcl oral tablet 100 mg, 150 mg                                    | 1 or 1b* | QL    |
| doxepin hcl oral capsule 10 mg, 25 mg, 50 mg, 75 mg                           | 1 or 1b* | DO    |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes   |
|---|----------|---------|
| doxepin hcl oral capsule 100 mg, 150 mg               | 1 or 1b* | QL      |
| doxepin hcl oral concentrate                          | 1 or 1b* | QL      |
| imipramine hcl oral tablet 10 mg, 25 mg               | 1 or 1b* | DO      |
| imipramine hcl oral tablet 50 mg                      | 1 or 1b* | QL      |
| imipramine pamoate oral capsule 100 mg, 75 mg         | 1 or 1b* | DO      |
| imipramine pamoate oral capsule 125 mg, 150 mg        | 1 or 1b* | QL      |
| nortriptyline hcl oral capsule 10 mg, 25 mg           | 1 or 1b* | DO      |
| nortriptyline hcl oral capsule 50 mg, 75 mg           | 1 or 1b* | QL      |
| nortriptyline hcl oral solution                       | 1 or 1b* | QL      |
| protriptyline hcl oral tablet 10 mg                   | 1 or 1b* | QL      |
| protriptyline hcl oral tablet 5 mg                    | 1 or 1b* | DO      |
| trimipramine maleate oral capsule                     | 1 or 1b* | QL      |
| <b>*ANTIDIABETICS*</b>                                |          |         |
| <b>*ALPHA-GLUCOSIDASE INHIBITORS***</b>               |          |         |
| acarbose oral tablet                                  | 1 or 1b* | QL      |
| miglitol oral tablet                                  | 1 or 1b* | QL      |
| <b>*ANTIDIABETIC-ANTI-CD3 ANTIBODIES***</b>           |          |         |
| <b>TZIELD INTRAVENOUS SOLUTION</b>                    | 5        | PA; LD  |
| <b>*BIGUANIDES***</b>                                 |          |         |
| metformin hcl er oral tablet extended release 24 hour | 1 or 1b* | QL      |
| metformin hcl oral solution                           | 3        | PA; QL  |
| metformin hcl oral tablet 1000 mg, 500 mg             | 1 or 1b* | QL      |
| metformin hcl oral tablet 850 mg                      | 1 or 1b* | \$0; QL |
| <b>*DIABETIC OTHER***</b>                             |          |         |
| <b>BAQSIMI ONE PACK NASAL POWDER</b>                  | 3        | QL      |
| <b>BAQSIMI TWO PACK NASAL POWDER</b>                  | 3        | QL      |
| diazoxide oral suspension                             | 1 or 1b* |         |

| Drug Name   | Tier     | Notes  |
|---|----------|--------|
| <b>GLUCAGON EMERGENCY INJECTION SOLUTION RECONSTITUTED 1 MG</b>     | 1 or 1b* | QL     |
| <b>GLUCAGON EMERGENCY INJECTION SOLUTION RECONSTITUTED 1 MG/ML</b>  | 3        | QL     |
| <b>GVOKE HYOPEN 1-PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR</b>      | 3        | QL     |
| <b>GVOKE HYOPEN 2-PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR</b>      | 3        | QL     |
| <b>GVOKE KIT SUBCUTANEOUS SOLUTION</b>                              | 3        | QL     |
| <b>GVOKE PFS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 1 MG/0.2ML</b> | 3        | QL     |
| <b>*DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS***</b>                |          |        |
| alogliptin benzoate oral tablet                                     | 1 or 1b* | ST; QL |
| <b>JANUVIA ORAL TABLET</b>  | 2        | ST; QL |
| <b>*DIPEPTIDYL PEPTIDASE-4 INHIBITOR-BIGUANIDE COMBINATIONS***</b>  |          |        |
| alogliptin-metformin hcl oral tablet                                | 1 or 1b* | ST; QL |
| <b>JANUMET ORAL TABLET</b>  | 2        | ST; QL |
| <b>JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR</b>              | 2        | ST; QL |
| <b>*DOPAMINE RECEPTOR AGONISTS - ERGOT DERIVATIVES***</b>           |          |        |
| <b>CYCLOSET ORAL TABLET</b>   | 3        |        |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| <b>*DPP-4 INHIBITOR-THIAZOLIDINEDIONE COMBINATIONS***</b>                    |          |        |
| alogliptin-pioglitazone oral tablet 12.5-30 mg, 25-15 mg, 25-30 mg, 25-45 mg | 1 or 1b* | ST; QL |
| <b>*HUMAN INSULIN***</b>   |          |        |
| BASAGLAR KWIKPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR                          | 2        | QL     |
| HUMALOG INJECTION SOLUTION   | 2        | QL     |
| HUMALOG JUNIOR KWIKPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR                    | 2        | QL     |
| HUMALOG KWIKPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML, 200 UNIT/ML  | 2        | QL     |
| HUMALOG MIX 50/50 KWIKPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR               | 2        | QL     |
| HUMALOG MIX 75/25 KWIKPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR               | 2        | QL     |
| HUMALOG MIX 75/25 SUBCUTANEOUS SUSPENSION                                    | 2        | QL     |
| HUMALOG SUBCUTANEOUS SOLUTION CARTRIDGE                                      | 2        | QL     |
| HUMULIN 70/30 KWIKPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR                   | 2        | QL     |
| HUMULIN 70/30 SUBCUTANEOUS SUSPENSION  | 2        | QL     |
| HUMULIN N KWIKPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR                       | 2        | QL     |

| Drug Name   | Tier | Notes  |
|---|------|--------|
| HUMULIN N SUBCUTANEOUS SUSPENSION                                 | 2    | QL     |
| HUMULIN R INJECTION SOLUTION                                      | 2    | QL     |
| HUMULIN R U-500 KWIKPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR        | 2    | PA; QL |
| INSULIN LISPRO (1 UNIT DIAL) SUBCUTANEOUS SOLUTION PEN-INJECTOR   | 2    | QL     |
| INSULIN LISPRO INJECTION SOLUTION                                 | 2    | QL     |
| INSULIN LISPRO JUNIOR KWIKPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR  | 2    | QL     |
| INSULIN LISPRO PROT & LISPRO SUBCUTANEOUS SUSPENSION PEN-INJECTOR | 2    | QL     |
| LANTUS SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR                | 2    | QL     |
| LANTUS SUBCUTANEOUS SOLUTION                                      | 2    | QL     |
| LYUMJEV INJECTION SOLUTION  | 2    | QL     |
| LYUMJEV KWIKPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR                | 2    | QL     |
| MYXREDLIN INTRAVENOUS SOLUTION                                    | 3    |        |
| TOUJEO MAX SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR            | 2    | QL     |
| TOUJEO SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR                | 2    | QL     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes  |
|---|----------|--------|
| TRESIBA FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR                      | 2        | QL     |
| TRESIBA SUBCUTANEOUS SOLUTION   | 2        | QL     |
| <b>*INCRETIN MIMETIC AGENTS (GIP &amp; GLP-1 RECEPTOR AGONISTS)***</b>    |          |        |
| MOUNJARO SUBCUTANEOUS SOLUTION AUTO-INJECTOR                              | 2        | PA; QL |
| <b>*INCRETIN MIMETIC AGENTS (GLP-1 RECEPTOR AGONISTS)***</b>              |          |        |
| liraglutide subcutaneous solution pen-injector                            | 1 or 1b* | PA; QL |
| OZEMPIC (0.25 OR 0.5 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/3ML | 2        | PA; QL |
| OZEMPIC (1 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 4 MG/3ML           | 2        | PA; QL |
| OZEMPIC (2 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR                    | 2        | PA; QL |
| RYBELSUS ORAL TABLET  | 2        | PA; QL |
| TRULICITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR                             | 2        | PA; QL |
| <b>*INSULIN-INCRETIN MIMETIC COMBINATIONS***</b>                          |          |        |
| SOLIQUA SUBCUTANEOUS SOLUTION PEN-INJECTOR                                | 2        | QL     |
| XULTOPHY SUBCUTANEOUS SOLUTION PEN-INJECTOR                               | 2        | QL     |

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| <b>*MEGLITINIDE ANALOGUES***</b>  |          |            |
| nateglinide oral tablet   | 1 or 1b* | QL         |
| repaglinide oral tablet   | 1 or 1b* | QL         |
| <b>*PROGESTERONE RECEPTOR ANTAGONISTS***</b>                                    |          |            |
| mifepristone oral tablet 300 mg   | 4        | PA; LD; QL |
| <b>*SGLT2 INHIBITOR - DPP-4 INHIBITOR - BIGUANIDE COMB***</b>                   |          |            |
| TRIJARDY XR ORAL TABLET EXTENDED RELEASE 24 HOUR                                | 2        | ST; QL     |
| <b>*SGLT2 INHIBITOR - DPP-4 INHIBITOR COMBINATIONS***</b>                       |          |            |
| GLYXAMBI ORAL TABLET  | 2        | ST; QL     |
| <b>*SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITORS***</b>                   |          |            |
| dapagliflozin propanediol oral tablet   | 1 or 1b* | PA; QL     |
| JARDIANCE ORAL TABLET   | 2        | ST; QL     |
| <b>*SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITOR-BIGUANIDE COMB***</b>             |          |            |
| dapagliflozin pro-metformin er oral tablet extended release 24 hour             | 1 or 1b* | ST; QL     |
| SYNJARDY ORAL TABLET  | 2        | ST; QL     |
| SYNJARDY XR ORAL TABLET EXTENDED RELEASE 24 HOUR                                | 2        | ST; QL     |
| XIGDUO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 10-500 MG, 2.5-1000 MG, 5-500 MG | 2        | ST; QL     |
| <b>*SULFONYLUREA-BIGUANIDE COMBINATIONS***</b>                                  |          |            |
| glipizide-metformin hcl oral tablet   | 1 or 1b* | QL         |
| glyburide-metformin oral tablet   | 1 or 1b* | QL         |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| <b>*SULFONYLUREAS***</b>                                |          |            |
| glimepiride oral tablet 1 mg, 2 mg, 4 mg                | 1 or 1b* | QL         |
| glipizide er oral tablet extended release 24 hour       | 1 or 1a* | QL         |
| glipizide oral tablet                                   | 1 or 1a* | QL         |
| glyburide oral tablet                                   | 1 or 1b* | QL         |
| <b>*SULFONYLUREA-THIAZOLIDINEDIONE COMBINATIONS***</b>  |          |            |
| pioglitazone hcl-glimepiride oral tablet                | 1 or 1b* | ST; QL     |
| <b>*THIAZOLIDINEDIONE-BIGUANIDE COMBINATIONS***</b>     |          |            |
| pioglitazone hcl-metformin hcl oral tablet              | 1 or 1b* | ST; QL     |
| <b>*THIAZOLIDINEDIONES***</b>                           |          |            |
| pioglitazone hcl oral tablet                            | 1 or 1b* | QL         |
| <b>*ANTIDIARRHEAL/PROBIOTIC AGENTS*</b>                 |          |            |
| <b>*ANTIDIARRHEAL - CHLORIDE CHANNEL ANTAGONISTS***</b> |          |            |
| MYTESI ORAL TABLET DELAYED RELEASE                      | 3        | PA; LD; QL |
| <b>*ANTIDIARRHEAL/PROBIOTIC AGENTS - MISC.***</b>       |          |            |
| BIOCORE DAILY ORAL CAPSULE                              | 3        |            |
| microwell oral capsule                                  | 3        |            |
| <b>*ANTIPERISTALTIC AGENTS***</b>                       |          |            |
| diphenoxylate-atropine oral liquid                      | 1 or 1b* |            |
| diphenoxylate-atropine oral tablet 2.5-0.025 mg         | 1 or 1b* |            |
| loperamide hcl oral capsule                             | 1 or 1b* | QL         |
| MOTOFEN ORAL TABLET                                     | 3        |            |

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| <b>*ANTIDOTES AND SPECIFIC ANTAGONISTS*</b>            |          |        |
| <b>*ANTIDOTE COMBINATIONS***</b>                       |          |        |
| NITHIODOLE INTRAVENOUS KIT 300MG/10ML&12.5 GM/50ML     | 3        |        |
| PREVDUO INTRAVENOUS SOLUTION PREFILLED SYRINGE         | 3        |        |
| <b>*ANTIDOTES - CHELATING AGENTS***</b>                |          |        |
| CHEMET ORAL CAPSULE                                    | 3        |        |
| deferasirox granules oral packet                       | 4        | PA; SP |
| deferasirox oral packet                                | 4        | PA; SP |
| deferasirox oral tablet                                | 4        | PA; SP |
| deferasirox oral tablet soluble                        | 4        | PA; SP |
| deferiprone oral tablet                                | 4        | PA; LD |
| FERRIPROX ORAL SOLUTION                                | 5        | PA; LD |
| FERRIPROX TWICE-A-DAY ORAL TABLET                      | 5        | PA; LD |
| <b>*ANTIDOTES AND SPECIFIC ANTAGONISTS***</b>          |          |        |
| acetylcysteine intravenous solution                    | 1 or 1b* |        |
| ANTICHOLIUM INTRAVENOUS SOLUTION                       | 3        |        |
| BRIDION INTRAVENOUS SOLUTION                           | 3        |        |
| CYANOKIT INTRAVENOUS SOLUTION RECONSTITUTED 5 GM       | 3        |        |
| deferoxamine mesylate injection solution reconstituted | 4        | SP     |
| DIGIFAB INTRAVENOUS SOLUTION RECONSTITUTED             | 3        |        |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| edetate calcium disodium injection solution                    | 3        |        |
| fomepizole intravenous solution 1.5 gm/1.5ml                   | 1 or 1b* |        |
| methylene blue (antidote) intravenous solution                 | 3        |        |
| methylene blue intravenous solution 50 mg/10ml                 | 1 or 1b* |        |
| <b>PRAXBIND INTRAVENOUS SOLUTION</b>                           | 3        |        |
| <b>PROTOPAM CHLORIDE INTRAVENOUS SOLUTION RECONSTITUTED</b>    | 3        |        |
| <b>RADIOGARDASE ORAL CAPSULE</b>                               | 3        |        |
| <b>SODIUM NITRITE INTRAVENOUS SOLUTION</b>                     | 3        |        |
| <b>SODIUM THIOSULFATE INTRAVENOUS SOLUTION 250 MG/ML</b>       | 3        |        |
| <b>VISTOGARD ORAL PACKET</b>                                   | 3        | LD; QL |
| <b>*BENZODIAZEPINE ANTAGONISTS***</b>                          |          |        |
| flumazenil intravenous solution                                | 1 or 1b* |        |
| <b>*CHOLINESTERASE INHIBITORS***</b>                           |          |        |
| pyridostigmine bromide er oral tablet extended release 24 hour | 3        |        |
| <b>*OPIOID ANTAGONISTS***</b>                                  |          |        |
| <b>KLOXXADO NASAL LIQUID</b>                                   | 2        | QL     |
| nalmefene hcl injection solution                               | 3        | QL     |
| naloxone hcl injection solution 0.4 mg/ml, 4 mg/10ml           | 1 or 1a* | QL     |
| naloxone hcl injection solution cartridge                      | 1 or 1a* | QL     |
| naloxone hcl injection solution prefilled syringe              | 1 or 1a* | QL     |
| naloxone hcl nasal liquid                                      | 1 or 1b* | QL     |
| naltrexone hcl oral tablet                                     | 1 or 1b* |        |

| Drug Name  | Tier     | Notes |
|--|----------|-------|
| <b>OPVEE NASAL SOLUTION</b>                                | 2        | QL    |
| <b>REXTOVY NASAL LIQUID</b>                                | 2        | QL    |
| <b>VIVITROL INTRAMUSCULAR SUSPENSION RECONSTITUTED</b>     | 5        | QL    |
| <b>ZURNAI INJECTION SOLUTION AUTO-INJECTOR</b>             | 2        | QL    |
| <b>*ANTIEMETICS*</b>                                       |          |       |
| <b>*5-HT3 RECEPTOR ANTAGONISTS***</b>                      |          |       |
| <b>ANZEMET ORAL TABLET 50 MG</b>                           | 3        | QL    |
| granisetron hcl intravenous solution 1 mg/ml, 4 mg/4ml     | 1 or 1b* |       |
| granisetron hcl oral tablet                                | 1 or 1b* | QL    |
| ondansetron hcl +rfid injection solution                   | 1 or 1b* |       |
| ondansetron hcl +rfid injection solution prefilled syringe | 1 or 1b* |       |
| ondansetron hcl injection solution 4 mg/2ml, 40 mg/20ml    | 1 or 1b* |       |
| ondansetron hcl injection solution prefilled syringe       | 1 or 1b* |       |
| ondansetron hcl oral solution 4 mg/5ml                     | 1 or 1b* | QL    |
| ondansetron hcl oral tablet                                | 1 or 1b* | QL    |
| ondansetron oral tablet dispersible                        | 1 or 1b* | QL    |
| palonosetron hcl intravenous solution 0.25 mg/5ml          | 1 or 1b* |       |
| palonosetron hcl intravenous solution prefilled syringe    | 1 or 1b* |       |
| <b>POSFREA INTRAVENOUS SOLUTION</b>                        | 3        |       |
| <b>SANCUSO TRANSDERMAL PATCH</b>                           | 3        | QL    |
| <b>SUSTOL SUBCUTANEOUS PREFILLED SYRINGE</b>               | 3        |       |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| <b>*ANTIEMETIC COMBINATIONS***</b>                  |          |            |
| <b>AKYNZEO (READY-TO-USE) INTRAVENOUS SOLUTION</b>  | 3        | PA; LD; QL |
| <b>AKYNZEO (TO-BE-DILUTED) INTRAVENOUS SOLUTION</b> | 3        | PA; LD; QL |
| <b>AKYNZEO INTRAVENOUS SOLUTION RECONSTITUTED</b>   | 3        | PA; LD; QL |
| <b>AKYNZEO ORAL CAPSULE</b>                         | 3        | QL         |
| <b>BONJESTA ORAL TABLET EXTENDED RELEASE</b>        | 3        | PA; QL     |
| doxylamine-pyridoxine oral tablet delayed release   | 1 or 1b* | PA; QL     |
| <b>*ANTIEMETICS - ANTICHOLINERGIC***</b>            |          |            |
| <b>DIMENHYDRINATE INJECTION SOLUTION</b>            | 3        |            |
| meclizine hcl oral tablet 25 mg                     | 1 or 1a* |            |
| meclizine hcl oral tablet 50 mg                     | 1 or 1b* |            |
| scopolamine transdermal patch 72 hour               | 1 or 1b* |            |
| <b>TIGAN INTRAMUSCULAR SOLUTION</b>                 | 3        |            |
| trimethobenzamide hcl oral capsule                  | 1 or 1b* |            |
| <b>*ANTIEMETICS - ANTIDOPAMINERGIC**</b>            |          |            |
| <b>BARHEMSYS INTRAVENOUS SOLUTION</b>               | 3        |            |
| <b>*ANTIEMETICS - MISCELLANEOUS***</b>              |          |            |
| dronabinol oral capsule                             | 1 or 1b* | QL         |
| <b>SYNDROS ORAL SOLUTION</b>                        | 3        | QL         |

| Drug Name   | Tier     | Notes  |
|---|----------|--------|
| <b>*SUBSTANCE P/NEUROKININ 1 (NK1) RECEPTOR ANTAGONISTS***</b>      |          |        |
| <b>APONVIE INTRAVENOUS EMULSION</b>                                 | 3        |        |
| aprepitant oral capsule   | 1 or 1b* | QL     |
| <b>CINVANTI INTRAVENOUS EMULSION</b>                                | 3        | QL     |
| <b>EMEND ORAL SUSPENSION RECONSTITUTED</b>                          | 3        | QL     |
| focinvez intravenous solution                                       | 3        | QL     |
| fosaprepitant dimeglumine intravenous solution reconstituted        | 1 or 1b* | QL     |
| <b>VARUBI (180 MG DOSE) ORAL TABLET THERAPY PACK</b>                | 3        | LD; QL |
| <b>*ANTIFUNGALS*</b>  |          |        |
| <b>*ANTIFUNGAL - GLUCAN SYNTHESIS INHIBITORS (ECHINOCANDINS)***</b> |          |        |
| <b>CASPOFUNGIN ACETATE INTRAVENOUS SOLUTION RECONSTITUTED</b>       | 3        | QL     |
| <b>ERAXIS INTRAVENOUS SOLUTION RECONSTITUTED</b>                    | 3        |        |
| <b>MICAFUNGIN SODIUM INTRAVENOUS SOLUTION RECONSTITUTED</b>         | 3        |        |
| micafungin sodium-nacl intravenous solution                         | 3        |        |
| <b>REZZAYO INTRAVENOUS SOLUTION RECONSTITUTED</b>                   | 3        |        |
| <b>*ANTIFUNGALS***</b>  |          |        |
| amphotericin b intravenous solution reconstituted                   | 1 or 1b* |        |
| amphotericin b liposome intravenous suspension reconstituted        | 1 or 1b* |        |
| flucytosine oral capsule  | 1 or 1b* | PA     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes      |
|--|----------|------------|
| griseofulvin microsize oral suspension   | 1 or 1b* |            |
| griseofulvin microsize oral tablet   | 1 or 1b* |            |
| griseofulvin ultramicrosize oral tablet 125 mg, 250 mg                                     | 1 or 1b* |            |
| nystatin oral tablet   | 1 or 1b* |            |
| terbinafine hcl oral tablet  | 1 or 1b* |            |
| <b>*IMIDAZOLES***</b>  |          |            |
| ketoconazole oral tablet   | 1 or 1b* | QL         |
| <b>*TETRAZOLES***</b>  |          |            |
| <b>VIVJOA ORAL CAPSULE THERAPY PACK</b>  | 3        | PA; LD; QL |
| <b>*TRIAZOLES***</b>   |          |            |
| <b>CRESEMBA INTRAVENOUS SOLUTION RECONSTITUTED</b>   | 3        | PA; QL     |
| <b>CRESEMBA ORAL CAPSULE</b>   | 3        | PA; QL     |
| fluconazole in sodium chloride intravenous solution 200-0.9 mg/100ml-%, 400-0.9 mg/200ml-% | 1 or 1b* |            |
| fluconazole oral suspension reconstituted  | 1 or 1b* | QL         |
| fluconazole oral tablet  | 1 or 1b* | QL         |
| itraconazole oral capsule  | 1 or 1b* | PA; QL     |
| itraconazole oral solution   | 1 or 1b* | PA; QL     |
| <b>NOXAFIL ORAL PACKET</b>   | 3        | PA; QL     |
| posaconazole intravenous solution  | 1 or 1b* |            |
| posaconazole oral suspension   | 1 or 1b* | PA; QL     |
| posaconazole oral tablet delayed release   | 1 or 1b* | PA; QL     |
| <b>TOLSURA ORAL CAPSULE</b>  | 3        | PA; QL     |
| voriconazole oral suspension reconstituted   | 1 or 1b* | PA; QL     |
| voriconazole oral tablet   | 1 or 1b* | PA; QL     |
| <b>*ANTIHISTAMINES*</b>  |          |            |
| <b>*ANTIHISTAMINES - ETHANOLAMINES***</b>  |          |            |
| carbinoxamine maleate er oral suspension extended release                                  | 1 or 1b* | ST; QL     |

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| carbinoxamine maleate oral solution                | 1 or 1b* | ST; QL |
| carbinoxamine maleate oral tablet 4 mg             | 1 or 1b* | ST; QL |
| carbzah oral solution                              | 1 or 1b* | ST; QL |
| <b>CLEMASTINE FUMARATE ORAL SYRUP</b>              | 3        | ST; QL |
| clemastine fumarate oral tablet 2.68 mg            | 1 or 1b* | ST; QL |
| diphenhydramine hcl injection solution             | 1 or 1b* |        |
| diphenhydramine hcl oral elixir                    | 1 or 1a* | QL     |
| <b>*ANTIHISTAMINES - NON-SEDATING***</b>           |          |        |
| cetirizine hcl oral solution                       | 1 or 1b* | BE; QL |
| desloratadine oral tablet                          | 1 or 1b* | QL     |
| desloratadine oral tablet dispersible              | 1 or 1b* | QL     |
| levocetirizine dihydrochloride oral solution       | 1 or 1b* | BE; QL |
| levocetirizine dihydrochloride oral tablet         | 1 or 1b* | BE; QL |
| <b>QUZYTIR INTRAVENOUS SOLUTION</b>                | 3        |        |
| <b>*ANTIHISTAMINES - PHENOTHIAZINES***</b>         |          |        |
| promethazine hcl injection solution                | 1 or 1a* |        |
| promethazine hcl oral solution                     | 1 or 1a* | QL     |
| promethazine hcl oral tablet                       | 1 or 1a* | QL     |
| promethazine hcl rectal suppository 12.5 mg, 25 mg | 1 or 1b* | QL     |
| promethegan rectal suppository                     | 1 or 1b* | QL     |
| <b>*ANTIHISTAMINES - PIPERIDINES***</b>            |          |        |
| cyproheptadine hcl oral syrup                      | 1 or 1b* |        |
| cyproheptadine hcl oral tablet                     | 1 or 1b* |        |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| <b>*ANTHYPERLIPIDEMI CS*</b>   |          |        |
| <b>*ACL INHIB-<br/>INTESTINAL<br/>CHOLESTEROL<br/>ABSORPTION INHIB<br/>COMB***</b> |          |        |
| NEXLIZET ORAL TABLET   | 3        | PA; QL |
| <b>*ADENOSINE TRIPHOSPHATE-CITRATE LYASE (ACL) INHIBITORS***</b>                   |          |        |
| NEXLETOL ORAL TABLET   | 3        | PA; QL |
| <b>*ANGIOPOIETIN-LIKE PROTEIN 3 (ANGPTL3) INHIBITORS***</b>                        |          |        |
| EVKEEZA INTRAVENOUS SOLUTION   | 5        | PA; LD |
| <b>*ANTHYPERLIPIDEMI CS - MISC.***</b>   |          |        |
| icosapent ethyl oral capsule   | 1 or 1b* | QL     |
| omega-3-acid ethyl esters oral capsule   | 1 or 1b* | PA; QL |
| <b>*BILE ACID SEQUESTRANTS***</b>  |          |        |
| cholestyramine light oral packet   | 1 or 1b* | QL     |
| cholestyramine light oral powder   | 1 or 1b* | QL     |
| cholestyramine oral packet   | 1 or 1b* | QL     |
| cholestyramine oral powder   | 1 or 1b* | QL     |
| colesevelam hcl oral packet  | 3        | QL     |
| colesevelam hcl oral tablet  | 1 or 1b* | QL     |
| colestipol hcl oral granules   | 1 or 1b* | QL     |
| colestipol hcl oral packet   | 1 or 1b* | QL     |
| colestipol hcl oral tablet   | 1 or 1b* | QL     |
| prevalite oral packet  | 1 or 1b* | QL     |
| prevalite oral powder  | 1 or 1b* | QL     |
| <b>*FIBRIC ACID DERIVATIVES***</b>   |          |        |
| fenofibrate micronized oral capsule 130 mg, 134 mg, 200 mg, 43 mg, 67 mg           | 1 or 1b* | QL     |
| fenofibrate oral capsule   | 1 or 1b* | QL     |
| fenofibrate oral tablet 120 mg, 40 mg  | 3        | ST; QL |

| Drug Name   | Tier     | Notes   |
|---|----------|---------|
| fenofibrate oral tablet 145 mg, 160 mg, 48 mg, 54 mg      | 1 or 1b* | QL      |
| fenofibric acid oral capsule delayed release              | 1 or 1b* | QL      |
| fenofibric acid oral tablet                               | 1 or 1b* | QL      |
| gemfibrozil oral tablet                                   | 1 or 1b* | QL      |
| <b>*HMG COA REDUCTASE INHIBITORS***</b>                   |          |         |
| ATORVALIQ ORAL SUSPENSION                                 | 3        | QL      |
| atorvastatin calcium oral tablet 10 mg, 20 mg             | 1 or 1b* | DO; \$0 |
| atorvastatin calcium oral tablet 40 mg                    | 1 or 1b* | DO      |
| atorvastatin calcium oral tablet 80 mg                    | 1 or 1b* | QL      |
| EZALLOR SPRINKLE ORAL CAPSULE SPRINKLE 10 MG, 20 MG, 5 MG | 3        | DO      |
| EZALLOR SPRINKLE ORAL CAPSULE SPRINKLE 40 MG              | 3        | QL      |
| FLOLIPID ORAL SUSPENSION                                  | 3        | QL      |
| fluvastatin sodium oral capsule                           | 1 or 1b* | DO; \$0 |
| lovastatin oral tablet 10 mg, 20 mg                       | 1 or 1b* | DO; \$0 |
| lovastatin oral tablet 40 mg                              | 1 or 1b* | \$0; QL |
| pravastatin sodium oral tablet 10 mg, 20 mg, 40 mg        | 1 or 1b* | DO; \$0 |
| pravastatin sodium oral tablet 80 mg                      | 1 or 1b* | \$0; QL |
| rosuvastatin calcium oral tablet 10 mg, 5 mg              | 1 or 1b* | DO; \$0 |
| rosuvastatin calcium oral tablet 20 mg                    | 1 or 1b* | DO      |
| rosuvastatin calcium oral tablet 40 mg                    | 1 or 1b* | QL      |
| simvastatin oral tablet 10 mg, 20 mg, 5 mg                | 1 or 1b* | DO; \$0 |
| simvastatin oral tablet 40 mg                             | 1 or 1b* | \$0; QL |
| simvastatin oral tablet 80 mg                             | 1 or 1b* | PA; QL  |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| <b>*INTEST CHOLEST ABSORP INHIB-HMG COA REDUCTASE INHIB COMB***</b> |          |            |
| ezetimibe-simvastatin oral tablet                                   | 1 or 1b* | ST; QL     |
| <b>*INTESTINAL CHOLESTEROL ABSORPTION INHIBITORS***</b>             |          |            |
| ezetimibe oral tablet   | 1 or 1b* | QL         |
| <b>*MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS***</b>      |          |            |
| JUXTAPID ORAL CAPSULE 10 MG, 5 MG                                   | 3        | PA; LD; DO |
| JUXTAPID ORAL CAPSULE 20 MG, 30 MG                                  | 3        | PA; LD; QL |
| <b>*NICOTINIC ACID DERIVATIVES***</b>                               |          |            |
| niacin (antihyperlipidemic) oral tablet                             | 1 or 1b* | ST; QL     |
| niacin er (antihyperlipidemic) oral tablet extended release         | 1 or 1b* | ST; QL     |
| niacor oral tablet  | 1 or 1b* | ST; QL     |
| <b>*PCSK9 INHIBITORS***</b>   |          |            |
| REPATHA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE                     | 3        | QL         |
| REPATHA SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR               | 3        | QL         |
| <b>*SMALL INTERFERING RNA (SIRNA) PCSK9 INHIBITORS***</b>           |          |            |
| LEQVIO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE                      | 5        | ST; LD; QL |
| <b>*ANTIHYPERTENSIVES</b>   |          |            |
| <b>*ACE INHIBITOR &amp; CALCIUM CHANNEL BLOCKER COMBINATIONS***</b> |          |            |
| amlodipine besy-benazepril hcl oral capsule                         | 1 or 1b* | QL         |

| Drug Name  | Tier     | Notes      |
|--|----------|------------|
| <b>PRESTALIA ORAL TABLET</b>                               | 3        | QL         |
| trandolapril-verapamil hcl er oral tablet extended release | 1 or 1b* | QL         |
| <b>*ACE INHIBITORS &amp; THIAZIDE/THIAZIDE-LIKE***</b>     |          |            |
| benazepril-hydrochlorothiazide oral tablet                 | 1 or 1b* | QL         |
| captopril-hydrochlorothiazide oral tablet                  | 1 or 1b* | QL         |
| enalapril-hydrochlorothiazide oral tablet                  | 1 or 1b* | QL         |
| fosinopril sodium-hctz oral tablet                         | 1 or 1b* | QL         |
| lisinopril-hydrochlorothiazide oral tablet                 | 1 or 1b* | QL         |
| quinapril-hydrochlorothiazide oral tablet                  | 1 or 1b* | QL         |
| <b>*ACE INHIBITORS***</b>                                  |          |            |
| benazepril hcl oral tablet                                 | 1 or 1a* | QL         |
| captopril oral tablet                                      | 1 or 1b* | QL         |
| enalapril maleate oral solution                            | 1 or 1b* | QL         |
| enalapril maleate oral tablet                              | 1 or 1b* | QL         |
| enalaprilat intravenous solution                           | 1 or 1b* |            |
| fosinopril sodium oral tablet                              | 1 or 1b* | QL         |
| lisinopril oral tablet                                     | 1 or 1a* | QL         |
| moexipril hcl oral tablet                                  | 1 or 1b* | QL         |
| perindopril erbumine oral tablet                           | 1 or 1b* | QL         |
| <b>QBRELIS ORAL SOLUTION</b>                               | 3        | QL         |
| quinapril hcl oral tablet                                  | 1 or 1b* | QL         |
| ramipril oral capsule                                      | 1 or 1b* | QL         |
| trandolapril oral tablet                                   | 1 or 1b* | QL         |
| <b>*AGENTS FOR PHEOCHROMOCYTOM A***</b>                    |          |            |
| metyrosine oral capsule                                    | 1 or 1b* | PA; QL; SP |
| phenoxybenzamine hcl oral capsule                          | 1 or 1b* | PA; QL     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes |
|--|----------|-------|
| phentolamine mesylate injection solution reconstituted                 | 1 or 1b* |       |
| <b>*ANGIOTENSIN II RECEPTOR ANTAG &amp; CA CHANNEL BLOCKER COMB***</b> |          |       |
| amlodipine besylate-valsartan oral tablet                              | 1 or 1b* | QL    |
| amlodipine-olmesartan oral tablet                                      | 1 or 1b* | QL    |
| telmisartan-amlodipine oral tablet                                     | 1 or 1b* | QL    |
| <b>*ANGIOTENSIN II RECEPTOR ANTAG &amp; THIAZIDE/THIAZIDE-LIKE***</b>  |          |       |
| candesartan cilexetil-hctz oral tablet                                 | 1 or 1b* | QL    |
| irbesartan-hydrochlorothiazide oral tablet                             | 1 or 1b* | QL    |
| losartan potassium-hctz oral tablet                                    | 1 or 1b* | QL    |
| olmesartan medoxomil-hctz oral tablet                                  | 1 or 1b* | QL    |
| telmisartan-hctz oral tablet   | 1 or 1b* | QL    |
| valsartan-hydrochlorothiazide oral tablet                              | 1 or 1b* | QL    |
| <b>*ANGIOTENSIN II RECEPTOR ANTAGONISTS***</b>                         |          |       |
| ARBLI ORAL SUSPENSION  | 3        | QL    |
| candesartan cilexetil oral tablet 16 mg, 32 mg                         | 1 or 1b* | QL    |
| candesartan cilexetil oral tablet 4 mg, 8 mg                           | 1 or 1b* | DO    |
| irbesartan oral tablet 150 mg, 75 mg                                   | 1 or 1b* | DO    |
| irbesartan oral tablet 300 mg  | 1 or 1b* | QL    |
| losartan potassium oral tablet 100 mg, 50 mg                           | 1 or 1b* | QL    |
| losartan potassium oral tablet 25 mg                                   | 1 or 1b* | DO    |
| olmesartan medoxomil oral tablet 20 mg, 5 mg                           | 1 or 1b* | DO    |
| olmesartan medoxomil oral tablet 40 mg                                 | 1 or 1b* | QL    |

| Drug Name   | Tier     | Notes |
|---|----------|-------|
| telmisartan oral tablet 20 mg, 40 mg                                | 1 or 1b* | DO    |
| telmisartan oral tablet 80 mg                                       | 1 or 1b* | QL    |
| valsartan oral solution   | 1 or 1b* | QL    |
| valsartan oral tablet 160 mg, 320 mg                                | 1 or 1b* | QL    |
| valsartan oral tablet 40 mg, 80 mg                                  | 1 or 1b* | DO    |
| <b>*ANGIOTENSIN II RECEPTOR ANT-CA CHANNEL BLOCKER-THIAZIDES***</b> |          |       |
| amlodipine-valsartan-hctz oral tablet                               | 1 or 1b* | QL    |
| olmesartan-amlodipine-hctz oral tablet                              | 1 or 1b* | QL    |
| <b>*ANTIADRENERGICS - CENTRALLY ACTING***</b>                       |          |       |
| clonidine hcl oral tablet   | 1 or 1a* | QL    |
| clonidine transdermal patch weekly                                  | 1 or 1b* | QL    |
| guanfacine hcl oral tablet  | 1 or 1b* |       |
| methyldopa oral tablet  | 1 or 1b* | QL    |
| <b>*ANTIADRENERGICS - PERIPHERALLY ACTING***</b>                    |          |       |
| doxazosin mesylate oral tablet                                      | 1 or 1b* | QL    |
| prazosin hcl oral capsule   | 1 or 1b* |       |
| terazosin hcl oral capsule  | 1 or 1b* | QL    |
| <b>*ANTIHYPERTENSIVES - MISC.***</b>                                |          |       |
| VECAMYL ORAL TABLET   | 3        |       |
| <b>*BETA BLOCKER &amp; DIURETIC COMBINATIONS***</b>                 |          |       |
| atenolol-chlorthalidone oral tablet                                 | 1 or 1b* | QL    |
| bisoprolol-hydrochlorothiazide oral tablet                          | 1 or 1b* | QL    |
| metoprolol-hydrochlorothiazide oral tablet                          | 1 or 1b* | QL    |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes  |
|---|----------|--------|
| <b>*DIRECT RENIN INHIBITORS***</b>                            |          |        |
| aliskiren fumarate oral tablet 150 mg                         | 1 or 1b* | DO     |
| aliskiren fumarate oral tablet 300 mg                         | 1 or 1b* | QL     |
| <b>*ENDOTHELIN RECEPTOR ANTAGONISTS***</b>                    |          |        |
| <b>TRYVIO ORAL TABLET</b>                                     | 3        | PA; QL |
| <b>*SELECTIVE ALDOSTERONE RECEPTOR ANTAGONISTS (SARAS)***</b> |          |        |
| eplerenone oral tablet  | 1 or 1b* |        |
| <b>*VASODILATORS***</b>                                       |          |        |
| hydralazine hcl injection solution                            | 1 or 1b* |        |
| hydralazine hcl oral tablet                                   | 1 or 1b* |        |
| minoxidil oral tablet   | 1 or 1b* |        |
| nitroprusside sodium intravenous solution                     | 1 or 1b* |        |
| nitroprusside sodium-nacl intravenous solution                | 1 or 1b* |        |
| sodium nitroprusside intravenous solution                     | 1 or 1b* |        |
| <b>*ANTI-INFECTIVE AGENTS - MISC.*</b>                        |          |        |
| <b>*ANTI-INFECTIVE AGENTS - MISC.***</b>                      |          |        |
| <b>IMPAVIDO ORAL CAPSULE</b>                                  | 3        | PA; QL |
| metronidazole oral capsule                                    | 1 or 1a* |        |
| metronidazole oral tablet 250 mg, 500 mg                      | 1 or 1a* |        |
| pentamidine isethionate inhalation solution reconstituted     | 1 or 1b* |        |
| pentamidine isethionate injection solution reconstituted      | 4        |        |
| tinidazole oral tablet  | 1 or 1b* | QL     |
| <b>TRIMETHOPRIM ORAL TABLET</b>                               | 1 or 1a* |        |
| <b>XIFAXAN ORAL TABLET</b>                                    | 3        | PA; QL |

| Drug Name  | Tier     | Notes |
|--|----------|-------|
| <b>*ANTI-INFECTIVE MISC. - COMBINATIONS***</b>   |          |       |
| sulfamethoxazole-trimethoprim intravenous solution   | 1 or 1b* |       |
| sulfamethoxazole-trimethoprim oral suspension  | 1 or 1a* |       |
| sulfamethoxazole-trimethoprim oral tablet  | 1 or 1a* |       |
| sulfatrim pediatric oral suspension  | 1 or 1a* |       |
| <b>*ANTIPROTOZOAL AGENTS***</b>  |          |       |
| atovaquone oral suspension   | 1 or 1b* |       |
| <b>LAMPIT ORAL TABLET</b>  | 3        |       |
| nitazoxanide oral tablet   | 1 or 1b* | QL    |
| <b>*BETA-LACTAMASE INHIBITOR - COMBINATIONS**</b>  |          |       |
| <b>XACDURO INTRAVENOUS SOLUTION RECONSTITUTED</b>  | 3        |       |
| <b>*CARBAPENEM COMBINATIONS***</b>   |          |       |
| imipenem-cilastatin intravenous solution reconstituted                                     | 1 or 1b* |       |
| <b>RECARBRIO INTRAVENOUS SOLUTION RECONSTITUTED</b>  | 3        |       |
| <b>VABOMERE INTRAVENOUS SOLUTION RECONSTITUTED</b>   | 3        |       |
| <b>*CARBAPENEMS***</b>   |          |       |
| ertapenem sodium injection solution reconstituted  | 1 or 1b* |       |
| meropenem intravenous solution reconstituted 1 gm, 500 mg                                  | 1 or 1b* |       |
| <b>MEROPENEM-SODIUM CHLORIDE INTRAVENOUS SOLUTION RECONSTITUTED 1 GM/50ML, 500 MG/50ML</b> | 3        |       |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes |
|--|----------|-------|
| <b>*CHLORAMPHENICALS</b><br><b>***</b>   |          |       |
| chloramphenicol sod succinate intravenous solution reconstituted   | 1 or 1b* |       |
| <b>*CYCLIC LIPOPEPTIDES***</b>   |          |       |
| <b>DAPTOMYCIN INTRAVENOUS SOLUTION RECONSTITUTED 500 MG</b>  | 3        |       |
| daptomycin-sodium chloride intravenous solution  | 3        |       |
| <b>*GLYCOPEPTIDES***</b>   |          |       |
| dalbavancin hcl intravenous solution reconstituted   | 1 or 1b* |       |
| <b>KIMYRSA INTRAVENOUS SOLUTION RECONSTITUTED</b>  | 3        |       |
| <b>ORBACTIV INTRAVENOUS SOLUTION RECONSTITUTED</b>   | 3        |       |
| <b>TYZAVAN INTRAVENOUS SOLUTION</b>  | 3        | QL    |
| vancomycin hcl in dextrose intravenous solution 1.5-5 gm/300ml-%   | 3        | QL    |
| <b>VANCOMYCIN HCL IN DEXTROSE INTRAVENOUS SOLUTION 1-5 GM/200ML-%, 500-5 MG/100ML-%, 750-5 MG/150ML-%</b>                          | 3        | QL    |
| <b>VANCOMYCIN HCL IN NAACL INTRAVENOUS SOLUTION 1-0.9 GM/200ML-%, 500-0.9 MG/100ML-%</b>   | 3        | QL    |
| <b>VANCOMYCIN HCL INTRAVENOUS SOLUTION 1000 MG/200ML, 1250 MG/250ML, 1500 MG/300ML, 1750 MG/350ML, 2000 MG/400ML, 750 MG/150ML</b> | 1 or 1b* | QL    |

| Drug Name  | Tier     | Notes |
|--|----------|-------|
| <b>VANCOMYCIN HCL INTRAVENOUS SOLUTION 500 MG/100ML</b>                                    | 3        | QL    |
| vancomycin hcl intravenous solution reconstituted 1 gm, 1.75 gm, 10 gm, 2 gm, 5 gm, 500 mg | 3        | QL    |
| vancomycin hcl intravenous solution reconstituted 100 gm                                   | 1 or 1b* | QL    |
| vancomycin hcl oral capsule  | 1 or 1b* | QL    |
| vancomycin hcl oral solution reconstituted 25 mg/ml, 50 mg/ml                              | 1 or 1b* | QL    |
| <b>VANCOMYCIN HCL ORAL SOLUTION RECONSTITUTED 250 MG/5ML</b>                               | 1 or 1b* | QL    |
| <b>VIBATIV INTRAVENOUS SOLUTION RECONSTITUTED 750 MG</b>                                   | 3        |       |
| <b>*LEPROSTATICS***</b>  |          |       |
| dapsone oral tablet  | 1 or 1b* |       |
| <b>*LINCOSAMIDES***</b>  |          |       |
| <b>CLEOCIN PHOSPHATE INJECTION SOLUTION 9 GM/60ML</b>                                      | 3        |       |
| clindamycin hcl oral capsule   | 1 or 1b* |       |
| clindamycin palmitate hcl oral solution reconstituted                                      | 1 or 1b* |       |
| clindamycin phosphate in d5w intravenous solution  | 1 or 1b* |       |
| <b>CLINDAMYCIN PHOSPHATE IN NAACL INTRAVENOUS SOLUTION</b>                                 | 3        |       |
| clindamycin phosphate injection solution 300 mg/2ml, 600 mg/4ml, 900 mg/6ml                | 1 or 1b* |       |
| lincomycin hcl injection solution  | 1 or 1b* |       |
| <b>*MONOBACTAM COMBINATIONS***</b>   |          |       |
| <b>EMBLAVEO INTRAVENOUS SOLUTION RECONSTITUTED</b>   | 3        |       |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes      |
|--|----------|------------|
| <b>*MONOBACTAMS***</b>                                       |          |            |
| aztreonam injection solution reconstituted                   | 1 or 1b* |            |
| <b>CAYSTON INHALATION SOLUTION RECONSTITUTED</b>             | 5        | LD; QL; SP |
| <b>*OXAZOLIDINONES***</b>                                    |          |            |
| linezolid in sodium chloride intravenous solution            | 3        |            |
| linezolid intravenous solution 600 mg/300ml                  | 1 or 1b* |            |
| linezolid oral suspension reconstituted                      | 1 or 1b* | PA; QL     |
| linezolid oral tablet  | 1 or 1b* | PA; QL     |
| <b>SIVEXTRO INTRAVENOUS SOLUTION RECONSTITUTED</b>           | 3        |            |
| <b>SIVEXTRO ORAL TABLET</b>                                  | 3        | PA; QL     |
| <b>*PENEM COMBINATIONS**</b>                                 |          |            |
| <b>ORLYNVAH ORAL TABLET</b>                                  | 3        | PA; QL     |
| <b>*POLYMYXINS***</b>  |          |            |
| colistimethate sodium (cba) injection solution reconstituted | 1 or 1b* |            |
| polymyxin b sulfate injection solution reconstituted         | 1 or 1b* |            |
| <b>*URINARY ANTI-INFECTIVES***</b>                           |          |            |
| <b>BLUJEPAL ORAL TABLET</b>                                  | 3        | ST; QL     |
| fosfomicin tromethamine oral packet                          | 1 or 1b* |            |
| methenamine hippurate oral tablet                            | 1 or 1b* |            |
| nitrofurantoin macrocrystal oral capsule                     | 1 or 1b* |            |
| nitrofurantoin monohydrate macro oral capsule                | 1 or 1b* |            |
| nitrofurantoin oral suspension 25 mg/5ml                     | 1 or 1b* |            |
| nitrofurantoin oral suspension 50 mg/5ml                     | 3        |            |

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| <b>*ANTIMALARIALS*</b>  |          |            |
| <b>*ANTIMALARIAL COMBINATIONS***</b>  |          |            |
| atovaquone-proguanil hcl oral tablet  | 1 or 1b* |            |
| <b>COARTEM ORAL TABLET</b>  | 3        |            |
| <b>*ANTIMALARIALS***</b>  |          |            |
| <b>ARAKODA ORAL TABLET</b>  | 3        | QL         |
| <b>ARTESUNATE INTRAVENOUS SOLUTION RECONSTITUTED</b>                        | 3        |            |
| chloroquine phosphate oral tablet   | 1 or 1a* |            |
| <b>HYDROXYCHLOROQUINE SULFATE ORAL TABLET 100 MG, 300 MG, 400 MG</b>        | 1 or 1b* | QL         |
| hydroxychloroquine sulfate oral tablet 200 mg                               | 1 or 1b* | QL         |
| <b>KRINTAFEL ORAL TABLET</b>  | 3        | QL         |
| mefloquine hcl oral tablet  | 1 or 1b* | QL         |
| pyrimethamine oral tablet   | 1 or 1b* | PA; QL     |
| quinine sulfate oral capsule  | 1 or 1b* | PA; QL     |
| <b>*ANTIMYASTHENIC/CHOLINERGIC AGENTS*</b>                                  |          |            |
| <b>*ANTIMYASTHENIC/CHOLINERGIC AGENTS***</b>                                |          |            |
| <b>BLOXIVERZ INTRAVENOUS SOLUTION PREFILLED SYRINGE</b>                     | 3        |            |
| <b>FIRDAPSE ORAL TABLET</b>   | 5        | PA; LD; QL |
| <b>NEOSTIGMINE METHYLSULFATE INTRAVENOUS SOLUTION 10 MG/10ML, 5 MG/10ML</b> | 3        |            |
| neostigmine methylsulfate rfid intravenous solution                         | 3        |            |
| pyridostigmine bromide er oral tablet extended release                      | 1 or 1b* |            |
| pyridostigmine bromide oral solution  | 1 or 1b* |            |
| pyridostigmine bromide oral tablet  | 1 or 1b* |            |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| <b>REGONOL<br/>INTRAVENOUS<br/>SOLUTION</b>                     | 3        |            |
| <b>*ANTIMYCOBACTERIAL AGENTS*</b>                               |          |            |
| <b>*ANTIMYCOBACTERIAL AGENTS***</b>                             |          |            |
| cycloserine oral capsule  | 1 or 1b* |            |
| ethambutol hcl oral tablet                                      | 1 or 1b* |            |
| isoniazid injection solution                                    | 1 or 1a* |            |
| isoniazid oral syrup  | 1 or 1a* |            |
| isoniazid oral tablet   | 1 or 1a* |            |
| <b>PRETOMANID ORAL<br/>TABLET</b>                               | 3        |            |
| <b>PRIFTIN ORAL TABLET</b>                                      | 2        |            |
| pyrazinamide oral tablet  | 1 or 1b* |            |
| rifabutin oral capsule  | 1 or 1b* |            |
| rifampin intravenous solution reconstituted                     | 1 or 1b* |            |
| rifampin oral capsule   | 1 or 1b* |            |
| <b>SIRTURO ORAL<br/>TABLET</b>                                  | 3        | LD         |
| <b>*ANTINEOPLASTICS<br/>AND ADJUNCTIVE<br/>THERAPIES*</b>       |          |            |
| <b>*ALKYLATING<br/>AGENTS***</b>                                |          |            |
| <b>BELRAPZO<br/>INTRAVENOUS<br/>SOLUTION</b>                    | 3        | PA; LD; SP |
| bendamustine hcl intravenous solution                           | 3        | PA; SP     |
| bendamustine hcl intravenous solution reconstituted             | 1 or 1b* | PA; SP     |
| <b>BENDEKA<br/>INTRAVENOUS<br/>SOLUTION</b>                     | 3        | PA; LD; SP |
| busulfan intravenous solution                                   | 1 or 1b* | SP         |
| carboplatin intravenous solution                                | 1 or 1b* | SP         |
| cisplatin intravenous solution 100 mg/100ml, 50 mg/50ml         | 1 or 1b* | SP         |
| <b>CISPLATIN<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b> | 3        | SP         |

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| <b>GRAFAPEX<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b> | 3        | PA; LD         |
| <b>KYXATA<br/>INTRAVENOUS<br/>SOLUTION</b>                     | 3        | LD             |
| <b>MYLERAN ORAL<br/>TABLET</b>                                 | 2        |                |
| oxaliplatin intravenous solution                               | 1 or 1b* | SP             |
| oxaliplatin intravenous solution reconstituted                 | 1 or 1b* | SP             |
| <b>TEPADINA<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b> | 3        | SP             |
| tepylute intravenous solution                                  | 3        | LD             |
| thiotepa injection solution reconstituted                      | 1 or 1b* | SP             |
| vivimusta intravenous solution                                 | 3        | PA; LD; SP     |
| <b>ZEPZELCA<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b> | 3        | PA; LD; SP     |
| <b>*ANDROGEN<br/>BIOSYNTHESIS<br/>INHIBITORS***</b>            |          |                |
| abiraterone acetate oral tablet                                | 1 or 1b* | PA; QL; SP     |
| <b>ABIRTEGA ORAL<br/>TABLET</b>                                | 1 or 1b* | PA; QL; SP     |
| <b>YONSA ORAL TABLET</b>                                       | 2        | PA; LD; QL; SP |
| <b>*ANTIADRENALS***</b>  |          |                |
| <b>LYSODREN ORAL<br/>TABLET</b>                                | 2        | LD; QL         |
| <b>*ANTIANDROGENS***</b>                                       |          |                |
| bicalutamide oral tablet                                       | 1 or 1b* | QL             |
| <b>ERLEADA ORAL<br/>TABLET</b>                                 | 2        | PA; LD; QL; SP |
| <b>EULEXIN ORAL<br/>CAPSULE</b>                                | 3        |                |
| nilutamide oral tablet   | 1 or 1b* | QL             |
| <b>NUBEQA ORAL TABLET</b>                                      | 2        | PA; LD; QL; SP |
| <b>XTANDI ORAL<br/>CAPSULE</b>                                 | 2        | PA; LD; QL; SP |
| <b>XTANDI ORAL TABLET</b>                                      | 2        | PA; LD; QL; SP |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes  |
|---|----------|--------|
| <b>*ANTIESTROGENS***</b>  |          |        |
| <b>SOLTAMOX ORAL SOLUTION</b>   | 2        | \$0    |
| tamoxifen citrate oral tablet   | 1 or 1b* | \$0    |
| toremifene citrate oral tablet  | 1 or 1b* |        |
| <b>*ANTIMETABOLITES***</b>  |          |        |
| <b>AVGEMSI INTRAVENOUS SOLUTION</b>   | 3        | LD; SP |
| <b>AXTLE INTRAVENOUS SOLUTION RECONSTITUTED</b>   | 3        | PA; LD |
| azacitidine injection suspension reconstituted  | 1 or 1b* | SP     |
| capecitabine oral tablet  | 1 or 1b* | PA; SP |
| cladribine intravenous solution 10 mg/10ml  | 1 or 1b* | SP     |
| clofarabine intravenous solution  | 1 or 1b* | SP     |
| cytarabine (pf) injection solution  | 1 or 1b* | SP     |
| cytarabine injection solution   | 1 or 1b* | SP     |
| decitabine intravenous solution reconstituted   | 1 or 1b* | SP     |
| floxuridine injection solution reconstituted  | 1 or 1b* | SP     |
| fludarabine phosphate intravenous solution 50 mg/2ml                                      | 1 or 1b* | SP     |
| fludarabine phosphate intravenous solution reconstituted                                  | 1 or 1b* | SP     |
| fluorouracil intravenous solution   | 1 or 1b* | SP     |
| <b>FOLOTYN INTRAVENOUS SOLUTION</b>   | 3        | SP     |
| <b>GEMCITABINE HCL INTRAVENOUS SOLUTION 1 GM/10ML, 1.5 GM/15ML, 2 GM/20ML, 200 MG/2ML</b> | 3        | SP     |
| gemcitabine hcl intravenous solution reconstituted  | 1 or 1b* | SP     |
| <b>INLEXZO INTRAVESICAL IMPLANT</b>   | 3        | PA; LD |
| <b>JYLAMVO ORAL SOLUTION</b>  | 3        | PA     |

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| mercaptopurine oral suspension  | 1 or 1b* | PA             |
| mercaptopurine oral tablet  | 1 or 1b* |                |
| methotrexate sodium (pf) injection solution 1 gm/40ml, 1000 mg/40ml, 250 mg/10ml, 50 mg/2ml | 1 or 1b* |                |
| methotrexate sodium injection solution 250 mg/10ml, 50 mg/2ml                               | 1 or 1b* |                |
| methotrexate sodium injection solution reconstituted  | 1 or 1b* |                |
| methotrexate sodium oral tablet   | 1 or 1b* |                |
| nelarabine intravenous solution   | 1 or 1b* | SP             |
| <b>ONUREG ORAL TABLET</b>   | 3        | PA; LD; QL; SP |
| pemetrexed disodium intravenous solution 1 gm/40ml, 100 mg/4ml, 500 mg/20ml                 | 3        | PA; SP         |
| pemetrexed disodium intravenous solution reconstituted                                      | 1 or 1b* | PA; SP         |
| pemetrexed intravenous solution 1 gm/40ml, 100 mg/4ml                                       | 3        | PA; SP         |
| pemetrexed intravenous solution 500 mg/20ml   | 3        | PA             |
| <b>PEMFEXY INTRAVENOUS SOLUTION</b>   | 3        | PA; LD         |
| <b>PEMRYDI RTU INTRAVENOUS SOLUTION</b>   | 3        | PA; SP         |
| pralatrexate intravenous solution   | 1 or 1b* | SP             |
| <b>TABLOID ORAL TABLET</b>  | 2        |                |
| <b>TREXALL ORAL TABLET</b>  | 2        | ST             |
| <b>XATMEP ORAL SOLUTION</b>   | 3        | PA             |
| <b>*ANTINEOPLASTIC - AKT INHIBITORS***</b>  |          |                |
| <b>TRUQAP ORAL TABLET 200 MG</b>  | 3        | PA; LD; QL     |
| <b>TRUQAP ORAL TABLET THERAPY PACK</b>  | 3        | PA; LD; QL     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier | Notes          |
|---|------|----------------|
| <b>*ANTINEOPLASTIC - ALK INHIBITORS***</b>                  |      |                |
| ALECENSA ORAL CAPSULE                                       | 2    | PA; LD; QL; SP |
| ALUNBRIG ORAL TABLET  | 2    | PA; LD; QL     |
| ALUNBRIG ORAL TABLET THERAPY PACK                           | 2    | PA; LD; QL     |
| LORBRENA ORAL TABLET  | 3    | PA; LD; QL; SP |
| XALKORI ORAL CAPSULE  | 3    | PA; LD; QL; SP |
| XALKORI ORAL CAPSULE SPRINKLE                               | 3    | PA; LD; QL; SP |
| ZYKADIA ORAL TABLET   | 3    | PA; LD; QL; SP |
| <b>*ANTINEOPLASTIC - ANTI-BCMA ANTIBODY-DRUG COMPLEX***</b> |      |                |
| BLENREP INTRAVENOUS SOLUTION RECONSTITUTED 70 MG            | 3    | PA             |
| <b>*ANTINEOPLASTIC - ANTIBODY COMBINATIONS***</b>           |      |                |
| OPDUALAG INTRAVENOUS SOLUTION                               | 3    | PA; LD; SP     |
| <b>*ANTINEOPLASTIC - ANTI-CCR4 ANTIBODIES***</b>            |      |                |
| POTELIGEO INTRAVENOUS SOLUTION                              | 3    | LD; SP         |
| <b>*ANTINEOPLASTIC - ANTI-CD19 ANTIBODIES***</b>            |      |                |
| MONJUVI INTRAVENOUS SOLUTION RECONSTITUTED                  | 3    | PA; LD         |
| <b>*ANTINEOPLASTIC - ANTI-CD19 ANTIBODY-DRUG COMPLEX***</b> |      |                |
| ZYNLONTA INTRAVENOUS SOLUTION RECONSTITUTED                 | 3    | PA; LD         |

| Drug Name   | Tier | Notes      |
|---|------|------------|
| <b>*ANTINEOPLASTIC - ANTI-CD20 ANTIBODIES***</b>            |      |            |
| ARZERRA INTRAVENOUS CONCENTRATE                             | 3    | PA; LD; SP |
| GAZYVA INTRAVENOUS SOLUTION                                 | 3    | PA; LD; SP |
| RIABNI INTRAVENOUS SOLUTION                                 | 3    | PA; LD; SP |
| RITUXAN INTRAVENOUS SOLUTION                                | 3    | PA; LD; SP |
| RUXIENCE INTRAVENOUS SOLUTION                               | 3    | PA; SP     |
| TRUXIMA INTRAVENOUS SOLUTION                                | 3    | PA; SP     |
| <b>*ANTINEOPLASTIC - ANTI-CD22 ANTIBODY-DRUG COMPLEX***</b> |      |            |
| BESONSA INTRAVENOUS SOLUTION RECONSTITUTED                  | 3    | PA; LD; SP |
| <b>*ANTINEOPLASTIC - ANTI-CD30 ANTIBODY-DRUG COMPLEX***</b> |      |            |
| ADCETRIS INTRAVENOUS SOLUTION RECONSTITUTED                 | 3    | PA; LD; SP |
| <b>*ANTINEOPLASTIC - ANTI-CD33 ANTIBODY-DRUG COMPLEX***</b> |      |            |
| MYLOTARG INTRAVENOUS SOLUTION RECONSTITUTED 4.5 MG          | 3    | PA; LD; SP |
| <b>*ANTINEOPLASTIC - ANTI-CD38 ANTIBODIES***</b>            |      |            |
| DARZALEX INTRAVENOUS SOLUTION                               | 3    | PA; LD; SP |
| SARCLISA INTRAVENOUS SOLUTION                               | 3    | PA; LD; SP |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier | Notes      |
|--|------|------------|
| <b>*ANTINEOPLASTIC - ANTI-CD79B ANTIBODY-DRUG COMPLEX***</b> |      |            |
| <b>POLIVY INTRAVENOUS SOLUTION RECONSTITUTED</b>             | 3    | PA; LD; SP |
| <b>*ANTINEOPLASTIC - ANTI-CLDN18.2 ANTIBODIES***</b>         |      |            |
| <b>VYLOY INTRAVENOUS SOLUTION RECONSTITUTED</b>              | 3    | PA; LD     |
| <b>*ANTINEOPLASTIC - ANTI-C-MET ANTIBODY-DRUG COMPLEX***</b> |      |            |
| <b>EMRELIS INTRAVENOUS SOLUTION RECONSTITUTED</b>            | 3    | PA; LD     |
| <b>*ANTINEOPLASTIC - ANTI-CTLA-4 ANTIBODIES***</b>           |      |            |
| <b>IMJUDO INTRAVENOUS SOLUTION</b>                           | 3    | PA; LD; SP |
| <b>YERVOY INTRAVENOUS SOLUTION</b>                           | 3    | PA; LD; SP |
| <b>*ANTINEOPLASTIC - ANTI-GD2 ANTIBODIES***</b>              |      |            |
| <b>DANYELZA INTRAVENOUS SOLUTION</b>                         | 3    | PA; LD     |
| <b>UNITUXIN INTRAVENOUS SOLUTION</b>                         | 3    | LD         |
| <b>*ANTINEOPLASTIC - ANTI-HER2 AGENTS***</b>                 |      |            |
| <b>HERCEPTIN INTRAVENOUS SOLUTION RECONSTITUTED 150 MG</b>   | 3    | LD; SP     |
| <b>HERCESSI INTRAVENOUS SOLUTION RECONSTITUTED</b>           | 3    | ST; LD; SP |
| <b>HERNEXEOS ORAL TABLET</b>                                 | 3    | PA; LD; QL |

| Drug Name   | Tier | Notes      |
|---|------|------------|
| <b>HERZUMA INTRAVENOUS SOLUTION RECONSTITUTED</b>               | 3    | ST; SP     |
| <b>KANJINTI INTRAVENOUS SOLUTION RECONSTITUTED</b>              | 3    | LD; SP     |
| <b>MARGENZA INTRAVENOUS SOLUTION</b>                            | 3    | PA; LD; SP |
| <b>OGIVRI INTRAVENOUS SOLUTION RECONSTITUTED</b>                | 3    | ST; LD; SP |
| <b>ONTRUZANT INTRAVENOUS SOLUTION RECONSTITUTED</b>             | 3    | ST; LD; SP |
| <b>PERJETA INTRAVENOUS SOLUTION</b>                             | 3    | PA; LD; SP |
| <b>TRAZIMERA INTRAVENOUS SOLUTION RECONSTITUTED</b>             | 3    | ST; SP     |
| <b>TUKYSA ORAL TABLET</b>                                       | 3    | PA; LD; QL |
| <b>ZIIHERA INTRAVENOUS SOLUTION RECONSTITUTED</b>               | 3    | PA; LD; SP |
| <b>*ANTINEOPLASTIC - ANTI-NECTIN-4 ANTIBODY-DRUG COMPLEX***</b> |      |            |
| <b>PADCEV INTRAVENOUS SOLUTION RECONSTITUTED</b>                | 3    | PA; LD; SP |
| <b>*ANTINEOPLASTIC - ANTI-PD-1 ANTIBODIES***</b>                |      |            |
| <b>JEMPERLI INTRAVENOUS SOLUTION</b>                            | 3    | PA; LD; SP |
| <b>KEYTRUDA INTRAVENOUS SOLUTION</b>                            | 3    | PA; LD; SP |
| <b>LIBTAYO INTRAVENOUS SOLUTION</b>                             | 3    | PA; LD     |
| <b>LOQTORZI INTRAVENOUS SOLUTION</b>                            | 3    | PA; LD; SP |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| OPDIVO INTRAVENOUS SOLUTION                               | 3        | PA; LD; SP     |
| TEVIMBRA INTRAVENOUS SOLUTION                             | 3        | PA; LD         |
| ZYNYZ INTRAVENOUS SOLUTION                                | 3        | PA; LD; QL; SP |
| <b>*ANTINEOPLASTIC - ANTI-PD-L1 ANTIBODIES***</b>         |          |                |
| BAVENCIO INTRAVENOUS SOLUTION                             | 3        | PA; LD         |
| IMFINZI INTRAVENOUS SOLUTION                              | 3        | PA; LD; SP     |
| TECENTRIQ INTRAVENOUS SOLUTION                            | 3        | PA; LD; SP     |
| UNLOXCYT INTRAVENOUS SOLUTION                             | 3        | PA; LD         |
| <b>*ANTINEOPLASTIC - ANTI-SLAMF7 ANTIBODIES***</b>        |          |                |
| EMPLICITI INTRAVENOUS SOLUTION RECONSTITUTED              | 3        | PA; LD; SP     |
| <b>*ANTINEOPLASTIC - ANTI-TF ANTIBODY-DRUG COMPLEX***</b> |          |                |
| TIVDAK INTRAVENOUS SOLUTION RECONSTITUTED                 | 3        | PA; LD; SP     |
| <b>*ANTINEOPLASTIC - BCL-2 INHIBITORS***</b>              |          |                |
| VENCLEXTA ORAL TABLET                                     | 3        | PA; LD; QL     |
| VENCLEXTA STARTING PACK ORAL TABLET THERAPY PACK          | 3        | PA; LD; QL     |
| <b>*ANTINEOPLASTIC - BCR-ABL KINASE INHIBITORS***</b>     |          |                |
| BOSULIF ORAL CAPSULE                                      | 2        | PA; QL; SP     |
| BOSULIF ORAL TABLET                                       | 2        | PA; QL; SP     |
| dasatinib oral tablet                                     | 1 or 1b* | PA; QL; SP     |
| ICLUSIG ORAL TABLET                                       | 3        | PA; LD; QL     |
| imatinib mesylate oral tablet                             | 1 or 1b* | PA; QL; SP     |

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| imkeldi oral solution                                  | 3        | PA; LD; QL     |
| nilotinib hcl oral capsule                             | 1 or 1b* | PA; QL; SP     |
| SCEMBLIX ORAL TABLET                                   | 3        | PA; LD; QL     |
| <b>*ANTINEOPLASTIC - BISPECIFIC T-CELL ENGAGERS***</b> |          |                |
| BLINCYTO INTRAVENOUS SOLUTION RECONSTITUTED            | 3        | PA; LD         |
| COLUMVI INTRAVENOUS SOLUTION                           | 3        | PA; LD; SP     |
| ELREXFIO SUBCUTANEOUS SOLUTION                         | 3        | PA; LD         |
| EPKINLY SUBCUTANEOUS SOLUTION                          | 3        | PA; LD         |
| IMDELLTRA INTRAVENOUS SOLUTION RECONSTITUTED           | 3        | PA; LD; SP     |
| KIMMTRAK INTRAVENOUS SOLUTION                          | 3        | PA; LD         |
| LUNSUMIO INTRAVENOUS SOLUTION                          | 3        | PA; LD; SP     |
| LUNSUMIO VELO SUBCUTANEOUS SOLUTION                    | 3        | PA; SP         |
| LYNOZYFIC INTRAVENOUS SOLUTION                         | 3        | PA; LD         |
| TALVEY SUBCUTANEOUS SOLUTION                           | 3        | PA; LD         |
| TECVAYLI SUBCUTANEOUS SOLUTION                         | 3        | PA; LD         |
| <b>*ANTINEOPLASTIC - BRAF KINASE INHIBITORS***</b>     |          |                |
| BRAFTOVI ORAL CAPSULE 75 MG                            | 3        | PA; LD; QL; SP |
| OJEMDA ORAL SUSPENSION RECONSTITUTED                   | 3        | PA; LD; QL     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| OJEMDA ORAL TABLET 100 MG                             | 3        | PA; LD; QL     |
| TAFINLAR ORAL CAPSULE                                 | 3        | PA; LD; QL; SP |
| TAFINLAR ORAL TABLET SOLUBLE                          | 3        | PA; LD; QL; SP |
| ZELBORAF ORAL TABLET                                  | 2        | PA; LD; QL; SP |
| <b>*ANTINEOPLASTIC - BTK INHIBITORS***</b>            |          |                |
| BRUKINSA ORAL CAPSULE                                 | 3        | PA; LD; QL     |
| BRUKINSA ORAL TABLET                                  | 3        | PA; QL         |
| CALQUENCE ORAL TABLET                                 | 2        | PA; LD; QL     |
| IMBRUVICA ORAL CAPSULE                                | 2        | PA; LD; QL     |
| IMBRUVICA ORAL SUSPENSION                             | 2        | PA; LD; QL     |
| IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG          | 2        | PA; LD; QL     |
| JAYPIRCA ORAL TABLET                                  | 3        | PA; LD; QL     |
| <b>*ANTINEOPLASTIC - CSF1R KINASE INHIBITORS***</b>   |          |                |
| ROMVIMZA ORAL CAPSULE                                 | 3        | PA; LD; QL     |
| <b>*ANTINEOPLASTIC - EGFR INHIBITORS***</b>           |          |                |
| ERBITUX INTRAVENOUS SOLUTION                          | 3        | PA; SP         |
| erlotinib hcl oral tablet                             | 1 or 1b* | PA; QL; SP     |
| gefitinib oral tablet                                 | 1 or 1b* | PA; QL; SP     |
| GILOTRIF ORAL TABLET                                  | 3        | PA; LD; QL     |
| LAZCLUZE ORAL TABLET                                  | 3        | PA; LD; QL     |
| PORTRAZZA INTRAVENOUS SOLUTION                        | 3        | LD; SP         |
| TAGRISSO ORAL TABLET                                  | 3        | PA; LD; QL; SP |
| VECTIBIX INTRAVENOUS SOLUTION 100 MG/5ML, 400 MG/20ML | 3        | PA; LD; SP     |

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| VIZIMPRO ORAL TABLET                                       | 3        | PA; LD; QL; SP |
| <b>*ANTINEOPLASTIC - FGFR KINASE INHIBITORS***</b>         |          |                |
| BALVERSA ORAL TABLET                                       | 3        | PA; LD; QL; SP |
| LYTGOBI (12 MG DAILY DOSE) ORAL TABLET THERAPY PACK        | 3        | PA; LD; QL     |
| LYTGOBI (16 MG DAILY DOSE) ORAL TABLET THERAPY PACK        | 3        | PA; LD; QL     |
| LYTGOBI (20 MG DAILY DOSE) ORAL TABLET THERAPY PACK        | 3        | PA; LD; QL     |
| PEMAZYRE ORAL TABLET                                       | 3        | PA; LD; QL     |
| <b>*ANTINEOPLASTIC - GAMMA SECRETASE INHIBITORS***</b>     |          |                |
| OGSIVEO ORAL TABLET 100 MG, 150 MG                         | 3        | PA; LD; QL     |
| <b>*ANTINEOPLASTIC - HEDGEHOG PATHWAY INHIBITORS***</b>    |          |                |
| DAURISMO ORAL TABLET                                       | 3        | PA; LD; QL; SP |
| ERIVEDGE ORAL CAPSULE                                      | 2        | PA; LD; QL; SP |
| ODOMZO ORAL CAPSULE  | 3        | PA; LD; QL; SP |
| <b>*ANTINEOPLASTIC - HIF-2-ALPHA INHIBITORS***</b>         |          |                |
| WELIREG ORAL TABLET  | 3        | PA; LD; QL     |
| <b>*ANTINEOPLASTIC - HISTONE DEACETYLASE INHIBITORS***</b> |          |                |
| BELEODAQ INTRAVENOUS SOLUTION RECONSTITUTED                | 3        | PA; LD; SP     |
| romidepsin intravenous solution reconstituted              | 1 or 1b* | PA; SP         |
| ZOLINZA ORAL CAPSULE                                       | 2        | PA; QL; SP     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier | Notes          |
|---|------|----------------|
| <b>*ANTINEOPLASTIC - HORMONAL AND RELATED AGENT COMBINATIONS***</b> |      |                |
| AKEEGA ORAL TABLET  | 3    | PA; LD; QL     |
| <b>*ANTINEOPLASTIC - IMMUNOMODULATORS***</b>                        |      |                |
| POMALYST ORAL CAPSULE   | 3    | PA; LD; QL; SP |
| <b>*ANTINEOPLASTIC - KRAS INHIBITORS***</b>                         |      |                |
| KRAZATI ORAL TABLET   | 3    | PA; LD; QL     |
| LUMAKRAS ORAL TABLET  | 3    | PA; LD; QL; SP |
| <b>*ANTINEOPLASTIC - MEK INHIBITORS***</b>                          |      |                |
| COTELLIC ORAL TABLET  | 3    | PA; LD; QL; SP |
| GOMEKLI ORAL CAPSULE  | 3    | PA; LD; QL     |
| GOMEKLI ORAL TABLET SOLUBLE   | 3    | PA; LD; QL     |
| KOSELUGO ORAL CAPSULE   | 3    | PA; LD; QL     |
| KOSELUGO ORAL CAPSULE SPRINKLE                                      | 3    | PA; QL         |
| MEKINIST ORAL SOLUTION RECONSTITUTED                                | 3    | PA; LD; QL; SP |
| MEKINIST ORAL TABLET  | 3    | PA; LD; QL; SP |
| MEKTOVI ORAL TABLET   | 3    | PA; LD; QL; SP |
| <b>*ANTINEOPLASTIC - MENIN INHIBITORS***</b>                        |      |                |
| KOMZIFTI ORAL CAPSULE   | 3    | AL; QL         |
| REVUFORJ ORAL TABLET  | 3    | PA; LD; QL     |
| <b>*ANTINEOPLASTIC - MET INHIBITORS***</b>                          |      |                |
| TABRECTA ORAL TABLET  | 3    | PA; QL; SP     |
| TEPMETKO ORAL TABLET  | 3    | PA; LD; QL     |

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| <b>*ANTINEOPLASTIC - MTOR KINASE INHIBITORS***</b>      |          |                |
| everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg      | 1 or 1b* | PA; SP         |
| everolimus oral tablet soluble                          | 1 or 1b* | PA; SP         |
| <b>FYARRO INTRAVENOUS SUSPENSION RECONSTITUTED</b>      | 3        | PA; LD         |
| temsirolimus intravenous solution                       | 1 or 1b* | PA; SP         |
| TORPENZ ORAL TABLET                                     | 1 or 1b* | PA; LD; SP     |
| <b>*ANTINEOPLASTIC - MULTIKINASE INHIBITORS***</b>      |          |                |
| CABOMETYX ORAL TABLET                                   | 2        | PA; LD; QL; SP |
| CAPRELSA ORAL TABLET                                    | 2        | PA; LD; QL     |
| COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG        | 3        | PA; LD; QL; SP |
| COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG | 3        | PA; LD; QL; SP |
| COMETRIQ (60 MG DAILY DOSE) ORAL KIT                    | 3        | PA; LD; QL; SP |
| ENSACOVE ORAL CAPSULE                                   | 3        | PA; LD; QL     |
| FOTIVDA ORAL CAPSULE                                    | 3        | PA; LD; QL     |
| HYRNUO ORAL TABLET                                      | 3        | PA; QL         |
| lapatinib ditosylate oral tablet                        | 1 or 1b* | PA; QL; SP     |
| NERLYNX ORAL TABLET                                     | 3        | PA; LD; QL; SP |
| pazopanib hcl oral tablet 200 mg                        | 1 or 1b* | PA; QL; SP     |
| QINLOCK ORAL TABLET                                     | 3        | PA; LD; QL     |
| RYDAPT ORAL CAPSULE                                     | 3        | PA; QL; SP     |
| sorafenib tosylate oral tablet                          | 1 or 1b* | PA; QL; SP     |
| STIVARGA ORAL TABLET                                    | 2        | PA; LD; QL; SP |
| sunitinib malate oral capsule                           | 1 or 1b* | PA; QL; SP     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| TURALIO ORAL CAPSULE 125 MG                              | 3        | PA; LD; QL     |
| VANFLYTA ORAL TABLET                                     | 3        | PA; LD; QL     |
| XOSPATA ORAL TABLET                                      | 3        | PA; LD; QL; SP |
| <b>*ANTINEOPLASTIC - MULTIPLE RECEPTOR ANTIBODIES***</b> |          |                |
| BIZENGRI (750 MG DOSE) INTRAVENOUS SOLUTION THERAPY PACK | 3        | PA; LD; QL     |
| RYBREVA NT INTRAVENOUS SOLUTION                          | 3        | PA; LD; SP     |
| <b>*ANTINEOPLASTIC - PDGFR-ALPHA INHIBITORS***</b>       |          |                |
| AYVAKIT ORAL TABLET                                      | 3        | PA; LD; QL     |
| <b>*ANTINEOPLASTIC - PROTEASE ACTIVATORS***</b>          |          |                |
| MODEYSO ORAL CAPSULE                                     | 3        | PA; LD; QL     |
| <b>*ANTINEOPLASTIC - PROTEASOME INHIBITORS***</b>        |          |                |
| bortezomib injection solution reconstituted 1 mg, 2.5 mg | 3        | SP             |
| bortezomib injection solution reconstituted 3.5 mg       | 1 or 1b* | SP             |
| BORUZU INJECTION SOLUTION                                | 3        | SP             |
| KYPROLIS INTRAVENOUS SOLUTION RECONSTITUTED              | 3        | PA; LD; SP     |
| NINLARO ORAL CAPSULE                                     | 3        | PA; LD; QL; SP |
| <b>*ANTINEOPLASTIC - RET INHIBITORS***</b>               |          |                |
| GAVRETO ORAL CAPSULE                                     | 3        | PA; LD; QL     |
| RETEVMO ORAL TABLET                                      | 3        | PA; LD; QL; SP |

| Drug Name  | Tier | Notes          |
|--|------|----------------|
| <b>*ANTINEOPLASTIC - TROPOMYOSIN RECEPTOR KINASE INHIBITORS***</b> |      |                |
| AUGTYRO ORAL CAPSULE   | 3    | PA; LD; QL     |
| IBTROZI ORAL CAPSULE   | 3    | PA; LD; QL     |
| ROZLYTREK ORAL CAPSULE   | 2    | PA; LD; QL; SP |
| ROZLYTREK ORAL PACKET  | 2    | PA; LD; QL; SP |
| VITRAKVI ORAL CAPSULE  | 2    | PA; LD; QL; SP |
| VITRAKVI ORAL SOLUTION   | 2    | PA; LD; QL; SP |
| <b>*ANTINEOPLASTIC - XPO1 INHIBITORS***</b>                        |      |                |
| XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG         | 3    | PA; LD; QL     |
| XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 10 MG          | 3    | PA; LD; QL     |
| XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG         | 3    | PA; LD; QL     |
| XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG          | 3    | PA; LD; QL     |
| XPOVIO (60 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK               | 3    | PA; LD; QL     |
| XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG          | 3    | PA; LD; QL     |
| XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 80 MG          | 3    | PA; QL         |
| XPOVIO (80 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK               | 3    | PA; LD; QL     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes      |
|--|----------|------------|
| <b>*ANTINEOPLASTIC ANTIBIOTICS***</b>                                |          |            |
| adriamycin intravenous solution reconstituted 50 mg                  | 1 or 1b* | SP         |
| bleomycin sulfate injection solution reconstituted                   | 1 or 1b* | SP         |
| dactinomycin intravenous solution reconstituted                      | 1 or 1b* | SP         |
| doxorubicin hcl intravenous solution reconstituted                   | 1 or 1b* | SP         |
| doxorubicin hcl liposomal intravenous suspension                     | 1 or 1b* | SP         |
| <b>ELLENC</b><br><b>INTRAVENOUS SOLUTION</b>                         | 3        | PA; SP     |
| idarubicin hcl intravenous solution                                  | 1 or 1b* | SP         |
| <b>JELMYTO SOLUTION RECONSTITUTED</b>                                | 3        | PA; LD     |
| mitomycin intravenous solution reconstituted                         | 1 or 1b* | PA; SP     |
| mitoxantrone hcl intravenous concentrate                             | 1 or 1b* | SP         |
| mutamycin intravenous solution reconstituted 40 mg, 5 mg             | 1 or 1b* | PA; SP     |
| valrubicin intravesical solution                                     | 1 or 1b* | SP         |
| <b>ZUSDURI INTRAVESICAL SOLUTION RECONSTITUTED 80 (2 X 40) MG</b>    | 3        | PA; LD     |
| <b>*ANTINEOPLASTIC - ANTIBODY FOR RADIOPHARMACEUTICAL THERAPY***</b> |          |            |
| <b>ZEVALIN Y-90 INTRAVENOUS KIT</b>                                  | 3        | PA; LD     |
| <b>*ANTINEOPLASTIC ANTIBODY-DRUG COMPLEXES***</b>                    |          |            |
| <b>ELAHERE INTRAVENOUS SOLUTION</b>                                  | 3        | PA; LD     |
| <b>ENHERTU INTRAVENOUS SOLUTION RECONSTITUTED</b>                    | 3        | PA; LD; SP |

| Drug Name   | Tier | Notes          |
|---|------|----------------|
| <b>KADCYLA INTRAVENOUS SOLUTION RECONSTITUTED</b>                 | 3    | PA; LD; SP     |
| <b>*ANTINEOPLASTIC COMBINATIONS***</b>                            |      |                |
| <b>AVMAPKI FAKZYNJA CO-PACK ORAL THERAPY PACK</b>                 | 3    | PA; LD; QL     |
| <b>DARZALEX FASPRO SUBCUTANEOUS SOLUTION</b>                      | 3    | PA; LD; SP     |
| <b>HERCEPTIN HYLECTA SUBCUTANEOUS SOLUTION</b>                    | 3    | LD; SP         |
| <b>INQOVI ORAL TABLET</b>   | 3    | PA; LD; QL; SP |
| <b>KEYTRUDA QLEX SUBCUTANEOUS SOLUTION</b>                        | 3    | PA; QL; SP     |
| <b>LONSURF ORAL TABLET</b>  | 3    | PA; LD; SP     |
| <b>OPDIVO QVANTIG SUBCUTANEOUS SOLUTION 300-5000 MG -UT/2.5ML</b> | 3    | PA; SP         |
| <b>OPDIVO QVANTIG SUBCUTANEOUS SOLUTION 600-10000 MG-UT/5ML</b>   | 3    | PA; LD; SP     |
| <b>PHESGO SUBCUTANEOUS SOLUTION</b>                               | 3    | PA; LD; SP     |
| <b>RITUXAN HYCELA SUBCUTANEOUS SOLUTION</b>                       | 3    | LD; SP         |
| <b>RYBREVANT FASPRO SUBCUTANEOUS SOLUTION</b>                     | 3    | PA             |
| <b>TECENTRIQ HYBREZA SUBCUTANEOUS SOLUTION</b>                    | 3    | PA; LD; SP     |
| <b>VYXEOS INTRAVENOUS SUSPENSION RECONSTITUTED 44-100 MG</b>      | 3    | LD; SP         |
| <b>*ANTINEOPLASTIC ENZYMES***</b>                                 |      |                |
| <b>ASPARLAS INTRAVENOUS SOLUTION</b>                              | 3    | PA; LD         |
| <b>ONCASPAR INJECTION SOLUTION</b>                                | 3    | PA; LD         |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes      |
|--|----------|------------|
| <b>RYLAZE<br/>INTRAMUSCULAR<br/>SOLUTION</b>                       | 3        | PA; LD; SP |
| <b>*ANTINEOPLASTIC<br/>RADIOPHARMACEUTIC<br/>ALS***</b>            |          |            |
| <b>LUTATHERA<br/>INTRAVENOUS<br/>SOLUTION</b>                      | 3        | PA; LD     |
| <b>PLUVICTO<br/>INTRAVENOUS<br/>SOLUTION</b>                       | 3        | PA; LD     |
| <b>STRONTIUM CHLORIDE<br/>SR-89 INTRAVENOUS<br/>SOLUTION</b>       | 3        | LD         |
| <b>XOFIGO INTRAVENOUS<br/>SOLUTION 30 MCCI/ML</b>                  | 3        | PA; LD     |
| <b>*ANTINEOPLASTICS -<br/>INTERLEUKINS &amp;<br/>AGONISTS***</b>   |          |            |
| <b>ANKTIVA<br/>INTRAVESICAL<br/>SOLUTION</b>                       | 3        | PA; LD     |
| <b>ELZONRIS<br/>INTRAVENOUS<br/>SOLUTION</b>                       | 3        | PA; LD     |
| <b>PROLEUKIN<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b>    | 3        | PA; SP     |
| <b>*ANTINEOPLASTICS -<br/>PHOTOACTIVATED<br/>AGENTS***</b>         |          |            |
| <b>PHOTOFRIN<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b>    | 3        |            |
| <b>UVADEX<br/>EXTRACORPOREAL<br/>SOLUTION</b>                      | 3        |            |
| <b>*ANTINEOPLASTICS<br/>MISC.***</b>                               |          |            |
| <b>ACTIMMUNE<br/>SUBCUTANEOUS<br/>SOLUTION</b>                     | 5        | PA; LD; SP |
| arsenic trioxide intravenous<br>solution                           | 1 or 1b* | SP         |
| <b>BESREMI<br/>SUBCUTANEOUS<br/>SOLUTION PREFILLED<br/>SYRINGE</b> | 3        | PA; LD; QL |

| Drug Name   | Tier     | Notes  |
|---|----------|--------|
| dacarbazine intravenous<br>solution reconstituted                           | 1 or 1b* | SP     |
| hydroxyurea oral capsule  | 1 or 1b* |        |
| <b>LYMPHIR<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b>               | 3        | PA; SP |
| <b>MATULANE ORAL<br/>CAPSULE</b>  | 2        | LD     |
| <b>NIPENT INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b>                    | 3        | SP     |
| <b>TICE BCG<br/>INTRAVESICAL<br/>SUSPENSION<br/>RECONSTITUTED</b>           | 5        | SP     |
| <b>*AROMATASE<br/>INHIBITORS***</b>   |          |        |
| anastrozole oral tablet   | 1 or 1b* | \$0    |
| exemestane oral tablet  | 1 or 1b* | \$0    |
| letrozole oral tablet   | 1 or 1b* | \$0    |
| <b>*CARBOXYPEPTIDASE<br/>ENZYME AGENTS***</b>                               |          |        |
| <b>VORAXAZE<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b>              | 3        | LD     |
| <b>*CARDIAC<br/>PROTECTIVE<br/>AGENTS***</b>                                |          |        |
| dexrazoxane hcl intravenous<br>solution reconstituted                       | 1 or 1b* | SP     |
| <b>*CHEMOTHERAPY<br/>ADJUNCTS -<br/>HYPERURICEMIA<br/>AGENTS***</b>         |          |        |
| <b>ELITEK INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b>                    | 3        | SP     |
| <b>*CHEMOTHERAPY<br/>ADJUNCTS -<br/>KERATINOCYTE<br/>GROWTH FACTORS***</b>  |          |        |
| <b>KEPIVANCE<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED 5.16<br/>MG</b> | 3        | SP     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| <b>*CYCLIN-DEPENDENT KINASES (CDK) INHIBITORS***</b>            |          |                |
| IBRANCE ORAL CAPSULE  | 2        | PA; LD; QL; SP |
| IBRANCE ORAL TABLET   | 2        | PA; LD; QL; SP |
| KISQALI (200 MG DOSE) ORAL TABLET THERAPY PACK                  | 2        | PA; LD; QL; SP |
| KISQALI (400 MG DOSE) ORAL TABLET THERAPY PACK                  | 2        | PA; LD; QL; SP |
| KISQALI (600 MG DOSE) ORAL TABLET THERAPY PACK                  | 2        | PA; LD; QL; SP |
| VERZENIO ORAL TABLET  | 3        | PA; LD; QL; SP |
| <b>*ESTROGEN RECEPTOR ANTAGONIST***</b>                         |          |                |
| fulvestrant intramuscular solution prefilled syringe            | 1 or 1b* | SP             |
| INLURIYO ORAL TABLET  | 3        | PA; QL         |
| <b>*FOLIC ACID ANTAGONISTS RESCUE AGENTS***</b>                 |          |                |
| KHAPZORY INTRAVENOUS SOLUTION RECONSTITUTED 175 MG              | 3        | PA; LD; SP     |
| LEDERLE LEUCOVORIN ORAL TABLET                                  | 1 or 1b* |                |
| leucovorin calcium injection solution                           | 1 or 1b* | PA             |
| leucovorin calcium injection solution reconstituted             | 1 or 1b* |                |
| leucovorin calcium oral tablet                                  | 1 or 1b* | QL             |
| levoleucovorin calcium intravenous solution reconstituted 50 mg | 1 or 1b* | PA             |
| levoleucovorin calcium pf intravenous solution                  | 1 or 1b* | PA             |
| VYKOURA INJECTION SOLUTION                                      | 3        | PA             |

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| <b>*GONADOTROPIN RELEASING HORMONE (GNRH) ANTAGONISTS***</b>               |          |                |
| FIRMAGON (240 MG DOSE) SUBCUTANEOUS SOLUTION RECONSTITUTED                 | 3        | PA; QL; SP     |
| FIRMAGON SUBCUTANEOUS SOLUTION RECONSTITUTED 80 MG                         | 3        | PA; QL; SP     |
| ORGOVYX ORAL TABLET  | 3        | PA; LD; QL     |
| <b>*IMIDAZOTETRAZINES ***</b>  |          |                |
| TEMODAR INTRAVENOUS SOLUTION RECONSTITUTED                                 | 2        | PA; SP         |
| temozolomide oral capsule  | 1 or 1b* | PA; QL; SP     |
| <b>*ISOCITRATE DEHYDROGENASE 1 &amp; 2 (IDH1 &amp; IDH2) INHIBITORS***</b> |          |                |
| VORANIGO ORAL TABLET   | 3        | PA; LD; QL     |
| <b>*ISOCITRATE DEHYDROGENASE-1 (IDH1) INHIBITORS***</b>                    |          |                |
| REZLIDHIA ORAL CAPSULE   | 3        | PA; LD; QL     |
| TIBSOVO ORAL TABLET  | 3        | PA; LD; QL     |
| <b>*ISOCITRATE DEHYDROGENASE-2 (IDH2) INHIBITORS***</b>                    |          |                |
| IDHIFA ORAL TABLET   | 3        | PA; LD; QL; SP |
| <b>*JANUS ASSOCIATED KINASE (JAK) INHIBITORS***</b>                        |          |                |
| INREBIC ORAL CAPSULE   | 3        | PA; LD; QL; SP |
| JAKAFI ORAL TABLET   | 2        | PA; LD; QL; SP |
| OJJAARA ORAL TABLET  | 3        | PA; LD; QL     |
| VONJO ORAL CAPSULE   | 3        | PA; LD; QL     |
| <b>*LHRH ANALOGS***</b>  |          |                |
| CAMCEVI SUBCUTANEOUS PREFILLED SYRINGE                                     | 3        | PA; LD; QL     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| <b>ELIGARD<br/>SUBCUTANEOUS KIT</b>  | 3        | PA; QL; SP     |
| leuprolide acetate injection kit   | 1 or 1b* | PA; SP         |
| <b>LUPRON DEPOT (1-MONTH)<br/>INTRAMUSCULAR KIT<br/>3.75 MG</b>            | 5        | PA; QL; SP     |
| <b>LUPRON DEPOT (1-MONTH)<br/>INTRAMUSCULAR KIT<br/>7.5 MG</b>             | 2        | QL; SP         |
| <b>LUPRON DEPOT (3-MONTH)<br/>INTRAMUSCULAR KIT<br/>11.25 MG</b>           | 5        | PA; QL; SP     |
| <b>LUPRON DEPOT (3-MONTH)<br/>INTRAMUSCULAR KIT<br/>22.5 MG</b>            | 2        | QL; SP         |
| <b>LUPRON DEPOT (4-MONTH)<br/>INTRAMUSCULAR KIT</b>                        | 2        | QL; SP         |
| <b>LUPRON DEPOT (6-MONTH)<br/>INTRAMUSCULAR KIT</b>                        | 2        | QL; SP         |
| <b>LUTRATE DEPOT<br/>INTRAMUSCULAR<br/>INJECTABLE</b>                      | 3        | LD; QL; SP     |
| <b>TRELSTAR MIXJECT<br/>INTRAMUSCULAR<br/>SUSPENSION<br/>RECONSTITUTED</b> | 3        | PA; QL; SP     |
| <b>VABRINTY<br/>SUBCUTANEOUS KIT<br/>22.5 MG, 45 MG</b>                    | 3        | PA; LD; QL; SP |
| <b>VABRINTY<br/>SUBCUTANEOUS KIT 30<br/>MG, 7.5 MG</b>                     | 3        | PA; QL; SP     |
| <b>ZOLADEX<br/>SUBCUTANEOUS<br/>IMPLANT</b>                                | 3        | PA; QL; SP     |
| <b>*MITOTIC<br/>INHIBITORS***</b>  |          |                |
| <b>BEIZRAY<br/>INTRAVENOUS<br/>CONCENTRATE</b>                             | 3        | SP             |
| <b>BEIZRAY<br/>INTRAVENOUS<br/>SOLUTION</b>                                | 3        |                |

| Drug Name  | Tier     | Notes      |
|--|----------|------------|
| <b>DOCIVYX<br/>INTRAVENOUS<br/>SOLUTION</b>  | 3        | LD; SP     |
| eribulin mesylate intravenous solution   | 1 or 1b* | PA; SP     |
| <b>ETOPOPHOS<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b>                            | 3        | SP         |
| etoposide intravenous solution 1 gm/50ml, 100 mg/5ml, 500 mg/25ml                          | 1 or 1b* | SP         |
| etoposide oral capsule   | 1 or 1b* | SP         |
| <b>IXEMPRA KIT<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b>                          | 3        | PA; SP     |
| <b>JEVTANA<br/>INTRAVENOUS<br/>SOLUTION</b>  | 3        | PA; LD; SP |
| paclitaxel intravenous concentrate 100 mg/16.7ml, 150 mg/25ml, 30 mg/5ml, 300 mg/50ml      | 1 or 1b* | SP         |
| <b>PACLITAXEL PROTEIN-<br/>BOUND PART<br/>INTRAVENOUS<br/>SUSPENSION<br/>RECONSTITUTED</b> | 3        | PA; SP     |
| vinblastine sulfate intravenous solution   | 1 or 1b* | SP         |
| vincristine sulfate intravenous solution   | 1 or 1b* | SP         |
| vinorelbine tartrate intravenous solution  | 1 or 1b* | SP         |
| <b>*MYELOPROTECTIVE<br/>AGENTS***</b>  |          |            |
| <b>COSELA INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b>                                   | 3        | PA; LD     |
| <b>*NITROGEN MUSTARDS<br/>AND RELATED<br/>ANALOGUES***</b>                                 |          |            |
| cyclophosphamide injection solution reconstituted  | 1 or 1b* | SP         |
| cyclophosphamide intravenous solution 1 gm/2ml, 2 gm/4ml                                   | 3        | LD; SP     |
| <b>CYCLOPHOSPHAMIDE<br/>INTRAVENOUS<br/>SOLUTION 1 GM/5ML,<br/>500 MG/2.5ML</b>            | 3        | SP         |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| cyclophosphamide intravenous solution 1000 mg/10ml, 2000 mg/20ml, 500 mg/5ml | 3        | SP     |
| <b>CYCLOPHOSPHAMIDE INTRAVENOUS SOLUTION 2 GM/10ML</b>                       | 3        |        |
| cyclophosphamide intravenous solution 500 mg/ml                              | 3        | LD     |
| cyclophosphamide oral capsule  | 1 or 1b* | SP     |
| <b>CYCLOPHOSPHAMIDE ORAL TABLET 50 MG</b>                                    | 3        |        |
| <b>EVOMELA INTRAVENOUS SOLUTION RECONSTITUTED</b>                            | 3        | LD; SP |
| <b>FRINDOVYX INTRAVENOUS SOLUTION 1 GM/2ML, 2 GM/4ML</b>                     | 3        | LD; SP |
| <b>FRINDOVYX INTRAVENOUS SOLUTION 500 MG/ML</b>                              | 3        | LD     |
| <b>HEPZATO W/50MM CATHETER INTRA-ARTERIAL SOLUTION RECONSTITUTED</b>         | 3        | LD     |
| <b>HEPZATO W/62MM CATHETER INTRA-ARTERIAL SOLUTION RECONSTITUTED</b>         | 3        | LD     |
| <b>IFEX INTRAVENOUS SOLUTION RECONSTITUTED 3 GM</b>                          | 3        | SP     |
| ifosfamide intravenous solution  | 1 or 1b* | SP     |
| ifosfamide intravenous solution reconstituted 1 gm                           | 1 or 1b* | SP     |
| <b>IFOSFAMIDE INTRAVENOUS SOLUTION RECONSTITUTED 3 GM</b>                    | 3        | SP     |
| ivra intravenous solution  | 3        | SP     |
| <b>LEUKERAN ORAL TABLET</b>  | 2        |        |
| melphalan hcl intravenous solution reconstituted                             | 1 or 1b* | SP     |

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| <b>*NITROSOUREAS***</b>                                     |          |                |
| carmustine intravenous solution reconstituted 100 mg        | 1 or 1b* | SP             |
| <b>GLIADEL WAFER IMPLANT WAFER</b>                          | 3        |                |
| lomustine oral capsule                                      | 1 or 1b* | AL; SP         |
| <b>*OLIGONUCLEOTIDE TELOMERASE INHIBITORS***</b>            |          |                |
| <b>RYTELO INTRAVENOUS SOLUTION RECONSTITUTED</b>            | 3        | PA; LD         |
| <b>*ORNITHINE DECARBOXYLASE (ODC) INHIBITORS***</b>         |          |                |
| <b>IWILFIN ORAL TABLET</b>                                  | 3        | PA; LD; QL     |
| <b>*OTOPROTECTIVE AGENTS***</b>                             |          |                |
| <b>PEDMARK INTRAVENOUS SOLUTION</b>                         | 3        | PA; LD         |
| <b>*PHOSPHATIDYLINOSI TOL 3-KINASE (PI3K) INHIBITORS***</b> |          |                |
| <b>COPIKTRA ORAL CAPSULE</b>                                | 3        | PA; LD; QL; SP |
| <b>ITOVEBI ORAL TABLET</b>                                  | 3        | PA; LD; QL; SP |
| <b>PIQRAY (200 MG DAILY DOSE) ORAL TABLET THERAPY PACK</b>  | 3        | PA; LD; QL     |
| <b>PIQRAY (250 MG DAILY DOSE) ORAL TABLET THERAPY PACK</b>  | 3        | PA; LD; QL     |
| <b>PIQRAY (300 MG DAILY DOSE) ORAL TABLET THERAPY PACK</b>  | 3        | PA; LD; QL     |
| <b>ZYDELIG ORAL TABLET</b>                                  | 3        | PA; LD; QL; SP |
| <b>*POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS***</b>   |          |                |
| <b>LYNPARZA ORAL TABLET</b>                                 | 3        | PA; LD; QL; SP |
| <b>RUBRACA ORAL TABLET</b>                                  | 3        | PA; LD; QL; SP |
| <b>TALZENNA ORAL CAPSULE</b>                                | 3        | PA; LD; QL; SP |
| <b>ZEJULA ORAL TABLET</b>                                   | 3        | PA; LD; QL; SP |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes      |
|--|----------|------------|
| <b>*PROGESTINS-ANTINEOPLASTIC***</b>                                 |          |            |
| megestrol acetate oral suspension 40 mg/ml, 400 mg/10ml, 800 mg/20ml | 1 or 1b* |            |
| megestrol acetate oral tablet  | 1 or 1b* |            |
| <b>*RETINOIDS***</b>   |          |            |
| tretinoin oral capsule   | 1 or 1b* |            |
| <b>*SELECTIVE ESTROGEN RECEPTOR DEGRADERS***</b>                     |          |            |
| ORSERDU ORAL TABLET  | 3        | PA; LD; QL |
| <b>*SELECTIVE RETINOID X RECEPTOR AGONISTS***</b>                    |          |            |
| bexarotene oral capsule  | 1 or 1b* | PA; QL; SP |
| <b>*TETRAHYDROISOQUINOLINES***</b>                                   |          |            |
| YONDELIS INTRAVENOUS SOLUTION RECONSTITUTED                          | 3        | LD; SP     |
| <b>*TOPOISOMERASE I INHIBITORS - ANTIBODY-DRUG COMPLEX***</b>        |          |            |
| DATROWAY INTRAVENOUS SOLUTION RECONSTITUTED                          | 3        | PA; LD; SP |
| TRODELVY INTRAVENOUS SOLUTION RECONSTITUTED                          | 3        | PA; LD     |
| <b>*TOPOISOMERASE I INHIBITORS***</b>                                |          |            |
| HYCAMTIN ORAL CAPSULE  | 2        | PA; SP     |
| irinotecan hcl intravenous solution                                  | 1 or 1b* | SP         |
| ONIVYDE INTRAVENOUS SUSPENSION                                       | 3        | LD; SP     |
| topotecan hcl intravenous solution reconstituted                     | 1 or 1b* | SP         |
| <b>*URINARY TRACT PROTECTIVE AGENTS***</b>                           |          |            |
| mesna intravenous solution   | 1 or 1b* | PA         |

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| mesna oral tablet   | 1 or 1b* | PA             |
| <b>*VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS***</b> |          |                |
| AVASTIN INTRAVENOUS SOLUTION                                    | 3        | PA; LD; SP     |
| CYRAMZA INTRAVENOUS SOLUTION                                    | 3        | PA; LD; SP     |
| FRUZAQLA ORAL CAPSULE   | 3        | PA; LD; QL     |
| INLYTA ORAL TABLET  | 2        | PA; LD; QL; SP |
| LENVIMA (10 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK            | 2        | PA; LD; QL; SP |
| LENVIMA (12 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK            | 2        | PA; LD; QL; SP |
| LENVIMA (14 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK            | 2        | PA; LD; QL; SP |
| LENVIMA (18 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK            | 2        | PA; LD; QL; SP |
| LENVIMA (20 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK            | 2        | PA; LD; QL; SP |
| LENVIMA (24 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK            | 2        | PA; LD; QL; SP |
| LENVIMA (4 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK             | 2        | PA; LD; QL; SP |
| LENVIMA (8 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK             | 2        | PA; LD; QL; SP |
| MVASI INTRAVENOUS SOLUTION                                      | 3        | PA; LD; SP     |
| ZALTRAP INTRAVENOUS SOLUTION                                    | 3        | PA; LD; SP     |
| <b>*ANTIPARKINSON AND RELATED THERAPY AGENTS*</b>               |          |                |
| <b>*ADENOSINE RECEPTOR ANTAGONIST***</b>                        |          |                |
| NOURIANZ ORAL TABLET  | 5        | PA; LD; QL; SP |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes      |
|--|----------|------------|
| <b>*ANTIPARKINSON ANTICHOLINERGICS***</b>                    |          |            |
| benztropine mesylate injection solution                      | 1 or 1a* |            |
| benztropine mesylate oral tablet                             | 1 or 1a* |            |
| trihexyphenidyl hcl oral solution                            | 1 or 1a* |            |
| trihexyphenidyl hcl oral tablet                              | 1 or 1a* |            |
| <b>*ANTIPARKINSON DOPAMINERGICS***</b>                       |          |            |
| amantadine hcl oral capsule                                  | 1 or 1b* | QL         |
| amantadine hcl oral solution                                 | 1 or 1b* | QL         |
| amantadine hcl oral tablet                                   | 1 or 1b* | QL         |
| bromocriptine mesylate oral capsule                          | 1 or 1b* |            |
| bromocriptine mesylate oral tablet                           | 1 or 1b* |            |
| <b>GOCOVRI ORAL CAPSULE EXTENDED RELEASE 24 HOUR 137 MG</b>  | 3        | PA; LD; QL |
| <b>GOCOVRI ORAL CAPSULE EXTENDED RELEASE 24 HOUR 68.5 MG</b> | 3        | PA; LD; DO |
| <b>INBRIJA INHALATION CAPSULE</b>                            | 5        | PA; LD; QL |
| <b>*ANTIPARKINSON MONOAMINE OXIDASE INHIBITORS***</b>        |          |            |
| rasagiline mesylate oral tablet                              | 1 or 1b* | QL         |
| selegiline hcl oral capsule                                  | 1 or 1b* |            |
| selegiline hcl oral tablet                                   | 1 or 1b* |            |
| <b>XADAGO ORAL TABLET</b>                                    | 3        | PA; QL     |
| <b>ZELAPAR ORAL TABLET DISPERSIBLE</b>                       | 3        | PA; QL     |
| <b>*CENTRAL/PERIPHERAL COMT INHIBITORS***</b>                |          |            |
| tolcapone oral tablet  | 1 or 1b* | PA; QL     |
| <b>*DECARBOXYLASE INHIBITORS***</b>                          |          |            |
| carbidopa oral tablet  | 1 or 1b* |            |
| <b>*LEVODOPA COMBINATIONS***</b>                             |          |            |
| carbidopa-levodopa er oral capsule extended release          | 1 or 1b* | QL         |

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| carbidopa-levodopa er oral tablet extended release 25-100 mg, 50-200 mg  | 1 or 1b* |                |
| carbidopa-levodopa oral tablet   | 1 or 1b* |                |
| carbidopa-levodopa oral tablet dispersible   | 1 or 1b* |                |
| carbidopa-levodopa-entacapone oral tablet 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg, 50-200-200 mg | 1 or 1b* |                |
| <b>DHIVY ORAL TABLET 25-100 MG</b>   | 3        |                |
| <b>DUOPA ENTERAL SUSPENSION</b>  | 3        | PA; LD; SP     |
| <b>RYTARY ORAL CAPSULE EXTENDED RELEASE</b>  | 3        | QL             |
| <b>VYALEV SUBCUTANEOUS SOLUTION 12-240 MG/ML</b>   | 3        | PA; LD; QL; SP |
| <b>*NONERGOLINE DOPAMINE RECEPTOR AGONISTS***</b>  |          |                |
| <b>APOKYN SUBCUTANEOUS SOLUTION CARTRIDGE</b>  | 5        | PA; LD; QL; SP |
| apomorphine hcl subcutaneous solution cartridge  | 4        | PA; QL; SP     |
| <b>NEUPRO TRANSDERMAL PATCH 24 HOUR</b>  | 3        | QL             |
| pramipexole dihydrochloride er oral tablet extended release 24 hour  | 1 or 1b* | QL             |
| pramipexole dihydrochloride oral tablet  | 1 or 1b* | QL             |
| ropinirole hcl er oral tablet extended release 24 hour   | 1 or 1b* |                |
| ropinirole hcl oral tablet   | 1 or 1b* |                |
| <b>*PERIPHERAL COMT INHIBITORS***</b>  |          |                |
| entacapone oral tablet   | 1 or 1b* | QL             |
| <b>ONGENTYS ORAL CAPSULE</b>   | 3        | PA; QL         |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| <b>*ANTIPSYCHOTICS/ANTIMANIC AGENTS*</b>                  |          |                |
| <b>*ANTIMANIC AGENTS***</b>                               |          |                |
| lithium carbonate er oral tablet extended release         | 1 or 1a* | QL             |
| lithium carbonate oral capsule                            | 1 or 1a* | QL             |
| lithium carbonate oral tablet                             | 1 or 1a* | QL             |
| lithium oral solution                                     | 1 or 1b* |                |
| <b>*ANTIPSYCHOTICS - MISC.***</b>                         |          |                |
| CAPLYTA ORAL CAPSULE 10.5 MG, 21 MG                       | 3        | DO; AL         |
| CAPLYTA ORAL CAPSULE 42 MG                                | 3        | AL; QL         |
| EQUETRO ORAL CAPSULE EXTENDED RELEASE 12 HOUR             | 3        | QL             |
| lurasidone hcl oral tablet 120 mg                         | 1 or 1b* | AL             |
| lurasidone hcl oral tablet 20 mg, 40 mg                   | 1 or 1b* | DO; AL         |
| lurasidone hcl oral tablet 60 mg, 80 mg                   | 1 or 1b* | AL; QL         |
| NUPLAZID ORAL CAPSULE                                     | 5        | PA; LD; QL; SP |
| NUPLAZID ORAL TABLET 10 MG                                | 5        | PA; LD; QL; SP |
| VRAYLAR ORAL CAPSULE 0.5 MG, 0.75 MG, 1.5 MG, 3 MG        | 2        | DO; AL         |
| VRAYLAR ORAL CAPSULE 4.5 MG, 6 MG                         | 2        | AL; QL         |
| ziprasidone hcl oral capsule 20 mg, 40 mg                 | 1 or 1b* | DO; AL         |
| ziprasidone hcl oral capsule 60 mg, 80 mg                 | 1 or 1b* | AL; QL         |
| ziprasidone mesylate intramuscular solution reconstituted | 1 or 1b* | AL; QL         |
| <b>*BENZISOXAZOLES***</b>                                 |          |                |
| FANAPT ORAL TABLET 1 MG, 2 MG, 4 MG, 6 MG                 | 3        | ST; DO         |
| FANAPT ORAL TABLET 10 MG, 12 MG, 8 MG                     | 3        | ST; QL         |
| FANAPT TITRATION PACK A ORAL TABLET                       | 3        | ST; QL         |

| Drug Name   | Tier     | Notes  |
|---|----------|--------|
| FANAPT TITRATION PACK B ORAL TABLET   | 3        | ST; QL |
| FANAPT TITRATION PACK C ORAL TABLET   | 3        | ST; QL |
| INVEGA HAFYERA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE   | 3        | AL; QL |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE  | 3        | AL; QL |
| INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 273 MG/0.88ML, 410 MG/1.32ML, 546 MG/1.75ML, 819 MG/2.63ML | 3        | AL; QL |
| paliperidone er oral tablet extended release 24 hour 1.5 mg, 3 mg   | 1 or 1b* | DO; AL |
| paliperidone er oral tablet extended release 24 hour 6 mg, 9 mg   | 1 or 1b* | AL; QL |
| PERSERIS SUBCUTANEOUS PREFILLED SYRINGE   | 3        | AL; QL |
| risperidone microspheres er intramuscular suspension reconstituted er   | 1 or 1b* | AL; QL |
| risperidone oral solution   | 1 or 1b* | AL; QL |
| risperidone oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg   | 1 or 1b* | DO; AL |
| risperidone oral tablet 3 mg, 4 mg  | 1 or 1b* | AL; QL |
| risperidone oral tablet dispersible 0.25 mg, 0.5 mg, 1 mg, 2 mg   | 1 or 1b* | DO; AL |
| risperidone oral tablet dispersible 3 mg, 4 mg  | 1 or 1b* | AL; QL |
| <b>*BUTYROPHENONES***</b>   |          |        |
| haloperidol decanoate intramuscular solution 100 mg/ml, 50 mg/ml  | 1 or 1b* | AL; QL |
| haloperidol lactate injection solution 5 mg/ml  | 1 or 1b* | AL     |
| haloperidol lactate oral concentrate 2 mg/ml  | 1 or 1b* | AL; QL |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes  |
|---|----------|--------|
| haloperidol oral tablet 0.5 mg, 1 mg, 2 mg  | 1 or 1b* | DO; AL |
| haloperidol oral tablet 10 mg, 20 mg, 5 mg  | 1 or 1b* | AL; QL |
| <b>*DIBENZODIAZEPINES*</b><br><b>**</b>   |          |        |
| clozapine oral tablet 100 mg, 200 mg  | 1 or 1b* | AL; QL |
| clozapine oral tablet 25 mg, 50 mg  | 1 or 1b* | DO; AL |
| clozapine oral tablet dispersible 100 mg, 150 mg, 200 mg                          | 1 or 1b* | AL; QL |
| clozapine oral tablet dispersible 12.5 mg, 25 mg                                  | 1 or 1b* | DO; AL |
| <b>VERSACLOZ ORAL SUSPENSION</b>  | 3        | AL; QL |
| <b>*DIBENZO-OXEPINO PYRROLES***</b>   |          |        |
| asenapine maleate sublingual tablet sublingual 10 mg                              | 1 or 1b* | AL; QL |
| asenapine maleate sublingual tablet sublingual 2.5 mg, 5 mg                       | 1 or 1b* | DO; AL |
| <b>SECUADO TRANSDERMAL PATCH 24 HOUR</b>  | 3        | ST; QL |
| <b>*DIBENZOTHIAZEPINE S***</b>  |          |        |
| quetiapine fumarate er oral tablet extended release 24 hour 150 mg, 200 mg        | 1 or 1b* | DO; AL |
| quetiapine fumarate er oral tablet extended release 24 hour 300 mg, 400 mg, 50 mg | 1 or 1b* | AL; QL |
| quetiapine fumarate oral tablet 100 mg, 200 mg, 25 mg, 50 mg                      | 1 or 1b* | DO; AL |
| quetiapine fumarate oral tablet 150 mg, 300 mg, 400 mg                            | 1 or 1b* | AL; QL |
| <b>*DIBENZOAZEPINES**</b><br><b>*</b>   |          |        |
| loxapine succinate oral capsule 10 mg, 25 mg, 5 mg                                | 1 or 1b* | DO; AL |
| loxapine succinate oral capsule 50 mg   | 1 or 1b* | AL; QL |

| Drug Name   | Tier     | Notes  |
|---|----------|--------|
| <b>*DIHYDROINDOLONES*</b><br><b>**</b>                  |          |        |
| molindone hcl oral tablet 10 mg, 5 mg                   | 1 or 1b* | DO; AL |
| molindone hcl oral tablet 25 mg                         | 1 or 1b* | AL; QL |
| <b>*PHENOTHIAZINES***</b>                               |          |        |
| chlorpromazine hcl injection solution                   | 1 or 1b* | AL     |
| <b>CHLORPROMAZINE HCL ORAL CONCENTRATE</b>              | 1 or 1b* | AL; QL |
| chlorpromazine hcl oral tablet 10 mg, 25 mg, 50 mg      | 1 or 1b* | DO; AL |
| chlorpromazine hcl oral tablet 100 mg, 200 mg           | 1 or 1b* | AL; QL |
| compro rectal suppository                               | 1 or 1b* | AL     |
| fluphenazine decanoate injection solution               | 1 or 1b* | AL     |
| fluphenazine hcl injection solution                     | 1 or 1b* | AL     |
| fluphenazine hcl oral concentrate                       | 1 or 1b* | AL; QL |
| fluphenazine hcl oral elixir                            | 1 or 1b* | AL; QL |
| fluphenazine hcl oral tablet 1 mg, 2.5 mg, 5 mg         | 1 or 1b* | DO; AL |
| fluphenazine hcl oral tablet 10 mg                      | 1 or 1b* | AL; QL |
| perphenazine oral tablet 16 mg, 4 mg, 8 mg              | 1 or 1b* | AL; QL |
| perphenazine oral tablet 2 mg                           | 1 or 1b* | DO; AL |
| prochlorperazine edisylate injection solution 10 mg/2ml | 1 or 1b* | AL     |
| prochlorperazine maleate oral tablet                    | 1 or 1a* | AL     |
| prochlorperazine rectal suppository                     | 1 or 1b* | AL     |
| thioridazine hcl oral tablet 10 mg, 25 mg, 50 mg        | 1 or 1b* | DO; AL |
| thioridazine hcl oral tablet 100 mg                     | 1 or 1b* | AL; QL |
| trifluoperazine hcl oral tablet 1 mg, 2 mg              | 1 or 1b* | DO; AL |
| trifluoperazine hcl oral tablet 10 mg, 5 mg             | 1 or 1b* | AL; QL |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| <b>*QUINOLINONE DERIVATIVES***</b>   |          |        |
| ABILIFY MAINTENA INTRAMUSCULAR PREFILLED SYRINGE                                 | 2        | AL; QL |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER                       | 2        | AL; QL |
| ABILIFY MYCITE MAINTENANCE KIT ORAL TABLET THERAPY PACK 10 MG, 15 MG, 2 MG, 5 MG | 3        | ST; DO |
| ABILIFY MYCITE MAINTENANCE KIT ORAL TABLET THERAPY PACK 20 MG, 30 MG             | 3        | ST; QL |
| ABILIFY MYCITE STARTER KIT ORAL TABLET THERAPY PACK                              | 3        | ST; QL |
| aripiprazole oral solution   | 1 or 1b* | AL; QL |
| aripiprazole oral tablet 10 mg, 15 mg, 2 mg, 5 mg                                | 1 or 1b* | DO; AL |
| aripiprazole oral tablet 20 mg, 30 mg  | 1 or 1b* | AL; QL |
| aripiprazole oral tablet dispersible   | 1 or 1b* | AL; QL |
| ARISTADA INITIO INTRAMUSCULAR PREFILLED SYRINGE                                  | 3        | AL; QL |
| ARISTADA INTRAMUSCULAR PREFILLED SYRINGE   | 3        | AL; QL |
| REXULTI ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG                                  | 3        | DO; AL |
| REXULTI ORAL TABLET 3 MG, 4 MG   | 3        | AL; QL |
| <b>*THIENBENZODIAZEPINES***</b>  |          |        |
| olanzapine intramuscular solution reconstituted                                  | 1 or 1b* | AL; QL |
| olanzapine oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg                               | 1 or 1b* | DO; AL |
| olanzapine oral tablet 15 mg, 20 mg  | 1 or 1b* | AL; QL |
| olanzapine oral tablet dispersible 10 mg, 5 mg                                   | 1 or 1b* | DO; AL |

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| olanzapine oral tablet dispersible 15 mg, 20 mg                           | 1 or 1b* | AL; QL     |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION RECONSTITUTED                   | 3        | AL; QL     |
| <b>*THIOXANTHENES***</b>  |          |            |
| thiothixene oral capsule 1 mg, 2 mg, 5 mg                                 | 1 or 1b* | ST; DO; AL |
| thiothixene oral capsule 10 mg  | 1 or 1b* | ST; AL; QL |
| <b>*ANTISEPTICS &amp; DISINFECTANTS*</b>                                  |          |            |
| <b>*CHLORINE ANTISEPTICS***</b>   |          |            |
| BENZALKONIUM CHLORIDE EXTERNAL SOLUTION                                   | 3        |            |
| <b>*IODINE ANTISEPTICS***</b>   |          |            |
| LUGOLS STRONG IODINE EXTERNAL SOLUTION                                    | 3        |            |
| <b>*ANTIVIRALS*</b>   |          |            |
| <b>*ANTIRETROVIRAL COMBINATIONS***</b>                                    |          |            |
| abacavir sulfate-lamivudine oral tablet                                   | 1 or 1b* | QL         |
| BIKTARVY ORAL TABLET  | 2        | QL         |
| CABENUVA INTRAMUSCULAR SUSPENSION EXTENDED RELEASE                        | 3        | PA; LD; QL |
| CIMDUO ORAL TABLET  | 3        | QL         |
| DELSTRIGO ORAL TABLET   | 3        | QL         |
| DESCOVY ORAL TABLET 120-15 MG   | 2        | QL         |
| DESCOVY ORAL TABLET 200-25 MG   | 2        | \$0; QL    |
| DOVATO ORAL TABLET  | 2        | QL         |
| efavirenz-emtricitab-tenofovir df oral tablet                             | 1 or 1b* | QL         |
| efavirenz-lamivudine-tenofovir oral tablet                                | 1 or 1b* | QL         |
| emtricitabine-tenofovir df oral tablet 100-150 mg, 133-200 mg, 167-250 mg | 1 or 1b* | QL         |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| emtricitabine-tenofovir df oral tablet 200-300 mg                   | 1 or 1b* | \$0; QL    |
| emtricitab- rilpivir-tenofov df oral tablet                         | 1 or 1b* | PA; QL     |
| <b>EVOTAZ ORAL TABLET</b>   | 3        | QL         |
| <b>GENVOYA ORAL TABLET</b>  | 2        | QL         |
| <b>JULUCA ORAL TABLET</b>   | 3        | PA; QL     |
| lamivudine-zidovudine oral tablet                                   | 1 or 1b* | QL         |
| lopinavir-ritonavir oral tablet                                     | 1 or 1b* | QL         |
| <b>ODEFSEY ORAL TABLET</b>  | 2        | QL         |
| <b>STRIBILD ORAL TABLET</b>   | 2        | QL         |
| <b>SYMTUZA ORAL TABLET</b>  | 2        | QL         |
| <b>TRIUMEQ ORAL TABLET</b>  | 2        | QL         |
| <b>TRIUMEQ PD ORAL TABLET SOLUBLE</b>                               | 2        | QL         |
| <b>*ANTIRETROVIRALS - CAPSID INHIBITORS***</b>                      |          |            |
| <b>SUNLENCA ORAL TABLET</b>   | 3        | PA; LD; QL |
| <b>SUNLENCA ORAL TABLET THERAPY PACK</b>                            | 3        | PA; LD; QL |
| <b>SUNLENCA SUBCUTANEOUS SOLUTION</b>                               | 3        | PA; LD; QL |
| <b>*ANTIRETROVIRALS - CCR5 ANTAGONISTS (ENTRY INHIBITOR)***</b>     |          |            |
| maraviroc oral tablet   | 1 or 1b* | QL         |
| <b>SELZENTRY ORAL SOLUTION</b>                                      | 3        | QL         |
| <b>*ANTIRETROVIRALS - CD4-DIRECTED POST-ATTACHMENT INHIBITOR***</b> |          |            |
| <b>TROGARZO INTRAVENOUS SOLUTION</b>                                | 3        | PA; LD; QL |

| Drug Name  | Tier     | Notes       |
|--|----------|-------------|
| <b>*ANTIRETROVIRALS - GPI20-DIRECTED ATTACHMENT INHIBITOR***</b> |          |             |
| <b>RUKOBIA ORAL TABLET EXTENDED RELEASE 12 HOUR</b>              | 3        | PA; QL      |
| <b>*ANTIRETROVIRALS - INTEGRASE INHIBITORS***</b>                |          |             |
| <b>APRETUDE INTRAMUSCULAR SUSPENSION EXTENDED RELEASE</b>        | 3        | LD; \$0; QL |
| <b>ISENTRESS HD ORAL TABLET</b>                                  | 3        | QL          |
| <b>ISENTRESS ORAL PACKET</b>                                     | 3        | QL          |
| <b>ISENTRESS ORAL TABLET</b>                                     | 3        | QL          |
| <b>ISENTRESS ORAL TABLET CHEWABLE</b>                            | 3        | QL          |
| <b>TIVICAY ORAL TABLET 50 MG</b>                                 | 3        | QL          |
| <b>TIVICAY PD ORAL TABLET SOLUBLE</b>                            | 3        | QL          |
| <b>*ANTIRETROVIRALS - PROTEASE INHIBITORS***</b>                 |          |             |
| <b>APTIVUS ORAL CAPSULE</b>                                      | 2        | PA; QL      |
| atazanavir sulfate oral capsule                                  | 1 or 1b* | QL          |
| darunavir oral tablet  | 1 or 1b* | QL          |
| fosamprenavir calcium oral tablet                                | 1 or 1b* | QL          |
| <b>NORVIR ORAL PACKET</b>  | 3        | QL          |
| <b>PREZISTA ORAL SUSPENSION</b>                                  | 2        | QL          |
| <b>PREZISTA ORAL TABLET 150 MG, 75 MG</b>                        | 2        | QL          |
| <b>REYATAZ ORAL PACKET</b>                                       | 2        | QL          |
| ritonavir oral tablet  | 1 or 1b* | QL          |
| <b>VIRACEPT ORAL TABLET</b>                                      | 2        | QL          |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes   |
|--|----------|---------|
| <b>*ANTIRETROVIRALS - RTI-NON-NUCLEOSIDE ANALOGUES***</b>          |          |         |
| <b>EDURANT ORAL TABLET</b>   | 2        | PA; QL  |
| <b>EDURANT PED ORAL TABLET SOLUBLE</b>                             | 2        | PA; QL  |
| efavirenz oral tablet  | 1 or 1b* | QL      |
| etravirine oral tablet   | 1 or 1b* | PA; QL  |
| <b>INTELENCE ORAL TABLET 25 MG</b>                                 | 2        | PA; QL  |
| nevirapine er oral tablet extended release 24 hour 400 mg          | 1 or 1b* | QL      |
| nevirapine oral suspension   | 1 or 1b* | QL      |
| nevirapine oral tablet   | 1 or 1b* | QL      |
| <b>PIFELTRO ORAL TABLET</b>  | 3        | QL      |
| rilpivirine hcl oral tablet  | 1 or 1b* | PA; QL  |
| <b>*ANTIRETROVIRALS - RTI-NUCLEOSIDE ANALOGUES- PURINES***</b>     |          |         |
| abacavir sulfate oral solution                                     | 1 or 1b* | QL      |
| abacavir sulfate oral tablet                                       | 1 or 1b* | QL      |
| <b>*ANTIRETROVIRALS - RTI-NUCLEOSIDE ANALOGUES- PYRIMIDINES***</b> |          |         |
| emtricitabine oral capsule   | 1 or 1b* | \$0; QL |
| <b>EMTRIVA ORAL SOLUTION</b>                                       | 2        | QL      |
| lamivudine oral solution   | 1 or 1b* | QL      |
| lamivudine oral tablet 150 mg, 300 mg                              | 1 or 1b* | PA; QL  |
| <b>*ANTIRETROVIRALS - RTI-NUCLEOSIDE ANALOGUES- THYMIDINES***</b>  |          |         |
| <b>RETROVIR INTRAVENOUS SOLUTION</b>                               | 2        |         |
| zidovudine oral capsule  | 1 or 1b* | QL      |
| zidovudine oral syrup  | 1 or 1b* | QL      |
| zidovudine oral tablet   | 1 or 1b* | QL      |

| Drug Name  | Tier     | Notes      |
|--|----------|------------|
| <b>*ANTIRETROVIRALS - RTI-NUCLEOTIDE ANALOGUES***</b>            |          |            |
| tenofovir disoproxil fumarate oral tablet                        | 1 or 1b* | \$0; QL    |
| <b>VIREAD ORAL POWDER</b>  | 2        | QL         |
| <b>VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG</b>                 | 2        | QL         |
| <b>*ANTIVIRAL COMBINATIONS***</b>                                |          |            |
| <b>PAXLOVID (150/100) ORAL TABLET THERAPY PACK</b>               | 1 or 1b* | QL         |
| <b>PAXLOVID (300/100 &amp; 150/100) ORAL TABLET THERAPY PACK</b> | 1 or 1b* | QL         |
| <b>PAXLOVID (300/100) ORAL TABLET THERAPY PACK</b>               | 1 or 1b* | QL         |
| <b>*CMV AGENTS***</b>  |          |            |
| cidofovir intravenous solution                                   | 1 or 1b* |            |
| foscarnet sodium intravenous solution 6000 mg/250ml              | 1 or 1b* |            |
| <b>GANCICLOVIR SODIUM INTRAVENOUS SOLUTION</b>                   | 5        | SP         |
| ganciclovir sodium intravenous solution reconstituted            | 4        | SP         |
| <b>LIVTENCITY ORAL TABLET</b>                                    | 5        | PA; LD; QL |
| <b>PREVYMIS INTRAVENOUS SOLUTION</b>                             | 5        | PA; QL; SP |
| <b>PREVYMIS ORAL PACKET</b>                                      | 5        | PA; QL     |
| <b>PREVYMIS ORAL TABLET</b>                                      | 5        | PA; QL     |
| valganciclovir hcl oral solution reconstituted                   | 1 or 1b* |            |
| valganciclovir hcl oral tablet                                   | 1 or 1b* |            |
| <b>*HEPATITIS B AGENTS***</b>                                    |          |            |
| adefovir dipivoxil oral tablet                                   | 4        | PA; QL; SP |
| <b>BARACLUDE ORAL SOLUTION</b>                                   | 5        | PA; QL     |
| entecavir oral tablet  | 4        | PA; QL     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name                                       | Tier     | Notes      |
|---|----------|------------|
| lamivudine oral tablet 100 mg                   | 1 or 1b* | PA; QL     |
| VEMLIDY ORAL TABLET                             | 4        | PA; QL; SP |
| <b>*HEPATITIS C AGENT - COMBINATIONS***</b>     |          |            |
| EPCLUSA ORAL PACKET                             | 4        | PA; QL; SP |
| EPCLUSA ORAL TABLET                             | 4        | PA; QL; SP |
| HARVONI ORAL PACKET                             | 4        | PA; QL; SP |
| HARVONI ORAL TABLET                             | 4        | PA; QL; SP |
| VOSEVI ORAL TABLET                              | 4        | PA; QL; SP |
| <b>*HEPATITIS C AGENTS***</b>                   |          |            |
| PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML        | 4        | LD; QL; SP |
| PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE | 4        | LD; QL; SP |
| ribavirin oral capsule                          | 4        | QL; SP     |
| ribavirin oral tablet 200 mg                    | 4        | QL; SP     |
| <b>*HERPES AGENTS - PURINE ANALOGUES***</b>     |          |            |
| acyclovir oral capsule                          | 1 or 1b* |            |
| acyclovir oral suspension                       | 1 or 1b* |            |
| acyclovir oral tablet                           | 1 or 1b* |            |
| acyclovir sodium intravenous solution           | 1 or 1b* |            |
| valacyclovir hcl oral tablet                    | 1 or 1b* | QL         |
| <b>*HERPES AGENTS - THYMIDINE ANALOGUES***</b>  |          |            |
| famciclovir oral tablet                         | 1 or 1b* | QL         |
| <b>*INFLUENZA AGENTS***</b>                     |          |            |
| rimantadine hcl oral tablet                     | 1 or 1b* |            |
| <b>*MISC. ANTIVIRALS***</b>                     |          |            |
| LAGEVRIO ORAL CAPSULE                           | 3        | QL         |
| TEMBEXA ORAL SUSPENSION                         | 3        |            |

| Drug Name   | Tier     | Notes |
|---|----------|-------|
| TEMBEXA ORAL TABLET   | 3        |       |
| TPOXX INTRAVENOUS SOLUTION  | 3        |       |
| TPOXX ORAL CAPSULE  | 3        |       |
| <b>*NEURAMINIDASE INHIBITORS***</b>                                   |          |       |
| oseltamivir phosphate oral capsule                                    | 1 or 1b* | QL    |
| oseltamivir phosphate oral suspension reconstituted                   | 1 or 1b* | QL    |
| RAPIVAB INTRAVENOUS SOLUTION  | 3        |       |
| RELENZA DISKHALER INHALATION AEROSOL POWDER BREATH ACTIVATED 5 MG/ACT | 2        | QL    |
| <b>*PA ENDONUCLEASE INHIBITORS***</b>                                 |          |       |
| XOFLUZA (40 MG DOSE) ORAL TABLET THERAPY PACK 1 X 40 MG               | 3        | QL    |
| XOFLUZA (80 MG DOSE) ORAL TABLET THERAPY PACK 1 X 80 MG               | 3        | QL    |
| <b>*RSV AGENTS - NUCLEOSIDE ANALOGUES***</b>                          |          |       |
| ribavirin inhalation solution reconstituted                           | 1 or 1b* |       |
| <b>*BETA BLOCKERS*</b>  |          |       |
| <b>*ALPHA-BETA BLOCKERS***</b>  |          |       |
| carvedilol oral tablet  | 1 or 1b* | QL    |
| carvedilol phosphate er oral capsule extended release 24 hour         | 1 or 1b* | QL    |
| labetalol hcl oral tablet   | 1 or 1b* | QL    |
| <b>*BETA BLOCKERS CARDIO-SELECTIVE***</b>                             |          |       |
| acebutolol hcl oral capsule   | 1 or 1b* |       |
| atenolol oral tablet  | 1 or 1a* |       |
| betaxolol hcl oral tablet   | 1 or 1b* |       |
| bisoprolol fumarate oral tablet                                       | 1 or 1b* |       |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes |
|--|----------|-------|
| esmolol hcl intravenous solution 100 mg/10ml                         | 1 or 1b* |       |
| <b>ESMOLOL HCL INTRAVENOUS SOLUTION 2000 MG/100ML, 2500 MG/250ML</b> | 3        |       |
| esmolol hcl-sodium chloride intravenous solution                     | 1 or 1b* |       |
| <b>KAPSPARGO SPRINKLE ORAL CAPSULE ER 24 HOUR SPRINKLE</b>           | 3        |       |
| <b>LOPRESSOR ORAL SOLUTION</b>                                       | 2        |       |
| metoprolol succinate er oral tablet extended release 24 hour         | 1 or 1b* |       |
| metoprolol tartrate intravenous solution 5 mg/5ml                    | 1 or 1a* |       |
| metoprolol tartrate oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg | 1 or 1a* |       |
| metoprolol tartrate oral tablet 12.5 mg                              | 1 or 1b* |       |
| nebivolol hcl oral tablet  | 1 or 1b* |       |
| <b>RAPIBLYK INTRAVENOUS SOLUTION RECONSTITUTED</b>                   | 3        |       |
| <b>*BETA BLOCKERS NON-SELECTIVE***</b>                               |          |       |
| <b>HEMANGEOL ORAL SOLUTION</b>                                       | 3        | LD    |
| <b>INDERAL XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR</b>              | 3        | QL    |
| <b>INNOPRAN XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR</b>             | 3        | QL    |
| nadolol oral tablet 20 mg, 40 mg, 80 mg                              | 1 or 1b* | QL    |
| pindolol oral tablet   | 1 or 1b* | QL    |
| propranolol hcl er oral capsule extended release 24 hour             | 1 or 1b* | QL    |
| propranolol hcl intravenous solution                                 | 1 or 1b* |       |
| propranolol hcl oral solution  | 1 or 1b* | QL    |
| propranolol hcl oral tablet  | 1 or 1b* | QL    |

| Drug Name   | Tier     | Notes |
|---|----------|-------|
| sotalol hcl (af) oral tablet  | 1 or 1b* | QL    |
| <b>SOTALOL HCL INTRAVENOUS SOLUTION</b>   | 3        |       |
| sotalol hcl oral tablet   | 1 or 1b* | QL    |
| <b>SOTYLIZE ORAL SOLUTION</b>   | 3        |       |
| timolol maleate oral tablet   | 1 or 1b* | QL    |
| <b>*CALCIUM CHANNEL BLOCKERS*</b>   |          |       |
| <b>*CALCIUM CHANNEL BLOCKERS***</b>   |          |       |
| amlodipine besylate oral tablet 10 mg, 5 mg   | 1 or 1b* | QL    |
| amlodipine besylate oral tablet 2.5 mg  | 1 or 1b* | DO    |
| cartia xt oral capsule extended release 24 hour 120 mg  | 1 or 1b* | DO    |
| cartia xt oral capsule extended release 24 hour 180 mg, 240 mg, 300 mg                              | 1 or 1b* | QL    |
| <b>CLEVIPREX INTRAVENOUS EMULSION 25 MG/50ML, 50 MG/100ML</b>                                       | 3        |       |
| diltiazem hcl er beads oral capsule extended release 24 hour 120 mg                                 | 1 or 1b* | DO    |
| diltiazem hcl er beads oral capsule extended release 24 hour 180 mg, 240 mg, 300 mg, 360 mg, 420 mg | 1 or 1b* | QL    |
| diltiazem hcl er coated beads oral capsule extended release 24 hour 120 mg                          | 1 or 1b* | DO    |
| diltiazem hcl er coated beads oral capsule extended release 24 hour 180 mg, 240 mg, 300 mg, 360 mg  | 1 or 1b* | QL    |
| diltiazem hcl er oral capsule extended release 12 hour 120 mg, 90 mg                                | 1 or 1b* | QL    |
| diltiazem hcl er oral capsule extended release 12 hour 60 mg  | 1 or 1b* | DO    |
| diltiazem hcl er oral capsule extended release 24 hour 120 mg                                       | 1 or 1b* | DO    |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| diltiazem hcl er oral capsule extended release 24 hour 180 mg, 240 mg                        | 1 or 1b* | QL     |
| diltiazem hcl er oral tablet extended release 24 hour 120 mg                                 | 1 or 1b* | DO     |
| diltiazem hcl er oral tablet extended release 24 hour 180 mg, 240 mg, 300 mg, 360 mg, 420 mg | 1 or 1b* | QL     |
| diltiazem hcl intravenous solution   | 1 or 1b* |        |
| <b>DILTIAZEM HCL INTRAVENOUS SOLUTION RECONSTITUTED</b>                                      | 3        |        |
| diltiazem hcl oral tablet 120 mg, 90 mg  | 1 or 1b* | QL     |
| diltiazem hcl oral tablet 30 mg, 60 mg   | 1 or 1b* | DO     |
| diltiazem hcl-sodium chloride intravenous solution 100-0.72 mg/100ml-%                       | 3        |        |
| dilt-xr oral capsule extended release 24 hour 120 mg   | 1 or 1b* | DO     |
| dilt-xr oral capsule extended release 24 hour 180 mg, 240 mg                                 | 1 or 1b* | QL     |
| felodipine er oral tablet extended release 24 hour 10 mg                                     | 1 or 1b* | QL     |
| felodipine er oral tablet extended release 24 hour 2.5 mg, 5 mg                              | 1 or 1b* | DO     |
| isradipine oral capsule 2.5 mg   | 1 or 1b* | DO     |
| isradipine oral capsule 5 mg   | 1 or 1b* | QL     |
| <b>KATERZIA ORAL SUSPENSION</b>  | 3        | QL     |
| levamlodipine maleate oral tablet 2.5 mg   | 1 or 1b* | ST; DO |
| levamlodipine maleate oral tablet 5 mg   | 1 or 1b* | ST; QL |
| matzim la oral tablet extended release 24 hour   | 1 or 1b* | QL     |
| nicardipine hcl in nacl intravenous solution 20-0.86 mg/200ml-%, 40-0.83 mg/200ml-%          | 1 or 1b* |        |
| nicardipine hcl oral capsule   | 1 or 1b* | QL     |

| Drug Name   | Tier     | Notes |
|---|----------|-------|
| nifedipine er oral tablet extended release 24 hour                                      | 1 or 1b* | QL    |
| nifedipine er osmotic release oral tablet extended release 24 hour 30 mg                | 1 or 1b* | DO    |
| nifedipine er osmotic release oral tablet extended release 24 hour 60 mg, 90 mg         | 1 or 1b* | QL    |
| nifedipine oral capsule 10 mg   | 1 or 1b* | DO    |
| nifedipine oral capsule 20 mg   | 1 or 1b* | QL    |
| nimodipine oral capsule   | 1 or 1b* | QL    |
| nimodipine oral solution  | 1 or 1b* | QL    |
| nisoldipine er oral tablet extended release 24 hour 17 mg, 8.5 mg                       | 1 or 1b* | DO    |
| nisoldipine er oral tablet extended release 24 hour 34 mg                               | 1 or 1b* | QL    |
| <b>NORLIQVA ORAL SOLUTION</b>   | 3        | QL    |
| <b>NYMALIZE ORAL SOLUTION 6 MG/ML</b>   | 3        | QL    |
| tiadylt er oral capsule extended release 24 hour 120 mg                                 | 1 or 1b* | DO    |
| tiadylt er oral capsule extended release 24 hour 180 mg, 240 mg, 300 mg, 360 mg, 420 mg | 1 or 1b* | QL    |
| verapamil hcl er oral capsule extended release 24 hour 120 mg, 180 mg                   | 1 or 1b* | DO    |
| verapamil hcl er oral capsule extended release 24 hour 200 mg, 240 mg, 300 mg, 360 mg   | 1 or 1b* | QL    |
| verapamil hcl er oral tablet extended release 120 mg                                    | 1 or 1b* | DO    |
| verapamil hcl er oral tablet extended release 180 mg, 240 mg                            | 1 or 1b* | QL    |
| verapamil hcl intravenous solution  | 1 or 1b* |       |
| verapamil hcl oral tablet 120 mg  | 1 or 1b* | QL    |
| verapamil hcl oral tablet 40 mg, 80 mg  | 1 or 1b* | DO    |
| <b>*CARDIOTONICS*</b>   |          |       |
| <b>*CARDIAC GLYCOSIDES***</b>   |          |       |
| digoxin injection solution  | 1 or 1b* |       |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| digoxin oral solution  | 1 or 1b* | QL             |
| digoxin oral tablet 125 mcg, 62.5 mcg  | 1 or 1b* | DO             |
| digoxin oral tablet 250 mcg  | 1 or 1b* | QL             |
| <b>LANOXIN PEDIATRIC INJECTION SOLUTION</b>  | 2        |                |
| <b>*INOTROPES***</b>   |          |                |
| dobutamine hcl intravenous solution 12.5 mg/ml   | 1 or 1b* |                |
| <b>DOBUTAMINE-DEXTROSE INTRAVENOUS SOLUTION</b>  | 3        |                |
| <b>DOPAMINE-DEXTROSE INTRAVENOUS SOLUTION</b>  | 3        |                |
| milrinone lactate in dextrose intravenous solution   | 1 or 1b* |                |
| milrinone lactate intravenous solution 10 mg/10ml, 20 mg/20ml, 50 mg/50ml                      | 1 or 1b* |                |
| <b>*CARDIOVASCULAR AGENTS - MISC.*</b>   |          |                |
| <b>*CALCIUM CHANNEL BLOCKER &amp; HMG COA REDUCTASE INHIBIT COMB***</b>                        |          |                |
| amlodipine-atorvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg, 5-80 mg            | 1 or 1b* | QL             |
| amlodipine-atorvastatin oral tablet 2.5-10 mg, 2.5-20 mg, 2.5-40 mg, 5-10 mg, 5-20 mg, 5-40 mg | 1 or 1b* | DO             |
| <b>*CARDIAC MYOSIN INHIBITORS***</b>   |          |                |
| <b>CAMZYOS ORAL CAPSULE</b>  | 5        | PA; LD; QL; SP |
| <b>*NEPRILYSIN INHIB (ARNI)-ANGIOTENSIN II RECEPT ANTAG COMB***</b>                            |          |                |
| <b>ENTRESTO ORAL CAPSULE SPRINKLE</b>  | 2        | QL             |
| sacubitril-valsartan oral tablet   | 1 or 1b* | QL             |

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| <b>*NITRATE &amp; VASODILATOR COMBINATIONS***</b>                    |          |                |
| isosorb dinitrate-hydralazine oral tablet 20-37.5 mg                 | 1 or 1b* | QL             |
| <b>*PDE INHIBITOR-ENDOTHELIN RECEPTOR ANTAGONIST COMBINATIONS***</b> |          |                |
| <b>OPSYNVI ORAL TABLET</b>   | 4        | PA; LD; QL; SP |
| <b>*PROSTAGLANDIN - IMPOTENCE AGENTS***</b>                          |          |                |
| <b>CAVERJECT IMPULSE INTRACAVERNOSAL KIT</b>                         | 3        | PA             |
| <b>CAVERJECT INTRACAVERNOSAL SOLUTION RECONSTITUTED</b>              | 3        | PA             |
| <b>EDEX (2 CARTRIDGE) INTRACAVERNOSAL KIT</b>                        | 3        |                |
| <b>EDEX (6 CARTRIDGE) INTRACAVERNOSAL KIT</b>                        | 3        |                |
| <b>*PROSTAGLANDIN VASODILATORS***</b>                                |          |                |
| alprostadil injection solution                                       | 1 or 1b* |                |
| <b>AURLUMYN INTRAVENOUS SOLUTION</b>                                 | 5        | LD             |
| epoprostenol sodium intravenous solution reconstituted               | 4        | PA; SP         |
| <b>ORENITRAM MONTH 1 ORAL TABLET EXTENDED RELEASE THERAPY PACK</b>   | 5        | PA; LD; SP     |
| <b>ORENITRAM MONTH 2 ORAL TABLET EXTENDED RELEASE THERAPY PACK</b>   | 5        | PA; LD; SP     |
| <b>ORENITRAM MONTH 3 ORAL TABLET EXTENDED RELEASE THERAPY PACK</b>   | 5        | PA; LD; SP     |
| <b>ORENITRAM ORAL TABLET EXTENDED RELEASE</b>                        | 5        | PA; LD; SP     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier | Notes          |
|---|------|----------------|
| REMODULIN INJECTION SOLUTION 100 MG/20ML, 20 MG/20ML, 200 MG/20ML, 50 MG/20ML, 8 MG/20ML                | 5    | PA; LD; SP     |
| treprostinil injection solution   | 4    | PA; LD; SP     |
| TYVASO DPI INSTITUTIONAL KIT INHALATION POWDER 16 MCG, 32 MCG, 48 MCG, 64 MCG                           | 5    | PA; LD; QL; SP |
| TYVASO DPI INSTITUTIONAL KIT INHALATION POWDER 80 MCG   | 5    | PA; QL; SP     |
| TYVASO DPI MAINTENANCE KIT INHALATION POWDER 112 X 32MCG & 112 X64MCG, 112 X 48MCG & 112 X64MCG, 80 MCG | 5    | PA; QL; SP     |
| TYVASO DPI MAINTENANCE KIT INHALATION POWDER 16 MCG, 32 MCG, 48 MCG, 64 MCG                             | 5    | PA; LD; QL; SP |
| TYVASO DPI TITRATION KIT INHALATION POWDER 16 & 32 & 48 MCG   | 5    | PA; LD; QL; SP |
| TYVASO INHALATION SOLUTION  | 5    | PA; LD; QL; SP |
| TYVASO REFILL KIT INHALATION SOLUTION   | 5    | PA; LD; QL; SP |
| TYVASO STARTER KIT INHALATION SOLUTION  | 5    | PA; LD; QL; SP |
| YUTREPIA INHALATION CAPSULE   | 5    | PA; LD; QL; SP |
| <b>*PULM HYPERTEN-SOLUBLE GUANYLATE CYCLASE STIMULATOR (SGC)***</b>                                     |      |                |
| ADEMPAS ORAL TABLET   | 4    | PA; LD; QL; SP |
| <b>*PULMONARY HYPERTENSION - ACTIVIN SIGNALING INHIBITOR***</b>   |      |                |
| WINREVAIR SUBCUTANEOUS KIT  | 5    | PA; LD; QL; SP |

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| <b>*PULMONARY HYPERTENSION - ENDOTHELIN RECEPTOR ANTAGONISTS***</b> |          |                |
| ambrisentan oral tablet   | 4        | PA; QL; SP     |
| bosentan oral tablet  | 4        | PA; LD; QL; SP |
| bosentan oral tablet soluble  | 4        | PA; LD; QL; SP |
| OPSUMIT ORAL TABLET   | 4        | PA; LD; QL; SP |
| <b>*PULMONARY HYPERTENSION - PHOSPHODIESTERASE INHIBITORS***</b>    |          |                |
| alyq oral tablet  | 4        | PA; QL; SP     |
| sildenafil citrate intravenous solution                             | 4        | PA; QL; SP     |
| sildenafil citrate oral suspension reconstituted                    | 4        | PA; QL; SP     |
| sildenafil citrate oral tablet 20 mg                                | 4        | PA; QL; SP     |
| tadalafil (pah) oral tablet   | 4        | PA; QL; SP     |
| TADLIQ ORAL SUSPENSION  | 5        | PA; QL; SP     |
| <b>*PULMONARY HYPERTENSION - PROSTACYCLIN RECEPTOR AGONIST***</b>   |          |                |
| UPTRAVI INTRAVENOUS SOLUTION RECONSTITUTED                          | 5        | PA; LD; QL     |
| UPTRAVI ORAL TABLET   | 5        | PA; LD; QL; SP |
| UPTRAVI TITRATION ORAL TABLET THERAPY PACK                          | 5        | PA; LD; QL; SP |
| <b>*SELECTIVE CGMP PHOSPHODIESTERASE TYPE 5 INHIBITORS***</b>       |          |                |
| sildenafil citrate oral tablet 100 mg, 25 mg, 50 mg                 | 1 or 1b* | PA             |
| tadalafil oral tablet 10 mg, 20 mg                                  | 1 or 1b* | PA             |
| tadalafil oral tablet 2.5 mg, 5 mg                                  | 1 or 1b* | PA; QL         |
| vardefafil hcl oral tablet dispersible                              | 1 or 1b* | PA             |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| <b>*SEPTAL AGENTS - ABLATION**</b>  |          |                |
| dehydrated alcohol intra-arterial solution  | 1 or 1b* |                |
| <b>*SINUS NODE INHIBITORS**</b>   |          |                |
| CORLANOR ORAL SOLUTION  | 3        | PA             |
| ivabradine hcl oral tablet  | 1 or 1b* | PA             |
| <b>*TRANSTHYRETIN STABILIZERS***</b>  |          |                |
| ATTRUBY ORAL TABLET THERAPY PACK  | 5        | PA; LD; QL     |
| VYNDAMAX ORAL CAPSULE   | 5        | PA; LD; QL; SP |
| <b>*VASOACTIVE SOLUBLE GUANYLATE CYCLASE STIMULATOR (SGC)***</b>                  |          |                |
| VERQUVO ORAL TABLET   | 3        | PA; QL         |
| <b>*CEPHALOSPORINS*</b>   |          |                |
| <b>*CEPHALOSPORIN COMBINATIONS***</b>   |          |                |
| AVYCAZ INTRAVENOUS SOLUTION RECONSTITUTED   | 3        |                |
| ZERBAXA INTRAVENOUS SOLUTION RECONSTITUTED  | 3        |                |
| <b>*CEPHALOSPORINS - 1ST GENERATION***</b>  |          |                |
| cefadroxil oral capsule   | 1 or 1b* |                |
| cefadroxil oral suspension reconstituted  | 1 or 1b* |                |
| cefadroxil oral tablet  | 1 or 1b* |                |
| cefazolin sodium injection solution reconstituted 1 gm, 10 gm, 2 gm, 3 gm, 500 mg | 1 or 1b* |                |
| CEFAZOLIN SODIUM INJECTION SOLUTION RECONSTITUTED 100 GM, 300 GM                  | 3        |                |
| cefazolin sodium intravenous solution reconstituted 1 gm                          | 1 or 1b* |                |

| Drug Name   | Tier     | Notes |
|---|----------|-------|
| cefazolin sodium intravenous solution reconstituted 2 gm, 3 gm                                | 3        |       |
| CEFAZOLIN SODIUM-DEXTROSE INTRAVENOUS SOLUTION 1-4 GM/50ML-%, 2-4 GM/100ML-%                  | 3        |       |
| cefazolin sodium-dextrose intravenous solution 3-4 gm/150ml-%                                 | 3        |       |
| CEFAZOLIN SODIUM-DEXTROSE INTRAVENOUS SOLUTION RECONSTITUTED 1-4 GM-%(50ML), 2-3 GM-%(50ML)   | 3        |       |
| cefazolin sodium-dextrose intravenous solution reconstituted 3-2 gm-%(50ml)                   | 3        |       |
| cephalexin oral capsule   | 1 or 1a* |       |
| cephalexin oral suspension reconstituted  | 1 or 1a* |       |
| cephalexin oral tablet  | 1 or 1a* |       |
| <b>*CEPHALOSPORINS - 2ND GENERATION***</b>  |          |       |
| CEFACTOR ER ORAL TABLET EXTENDED RELEASE 12 HOUR  | 3        |       |
| cefaclor oral capsule   | 1 or 1b* |       |
| cefaclor oral suspension reconstituted 250 mg/5ml   | 1 or 1b* |       |
| cefotetan disodium injection solution reconstituted 1 gm, 2 gm                                | 1 or 1b* |       |
| cefoxitin sodium intravenous solution reconstituted   | 1 or 1b* |       |
| CEFOXITIN SODIUM-DEXTROSE INTRAVENOUS SOLUTION RECONSTITUTED 1-4 GM-%(50ML), 2-2.2 GM-%(50ML) | 3        |       |
| cefprozil oral suspension reconstituted   | 1 or 1b* |       |
| cefprozil oral tablet   | 1 or 1b* |       |
| cefuroxime axetil oral tablet   | 1 or 1b* |       |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes |
|--|----------|-------|
| cefuroxime sodium injection solution reconstituted 750 mg  | 1 or 1b* |       |
| cefuroxime sodium intravenous solution reconstituted 1.5 gm  | 1 or 1b* |       |
| <b>*CEPHALOSPORINS - 3RD GENERATION***</b>   |          |       |
| cefdinir oral capsule  | 1 or 1b* |       |
| cefdinir oral suspension reconstituted   | 1 or 1b* |       |
| cefixime oral capsule  | 1 or 1b* |       |
| cefixime oral suspension reconstituted   | 1 or 1b* |       |
| cefixime oral tablet   | 1 or 1b* | PA    |
| cefotaxime sodium injection solution reconstituted 1 gm, 2 gm  | 3        |       |
| cefpodoxime proxetil oral suspension reconstituted   | 1 or 1b* |       |
| cefpodoxime proxetil oral tablet   | 1 or 1b* |       |
| ceftazidime injection solution reconstituted 1 gm, 6 gm  | 1 or 1b* |       |
| ceftazidime intravenous solution reconstituted   | 1 or 1b* |       |
| ceftriaxone sodium in dextrose intravenous solution  | 1 or 1b* |       |
| ceftriaxone sodium injection solution reconstituted 1 gm, 2 gm, 250 mg, 500 mg                             | 1 or 1b* |       |
| <b>CEFTRIAZONE SODIUM INJECTION SOLUTION RECONSTITUTED 100 GM</b>  | 3        |       |
| ceftriaxone sodium intravenous solution reconstituted  | 1 or 1b* |       |
| <b>CEFTRIAZONE SODIUM-DEXTROSE INTRAVENOUS SOLUTION RECONSTITUTED 1-3.74 GM-%(50ML), 2-2.22 GM-%(50ML)</b> | 3        |       |
| tazicef injection solution reconstituted 1 gm  | 1 or 1b* |       |
| <b>TAZICEF INTRAVENOUS SOLUTION</b>  | 3        |       |

| Drug Name  | Tier     | Notes |
|--|----------|-------|
| tazicef intravenous solution reconstituted   | 1 or 1b* |       |
| <b>*CEPHALOSPORINS - 4TH GENERATION***</b>   |          |       |
| cefepime hcl injection solution reconstituted 1 gm   | 1 or 1b* |       |
| <b>CEFEPIME HCL INTRAVENOUS SOLUTION</b>   | 3        |       |
| <b>CEFEPIME HCL INTRAVENOUS SOLUTION RECONSTITUTED 100 GM</b>                              | 3        |       |
| cefepime hcl intravenous solution reconstituted 2 gm                                       | 1 or 1b* |       |
| <b>CEFEPIME-DEXTROSE INTRAVENOUS SOLUTION RECONSTITUTED 1-5 GM-%(50ML), 2-5 GM-%(50ML)</b> | 3        |       |
| <b>*CEPHALOSPORINS - 5TH GENERATION***</b>   |          |       |
| ceftaroline fosamil intravenous solution reconstituted                                     | 1 or 1b* |       |
| <b>ZEVTERA INTRAVENOUS SOLUTION RECONSTITUTED</b>  | 3        |       |
| <b>*CEPHALOSPORINS - SIDEROPHORES***</b>   |          |       |
| <b>FETROJA INTRAVENOUS SOLUTION RECONSTITUTED</b>  | 3        |       |
| <b>*CONTRACEPTIVES*</b>  |          |       |
| <b>*BIPHASIC CONTRACEPTIVES - ORAL***</b>  |          |       |
| azurette oral tablet   | 1 or 1b* | \$0   |
| desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5)                         | 1 or 1b* | \$0   |
| kariva oral tablet   | 1 or 1b* | \$0   |
| <b>LO LOESTRIN FE ORAL TABLET</b>  | 2        |       |
| pimtree oral tablet  | 1 or 1b* | \$0   |
| simliya oral tablet  | 1 or 1b* | \$0   |
| violele oral tablet  | 1 or 1b* | \$0   |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026







| <b>Drug Name</b>  | <b>Tier</b> | <b>Notes</b> |
|---|-------------|--------------|
| jencycla oral tablet  | 1 or 1b*    | \$0          |
| lyleq oral tablet   | 1 or 1b*    | \$0          |
| lyza oral tablet  | 1 or 1b*    | \$0          |
| <b>MELEYA ORAL TABLET</b>   | 1 or 1b*    | \$0          |
| nora-be oral tablet   | 1 or 1b*    | \$0          |
| norethindrone oral tablet   | 1 or 1b*    | \$0          |
| norlyroc oral tablet  | 1 or 1b*    | \$0          |
| <b>OPILL ORAL TABLET</b>  | 2           | \$0          |
| <b>ORQUIDEA ORAL TABLET</b>                                       | 1 or 1b*    | \$0          |
| sharobel oral tablet  | 1 or 1b*    | \$0          |
| <b>SLYND ORAL TABLET</b>  | 3           |              |
| <b>*TRIPHASIC CONTRACEPTIVES - ORAL***</b>                        |             |              |
| alyacen 7/7/7 oral tablet   | 1 or 1a*    | \$0          |
| aranelle oral tablet  | 1 or 1a*    | \$0          |
| dasetta 7/7/7 oral tablet   | 1 or 1a*    | \$0          |
| levonest oral tablet  | 1 or 1a*    | \$0          |
| levonorg-eth estrad triphasic oral tablet 50-30/75-40/ 125-30 mcg | 1 or 1a*    | \$0          |
| norgestim-eth estrad triphasic oral tablet                        | 1 or 1b*    | \$0          |
| nortrel 7/7/7 oral tablet   | 1 or 1a*    | \$0          |
| nylia 7/7/7 oral tablet   | 1 or 1a*    | \$0          |
| tilia fe oral tablet  | 1 or 1b*    | \$0          |
| tri-estarylla oral tablet   | 1 or 1b*    | \$0          |
| tri-legest fe oral tablet   | 1 or 1b*    | \$0          |
| tri-linyah oral tablet  | 1 or 1b*    | \$0          |
| tri-lo-estarylla oral tablet                                      | 1 or 1b*    | \$0          |
| tri-lo-marzia oral tablet   | 1 or 1b*    | \$0          |
| tri-lo-mili oral tablet   | 1 or 1b*    | \$0          |
| tri-lo-sprintec oral tablet                                       | 1 or 1b*    | \$0          |
| tri-mili oral tablet  | 1 or 1b*    | \$0          |
| tri-sprintec oral tablet  | 1 or 1b*    | \$0          |
| tri-vylibra lo oral tablet  | 1 or 1b*    | \$0          |
| tri-vylibra oral tablet   | 1 or 1b*    | \$0          |
| velivet oral tablet   | 1 or 1a*    | \$0          |
| <b>XARAH FE ORAL TABLET</b>                                       | 1 or 1b*    | \$0          |

| <b>Drug Name</b>  | <b>Tier</b> | <b>Notes</b> |
|---|-------------|--------------|
| <b>*CORTICOSTEROIDS*</b>  |             |              |
| <b>*GLUCOCORTICOSTEROIDS***</b>   |             |              |
| <b>ALKINDI SPRINKLE ORAL CAPSULE SPRINKLE</b>   | 3           | PA; LD       |
| budesonide er oral tablet extended release 24 hour                                    | 1 or 1b*    | QL           |
| budesonide oral capsule delayed release particles                                     | 1 or 1b*    | QL           |
| <b>DEPO-MEDROL INJECTION SUSPENSION 20 MG/ML</b>                                      | 3           |              |
| dexameth sod phos (pf) +rfid injection solution prefilled syringe                     | 1 or 1b*    |              |
| <b>DEXAMETHASONE INTENSOL ORAL CONCENTRATE</b>  | 2           |              |
| dexamethasone oral elixir   | 1 or 1a*    |              |
| dexamethasone oral solution   | 1 or 1a*    |              |
| dexamethasone oral tablet   | 1 or 1a*    |              |
| dexamethasone oral tablet therapy pack  | 1 or 1b*    |              |
| <b>DEXAMETHASONE SOD PHOS (PF) INJECTION SOLUTION PREFILLED SYRINGE</b>               | 1 or 1b*    |              |
| dexamethasone sod phos +rfid injection solution prefilled syringe                     | 1 or 1b*    |              |
| <b>DEXAMETHASONE SOD PHOSPHATE PF INJECTION SOLUTION</b>                              | 1 or 1b*    |              |
| dexamethasone sodium phosphate injection solution 100 mg/10ml, 120 mg/30ml, 20 mg/5ml | 1 or 1b*    |              |
| <b>HEMADY ORAL TABLET</b>   | 3           | PA; QL       |
| <b>HEXATRIONE INTRA-ARTICULAR SUSPENSION</b>  | 3           |              |
| hidex 6-day oral tablet therapy pack  | 1 or 1b*    |              |
| hydrocortisone oral tablet  | 1 or 1b*    |              |
| hydrocortisone sod suc (pf) injection solution reconstituted                          | 1 or 1b*    |              |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes      |
|--|----------|------------|
| <b>KENALOG-80 INJECTION SUSPENSION</b>   | 3        |            |
| <b>MEDROL ORAL TABLET 2 MG</b>   | 2        |            |
| methylprednisolone oral tablet   | 1 or 1a* |            |
| methylprednisolone oral tablet therapy pack  | 1 or 1a* |            |
| methylprednisolone sodium succ injection solution reconstituted 1000 mg, 125 mg, 40 mg, 500 mg   | 1 or 1b* |            |
| <b>ORAPRED ODT ORAL TABLET DISPERSIBLE</b>   | 3        | QL         |
| prednisolone oral solution   | 1 or 1a* |            |
| prednisolone oral tablet   | 1 or 1b* |            |
| prednisolone sodium phosphate oral solution 10 mg/5ml, 15 mg/5ml, 20 mg/5ml, 25 mg/5ml, 5 mg/5ml | 1 or 1a* |            |
| prednisolone sodium phosphate oral tablet dispersible  | 3        |            |
| <b>PREDNISONE INTENSOL ORAL CONCENTRATE</b>  | 3        |            |
| prednisone oral solution   | 1 or 1a* |            |
| prednisone oral tablet   | 1 or 1a* |            |
| prednisone oral tablet therapy pack  | 1 or 1a* |            |
| <b>SOLU-CORTEF INJECTION SOLUTION RECONSTITUTED 1000 MG, 250 MG, 500 MG</b>                      | 3        |            |
| <b>SOLU-MEDROL (PF) INJECTION SOLUTION RECONSTITUTED</b>   | 3        |            |
| <b>SOLU-MEDROL INJECTION SOLUTION RECONSTITUTED 2 GM</b>   | 3        |            |
| taperdex 12-day oral tablet therapy pack   | 1 or 1b* |            |
| taperdex 6-day oral tablet therapy pack  | 1 or 1b* |            |
| taperdex 7-day oral tablet therapy pack 1.5 mg (27)  | 1 or 1b* |            |
| <b>TARPEYO ORAL CAPSULE DELAYED RELEASE</b>  | 5        | PA; LD; QL |

| Drug Name  | Tier     | Notes      |
|--|----------|------------|
| triamcinolone acetonide injection suspension 10 mg/ml          | 1 or 1b* |            |
| <b>ZILRETTA INTRA-ARTICULAR SUSPENSION RECONSTITUTED ER</b>    | 5        | PA; LD; QL |
| <b>*MINERALOCORTICOIDSD***</b>                                 |          |            |
| fludrocortisone acetate oral tablet                            | 1 or 1b* |            |
| <b>*COUGH/COLD/ALLERGY*</b>                                    |          |            |
| <b>*ANTITUSSIVE - NONNARCOTIC***</b>                           |          |            |
| benzonatate oral capsule 100 mg, 200 mg                        | 1 or 1b* |            |
| <b>*ANTITUSSIVE - OPIOID***</b>                                |          |            |
| hydrocodone bit-homatrop mbr oral solution                     | 1 or 1a* | AL; QL     |
| hydrocodone bit-homatrop mbr oral tablet                       | 1 or 1a* | QL         |
| hydromet oral solution   | 1 or 1a* | AL; QL     |
| <b>*ANTITUSSIVE-EXPECTORANT***</b>                             |          |            |
| <b>CODITUSSIN AC ORAL LIQUID</b>                               | 3        | AL         |
| g tussin ac oral solution                                      | 1 or 1a* | AL; QL     |
| guaifenesin-codeine oral solution                              | 1 or 1a* | AL; QL     |
| <b>MAR-COF CG EXPECTORANT ORAL LIQUID</b>                      | 2        | AL         |
| maxi-tuss ac oral solution                                     | 1 or 1a* | AL; QL     |
| <b>NINJACOF-XG ORAL LIQUID</b>                                 | 3        | AL         |
| <b>*ANTITUSSIVE-EXPECTORANTS-DECONGESTANT***</b>               |          |            |
| <b>CODITUSSIN DAC ORAL LIQUID</b>                              | 3        | AL         |
| <b>*DECONGESTANT &amp; ANTIHISTAMINE***</b>                    |          |            |
| <b>CLARINEX-D 12 HOUR ORAL TABLET EXTENDED RELEASE 12 HOUR</b> | 3        | ST; QL     |
| promethazine-phenylephrine oral syrup                          | 1 or 1b* | QL         |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summaryfor more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| <b>*MISC. RESPIRATORY INHALANTS***</b>                                 |          |        |
| <b>NEBUSAL INHALATION NEBULIZATION SOLUTION 3 %</b>                    | 1 or 1b* |        |
| sodium chloride inhalation nebulization solution 0.9 %, 10 %, 3 %, 7 % | 1 or 1b* |        |
| <b>*MUCOLYTICS***</b>  |          |        |
| acetylcysteine inhalation solution                                     | 1 or 1b* |        |
| <b>*NON-NARC ANTITUSSIVE-ANTI-HISTAMINE***</b>                         |          |        |
| promethazine-dm oral syrup 6.25-15 mg/5ml                              | 1 or 1a* | QL     |
| <b>*NON-NARC ANTITUSSIVE-DECONGESTANT-ANTI-HISTAMINE***</b>            |          |        |
| pseudoeph-bromphen-dm oral syrup 30-2-10 mg/5ml                        | 1 or 1b* |        |
| <b>*OPIOID ANTITUSSIVE-ANTI-HISTAMINE***</b>                           |          |        |
| duratuss ac oral liquid  | 3        |        |
| hydrocod poli-chlorphe poli er oral suspension extended release        | 1 or 1b* | AL; QL |
| promethazine-codeine oral solution                                     | 1 or 1a* | AL; QL |
| promethazine-codeine oral syrup  | 1 or 1a* | AL; QL |
| <b>TUXARIN ER ORAL TABLET EXTENDED RELEASE 12 HOUR</b>                 | 3        | AL; QL |
| <b>*OPIOID ANTITUSSIVE-DECONGESTANT-ANTI-HISTAMINE***</b>              |          |        |
| <b>MAXI-TUSS CD ORAL LIQUID</b>  | 2        | AL; QL |
| <b>PRO-RED AC ORAL SYRUP 5-1-9 MG/5ML</b>                              | 3        | PA     |
| <b>RYDEX ORAL LIQUID</b>   | 2        | AL; QL |
| <b>*DERMATOLOGICALS*</b>   |          |        |
| <b>*ACNE ANTIBIOTICS***</b>  |          |        |
| clindacin etz external swab  | 1 or 1b* | QL     |
| <b>CLINDACIN EXTERNAL FOAM</b>   | 1 or 1b* | QL     |
| clindacin-p external swab  | 1 or 1b* | QL     |

| Drug Name   | Tier     | Notes  |
|---|----------|--------|
| clindamycin phos (once-daily) external gel  | 1 or 1b* | QL     |
| clindamycin phos (twice-daily) external gel                                       | 1 or 1b* | QL     |
| clindamycin phosphate external foam   | 1 or 1b* | QL     |
| clindamycin phosphate external lotion   | 1 or 1b* | QL     |
| clindamycin phosphate external solution   | 1 or 1b* | QL     |
| clindamycin phosphate external swab   | 1 or 1b* | QL     |
| dapsone external gel  | 3        | ST; QL |
| ery external pad  | 1 or 1b* | QL     |
| erythromycin external gel   | 1 or 1b* | QL     |
| erythromycin external solution  | 1 or 1b* | QL     |
| sulfacetamide sodium (acne) external lotion                                       | 1 or 1b* |        |
| <b>*ACNE COMBINATIONS***</b>  |          |        |
| adapalene-benzoyl peroxide external gel   | 1 or 1b* | PA; QL |
| benzoyl peroxide-erythromycin external gel  | 1 or 1b* | QL     |
| clindamycin phos-benzoyl perox external gel 1-5 %, 1.2-2.5 %, 1.2-3.75 %, 1.2-5 % | 1 or 1b* | QL     |
| clindamycin-tretinoin external gel  | 3        | PA; QL |
| neuac external gel  | 1 or 1b* | QL     |
| <b>*ACNE PRODUCTS***</b>  |          |        |
| <b>ABSORICA LD ORAL CAPSULE</b>   | 3        | PA     |
| <b>ABSORICA ORAL CAPSULE</b>  | 3        | PA     |
| accutane oral capsule   | 2        | PA     |
| adapalene external cream  | 1 or 1b* | PA; QL |
| adapalene external gel  | 1 or 1b* | PA; QL |
| adapalene external pad  | 1 or 1b* | PA; QL |
| amnestem oral capsule 10 mg, 20 mg, 40 mg   | 2        | PA     |
| <b>AMNESTEM ORAL CAPSULE 30 MG</b>  | 2        | PA     |
| claravis oral capsule   | 2        | PA     |
| isotretinoin oral capsule   | 2        | PA     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes  |
|---|----------|--------|
| <b>RETIN-A MICRO PUMP EXTERNAL GEL 0.06 %</b>             | 3        | PA; QL |
| tretinoin external cream                                  | 1 or 1b* | PA; QL |
| tretinoin external gel                                    | 1 or 1b* | PA; QL |
| tretinoin microsphere external gel                        | 1 or 1b* | ST; QL |
| tretinoin microsphere pump external gel                   | 1 or 1b* | ST; QL |
| <b>WINLEVI EXTERNAL CREAM</b>                             | 2        | PA; QL |
| zenatane oral capsule                                     | 2        | PA     |
| <b>*AGENTS FOR EXTERNAL GENITAL AND PERIANAL WARTS***</b> |          |        |
| <b>VEREGEN EXTERNAL OINTMENT</b>                          | 3        | ST; QL |
| <b>*AGENTS FOR FACIAL WRINKLES - RETINOIDS***</b>         |          |        |
| <b>RENOVA EXTERNAL CREAM</b>                              | 3        | PA; QL |
| <b>RENOVA PUMP EXTERNAL CREAM</b>                         | 3        | PA; QL |
| <b>*ANTIBIOTIC STEROID COMBINATIONS - TOPICAL***</b>      |          |        |
| <b>NEO-SYNALAR EXTERNAL CREAM</b>                         | 3        |        |
| <b>*ANTIBIOTICS - TOPICAL***</b>                          |          |        |
| gentamicin sulfate external cream                         | 1 or 1b* | QL     |
| gentamicin sulfate external ointment                      | 1 or 1b* | QL     |
| mupirocin external ointment                               | 1 or 1b* | QL     |
| <b>*ANTIFUNGALS - TOPICAL COMBINATIONS***</b>             |          |        |
| clotrimazole-betamethasone external cream                 | 1 or 1b* | QL     |
| clotrimazole-betamethasone external lotion                | 1 or 1b* | QL     |
| <b>MICONATATE EXTERNAL THERAPY PACK</b>                   | 3        |        |
| miconazole-zinc oxide-petrolat external ointment          | 1 or 1b* | QL     |

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| nystatin-triamcinolone external cream                               | 1 or 1b* | QL         |
| nystatin-triamcinolone external ointment                            | 1 or 1b* | QL         |
| <b>*ANTIFUNGALS - TOPICAL***</b>                                    |          |            |
| cicloclan external solution   | 1 or 1b* | QL         |
| ciclopirox external gel   | 1 or 1b* | QL         |
| ciclopirox external shampoo   | 1 or 1b* | QL         |
| ciclopirox external solution  | 1 or 1b* | QL         |
| ciclopirox olamine external cream                                   | 1 or 1b* | QL         |
| ciclopirox olamine external suspension                              | 1 or 1b* | QL         |
| <b>KLAYESTA EXTERNAL POWDER</b>                                     | 1 or 1b* | QL         |
| naftifine hcl external cream  | 1 or 1b* | ST; QL     |
| naftifine hcl external gel 2 %                                      | 1 or 1b* | ST; QL     |
| nyamyc external powder  | 1 or 1b* | QL         |
| nystatin external cream   | 1 or 1b* | QL         |
| nystatin external ointment  | 1 or 1b* | QL         |
| nystatin external powder  | 1 or 1b* | QL         |
| nystop external powder  | 1 or 1b* | QL         |
| <b>*ANTI-INFLAMMATORY AGENTS - TOPICAL***</b>                       |          |            |
| diclofenac sodium external gel 1 %                                  | 1 or 1b* | BE; QL     |
| <b>*ANTINEOPLASTIC ALKYLATING AGENTS - TOPICAL***</b>               |          |            |
| <b>VALCHLOR EXTERNAL GEL</b>  | 3        | PA; LD; QL |
| <b>*ANTINEOPLASTIC ANTIMETABOLITES - TOPICAL***</b>                 |          |            |
| fluorouracil external cream   | 1 or 1b* | AL; QL     |
| fluorouracil external solution                                      | 1 or 1b* | AL; QL     |
| <b>TOLAK EXTERNAL CREAM</b>   | 3        | ST; QL     |
| <b>*ANTINEOPLASTIC OR PREMALIGNANT LESIONS - TOPICAL NSAID'S***</b> |          |            |
| diclofenac sodium external gel 3 %                                  | 1 or 1b* | PA; QL     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| <b>*ANTINEOPLASTIC RETINOIDS - TOPICAL***</b>                         |          |                |
| PANRETIN EXTERNAL GEL   | 3        | SP             |
| <b>*ANTIPRURITICS - TOPICAL***</b>                                    |          |                |
| doxepin hcl external cream  | 1 or 1b* | PA; QL         |
| <b>*ANTIPSORIATICS - SYSTEMIC***</b>                                  |          |                |
| acitretin oral capsule  | 1 or 1b* | QL             |
| COSENTYX (300 MG DOSE) SUBCUTANEOUS SOLUTION PREFILLED SYRINGE        | 4        | PA; LD; QL; SP |
| COSENTYX SENSOREADY (300 MG) SUBCUTANEOUS SOLUTION AUTO-INJECTOR      | 4        | PA; LD; QL; SP |
| COSENTYX SENSOREADY PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML | 4        | PA; LD; QL; SP |
| COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE                      | 4        | PA; LD; QL; SP |
| COSENTYX UNOREADY SUBCUTANEOUS SOLUTION AUTO-INJECTOR                 | 4        | PA; LD; QL; SP |
| methoxsalen rapid oral capsule  | 1 or 1b* | SP             |
| SELARSDI SUBCUTANEOUS SOLUTION  | 4        | PA; QL; SP     |
| SELARSDI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE                      | 4        | PA; QL; SP     |
| SKYRIZI PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR                       | 4        | PA; QL; SP     |
| SKYRIZI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE                       | 4        | PA; QL; SP     |

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| SPEVIGO INTRAVENOUS SOLUTION                              | 5        | PA; LD; QL |
| SPEVIGO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE           | 5        | PA; LD; QL |
| STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML                 | 4        | PA; QL; SP |
| STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE           | 4        | PA; QL; SP |
| TREMFYA ONE-PRESS SUBCUTANEOUS SOLUTION PEN-INJECTOR      | 4        | PA; QL; SP |
| TREMFYA PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100 MG/ML | 4        | PA; QL; SP |
| TREMFYA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML | 4        | PA; QL; SP |
| <b>*ANTIPSORIATICS***</b>                                 |          |            |
| calcipotriene external cream                              | 1 or 1b* | QL         |
| calcipotriene external foam                               | 1 or 1b* | ST; QL     |
| calcipotriene external ointment                           | 1 or 1b* | QL         |
| calcipotriene external solution                           | 1 or 1b* | QL         |
| calcitrene external ointment                              | 1 or 1b* | QL         |
| calcitriol external ointment                              | 1 or 1b* | QL         |
| tazarotene external cream                                 | 1 or 1b* | QL         |
| tazarotene external gel                                   | 1 or 1b* | ST; QL     |
| VTAMA EXTERNAL CREAM                                      | 2        | QL         |
| <b>*ANTISEBORRHEIC PRODUCTS***</b>                        |          |            |
| selenium sulfide external lotion                          | 1 or 1a* | QL         |
| <b>*ANTIVIRAL TOPICAL COMBINATIONS***</b>                 |          |            |
| XERESE EXTERNAL CREAM                                     | 3        | PA; QL     |
| <b>*ANTIVIRALS - TOPICAL***</b>                           |          |            |
| acyclovir external cream                                  | 1 or 1b* | PA; QL     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| acyclovir external ointment   | 1 or 1b* | QL             |
| penciclovir external cream  | 1 or 1b* | PA; QL         |
| <b>ZELSUVMI EXTERNAL GEL</b>  | 3        | PA; QL         |
| <b>*ATOPIC DERMATITIS - JANUS KINASE (JAK) INHIBITORS***</b>                      |          |                |
| <b>OPZELURA EXTERNAL CREAM</b>  | 2        | QL             |
| <b>*ATOPIC DERMATITIS - MONOCLONAL ANTIBODIES***</b>                              |          |                |
| <b>DUPIXENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR</b>                               | 4        | PA; SP         |
| <b>DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/1.14ML, 300 MG/2ML</b> | 4        | PA; SP         |
| <b>EBGLYSS SUBCUTANEOUS SOLUTION AUTO-INJECTOR</b>                                | 4        | PA; LD; QL; SP |
| <b>EBGLYSS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE</b>                            | 4        | PA; LD; QL; SP |
| <b>*BURN PRODUCTS***</b>  |          |                |
| silver sulfadiazine external cream  | 1 or 1a* |                |
| ssd external cream  | 1 or 1a* |                |
| <b>SULFAMYLON EXTERNAL CREAM</b>  | 3        |                |
| <b>*CORTICOSTEROIDS - TOPICAL***</b>  |          |                |
| ala-cort external cream 1 %   | 1 or 1a* | QL             |
| alclometasone dipropionate external cream   | 1 or 1b* | QL             |
| alclometasone dipropionate external ointment                                      | 1 or 1b* | QL             |
| amcinonide external cream   | 3        | QL             |
| betamethasone dipropionate aug external cream                                     | 1 or 1b* | QL             |
| betamethasone dipropionate aug external gel                                       | 1 or 1b* | QL             |
| betamethasone dipropionate aug external lotion                                    | 1 or 1b* | QL             |

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| betamethasone dipropionate aug external ointment | 1 or 1b* | QL     |
| betamethasone dipropionate external cream        | 1 or 1b* | QL     |
| betamethasone dipropionate external lotion       | 1 or 1b* | QL     |
| betamethasone dipropionate external ointment     | 1 or 1b* | QL     |
| betamethasone valerate external cream            | 1 or 1b* | QL     |
| betamethasone valerate external foam             | 3        | ST; QL |
| betamethasone valerate external lotion           | 1 or 1b* | QL     |
| betamethasone valerate external ointment         | 1 or 1b* | QL     |
| clobetasol prop emollient base external cream    | 1 or 1b* |        |
| clobetasol propionate e external cream           | 1 or 1b* | QL     |
| clobetasol propionate emulsion external foam     | 1 or 1b* | QL     |
| clobetasol propionate external cream 0.05 %      | 1 or 1b* | QL     |
| clobetasol propionate external foam              | 1 or 1b* | QL     |
| clobetasol propionate external gel               | 1 or 1b* | QL     |
| clobetasol propionate external liquid            | 1 or 1b* | QL     |
| clobetasol propionate external lotion            | 1 or 1b* | QL     |
| clobetasol propionate external ointment          | 1 or 1b* | QL     |
| clobetasol propionate external shampoo           | 1 or 1b* | QL     |
| clobetasol propionate external solution          | 1 or 1b* | QL     |
| clorcortolone pivalate external cream            | 3        | ST; QL |
| clodan external shampoo                          | 1 or 1b* | QL     |
| desonide external cream                          | 1 or 1b* | QL     |
| desonide external gel                            | 1 or 1b* | QL     |
| desonide external lotion                         | 1 or 1b* | QL     |
| desonide external ointment                       | 1 or 1b* | QL     |
| desoximetasone external cream                    | 3        | ST; QL |
| desoximetasone external gel                      | 3        | ST; QL |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name                                   | Tier     | Notes  |
|---|----------|--------|
| desoximetasone external liquid              | 3        | ST; QL |
| desoximetasone external ointment            | 3        | ST; QL |
| diflorasone diacetate external cream        | 3        | ST; QL |
| diflorasone diacetate external ointment     | 3        | ST; QL |
| fluocinolone acetonide body external oil    | 1 or 1b* | QL     |
| fluocinolone acetonide external cream       | 1 or 1b* | QL     |
| fluocinolone acetonide external ointment    | 1 or 1b* | QL     |
| fluocinolone acetonide external solution    | 1 or 1b* | QL     |
| fluocinolone acetonide scalp external oil   | 1 or 1b* | QL     |
| fluocinonide emulsified base external cream | 1 or 1b* | QL     |
| fluocinonide external cream                 | 1 or 1b* | QL     |
| fluocinonide external gel                   | 1 or 1b* | QL     |
| fluocinonide external ointment              | 1 or 1b* | QL     |
| fluocinonide external solution              | 1 or 1b* | QL     |
| flurandrenolide external lotion             | 3        | ST; QL |
| fluticasone propionate external cream       | 1 or 1b* | QL     |
| fluticasone propionate external lotion      | 1 or 1b* | QL     |
| fluticasone propionate external ointment    | 1 or 1b* | QL     |
| halcinonide external cream                  | 3        | ST; QL |
| halobetasol propionate external cream       | 1 or 1b* | QL     |
| halobetasol propionate external ointment    | 1 or 1b* | QL     |
| hydrocortisone butyrate external cream      | 3        | ST; QL |
| hydrocortisone butyrate external lotion     | 3        | ST; QL |
| hydrocortisone butyrate external ointment   | 3        | ST; QL |
| hydrocortisone butyrate external solution   | 3        | ST; QL |
| hydrocortisone external cream 2.5 %         | 1 or 1a* | QL     |

| Drug Name   | Tier     | Notes  |
|---|----------|--------|
| hydrocortisone external lotion 2.5 %                            | 1 or 1a* | QL     |
| hydrocortisone external ointment 2.5 %                          | 1 or 1a* | QL     |
| hydrocortisone valerate external cream                          | 3        | ST; QL |
| hydrocortisone valerate external ointment                       | 3        | ST; QL |
| mometasone furoate external cream                               | 1 or 1b* | QL     |
| mometasone furoate external ointment                            | 1 or 1b* | QL     |
| mometasone furoate external solution                            | 1 or 1b* | QL     |
| tovet external foam   | 1 or 1b* | QL     |
| triamcinolone acetonide external aerosol solution               | 3        | ST; QL |
| triamcinolone acetonide external cream                          | 1 or 1a* | QL     |
| triamcinolone acetonide external lotion                         | 1 or 1a* | QL     |
| triamcinolone acetonide external ointment 0.025 %, 0.1 %, 0.5 % | 1 or 1a* | QL     |
| triamcinolone acetonide external ointment 0.05 %                | 3        | ST; QL |
| triamcinolone in absorbbase external ointment                   | 3        | ST; QL |
| triderm external cream 0.5 %                                    | 1 or 1a* | QL     |
| <b>*DEPIGMENTING COMBINATIONS***</b>                            |          |        |
| <b>TRI-LUMA EXTERNAL CREAM</b>                                  | 3        |        |
| <b>*EMOLLIENT/KERATOLYTIC AGENTS***</b>                         |          |        |
| <b>DERMACINRX URACIN EXTERNAL CREAM</b>                         | 3        |        |
| <b>*ENZYMES - TOPICAL***</b>                                    |          |        |
| <b>NEXOBRID EXTERNAL GEL</b>                                    | 3        | PA; QL |
| <b>SANTYL EXTERNAL OINTMENT</b>                                 | 3        | PA; QL |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes  |
|---|----------|--------|
| <b>*GLABELLAR LINES (FROWN LINES) AGENTS***</b>             |          |        |
| <b>BOTOX COSMETIC INTRAMUSCULAR SOLUTION RECONSTITUTED</b>  | 5        | PA     |
| <b>JEUVEAU INTRAMUSCULAR SOLUTION RECONSTITUTED</b>         | 3        |        |
| <b>*IMIDAZOLE-RELATED ANTIFUNGALS - TOPICAL***</b>          |          |        |
| clotrimazole external cream                                 | 1 or 1b* | QL     |
| econazole nitrate external cream                            | 1 or 1b* | QL     |
| econazole nitrate external foam                             | 3        | ST; QL |
| <b>ECOZA EXTERNAL FOAM</b>                                  | 3        | ST; QL |
| <b>ERTACZO EXTERNAL CREAM</b>                               | 3        | ST; QL |
| <b>JUBLIA EXTERNAL SOLUTION</b>                             | 3        | QL     |
| ketoconazole external cream                                 | 1 or 1b* | QL     |
| ketoconazole external foam                                  | 3        | QL     |
| ketoconazole external shampoo 2 %                           | 1 or 1b* | QL     |
| ketodan external foam                                       | 3        | QL     |
| luliconazole external cream                                 | 1 or 1b* | ST; QL |
| oxiconazole nitrate external cream                          | 3        | ST; QL |
| <b>OXISTAT EXTERNAL LOTION</b>                              | 3        | ST; QL |
| sulconazole nitrate external cream                          | 1 or 1b* | ST; QL |
| sulconazole nitrate external solution                       | 1 or 1b* | ST; QL |
| <b>*IMMUNOMODULATORS IMIDAZOQUINOLINAMINES - TOPICAL***</b> |          |        |
| imiquimod external cream                                    | 1 or 1b* | QL     |
| imiquimod pump external cream                               | 1 or 1b* | ST; QL |

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| <b>*KERATOLYTIC/ANTIMITOTIC/VESICANT AGENTS***</b>        |          |            |
| <b>DERMACINRX SALICYLIC ACID EXTERNAL GEL</b>             | 3        |            |
| podofilox external gel                                    | 1 or 1b* | QL         |
| podofilox external solution                               | 1 or 1b* | QL         |
| <b>YCANTH EXTERNAL SOLUTION</b>                           | 3        | PA; LD; QL |
| <b>*LINIMENTS***</b>                                      |          |            |
| <b>TURPENTINE EXTERNAL SPIRIT</b>                         | 3        |            |
| <b>*LOCAL ANESTHETICS - TOPICAL***</b>                    |          |            |
| dyclopro external solution                                | 3        |            |
| glydo external prefilled syringe                          | 1 or 1b* |            |
| lidocaine external ointment 5 %                           | 1 or 1b* | QL         |
| lidocaine external patch 5 %                              | 1 or 1b* | PA; QL     |
| lidocaine hcl external solution                           | 1 or 1b* | QL         |
| lidocaine hcl urethral/mucosal external gel               | 1 or 1b* |            |
| lidocaine hcl urethral/mucosal external prefilled syringe | 1 or 1b* |            |
| <b>TRIDACAINE II EXTERNAL PATCH</b>                       | 1 or 1b* | PA; QL     |
| <b>TRIDACAINE III EXTERNAL PATCH</b>                      | 1 or 1b* | PA; QL     |
| <b>ZTLIDO EXTERNAL PATCH</b>                              | 2        | PA; QL     |
| <b>*MACROLIDE IMMUNOSUPPRESSANTS - TOPICAL***</b>         |          |            |
| <b>HYFTOR EXTERNAL GEL</b>                                | 3        | PA; LD; QL |
| pimecrolimus external cream                               | 1 or 1b* | ST; QL     |
| tacrolimus external ointment                              | 1 or 1b* | ST; QL     |
| <b>*MELANOCORTIN RECEPTOR AGONISTS (UV PROTECTIVE)***</b> |          |            |
| <b>SCENESSE SUBCUTANEOUS IMPLANT</b>                      | 3        | PA; LD; QL |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| <b>*MICROTUBULE INHIBITORS - TOPICAL***</b>                |          |        |
| KLISYRI (250 MG) EXTERNAL OINTMENT                         | 3        | ST; QL |
| KLISYRI (350 MG) EXTERNAL OINTMENT                         | 3        | ST; QL |
| <b>*MISC. DERMATOLOGICAL PRODUCTS***</b>                   |          |        |
| ILIDERM EXTERNAL EMULSION                                  | 3        |        |
| <b>*MISC. TOPICAL***</b>                                   |          |        |
| QBREXZA EXTERNAL PAD                                       | 3        | PA; QL |
| <b>*OXABOROLE-RELATED ANTIFUNGALS - TOPICAL***</b>         |          |        |
| tavorole external solution                                 | 1 or 1b* | ST; QL |
| <b>*PHOSPHODIESTERASE 4 (PDE4) INHIBITORS - TOPICAL***</b> |          |        |
| EUCRISA EXTERNAL OINTMENT                                  | 2        | QL     |
| <b>*PHOTODYNAMIC THERAPY AGENTS - TOPICAL***</b>           |          |        |
| AMELUZ EXTERNAL GEL  | 3        |        |
| LEVULAN KERASTICK EXTERNAL SOLUTION RECONSTITUTED          | 3        |        |
| <b>*PROSTAGLANDINS - TOPICAL***</b>                        |          |        |
| bimatoprost external solution                              | 1 or 1b* |        |
| <b>*ROSACEA AGENTS***</b>                                  |          |        |
| azelaic acid external gel                                  | 1 or 1b* | QL     |
| brimonidine tartrate external gel                          | 1 or 1b* | QL     |
| FINACEA EXTERNAL FOAM                                      | 2        | QL     |
| ivermectin external cream                                  | 1 or 1b* | QL     |
| metronidazole external cream                               | 1 or 1b* | QL     |
| metronidazole external gel                                 | 1 or 1b* | QL     |
| metronidazole external lotion                              | 1 or 1b* | QL     |
| MIRVASO EXTERNAL GEL                                       | 3        | QL     |

| Drug Name  | Tier     | Notes |
|--|----------|-------|
| ZILXI EXTERNAL FOAM                              | 2        | QL    |
| <b>*SCABICIDES &amp; PEDICULICIDES***</b>        |          |       |
| croton external lotion                           | 1 or 1b* | QL    |
| malathion external lotion                        | 1 or 1b* | QL    |
| PRURADIK EXTERNAL LOTION                         | 1 or 1b* | QL    |
| spinosad external suspension                     | 1 or 1b* | QL    |
| <b>*SCAR TREATMENT PRODUCTS***</b>               |          |       |
| COPASIL EXTERNAL GEL                             | 3        |       |
| <b>*SEBORRHEIC KERATOSIS PRODUCTS**</b>          |          |       |
| ESKATA EXTERNAL SOLUTION                         | 3        |       |
| <b>*STEROID-LOCAL ANESTHETIC COMBINATIONS***</b> |          |       |
| EPIFOAM EXTERNAL FOAM                            | 3        |       |
| PRAMOSONE EXTERNAL CREAM 1-1 %                   | 2        |       |
| PRAMOSONE EXTERNAL LOTION                        | 2        |       |
| <b>*TAR PRODUCTS***</b>                          |          |       |
| coal tar external solution                       | 3        |       |
| <b>*TISSUE REPLACEMENTS***</b>                   |          |       |
| AMNIOTEXT EXTERNAL SHEET                         | 3        |       |
| AMPHENOL-40 INJECTION SUSPENSION RECONSTITUTED   | 3        |       |
| CYGNUS DUAL EXTERNAL SHEET                       | 3        |       |
| KARDIAMEMBRANE EXTERNAL SHEET                    | 3        |       |
| NEOX 100 EXTERNAL SHEET                          | 3        |       |
| NEOX CORD 1K EXTERNAL SHEET                      | 3        |       |
| PALINGEN FLOW INJECTION LIQUID                   | 3        |       |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| PALINGEN HYDROMEMBRANE EXTERNAL SHEET                     | 3        |            |
| PALINGEN INOVOFLO INJECTION LIQUID                        | 3        |            |
| PALINGEN MEMBRANE EXTERNAL SHEET                          | 3        |            |
| PALINGEN XPLUS HYDROMEMBRANE EXTERNAL SHEET               | 3        |            |
| PALINGEN XPLUS MEMBRANE EXTERNAL SHEET                    | 3        |            |
| VIA MATRIX EXTERNAL SHEET                                 | 3        |            |
| <b>*TOPICAL ANESTHETIC COMBINATIONS***</b>                |          |            |
| lidocaine-prilocaine external cream                       | 1 or 1b* | QL         |
| lidocaine-prilocaine external kit                         | 1 or 1b* | QL         |
| LIDOTHOL ES EXTERNAL PATCH                                | 3        |            |
| VENIPUNCTURE PX1 PHLEBOTOMY EXTERNAL KIT                  | 3        |            |
| <b>*TOPICAL ANESTHETIC GASES***</b>                       |          |            |
| HURRI-FREEZE MEDIUM STREAM EXTERNAL AEROSOL               | 3        |            |
| HURRI-FREEZE MIST SPRAY EXTERNAL AEROSOL                  | 3        |            |
| <b>*TOPICAL SELECTIVE RETINOID X RECEPTOR AGONISTS***</b> |          |            |
| bexarotene external gel                                   | 1 or 1b* | PA; QL; SP |
| <b>*TOPICAL STEROID COMBINATIONS***</b>                   |          |            |
| calcipotriene-betameth diprop external ointment           | 2        | ST; QL     |
| calcipotriene-betameth diprop external suspension         | 2        | ST; QL     |
| DUOBRII EXTERNAL LOTION                                   | 3        | ST; QL     |
| ENSTILAR EXTERNAL FOAM                                    | 3        | ST; QL     |

| Drug Name  | Tier     | Notes      |
|--|----------|------------|
| <b>*TYPE II 5-ALPHA REDUCTASE INHIBITORS***</b>  |          |            |
| finasteride oral tablet 1 mg   | 1 or 1b* |            |
| <b>*WOUND CARE COMBINATIONS***</b>   |          |            |
| XEROFORM OCCLUSIVE GAUZE STRIP EXTERNAL  | 3        |            |
| <b>*WOUND DRESSINGS***</b>   |          |            |
| FILSUVEZ EXTERNAL GEL  | 5        | PA; LD; QL |
| KENDALL HYDROGEL WOUND DRESS EXTERNAL  | 3        |            |
| <b>*DIAGNOSTIC PRODUCTS*</b>   |          |            |
| <b>*DIAGNOSTIC TESTS***</b>  |          |            |
| ACCU-CHEK AVIVA PLUS IN VITRO STRIP  | 2        | QL         |
| ACCU-CHEK GUIDE TEST IN VITRO STRIP  | 2        | QL         |
| ACCU-CHEK SMARTVIEW IN VITRO STRIP   | 2        | QL         |
| ACCUTREND GLUCOSE IN VITRO STRIP   | 2        | QL         |
| FREESTYLE INSULINX TEST IN VITRO STRIP   | 2        | QL         |
| FREESTYLE LITE TEST IN VITRO STRIP   | 2        | QL         |
| FREESTYLE PRECISION NEO TEST IN VITRO STRIP  | 2        | QL         |
| FREESTYLE TEST IN VITRO STRIP  | 2        | QL         |
| <b>*DIGESTIVE AIDS*</b>  |          |            |
| <b>*DIGESTIVE ENZYMES***</b>   |          |            |
| CREON ORAL CAPSULE DELAYED RELEASE PARTICLES   | 2        | QL         |
| PANCREAZE ORAL CAPSULE DELAYED RELEASE PARTICLES 10500-35500 UNIT, 16800-56800 UNIT, 21000-54700 UNIT, 2600-8800 UNIT, 37000-97300 UNIT, 4200-14200 UNIT | 3        | ST; QL     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| <b>PERTZYE ORAL CAPSULE DELAYED RELEASE PARTICLES</b>   | 3        | ST; QL     |
| <b>SUCRAID ORAL SOLUTION</b>  | 5        | PA; LD; QL |
| <b>VIKACE ORAL TABLET</b>   | 2        | QL         |
| <b>ZENPEP ORAL CAPSULE DELAYED RELEASE PARTICLES 10000-32000 UNIT, 15000-47000 UNIT, 20000-63000 UNIT, 25000-79000 UNIT, 3000-10000 UNIT, 40000-126000 UNIT, 5000-24000 UNIT, 60000-189600 UNIT</b> | 2        | QL         |
| <b>*DIURETICS*</b>  |          |            |
| <b>*CARBONIC ANHYDRASE INHIBITORS***</b>  |          |            |
| acetazolamide er oral capsule extended release 12 hour  | 1 or 1b* |            |
| acetazolamide oral tablet   | 1 or 1b* |            |
| acetazolamide sodium injection solution reconstituted   | 1 or 1b* |            |
| dichlorphenamide oral tablet  | 4        | PA; QL     |
| methazolamide oral tablet   | 1 or 1b* |            |
| <b>ORMALVI ORAL TABLET</b>  | 4        | PA; LD; QL |
| <b>*DIURETIC COMBINATIONS***</b>  |          |            |
| amiloride-hydrochlorothiazide oral tablet   | 1 or 1b* |            |
| spironolactone-hctz oral tablet   | 1 or 1b* |            |
| triamterene-hctz oral capsule 37.5-25 mg  | 1 or 1a* |            |
| triamterene-hctz oral tablet  | 1 or 1a* |            |
| <b>*LOOP DIURETICS***</b>   |          |            |
| bumetanide injection solution   | 1 or 1b* |            |
| bumetanide oral tablet  | 1 or 1b* |            |
| ethacrynate sodium intravenous solution reconstituted   | 1 or 1b* |            |
| ethacrynic acid oral tablet   | 1 or 1b* |            |
| <b>FUROSCIX SUBCUTANEOUS CARTRIDGE KIT</b>  | 5        | PA; QL     |

| Drug Name  | Tier     | Notes |
|--|----------|-------|
| furosemide oral solution 10 mg/ml, 8 mg/ml               | 1 or 1a* |       |
| furosemide oral tablet                                   | 1 or 1a* |       |
| torseamide oral tablet                                   | 1 or 1b* |       |
| <b>*OSMOTIC DIURETICS***</b>                             |          |       |
| mannitol intravenous solution 20 %, 25 %                 | 3        |       |
| osmitrol intravenous solution 10 %, 20 %                 | 3        |       |
| <b>*POTASSIUM SPARING DIURETICS***</b>                   |          |       |
| amiloride hcl oral tablet                                | 1 or 1b* |       |
| spironolactone oral suspension                           | 1 or 1b* |       |
| spironolactone oral tablet                               | 1 or 1a* |       |
| triamterene oral capsule                                 | 1 or 1b* |       |
| <b>*THIAZIDES AND THIAZIDE-LIKE DIURETICS***</b>         |          |       |
| chlorothiazide sodium intravenous solution reconstituted | 1 or 1b* |       |
| chlorthalidone oral tablet 25 mg, 50 mg                  | 1 or 1a* |       |
| <b>DIURIL ORAL SUSPENSION</b>                            | 3        |       |
| <b>HEMICLOR ORAL TABLET</b>                              | 2        |       |
| hydrochlorothiazide oral capsule                         | 1 or 1a* |       |
| hydrochlorothiazide oral tablet                          | 1 or 1a* |       |
| indapamide oral tablet                                   | 1 or 1b* |       |
| <b>INZIRQO ORAL SUSPENSION RECONSTITUTED</b>             | 3        |       |
| metolazone oral tablet                                   | 1 or 1b* |       |
| <b>THALITONE ORAL TABLET</b>                             | 3        |       |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes                                       |
|--|----------|---|
| <b>*ENDOCRINE AND METABOLIC AGENTS - MISC.*</b>              |          |   |
| <b>*ABORTIFACIENT - PROGESTERONE RECEPTOR ANTAGONISTS***</b> |          |   |
| mifepristone oral tablet 200 mg                              | 1 or 1b* | \$0 for Fully insured members in California |
| <b>*ACID SPHINGOMYELINASE DEFICIENCY (ASMD) - AGENTS***</b>  |          |   |
| XENPOZYME INTRAVENOUS SOLUTION RECONSTITUTED                 | 5        | PA; LD; SP                                  |
| <b>*ADENOSINE DEAMINASE SCID TREATMENT - AGENTS***</b>       |          |   |
| REVCIVI INTRAMUSCULAR SOLUTION                               | 5        | PA; LD                                      |
| <b>*ALPHA-MANNOSIDOSIS TREATMENT - AGENTS***</b>             |          |   |
| LAMZEDE INTRAVENOUS SOLUTION RECONSTITUTED                   | 5        | PA; LD                                      |
| <b>*ATP-SENSITIVE POTASSIUM CHANNEL ACTIVATORS***</b>        |          |   |
| VYKAT XR ORAL TABLET EXTENDED RELEASE 24 HOUR                | 5        | PA; LD; QL                                  |
| <b>*BISPHOSPHONATES***</b>                                   |          |   |
| alendronate sodium oral solution                             | 1 or 1b* | QL  |
| alendronate sodium oral tablet 10 mg, 35 mg, 70 mg           | 1 or 1b* | QL  |
| BINOSTO ORAL TABLET EFFERVESCENT                             | 3        | QL  |
| FOSAMAX PLUS D ORAL TABLET                                   | 2        | QL  |
| ibandronate sodium intravenous solution 3 mg/3ml             | 4        |   |

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| ibandronate sodium oral tablet                                    | 1 or 1b* | QL         |
| pamidronate disodium intravenous solution 30 mg/10ml, 90 mg/10ml  | 4        | SP         |
| <b>PAMIDRONATE DISODIUM INTRAVENOUS SOLUTION 6 MG/ML</b>          | 4        | SP         |
| risedronate sodium oral tablet 150 mg, 30 mg, 35 mg, 5 mg         | 1 or 1b* | QL         |
| risedronate sodium oral tablet delayed release                    | 1 or 1b* | QL         |
| zoledronic acid intravenous concentrate                           | 1 or 1b* | PA; SP     |
| <b>ZOLEDRONIC ACID INTRAVENOUS SOLUTION 4 MG/100ML</b>            | 4        | PA; SP     |
| zoledronic acid intravenous solution 5 mg/100ml                   | 4        | PA; QL; SP |
| <b>*CALCIMIMETIC AGENTS***</b>                                    |          |            |
| cinacalcet hcl oral tablet  | 4        | PA; QL     |
| <b>PARSABIV INTRAVENOUS SOLUTION</b>                              | 5        | PA; LD     |
| <b>*CALCITONINS***</b>  |          |            |
| calcitonin (salmon) injection solution                            | 4        |            |
| calcitonin (salmon) nasal solution                                | 1 or 1b* | QL         |
| <b>*CARNITINE REPLENISHER - AGENTS***</b>                         |          |            |
| levocarnitine intravenous solution                                | 1 or 1b* |            |
| levocarnitine oral solution                                       | 1 or 1b* |            |
| levocarnitine oral tablet   | 1 or 1b* |            |
| levocarnitine sf oral solution                                    | 1 or 1b* |            |
| <b>*CKD AGENT-SODIUM/HYDROGEN EXCHANGER 3 (NHE3) INHIBITOR***</b> |          |            |
| <b>XPHOZAH ORAL TABLET</b>  | 3        | PA; LD; QL |
| <b>*CORTICOTROPIN***</b>  |          |            |
| <b>ACTHAR GEL SUBCUTANEOUS PEN-INJECTOR</b>                       | 4        | PA; LD; SP |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| ACTHAR INJECTION GEL  | 4        | PA; LD; SP |
| CORTROPHIN GEL SUBCUTANEOUS PREFILLED SYRINGE                       | 4        | PA; LD; SP |
| CORTROPHIN INJECTION GEL  | 4        | PA; LD; SP |
| <b>*CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR TYPE 1 ANTAG*</b> |          |            |
| CRENESSITY ORAL CAPSULE   | 5        | PA; LD; QL |
| CRENESSITY ORAL SOLUTION  | 5        | PA; LD; QL |
| <b>*CORTISOL SYNTHESIS INHIBITORS***</b>                            |          |            |
| ISTURISA ORAL TABLET 1 MG, 5 MG                                     | 5        | PA; LD; QL |
| <b>*DOPAMINE RECEPTOR AGONISTS***</b>                               |          |            |
| cabergoline oral tablet   | 1 or 1b* | QL         |
| <b>*FABRY DISEASE - AGENTS***</b>                                   |          |            |
| ELFABRIO INTRAVENOUS SOLUTION                                       | 5        | PA; LD; SP |
| FABRAZYME INTRAVENOUS SOLUTION RECONSTITUTED                        | 5        | PA; LD; SP |
| GALAFOLD ORAL CAPSULE   | 5        | PA; LD; QL |
| <b>*FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) - AGENTS***</b>         |          |            |
| REDEMPLO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE                    | 5        | PA; QL     |
| TRYNGOLZA SUBCUTANEOUS SOLUTION AUTO-INJECTOR                       | 5        | PA; LD; QL |

| Drug Name   | Tier | Notes          |
|---|------|----------------|
| <b>*GAA DEFICIENCY TREATMENT - AGENTS***</b>        |      |                |
| LUMIZYME INTRAVENOUS SOLUTION RECONSTITUTED         | 5    | PA; LD; SP     |
| NEXVIAZYME INTRAVENOUS SOLUTION RECONSTITUTED       | 5    | PA; LD; SP     |
| OPFOLDA ORAL CAPSULE                                | 5    | PA; LD; QL; SP |
| POMBILITI INTRAVENOUS SOLUTION RECONSTITUTED        | 5    | PA; LD; SP     |
| <b>*GNRH/LHRH ANTAGONISTS***</b>                    |      |                |
| cetorelix acetate subcutaneous kit                  | 4    | PA; SP         |
| fyremadel subcutaneous solution prefilled syringe   | 4    | PA; SP         |
| ORILISSA ORAL TABLET                                | 2    | PA; QL         |
| <b>*GROWTH HORMONE RECEPTOR ANTAGONISTS***</b>      |      |                |
| SOMAVERT SUBCUTANEOUS SOLUTION RECONSTITUTED        | 5    | PA; LD; QL; SP |
| <b>*GROWTH HORMONE RELEASING HORMONES (GHRH)***</b> |      |                |
| EGRIFTA SV SUBCUTANEOUS SOLUTION RECONSTITUTED      | 5    | PA; LD; QL     |
| EGRIFTA WR SUBCUTANEOUS KIT                         | 5    | PA; LD; QL     |
| <b>*GROWTH HORMONES***</b>                          |      |                |
| GENOTROPIN MINIQUICK SUBCUTANEOUS PREFILLED SYRINGE | 4    | PA; QL; SP     |
| GENOTROPIN SUBCUTANEOUS CARTRIDGE                   | 4    | PA; QL; SP     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| <b>HUMATROPE INJECTION CARTRIDGE</b>   | 4        | PA; QL; SP     |
| <b>NORDITROPIN FLEXPRO SUBCUTANEOUS SOLUTION PEN-INJECTOR 10 MG/1.5ML, 15 MG/1.5ML, 5 MG/1.5ML</b> | 4        | PA; QL; SP     |
| <b>SEROSTIM SUBCUTANEOUS SOLUTION RECONSTITUTED 4 MG, 5 MG, 6 MG</b>                               | 5        | PA; LD; QL     |
| <b>SKYTROFA SUBCUTANEOUS CARTRIDGE</b>   | 4        | PA; LD; QL; SP |
| <b>*HEREDITARY OROTIC ACIDURIA TREATMENT - AGENTS**</b>  |          |                |
| <b>XURIDEN ORAL PACKET</b>   | 3        | PA; LD; QL     |
| <b>*HEREDITARY TYROSINEMIA TYPE 1 (HT-1) TREATMENT - AGENTS***</b>                                 |          |                |
| nitisinone oral capsule 10 mg, 2 mg, 5 mg  | 4        | PA; SP         |
| nitisinone oral capsule 20 mg  | 4        | PA             |
| <b>NITYR ORAL TABLET</b>   | 5        | PA; LD         |
| <b>ORFADIN ORAL SUSPENSION</b>   | 5        | PA; LD         |
| <b>*HOMOCYSTINURIA TREATMENT - AGENTS***</b>   |          |                |
| betaine oral powder  | 1 or 1b* | LD             |
| <b>*HYPERAMMONEMIA TREATMENT - AGENTS***</b>   |          |                |
| carglumic acid oral tablet soluble   | 4        | PA; LD         |
| <b>*HYPERPARATHYROID TREATMENT - VITAMIN D ANALOGS***</b>  |          |                |
| calcitriol intravenous solution 1 mcg/ml   | 1 or 1b* | PA             |
| calcitriol oral capsule  | 1 or 1b* | PA             |
| calcitriol oral solution   | 1 or 1b* | PA             |
| doxercalciferol intravenous solution   | 1 or 1b* | PA             |

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| doxercalciferol oral capsule  | 1 or 1b* | PA             |
| paricalcitol intravenous solution                                   | 1 or 1b* | PA             |
| paricalcitol oral capsule   | 1 or 1b* | PA             |
| <b>RAYALDEE ORAL CAPSULE EXTENDED RELEASE</b>                       | 3        | PA; QL         |
| <b>*HYPOPARATHYROID TREATMENT - PARATHYROID HORMONE ANALOGS***</b>  |          |                |
| <b>YORVIPATH SUBCUTANEOUS SOLUTION PEN-INJECTOR</b>                 | 5        | PA; LD; QL     |
| <b>*HYPOPHOSPHATASIA (HPP) AGENTS***</b>                            |          |                |
| <b>STRENSIQ SUBCUTANEOUS SOLUTION</b>                               | 5        | PA; LD         |
| <b>*INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR INHIBITORS(IGF-1R)***</b> |          |                |
| <b>TEPEZZA INTRAVENOUS SOLUTION RECONSTITUTED</b>                   | 5        | PA; LD; QL     |
| <b>*INSULIN-LIKE GROWTH FACTORS (SOMATOMEDINS)***</b>               |          |                |
| <b>INCRELEX SUBCUTANEOUS SOLUTION</b>                               | 5        | PA; LD         |
| <b>*LEPTIN ANALOGUES***</b>   |          |                |
| <b>MYALEPT SUBCUTANEOUS SOLUTION RECONSTITUTED</b>                  | 5        | PA; LD; QL     |
| <b>*LHRH/GNRH AGONIST ANALOG PITUITARY SUPPRESSANTS***</b>          |          |                |
| <b>FENSOLVI (6 MONTH) SUBCUTANEOUS KIT</b>                          | 3        | PA; LD; QL; SP |
| <b>LUPRON DEPOT-PED (1-MONTH) INTRAMUSCULAR KIT</b>                 | 5        | PA; QL; SP     |
| <b>LUPRON DEPOT-PED (3-MONTH) INTRAMUSCULAR KIT</b>                 | 5        | PA; QL; SP     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier | Notes          |
|---|------|----------------|
| LUPRON DEPOT-PED (6-MONTH) INTRAMUSCULAR KIT        | 5    | PA; QL; SP     |
| SUPPRELIN LA SUBCUTANEOUS KIT                       | 5    | PA; LD; QL; SP |
| SYNAREL NASAL SOLUTION                              | 5    | PA; QL; SP     |
| TRIPTODUR INTRAMUSCULAR SUSPENSION RECONSTITUTED ER | 5    | PA; LD; QL     |
| *LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY - AGENTS*** |      |                |
| KANUMA INTRAVENOUS SOLUTION                         | 3    | PA; LD; SP     |
| *MELANOCORTIN 4 (MC4) RECEPTOR AGONISTS***          |      |                |
| IMCIVREE SUBCUTANEOUS SOLUTION                      | 5    | PA; LD; BE; QL |
| *MITOCHONDRIAL CARDIOLIPIN BINDERS***               |      |                |
| FORZINITY SUBCUTANEOUS SOLUTION                     | 5    | PA; QL         |
| *MOLYBDENUM COFACTOR DEFICIENCY (MOCD) - AGENTS***  |      |                |
| NULIBRY INTRAVENOUS SOLUTION RECONSTITUTED          | 5    | PA; LD         |
| *MUCOPOLYSACCHARI DOSIS I (MPS I) - AGENTS***       |      |                |
| ALDURAZYME INTRAVENOUS SOLUTION                     | 5    | PA; LD; SP     |
| *MUCOPOLYSACCHARI DOSIS II (MPS II) - AGENTS***     |      |                |
| ELAPRASE INTRAVENOUS SOLUTION                       | 5    | PA; LD; SP     |

| Drug Name   | Tier | Notes          |
|---|------|----------------|
| *MUCOPOLYSACCHARI DOSIS IV (MPS IV) - AGENTS***             |      |                |
| VIMIZIM INTRAVENOUS SOLUTION                                | 5    | PA; LD; SP     |
| *MUCOPOLYSACCHARI DOSIS VI (MPS VI) - AGENTS***             |      |                |
| NAGLAZYME INTRAVENOUS SOLUTION                              | 5    | PA; LD; SP     |
| *MUCOPOLYSACCHARI DOSIS VII (MPS VII) - AGENTS***           |      |                |
| MEPSEVII INTRAVENOUS SOLUTION                               | 5    | PA; LD         |
| *NATRIURETIC PEPTIDES***                                    |      |                |
| VOXZOGO SUBCUTANEOUS SOLUTION RECONSTITUTED                 | 5    | PA; LD; QL; SP |
| *NEUROKININ 3 (NK3) RECEPTOR ANTAGONISTS***                 |      |                |
| VEOZAH ORAL TABLET  | 3    | PA; QL         |
| *NON-STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS***    |      |                |
| KERENDIA ORAL TABLET  | 3    | PA; QL         |
| *OVULATION STIMULANTS-GONADOTROPINS***                      |      |                |
| CHORIONIC GONADOTROPIN INTRAMUSCULAR SOLUTION RECONSTITUTED | 5    | PA; SP         |
| GONAL-F INJECTION SOLUTION RECONSTITUTED 450 UNIT           | 4    | PA; SP         |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes      |
|--|----------|------------|
| <b>GONAL-F RFF<br/>REDIJECT<br/>SUBCUTANEOUS<br/>SOLUTION PEN-<br/>INJECTOR 300<br/>UNT/0.48ML, 450<br/>UNT/0.72ML, 900<br/>UNT/1.44ML</b> | 4        | PA; SP     |
| <b>MENOPUR<br/>SUBCUTANEOUS<br/>SOLUTION<br/>RECONSTITUTED</b>   | 5        | PA; SP     |
| <b>NOVAREL<br/>INTRAMUSCULAR<br/>SOLUTION<br/>RECONSTITUTED 5000<br/>UNIT</b>  | 5        | PA; SP     |
| <b>OVIDREL<br/>SUBCUTANEOUS<br/>SOLUTION PREFILLED<br/>SYRINGE</b>   | 5        | PA; SP     |
| <b>PREGNYL<br/>INTRAMUSCULAR<br/>SOLUTION<br/>RECONSTITUTED</b>  | 5        | PA; SP     |
| <b>*OVULATION<br/>STIMULANTS-<br/>SYNTHETIC***</b>   |          |            |
| <b>CLOMID ORAL TABLET</b>  | 1 or 1b* | PA         |
| clomiphene citrate oral tablet   | 1 or 1b* | PA         |
| <b>MILOPHENE ORAL<br/>TABLET</b>   | 1 or 1b* | PA         |
| <b>*PARATHYROID<br/>HORMONE AND<br/>DERIVATIVES***</b>   |          |            |
| teriparatide subcutaneous<br>solution pen-injector 560<br>mcg/2.24ml   | 4        | PA; QL; SP |
| <b>*PHENYLKETONURIA<br/>TREATMENT -<br/>AGENTS***</b>  |          |            |
| <b>JAVYGTOR ORAL<br/>PACKET</b>  | 4        | PA; LD     |
| <b>JAVYGTOR ORAL<br/>TABLET</b>  | 4        | PA; LD     |
| <b>PALYNZIQ<br/>SUBCUTANEOUS<br/>SOLUTION PREFILLED<br/>SYRINGE 10 MG/0.5ML,<br/>2.5 MG/0.5ML</b>  | 5        | PA; LD; SP |

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| <b>PALYNZIQ<br/>SUBCUTANEOUS<br/>SOLUTION PREFILLED<br/>SYRINGE 20 MG/ML</b> | 5        | PA; LD; QL; SP |
| sapropterin dihydrochloride<br>oral packet                                   | 4        | PA; SP         |
| sapropterin dihydrochloride<br>oral tablet                                   | 4        | PA; SP         |
| <b>SEPHIENCE ORAL<br/>PACKET</b>   | 5        | PA; LD         |
| <b>ZELVYSIA ORAL<br/>PACKET</b>  | 4        | PA             |
| <b>*RANK LIGAND<br/>(RANKL)<br/>INHIBITORS***</b>                            |          |                |
| <b>PROLIA<br/>SUBCUTANEOUS<br/>SOLUTION PREFILLED<br/>SYRINGE</b>            | 3        | PA; QL; SP     |
| <b>XGEVA<br/>SUBCUTANEOUS<br/>SOLUTION</b>                                   | 3        | PA; QL; SP     |
| <b>*SCLEROSTIN<br/>INHIBITORS***</b>   |          |                |
| <b>EVENITY<br/>SUBCUTANEOUS<br/>SOLUTION PREFILLED<br/>SYRINGE</b>           | 5        | PA; QL; SP     |
| <b>*SELECTIVE<br/>ESTROGEN RECEPTOR<br/>MODULATORS<br/>(SERMS)***</b>        |          |                |
| <b>OSPHENA ORAL<br/>TABLET</b>   | 3        | PA; QL         |
| raloxifene hcl oral tablet   | 1 or 1b* | \$0; QL        |
| <b>*SELECTIVE<br/>VASOPRESSIN V2-<br/>RECEPTOR<br/>ANTAGONISTS***</b>        |          |                |
| tolvaptan oral tablet  | 4        | PA; LD; QL; SP |
| tolvaptan oral tablet therapy<br>pack  | 4        | PA; LD; QL     |
| <b>*SOMATOSTATIC<br/>AGENTS***</b>   |          |                |
| <b>BYNFEZIA PEN<br/>SUBCUTANEOUS<br/>SOLUTION PEN-<br/>INJECTOR</b>          | 5        | PA; QL; SP     |
| <b>LANREOTIDE ACETATE<br/>SUBCUTANEOUS<br/>SOLUTION</b>                      | 5        | PA; LD; QL; SP |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| <b>MYCAPSSA ORAL CAPSULE DELAYED RELEASE</b>   | 5        | PA; LD; QL     |
| octreotide acetate injection solution 100 mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml | 4        | PA; SP         |
| octreotide acetate intramuscular kit   | 4        | PA; QL; SP     |
| octreotide acetate subcutaneous solution prefilled syringe                                       | 4        | PA; SP         |
| <b>PALSONIFY ORAL TABLET</b>   | 5        | PA; QL         |
| <b>SIGNIFOR LAR INTRAMUSCULAR SUSPENSION RECONSTITUTED ER</b>                                    | 5        | PA; LD; QL     |
| <b>SIGNIFOR SUBCUTANEOUS SOLUTION</b>  | 5        | PA; LD; QL     |
| <b>SOMATULINE DEPOT SUBCUTANEOUS SOLUTION</b>  | 5        | PA; LD; QL; SP |
| <b>*UREA CYCLE DISORDER - AGENTS***</b>  |          |                |
| glycerol phenylbutyrate oral liquid  | 1 or 1b* | PA; QL; SP     |
| <b>OLPRUVA (2 GM DOSE) ORAL THERAPY PACK</b>   | 5        | PA; LD; QL     |
| <b>OLPRUVA (3 GM DOSE) ORAL THERAPY PACK</b>   | 5        | PA; LD; QL     |
| <b>OLPRUVA (4 GM DOSE) ORAL THERAPY PACK</b>   | 5        | PA; LD; QL     |
| <b>OLPRUVA (5 GM DOSE) ORAL THERAPY PACK</b>   | 5        | PA; LD; QL     |
| <b>OLPRUVA (6 GM DOSE) ORAL THERAPY PACK</b>   | 5        | PA; LD; QL     |
| <b>OLPRUVA (6.67 GM DOSE) ORAL THERAPY PACK</b>  | 5        | PA; LD; QL     |
| <b>PHEBURANE ORAL PELLET</b>   | 5        | PA; LD; QL; SP |
| sod benz-sod phenylacet intravenous solution   | 1 or 1b* |                |
| sodium phenylbutyrate oral powder 3 gm/tsp   | 1 or 1b* | PA; QL; SP     |
| sodium phenylbutyrate oral tablet  | 1 or 1b* | PA; QL; SP     |

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| <b>*VASOPRESSIN***</b>  |          |                |
| desmopressin ace spray refrig nasal solution  | 1 or 1b* |                |
| desmopressin acetate injection solution   | 1 or 1b* |                |
| desmopressin acetate oral tablet  | 1 or 1b* | QL             |
| desmopressin acetate pf injection solution  | 1 or 1b* |                |
| desmopressin acetate spray nasal solution   | 1 or 1b* |                |
| <b>TERLIVAZ INTRAVENOUS SOLUTION RECONSTITUTED</b>                                    | 3        |                |
| vasopressin +rfid intravenous solution  | 1 or 1b* |                |
| vasopressin-sodium chloride intravenous solution 20-0.9 ut/100ml-%, 40-0.9 ut/100ml-% | 3        |                |
| <b>VASOSTRICT INTRAVENOUS SOLUTION 20-5 UT/100ML-%, 40-5 UT/100ML-%</b>               | 3        |                |
| <b>*X-LINKED HYPOPHOSPHATEMIA (XLH) TREATMENT - AGENTS***</b>                         |          |                |
| <b>CRYSVITA SUBCUTANEOUS SOLUTION</b>   | 5        | PA; LD; QL; SP |
| <b>*ESTROGENS*</b>  |          |                |
| <b>*ESTROGEN &amp; PROGESTIN***</b>   |          |                |
| <b>ABIGALE LO ORAL TABLET</b>   | 1 or 1b* |                |
| <b>ABIGALE ORAL TABLET</b>  | 1 or 1b* |                |
| <b>ANGELIQ ORAL TABLET</b>  | 3        |                |
| <b>BIJUVA ORAL CAPSULE</b>  | 2        | QL             |
| <b>CLIMARA PRO TRANSDERMAL PATCH WEEKLY</b>   | 2        | QL             |
| <b>COMBIPATCH TRANSDERMAL PATCH TWICE WEEKLY</b>                                      | 2        | QL             |
| estradiol-norethindrone acet oral tablet  | 1 or 1b* |                |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes  |
|---|----------|--------|
| fyavolv oral tablet   | 1 or 1b* |        |
| jinteli oral tablet   | 1 or 1b* |        |
| mimvey oral tablet  | 1 or 1b* |        |
| norethindrone-eth estradiol oral tablet   | 1 or 1b* |        |
| <b>PREMPHASE ORAL TABLET</b>  | 2        |        |
| <b>PREMPRO ORAL TABLET</b>  | 2        |        |
| <b>*ESTROGEN-PROGESTIN-GNRH ANTAGONIST***</b>   |          |        |
| <b>MYFEMBREE ORAL TABLET</b>  | 3        | PA; QL |
| <b>ORIAHNN ORAL CAPSULE THERAPY PACK</b>  | 3        | PA; QL |
| <b>*ESTROGENS***</b>  |          |        |
| <b>ALORA TRANSDERMAL PATCH TWICE WEEKLY 0.025 MG/24HR, 0.075 MG/24HR, 0.1 MG/24HR</b> | 3        | QL     |
| <b>DEPO-ESTRADIOL INTRAMUSCULAR OIL</b>   | 3        |        |
| dotti transdermal patch twice weekly  | 1 or 1b* | QL     |
| estradiol oral tablet   | 1 or 1b* |        |
| estradiol transdermal gel   | 1 or 1b* | QL     |
| estradiol transdermal patch twice weekly  | 1 or 1b* | QL     |
| estradiol transdermal patch weekly  | 1 or 1b* | QL     |
| estradiol valerate intramuscular oil  | 1 or 1b* |        |
| estrogens conjugated oral tablet  | 1 or 1b* | QL     |
| <b>EVAMIST TRANSDERMAL SOLUTION</b>   | 2        | QL     |
| lyllana transdermal patch twice weekly  | 1 or 1b* | QL     |
| <b>MENOSTAR TRANSDERMAL PATCH WEEKLY</b>  | 3        | QL     |
| <b>PREMARIN INJECTION SOLUTION RECONSTITUTED</b>                                      | 2        |        |

| Drug Name  | Tier     | Notes      |
|--|----------|------------|
| <b>*ESTROGEN-SELECTIVE ESTROGEN RECEPTOR MODULATOR COMB***</b> |          |            |
| <b>DUAVEE ORAL TABLET</b>                                      | 3        | PA; QL     |
| <b>*FLUOROQUINOLONES*</b>                                      |          |            |
| <b>*FLUOROQUINOLONES***</b>                                    |          |            |
| <b>BAXDELA INTRAVENOUS SOLUTION RECONSTITUTED</b>              | 3        |            |
| <b>BAXDELA ORAL TABLET</b>                                     | 3        | PA         |
| <b>CIPRO ORAL SUSPENSION RECONSTITUTED</b>                     | 3        |            |
| ciprofloxacin hcl oral tablet 250 mg, 500 mg, 750 mg           | 1 or 1b* |            |
| ciprofloxacin in d5w intravenous solution                      | 1 or 1b* |            |
| levofloxacin in d5w intravenous solution                       | 1 or 1b* |            |
| levofloxacin intravenous solution                              | 1 or 1b* | QL         |
| levofloxacin oral solution                                     | 1 or 1b* |            |
| levofloxacin oral tablet                                       | 1 or 1b* |            |
| moxifloxacin hcl in nacl intravenous solution                  | 1 or 1b* |            |
| <b>MOXIFLOXACIN HCL INTRAVENOUS SOLUTION</b>                   | 3        |            |
| moxifloxacin hcl oral tablet                                   | 1 or 1b* |            |
| ofloxacin oral tablet 300 mg, 400 mg                           | 1 or 1b* |            |
| <b>*GASTROINTESTINAL AGENTS - MISC.*</b>                       |          |            |
| <b>*5-HT4 RECEPTOR AGONISTS***</b>                             |          |            |
| prucalopride succinate oral tablet                             | 1 or 1b* | QL         |
| <b>*BILE ACID SYNTHESIS DISORDER AGENTS***</b>                 |          |            |
| <b>CHOLBAM ORAL CAPSULE</b>                                    | 3        | PA; LD; QL |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| <b>*CIC AGENTS - GUANYLATE CYCLASE-C (GC-C) AGONISTS***</b>       |          |                |
| TRULANCE ORAL TABLET  | 3        | QL             |
| <b>*GALLSTONE SOLUBILIZING AGENTS***</b>                          |          |                |
| ursodiol oral capsule 300 mg                                      | 1 or 1b* |                |
| ursodiol oral tablet  | 1 or 1b* |                |
| <b>*GASTROINTESTINAL ANTIALLERGY AGENTS***</b>                    |          |                |
| cromolyn sodium oral concentrate                                  | 1 or 1b* |                |
| <b>*GASTROINTESTINAL CHLORIDE CHANNEL ACTIVATORS***</b>           |          |                |
| lubiprostone oral capsule   | 1 or 1b* | QL             |
| <b>*GASTROINTESTINAL STIMULANTS***</b>                            |          |                |
| GIMOTI NASAL SOLUTION   | 3        | PA; QL         |
| metoclopramide hcl +rfid injection solution                       | 1 or 1a* |                |
| metoclopramide hcl injection solution                             | 1 or 1a* |                |
| metoclopramide hcl oral solution 10 mg/10ml, 5 mg/5ml             | 1 or 1a* | QL             |
| metoclopramide hcl oral tablet                                    | 1 or 1a* | QL             |
| metoclopramide hcl oral tablet dispersible 5 mg                   | 1 or 1a* | QL             |
| <b>*GLUCAGON-LIKE PEPTIDE-2 (GLP-2) ANALOGS***</b>                |          |                |
| GATTEX SUBCUTANEOUS KIT   | 3        | PA; LD; SP     |
| <b>*HEPATOTROPICS - THYROID HORMONE RECEPTOR-BETA AGONISTS***</b> |          |                |
| REZDIFFRA ORAL TABLET   | 5        | PA; LD; QL; SP |
| <b>*IBS AGENT - GUANYLATE CYCLASE-C (GC-C) AGONISTS***</b>        |          |                |
| LINZESS ORAL CAPSULE  | 2        | QL             |

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| <b>*IBS AGENT - MU-OPIOID RECEPTOR AGONISTS***</b>          |          |            |
| VIBERZI ORAL TABLET   | 3        | QL         |
| <b>*IBS AGENT - SELECTIVE 5-HT3 RECEPTOR ANTAGONISTS***</b> |          |            |
| alosetron hcl oral tablet                                   | 1 or 1b* | PA; QL     |
| <b>*ILEAL BILE ACID TRANSPORTER (IBAT) INHIBITORS***</b>    |          |            |
| BYLVAY (PELLETS) ORAL CAPSULE SPRINKLE                      | 5        | PA; LD; QL |
| BYLVAY ORAL CAPSULE   | 5        | PA; LD; QL |
| LIVMARLI ORAL SOLUTION                                      | 5        | PA; LD; QL |
| LIVMARLI ORAL TABLET  | 5        | PA; LD; QL |
| <b>*INFLAMMATORY BOWEL AGENTS***</b>                        |          |            |
| balsalazide disodium oral capsule                           | 1 or 1b* | QL         |
| DIPENTUM ORAL CAPSULE                                       | 3        | ST; QL     |
| mesalamine er oral capsule extended release                 | 1 or 1b* | ST; QL     |
| mesalamine er oral capsule extended release 24 hour         | 1 or 1b* | QL         |
| mesalamine oral capsule delayed release                     | 1 or 1b* | QL         |
| mesalamine oral tablet delayed release                      | 1 or 1b* | QL         |
| mesalamine rectal enema                                     | 1 or 1b* | QL         |
| mesalamine rectal suppository                               | 1 or 1b* | QL         |
| mesalamine-cleanser rectal kit                              | 1 or 1b* | QL         |
| PENTASA ORAL CAPSULE EXTENDED RELEASE 250 MG                | 2        | QL         |
| sulfasalazine oral tablet                                   | 1 or 1b* | QL         |
| sulfasalazine oral tablet delayed release                   | 1 or 1b* | QL         |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| <b>*INTEGRIN RECEPTOR ANTAGONISTS***</b>                    |          |                |
| ENTYVIO INTRAVENOUS SOLUTION RECONSTITUTED                  | 4        | PA; LD; QL; SP |
| ENTYVIO PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR             | 4        | PA; LD; QL; SP |
| <b>*INTERLEUKIN ANTAGONISTS***</b>                          |          |                |
| SELARSDI INTRAVENOUS SOLUTION                               | 4        | PA; QL; SP     |
| SKYRIZI INTRAVENOUS SOLUTION                                | 4        | PA; QL; SP     |
| SKYRIZI SUBCUTANEOUS SOLUTION CARTRIDGE                     | 4        | PA; QL; SP     |
| STELARA INTRAVENOUS SOLUTION                                | 4        | PA; QL; SP     |
| TREMFYA INTRAVENOUS SOLUTION                                | 4        | PA; QL; SP     |
| TREMFYA PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/2ML  | 4        | PA; QL; SP     |
| TREMFYA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/2ML  | 4        | PA; QL; SP     |
| TREMFYA-CD/UC INDUCTION SUBCUTANEOUS SOLUTION AUTO-INJECTOR | 4        | PA; QL; SP     |
| <b>*INTESTINAL ACIDIFIERS***</b>                            |          |                |
| enulose oral solution                                       | 1 or 1b* |                |
| generlac oral solution                                      | 1 or 1b* |                |
| lactulose encephalopathy oral solution 10 gm/15ml           | 1 or 1b* |                |
| <b>*LIVE FECAL MICROBIOTA (HUMAN)**</b>                     |          |                |
| REBYOTA RECTAL SUSPENSION                                   | 5        | PA; LD; QL     |
| VOWST ORAL CAPSULE  | 5        | PA; LD; QL     |

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| <b>*PERIPHERAL OPIOID RECEPTOR ANTAGONISTS***</b>              |          |                |
| alvimopan oral capsule   | 1 or 1b* |                |
| MOVANTIK ORAL TABLET   | 2        | QL             |
| RELISTOR ORAL TABLET   | 3        | ST; QL         |
| RELISTOR SUBCUTANEOUS SOLUTION 12 MG/0.6ML                     | 3        | ST; QL         |
| RELISTOR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE               | 3        | ST; QL         |
| SYMPROIC ORAL TABLET   | 3        | ST; QL         |
| <b>*PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS***</b> |          |                |
| IQIRVO ORAL TABLET   | 4        | PA; LD; QL; SP |
| <b>*PHOSPHATE BINDER AGENTS***</b>                             |          |                |
| calcium acetate (phos binder) oral capsule                     | 1 or 1b* | QL             |
| calcium acetate oral tablet 667 mg                             | 1 or 1b* | QL             |
| ferric citrate oral tablet                                     | 1 or 1b* | QL             |
| FOSRENOL ORAL PACKET   | 3        | ST; QL         |
| lanthanum carbonate oral tablet chewable                       | 1 or 1b* | QL             |
| sevelamer carbonate oral packet                                | 1 or 1b* | QL             |
| sevelamer carbonate oral tablet                                | 1 or 1b* | QL             |
| sevelamer hcl oral tablet                                      | 1 or 1b* | QL             |
| VELPHORO ORAL TABLET CHEWABLE                                  | 2        | QL             |
| <b>*TRYPTOPHAN HYDROXYLASE INHIBITORS***</b>                   |          |                |
| XERMELO ORAL TABLET  | 5        | PA; LD; QL     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| <b>*TUMOR NECROSIS FACTOR ALPHA BLOCKERS***</b>                       |          |            |
| AVSOLA INTRAVENOUS SOLUTION RECONSTITUTED                             | 4        | PA; LD; SP |
| INFLIXIMAB INTRAVENOUS SOLUTION RECONSTITUTED                         | 4        | PA; LD; SP |
| REMICADE INTRAVENOUS SOLUTION RECONSTITUTED                           | 4        | PA; SP     |
| <b>*GENERAL ANESTHETICS*</b>  |          |            |
| <b>*ANESTHETICS - MISC.***</b>  |          |            |
| DIPRIVAN INTRAVENOUS EMULSION 100 MG/10ML                             | 3        |            |
| etomidate intravenous solution  | 1 or 1b* |            |
| ketamine hcl injection solution 50 mg/ml                              | 1 or 1b* |            |
| propofol intravenous emulsion 1000 mg/100ml, 200 mg/20ml, 500 mg/50ml | 1 or 1b* |            |
| <b>*BARBITURATE ANESTHETICS***</b>                                    |          |            |
| methohexital sodium injection solution reconstituted                  | 1 or 1b* |            |
| <b>*VOLATILE ANESTHETICS***</b>                                       |          |            |
| desflurane inhalation solution  | 1 or 1b* |            |
| isoflurane inhalation solution  | 1 or 1b* |            |
| sevoflurane inhalation solution                                       | 1 or 1b* |            |
| terrell inhalation solution   | 1 or 1b* |            |
| <b>*GENITOURINARY AGENTS - MISCELLANEOUS*</b>                         |          |            |
| <b>*5-ALPHA REDUCTASE INHIBITORS***</b>                               |          |            |
| dutasteride oral capsule  | 1 or 1b* | QL         |
| finasteride oral tablet 5 mg  | 1 or 1b* | QL         |

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| <b>*ALPHA 1-ADRENOCEPTOR ANTAGONISTS***</b>           |          |            |
| alfuzosin hcl er oral tablet extended release 24 hour | 1 or 1b* | QL         |
| CARDURA XL ORAL TABLET EXTENDED RELEASE 24 HOUR       | 3        | QL         |
| silodosin oral capsule                                | 1 or 1b* | QL         |
| tamsulosin hcl oral capsule                           | 1 or 1b* | QL         |
| <b>*ANTI-INFECTIVE GENITOURINARY IRRIGANTS***</b>     |          |            |
| neomycin-polymyxin b gu irrigation solution           | 1 or 1b* |            |
| <b>*CITRATES***</b>                                   |          |            |
| potassium citrate er oral tablet extended release     | 1 or 1b* |            |
| <b>*CYSTINOSIS AGENTS***</b>                          |          |            |
| CYSTAGON ORAL CAPSULE                                 | 5        | PA; LD; SP |
| PROCYSBI ORAL CAPSULE DELAYED RELEASE                 | 5        | PA; LD     |
| PROCYSBI ORAL PACKET                                  | 5        | PA; LD     |
| <b>*GENITOURINARY IRRIGANTS***</b>                    |          |            |
| acetic acid irrigation solution                       | 1 or 1b* |            |
| argyle sterile saline irrigation solution             | 3        |            |
| curity sterile saline irrigation solution             | 3        |            |
| glycine irrigation solution                           | 1 or 1b* |            |
| glycine urologic irrigation solution                  | 1 or 1b* |            |
| RENACIDIN IRRIGATION SOLUTION                         | 3        |            |
| sodium chloride irrigation solution 0.9 %             | 1 or 1b* |            |
| SORBITOL IRRIGATION SOLUTION 3 %                      | 3        |            |
| SORBITOL-MANNITOL IRRIGATION SOLUTION                 | 3        |            |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| <b>*IGAN AGENTS - ENDOTHELIN &amp; ANGIOTENSIN II RECEPTOR ANTAG***</b> |          |                |
| FILSPARI ORAL TABLET  | 5        | PA; LD; QL; SP |
| <b>*INTERSTITIAL CYSTITIS AGENTS***</b>                                 |          |                |
| ELMIRON ORAL CAPSULE  | 3        | QL             |
| RIMSO-50 INTRAVESICAL SOLUTION  | 3        |                |
| <b>*PHOSPHATES***</b>   |          |                |
| K-PHOS NO 2 ORAL TABLET   | 3        |                |
| <b>*PROSTATIC HYPERTROPHY AGENT COMBINATIONS***</b>                     |          |                |
| dutasteride-tamsulosin hcl oral capsule                                 | 1 or 1b* | QL             |
| <b>*SMALL INTERFERING RIBONUCLEIC ACID AGENTS (SIRNA)***</b>            |          |                |
| OXLUMO SUBCUTANEOUS SOLUTION  | 5        | PA; LD; SP     |
| RIVFLOZA SUBCUTANEOUS SOLUTION  | 5        | PA; LD; QL; SP |
| RIVFLOZA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE                        | 5        | PA; LD; QL; SP |
| <b>*URINARY STONE AGENTS***</b>   |          |                |
| LITHOSTAT ORAL TABLET   | 3        |                |
| tiopronin oral tablet   | 1 or 1b* | PA; QL         |
| tiopronin oral tablet delayed release                                   | 1 or 1b* | PA; LD; QL     |
| VENXXIVA ORAL TABLET DELAYED RELEASE                                    | 1 or 1b* | PA; LD; QL     |
| <b>*GOUT AGENTS*</b>  |          |                |
| <b>*GOUT AGENT COMBINATIONS***</b>                                      |          |                |
| colchicine-probenecid oral tablet                                       | 1 or 1b* |                |

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| <b>*GOUT AGENTS***</b>   |          |                |
| allopurinol oral tablet 100 mg, 300 mg                             | 1 or 1a* | QL             |
| allopurinol sodium intravenous solution reconstituted              | 1 or 1b* |                |
| colchicine oral tablet   | 1 or 1b* | QL             |
| febuxostat oral tablet   | 1 or 1b* | ST; QL         |
| GLOPERBA ORAL SOLUTION   | 3        | ST; QL         |
| KRYSTEXXA INTRAVENOUS SOLUTION                                     | 5        | PA; LD; QL; SP |
| <b>*URICOSURICS***</b>   |          |                |
| probenecid oral tablet   | 1 or 1b* |                |
| <b>*HEMATOLOGICAL AGENTS - MISC.*</b>                              |          |                |
| <b>*AGENTS FOR CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA*</b> |          |                |
| adzynma intravenous kit  | 5        | PA; LD         |
| <b>*AMINOLEVULINATE SYNTHASE 1-DIRECTED SIRNA***</b>               |          |                |
| GIVLAARI SUBCUTANEOUS SOLUTION                                     | 5        | PA; LD; SP     |
| <b>*ANTIHEMOPHILIC PRODUCTS - ANTITHROMBIN-DIRECTED SIRNA***</b>   |          |                |
| QFITLIA SUBCUTANEOUS SOLUTION                                      | 5        | PA; LD         |
| QFITLIA SUBCUTANEOUS SOLUTION AUTO-INJECTOR                        | 5        | PA; LD         |
| <b>*ANTIHEMOPHILIC PRODUCTS - MONOCLONAL ANTIBODIES***</b>         |          |                |
| ALHEMO SUBCUTANEOUS SOLUTION PEN-INJECTOR                          | 5        | PA; LD; SP     |
| HEMLIBRA SUBCUTANEOUS SOLUTION                                     | 5        | PA; LD; SP     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier | Notes      |
|---|------|------------|
| <b>HYMPAVZI<br/>SUBCUTANEOUS<br/>SOLUTION AUTO-<br/>INJECTOR</b>  | 5    | PA; LD; SP |
| <b>*ANTIHEMOPHILIC<br/>PRODUCTS***</b>  |      |            |
| <b>ADVATE INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b>  | 4    | PA; LD; SP |
| <b>ADYNOVATE<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b>   | 5    | PA; LD; SP |
| <b>AFSTYLA<br/>INTRAVENOUS KIT</b>  | 5    | PA; LD; SP |
| <b>ALPHANATE<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED 1000<br/>UNIT, 1500 UNIT, 2000<br/>UNIT, 250 UNIT, 500<br/>UNIT</b>           | 5    | PA; LD; SP |
| <b>ALPHANINE SD<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b>  | 5    | PA; LD; SP |
| <b>ALPROLIX<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b>  | 5    | PA; LD; SP |
| <b>ALTUVIHO<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED 1000<br/>UNIT, 2000 UNIT, 250<br/>UNIT, 3000 UNIT, 4000<br/>UNIT, 500 UNIT</b> | 5    | PA; LD; SP |
| <b>BALFAXAR<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b>  | 3    |            |
| <b>BENEFIX<br/>INTRAVENOUS KIT</b>  | 5    | PA; LD; SP |
| <b>COAGADEX<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b>  | 5    | PA; LD; SP |
| <b>CORIFACT<br/>INTRAVENOUS KIT</b>   | 5    | PA; LD; SP |
| <b>ELOCTATE<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b>  | 5    | PA; LD; SP |

| Drug Name   | Tier | Notes      |
|---|------|------------|
| <b>ESPEROCT<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b>  | 5    | PA; LD; SP |
| <b>FEIBA INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED 1000<br/>UNIT, 2500 UNIT, 500<br/>UNIT</b>                      | 5    | PA; LD; SP |
| <b>FIBRYGA<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b>   | 5    | PA; LD; SP |
| <b>HEMOFIL M<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED 1000<br/>UNIT, 1700 UNIT, 250<br/>UNIT, 500 UNIT</b>    | 5    | PA; LD; SP |
| <b>HUMATE-P<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED 1000-<br/>2400 UNIT, 250-600 UNIT,<br/>500-1200 UNIT</b> | 5    | PA; LD; SP |
| <b>IDELVION<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b>  | 5    | PA; LD; SP |
| <b>IXINITY INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED 1000<br/>UNIT, 1500 UNIT, 3000<br/>UNIT, 500 UNIT</b>         | 5    | PA; LD; SP |
| <b>JIVI INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b>  | 5    | PA; LD; SP |
| <b>KCENTRA<br/>INTRAVENOUS KIT</b>  | 3    |            |
| <b>KOATE INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b>   | 5    | PA; LD; SP |
| <b>KOATE-DVI<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED 1000<br/>UNIT</b>                                       | 5    | PA; LD; SP |
| <b>KOVALTRY<br/>INTRAVENOUS<br/>SOLUTION<br/>RECONSTITUTED</b>  | 5    | PA; LD; SP |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier | Notes      |
|---|------|------------|
| NOVOEIGHT INTRAVENOUS SOLUTION RECONSTITUTED                    | 4    | LD; SP     |
| NOVOSEVEN RT INTRAVENOUS SOLUTION RECONSTITUTED                 | 5    | PA; LD; SP |
| NUWIQ INTRAVENOUS KIT   | 5    | PA; LD; SP |
| NUWIQ INTRAVENOUS SOLUTION RECONSTITUTED                        | 5    | PA; LD; SP |
| obizur intravenous solution reconstituted                       | 5    | PA; LD; SP |
| PROFILNINE INTRAVENOUS SOLUTION RECONSTITUTED                   | 5    | PA; LD; SP |
| REBINYN INTRAVENOUS SOLUTION RECONSTITUTED                      | 5    | PA; LD; SP |
| RECOMBINATE INTRAVENOUS SOLUTION RECONSTITUTED                  | 5    | PA; LD; SP |
| RIASTAP INTRAVENOUS SOLUTION RECONSTITUTED                      | 3    | PA; LD; SP |
| RIXUBIS INTRAVENOUS SOLUTION RECONSTITUTED                      | 5    | PA; LD; SP |
| SEVENFACT INTRAVENOUS SOLUTION RECONSTITUTED                    | 5    | PA; LD; SP |
| TRETTEN INTRAVENOUS SOLUTION RECONSTITUTED 2500 UNIT            | 5    | PA; LD; SP |
| VONVENDI INTRAVENOUS SOLUTION RECONSTITUTED                     | 5    | PA; LD; SP |
| WILATE INTRAVENOUS KIT  | 5    | PA; LD; SP |
| XYNTHA INTRAVENOUS KIT 1000 UNIT, 2000 UNIT, 250 UNIT, 500 UNIT | 5    | PA; LD; SP |

| Drug Name   | Tier | Notes          |
|---|------|----------------|
| XYNTHA SOLOFUSE INTRAVENOUS KIT                           | 5    | PA; LD; SP     |
| <b>*ANTI-VON WILLEBRAND FACTOR AGENTS***</b>              |      |                |
| CABLIVI INJECTION KIT                                     | 5    | PA; LD         |
| <b>*BRADYKININ B2 RECEPTOR ANTAGONISTS***</b>             |      |                |
| icatibant acetate subcutaneous solution prefilled syringe | 4    | PA; QL; SP     |
| sajazir subcutaneous solution prefilled syringe           | 4    | PA; LD; QL     |
| <b>*C1 ESTERASE INHIBITORS***</b>                         |      |                |
| BERINERT INTRAVENOUS KIT                                  | 5    | PA; LD; QL; SP |
| CINRYZE INTRAVENOUS SOLUTION RECONSTITUTED                | 5    | PA; LD; QL; SP |
| HAEGARDA SUBCUTANEOUS SOLUTION RECONSTITUTED              | 5    | PA; LD; QL; SP |
| RUCONEST INTRAVENOUS SOLUTION RECONSTITUTED               | 5    | PA; LD; QL; SP |
| <b>*COMPLEMENT C1 INHIBITORS***</b>                       |      |                |
| ENJAYMO INTRAVENOUS SOLUTION                              | 5    | PA; LD; QL; SP |
| <b>*COMPLEMENT C3 INHIBITORS***</b>                       |      |                |
| EMPAVELI SUBCUTANEOUS SOLUTION                            | 5    | PA; LD; QL     |
| <b>*COMPLEMENT C5 INHIBITORS***</b>                       |      |                |
| PIASKY INJECTION SOLUTION                                 | 5    | PA; LD; QL; SP |
| SOLIRIS INTRAVENOUS SOLUTION 300 MG/30ML                  | 5    | PA; LD; QL; SP |
| ULTOMIRIS INTRAVENOUS SOLUTION 1100 MG/11ML, 300 MG/3ML   | 5    | PA; LD; QL; SP |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| VEOPOZ INJECTION SOLUTION   | 5        | PA; LD; QL |
| ZILBRYSQ SUBCUTANEOUS SOLUTION PREFILLED SYRINGE                        | 5        | PA; LD; QL |
| <b>*COMPLEMENT C5A INHIBITORS***</b>                                    |          |            |
| gohibic intravenous solution  | 3        |            |
| <b>*COMPLEMENT C5A RECEPTOR INHIBITORS***</b>                           |          |            |
| TAVNEOS ORAL CAPSULE  | 5        | PA; LD; QL |
| <b>*COMPLEMENT FACTOR B INHIBITORS***</b>                               |          |            |
| FABHALTA ORAL CAPSULE   | 5        | PA; LD; QL |
| <b>*COMPLEMENT FACTOR D INHIBITORS***</b>                               |          |            |
| VOYDEYA ORAL TABLET   | 5        | PA; LD; QL |
| VOYDEYA ORAL TABLET THERAPY PACK  | 5        | PA; LD; QL |
| <b>*COMPLEMENT MASP-2 INHIBITORS***</b>                                 |          |            |
| YARTEMLEA INTRAVENOUS SOLUTION  | 5        | PA         |
| <b>*DIRECT-ACTING P2Y12 INHIBITORS***</b>                               |          |            |
| KENGREAL INTRAVENOUS SOLUTION RECONSTITUTED                             | 3        |            |
| ticagrelor oral tablet  | 1 or 1b* | QL         |
| <b>*GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITORS***</b>                    |          |            |
| AGGRASTAT INTRAVENOUS CONCENTRATE                                       | 3        |            |
| eptifibatide intravenous solution 20 mg/10ml, 200 mg/100ml, 75 mg/100ml | 1 or 1b* |            |
| tirofiban hcl in nacl intravenous solution                              | 1 or 1b* |            |

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| <b>*HEMATORHEOLOGIC AGENTS***</b>                               |          |                |
| pentoxifylline er oral tablet extended release                  | 1 or 1b* |                |
| <b>*HEMIN***</b>  |          |                |
| PANHEMATIN INTRAVENOUS SOLUTION RECONSTITUTED 350 MG            | 3        |                |
| <b>*HUMAN PROTEIN C***</b>                                      |          |                |
| CEPROTIN INTRAVENOUS SOLUTION RECONSTITUTED                     | 5        | LD; SP         |
| <b>*PHOSPHODIESTERASE III INHIBITORS***</b>                     |          |                |
| cilostazol oral tablet  | 1 or 1b* |                |
| <b>*PLASMA EXPANDERS***</b>                                     |          |                |
| hetastarch-nacl intravenous solution                            | 1 or 1b* |                |
| HEXTEND INTRAVENOUS SOLUTION                                    | 3        |                |
| lmd in d5w intravenous solution                                 | 1 or 1b* |                |
| lmd in nacl intravenous solution                                | 1 or 1b* |                |
| <b>*PLASMA KALLIKREIN INHIBITORS - MONOCLONAL ANTIBODIES***</b> |          |                |
| TAKHZYRO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE                | 5        | PA; LD; QL; SP |
| <b>*PLASMA KALLIKREIN INHIBITORS***</b>                         |          |                |
| EKTERLY ORAL TABLET   | 5        | PA; LD; QL; SP |
| KALBITOR SUBCUTANEOUS SOLUTION                                  | 5        | PA; LD; QL; SP |
| ORLADEYO ORAL CAPSULE   | 5        | PA; LD; QL     |
| <b>*PLASMA PROTEINS***</b>                                      |          |                |
| ALBUKED 25 INTRAVENOUS SOLUTION                                 | 3        |                |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier | Notes      |
|---|------|------------|
| ALBUKED 5 INTRAVENOUS SOLUTION                            | 3    |            |
| ALBUMIN HUMAN INTRAVENOUS SOLUTION                        | 3    |            |
| ALBUMINEX INTRAVENOUS SOLUTION                            | 3    |            |
| ALBUMIN-ZLB INTRAVENOUS SOLUTION                          | 3    |            |
| ALBURX INTRAVENOUS SOLUTION                               | 3    |            |
| ALBUTEIN INTRAVENOUS SOLUTION                             | 3    |            |
| FLEXBUMIN INTRAVENOUS SOLUTION                            | 3    |            |
| KEDBUMIN INTRAVENOUS SOLUTION                             | 3    |            |
| OCTAPLAS BLOOD GROUP A INTRAVENOUS SOLUTION               | 3    |            |
| OCTAPLAS BLOOD GROUP AB INTRAVENOUS SOLUTION              | 3    |            |
| OCTAPLAS BLOOD GROUP B INTRAVENOUS SOLUTION               | 3    |            |
| OCTAPLAS BLOOD GROUP O INTRAVENOUS SOLUTION               | 3    |            |
| RYPLAZIM INTRAVENOUS SOLUTION RECONSTITUTED               | 5    | PA; LD; SP |
| THROMBATE III INTRAVENOUS SOLUTION RECONSTITUTED 500 UNIT | 3    |            |

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| <b>*PLATELET AGGREGATION INHIBITOR COMBINATIONS***</b>        |          |            |
| aspirin-dipyridamole er oral capsule extended release 12 hour | 1 or 1b* | QL         |
| YOSPRALA ORAL TABLET DELAYED RELEASE                          | 3        | PA; QL     |
| <b>*PLATELET AGGREGATION INHIBITORS***</b>                    |          |            |
| dipyridamole oral tablet                                      | 1 or 1b* |            |
| <b>*PROTAMINE***</b>  |          |            |
| protamine sulfate intravenous solution                        | 1 or 1b* |            |
| <b>*PROTEASE-ACTIVATED RECEPTOR-1 (PAR-1) ANTAGONISTS***</b>  |          |            |
| ZONTIVITY ORAL TABLET   | 3        | PA; QL     |
| <b>*PYRUVATE KINASE ACTIVATORS***</b>                         |          |            |
| PYRUKYND ORAL TABLET  | 5        | PA; LD; QL |
| PYRUKYND TAPER PACK ORAL TABLET THERAPY PACK                  | 5        | PA; LD; QL |
| <b>*QUINAZOLINE AGENTS***</b>                                 |          |            |
| anagrelide hcl oral capsule                                   | 1 or 1b* | QL         |
| <b>*SPLEEN TYROSINE KINASE (SYK) INHIBITORS***</b>            |          |            |
| TAVALISSE ORAL TABLET   | 5        | PA; LD; QL |
| <b>*THIENOPYRIDINE DERIVATIVES***</b>                         |          |            |
| clopidogrel bisulfate oral tablet                             | 1 or 1b* | QL         |
| prasugrel hcl oral tablet                                     | 1 or 1b* | QL         |
| <b>*THROMBOLYTIC AGENT - MISC***</b>                          |          |            |
| DEFITELIO INTRAVENOUS SOLUTION                                | 5        | LD         |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| <b>*TISSUE PLASMINOGEN ACTIVATORS***</b>             |          |                |
| ACTIVASE INTRAVENOUS SOLUTION RECONSTITUTED          | 3        |                |
| CATHFLO ACTIVASE INJECTION SOLUTION RECONSTITUTED    | 3        |                |
| TNKASE INTRAVENOUS KIT                               | 3        |                |
| <b>*HEMATOPOIETIC AGENTS*</b>                        |          |                |
| <b>*AGENTS FOR GAUCHER DISEASE***</b>                |          |                |
| CERDELGA ORAL CAPSULE                                | 2        | PA; LD; QL; SP |
| CEREZYME INTRAVENOUS SOLUTION RECONSTITUTED 400 UNIT | 2        | PA; LD; SP     |
| ELELYSO INTRAVENOUS SOLUTION RECONSTITUTED           | 5        | PA; LD; SP     |
| miglustat oral capsule                               | 2        | PA; QL; SP     |
| VPRIV INTRAVENOUS SOLUTION RECONSTITUTED             | 5        | PA; LD; SP     |
| YARGESA ORAL CAPSULE                                 | 2        | PA; LD; QL; SP |
| <b>*AMINO ACIDS***</b>                               |          |                |
| l-glutamine oral packet                              | 4        | PA; SP         |
| <b>*COBALAMINS***</b>                                |          |                |
| cyanocobalamin injection solution 1000 mcg/ml        | 1 or 1a* |                |
| hydroxocobalamin acetate intramuscular solution      | 1 or 1b* |                |
| <b>*CXCR4 RECEPTOR ANTAGONIST***</b>                 |          |                |
| APHEXDA SUBCUTANEOUS SOLUTION RECONSTITUTED          | 5        | PA; LD         |
| plerixafor subcutaneous solution                     | 4        | PA; SP         |
| XOLREMDI ORAL CAPSULE                                | 5        | PA; LD; QL     |

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| <b>*CYTOTOXIC AGENTS***</b>   |          |            |
| DROXIA ORAL CAPSULE   | 2        |            |
| SIKLOS ORAL TABLET  | 3        | PA; SP     |
| XROMI ORAL SOLUTION   | 5        | PA         |
| <b>*ERYTHROID MATURATION AGENTS***</b>  |          |            |
| REBLOZYL SUBCUTANEOUS SOLUTION RECONSTITUTED  | 5        | PA; LD; SP |
| <b>*ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)***</b>   |          |            |
| ARANESP (ALBUMIN FREE) INJECTION SOLUTION 100 MCG/ML, 200 MCG/ML, 25 MCG/ML, 40 MCG/ML, 60 MCG/ML                 | 4        | PA; QL; SP |
| ARANESP (ALBUMIN FREE) INJECTION SOLUTION PREFILLED SYRINGE   | 4        | PA; QL; SP |
| EPOGEN INJECTION SOLUTION 10000 UNIT/ML, 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML                  | 5        | PA; QL; SP |
| MIRCERA INJECTION SOLUTION PREFILLED SYRINGE  | 5        | PA; LD; QL |
| PROCRIT INJECTION SOLUTION  | 4        | PA; QL; SP |
| RETACRIT INJECTION SOLUTION 10000 UNIT/ML, 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML, 40000 UNIT/ML | 4        | PA; QL; SP |
| <b>*FOLIC ACID/FOLATE COMBINATIONS***</b>   |          |            |
| foltabs 800 oral tablet   | 1 or 1b* | \$0        |
| <b>*FOLIC ACID/FOLATES***</b>   |          |            |
| cvs folic acid oral tablet 800 mcg  | 1 or 1a* | \$0        |
| fa-8 oral capsule   | 1 or 1b* | \$0        |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| folate oral tablet  | 1 or 1a* | \$0            |
| folic acid injection solution                                 | 1 or 1a* |                |
| folic acid oral capsule 0.8 mg                                | 1 or 1b* | \$0            |
| folic acid oral tablet 1 mg                                   | 1 or 1a* |                |
| folic acid oral tablet 400 mcg, 800 mcg                       | 1 or 1a* | \$0            |
| ft folic acid oral tablet                                     | 1 or 1a* | \$0            |
| gnp folic acid oral tablet                                    | 1 or 1a* | \$0            |
| kp folic acid oral tablet 800 mcg                             | 1 or 1a* | \$0            |
| qc folic acid oral tablet                                     | 1 or 1a* | \$0            |
| true folic acid oral tablet 400 mcg                           | 1 or 1a* | \$0            |
| yl folic acid oral tablet                                     | 1 or 1a* | \$0            |
| <b>*GRANULOCYTE COLONY-STIMULATING FACTORS (G-CSF)***</b>     |          |                |
| <b>GRANIX SUBCUTANEOUS SOLUTION 300 MCG/ML</b>                | 5        | PA; SP         |
| <b>GRANIX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE</b>         | 5        | PA; SP         |
| <b>NEULASTA ONPRO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE</b> | 4        | PA; QL; SP     |
| <b>NEULASTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE</b>       | 4        | PA; QL; SP     |
| <b>ROLVEDON SUBCUTANEOUS SOLUTION PREFILLED SYRINGE</b>       | 5        | PA; LD; QL; SP |
| <b>UDENYCA ONBODY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE</b> | 4        | PA; QL; SP     |
| <b>UDENYCA SUBCUTANEOUS SOLUTION AUTO-INJECTOR</b>            | 4        | PA; QL; SP     |
| <b>UDENYCA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE</b>        | 4        | PA; QL; SP     |

| Drug Name   | Tier | Notes          |
|---|------|----------------|
| <b>ZARXIO INJECTION SOLUTION PREFILLED SYRINGE</b>                  | 4    | PA; SP         |
| <b>*GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR(GM-CSF)***</b> |      |                |
| <b>LEUKINE INJECTION SOLUTION RECONSTITUTED</b>                     | 5    | PA; SP         |
| <b>*IRON COMBINATIONS***</b>  |      |                |
| <b>NIFEREX ORAL TABLET</b>  | 3    |                |
| <b>*IRON***</b>   |      |                |
| ferumoxytol intravenous solution                                    | 4    | QL; SP         |
| <b>INFED INJECTION SOLUTION</b>                                     | 5    | SP             |
| iron sucrose intravenous solution                                   | 4    | QL; SP         |
| na ferric gluc cplx in sucrose intravenous solution                 | 4    | QL; SP         |
| <b>*SELECTIN BLOCKERS***</b>  |      |                |
| <b>ADAKVEO INTRAVENOUS SOLUTION</b>                                 | 5    | PA; SP         |
| <b>*THROMBOPOIETIN (TPO) RECEPTOR AGONISTS***</b>                   |      |                |
| <b>DOPTELET ORAL TABLET 20 MG</b>                                   | 5    | PA; LD; QL; SP |
| <b>DOPTELET SPRINKLE ORAL CAPSULE SPRINKLE</b>                      | 5    | PA; LD; QL; SP |
| eltrombopag olamine oral packet 12.5 mg                             | 4    | PA; DO; SP     |
| eltrombopag olamine oral packet 25 mg                               | 4    | PA; QL; SP     |
| eltrombopag olamine oral tablet 12.5 mg, 25 mg                      | 4    | PA; LD; DO; SP |
| eltrombopag olamine oral tablet 50 mg, 75 mg                        | 4    | PA; LD; QL; SP |
| <b>MUPLETA ORAL TABLET</b>  | 5    | PA; QL; SP     |
| <b>NPLATE SUBCUTANEOUS SOLUTION RECONSTITUTED</b>                   | 5    | PA; SP         |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes |
|---|----------|-------|
| <b>*HEMOSTATICS*</b>                              |          |       |
| <b>*HEMOSTATIC COMBINATIONS - TOPICAL***</b>      |          |       |
| ARTISS EXTERNAL KIT                               | 3        |       |
| TISSEEL EXTERNAL KIT                              | 3        |       |
| TISSEEL EXTERNAL SOLUTION                         | 3        |       |
| VISTASEAL EXTERNAL PREFILLED SYRINGE KIT          | 3        |       |
| <b>*HEMOSTATICS - SYSTEMIC***</b>                 |          |       |
| aminocaproic acid intravenous solution            | 1 or 1b* |       |
| aminocaproic acid oral solution                   | 1 or 1b* | QL    |
| aminocaproic acid oral tablet 1000 mg             | 1 or 1b* |       |
| aminocaproic acid oral tablet 500 mg              | 1 or 1b* | QL    |
| tranexamic acid intravenous solution 1000 mg/10ml | 1 or 1b* |       |
| tranexamic acid oral tablet                       | 1 or 1b* | QL    |
| <b>*HEMOSTATICS - TOPICAL***</b>                  |          |       |
| ACTIFOAM COLLAGEN SPONGE EXTERNAL                 | 3        |       |
| AVITENE EXTERNAL PAD                              | 3        |       |
| AVITENE FLOUR EXTERNAL POWDER                     | 3        |       |
| ENDO AVITENE EXTERNAL                             | 3        |       |
| GELFILM EXTERNAL FILM                             | 3        |       |
| GEL-FLOW NT EXTERNAL PREFILLED SYRINGE            | 3        |       |
| GELFOAM COMPRESSED SIZE 100 EXTERNAL              | 3        |       |
| GELFOAM MOUTH/THROAT POWDER                       | 3        |       |
| GELFOAM SPONGE SIZE 200 EXTERNAL                  | 3        |       |

| Drug Name   | Tier | Notes |
|---|------|-------|
| GELFOAM SPONGE SIZE 50 EXTERNAL                     | 3    |       |
| INSTAT EXTERNAL PAD                                 | 3    |       |
| INTERCEED (TC7) EXTERNAL PAD                        | 3    |       |
| INTERCEED EXTERNAL PAD                              | 3    |       |
| RECOTHROM EXTERNAL SOLUTION RECONSTITUTED           | 3    |       |
| RECOTHROM SPRAY KIT EXTERNAL SOLUTION RECONSTITUTED | 3    |       |
| SURGICEL FIBRILLAR EXTERNAL PAD                     | 3    |       |
| SURGICEL NU-KNIT EXTERNAL PAD                       | 3    |       |
| SURGICEL SNOW 1"X2" EXTERNAL PAD                    | 3    |       |
| SURGICEL SNOW 2"X4" EXTERNAL PAD                    | 3    |       |
| SURGICEL SNOW 4"X4" EXTERNAL PAD                    | 3    |       |
| SYRINGE AVITENE EXTERNAL                            | 3    |       |
| THROMBIN-JMI EPISTAXIS EXTERNAL KIT                 | 3    |       |
| THROMBIN-JMI EXTERNAL KIT                           | 3    |       |
| THROMBIN-JMI EXTERNAL SOLUTION RECONSTITUTED        | 3    |       |
| THROMBOGEN EXTERNAL KIT                             | 3    |       |
| THROMBOGEN EXTERNAL SOLUTION RECONSTITUTED          | 3    |       |
| ULTRAFOAM SPONGE 2X6.25X7CM EXTERNAL                | 3    |       |
| ULTRAFOAM SPONGE 8X12.5X1CM EXTERNAL                | 3    |       |
| ULTRAFOAM SPONGE 8X12.5X3CM EXTERNAL                | 3    |       |
| ULTRAFOAM SPONGE 8X25X1CM EXTERNAL                  | 3    |       |
| ULTRAFOAM SPONGE 8X6.25X1CM EXTERNAL                | 3    |       |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| <b>*HYPNOTICS/SEDATIVE S/SLEEP DISORDER AGENTS*</b>                                      |          |        |
| <b>*BARBITURATE HYPNOTICS***</b>   |          |        |
| pentobarbital sodium injection solution  | 1 or 1b* |        |
| phenobarbital oral elixir  | 1 or 1b* | QL     |
| phenobarbital oral tablet 100 mg, 60 mg, 64.8 mg, 97.2 mg                                | 1 or 1b* | QL     |
| phenobarbital oral tablet 15 mg, 16.2 mg, 30 mg, 32.4 mg                                 | 1 or 1b* | DO     |
| phenobarbital sodium injection solution  | 1 or 1b* |        |
| <b>SEZABY INTRAVENOUS SOLUTION RECONSTITUTED</b>   | 3        |        |
| <b>*BENZODIAZEPINE HYPNOTICS***</b>  |          |        |
| <b>BYFAVO INTRAVENOUS SOLUTION RECONSTITUTED</b>   | 5        |        |
| estazolam oral tablet  | 1 or 1b* | QL     |
| flurazepam hcl oral capsule  | 1 or 1b* | QL     |
| midazolam hcl (pf) +rfid injection solution  | 1 or 1b* |        |
| midazolam hcl (pf) injection solution  | 1 or 1b* |        |
| midazolam hcl injection solution 10 mg/10ml, 10 mg/2ml, 25 mg/5ml, 5 mg/ml, 50 mg/10ml   | 1 or 1b* |        |
| midazolam hcl oral syrup   | 1 or 1b* | QL     |
| midazolam-sodium chloride (pf) intravenous solution 100-0.8 mg/100ml-%, 50-0.8 mg/50ml-% | 3        |        |
| midazolam-sodium chloride (pf) intravenous solution 100-0.9 mg/100ml-%, 50-0.9 mg/50ml-% | 1 or 1b* |        |
| quazepam oral tablet   | 1 or 1b* | QL     |
| temazepam oral capsule   | 1 or 1b* | QL     |
| triazolam oral tablet  | 1 or 1b* | QL     |
| <b>*HYPNOTICS - TRICYCLIC AGENTS***</b>  |          |        |
| doxepin hcl oral tablet  | 1 or 1b* | ST; QL |

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| <b>*NON-BENZODIAZEPINE - GABA-RECEPTOR MODULATORS***</b>                                  |          |            |
| <b>EDLUAR SUBLINGUAL TABLET SUBLINGUAL</b>  | 3        | ST; QL     |
| eszopiclone oral tablet   | 1 or 1b* | QL         |
| zaleplon oral capsule   | 1 or 1b* | QL         |
| zolpidem tartrate er oral tablet extended release   | 1 or 1b* | QL         |
| zolpidem tartrate oral tablet   | 1 or 1b* | QL         |
| zolpidem tartrate sublingual tablet sublingual  | 1 or 1b* | ST; QL     |
| <b>*OREXIN RECEPTOR ANTAGONISTS***</b>  |          |            |
| <b>QUVIVIQ ORAL TABLET</b>  | 3        | ST; QL     |
| <b>*SELECTIVE ALPHA2-ADRENORECEPTOR AGONIST SEDATIVES***</b>                              |          |            |
| dexmedetomidine hcl in nacl intravenous solution 200 mcg/50ml, 400 mcg/100ml, 80 mcg/20ml | 1 or 1b* |            |
| dexmedetomidine hcl intravenous solution 200 mcg/2ml                                      | 1 or 1b* |            |
| <b>DEXMEDETOMIDINE HCL-DEXTROSE INTRAVENOUS SOLUTION</b>                                  | 3        |            |
| <b>IGALMI SUBLINGUAL FILM</b>   | 3        | PA; QL     |
| <b>PRECEDEX INTRAVENOUS SOLUTION 1000 MCG/250ML</b>                                       | 3        |            |
| <b>*SELECTIVE MELATONIN RECEPTOR AGONISTS***</b>  |          |            |
| <b>HETLIOZ LQ ORAL SUSPENSION</b>   | 5        | PA; LD; QL |
| ramelteon oral tablet   | 1 or 1b* | QL         |
| tasimelteon oral capsule  | 4        | PA; QL     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes   |
|---|----------|---------|
| <b>*LAXATIVES*</b>  |          |         |
| <b>*BOWEL EVACUANT COMBINATIONS***</b>                            |          |         |
| <b>GAVILYTE-C ORAL SOLUTION RECONSTITUTED</b>                     | 1 or 1a* | \$0; QL |
| gavilyte-g oral solution reconstituted                            | 1 or 1a* | \$0; QL |
| <b>GAVILYTE-N WITH FLAVOR PACK ORAL SOLUTION RECONSTITUTED</b>    | 1 or 1a* | \$0; QL |
| na sulfate-k sulfate-mg sulf oral solution 17.5-3.13-1.6 gm/177ml | 1 or 1b* | \$0; QL |
| peg 3350-kcl-na bicarb-nacl oral solution reconstituted           | 1 or 1a* | \$0; QL |
| peg-3350/electrolytes oral solution reconstituted                 | 1 or 1a* | \$0; QL |
| peg-3350/electrolytes/ascorbat oral solution reconstituted        | 1 or 1b* | \$0; QL |
| peg-kcl-nacl-nasulf-na asc-c oral solution reconstituted          | 1 or 1b* | \$0; QL |
| <b>PEG-PREP ORAL KIT</b>  | 3        | QL      |
| <b>*ELECTROLYTE-BASED OSMOTIC LAXATIVES***</b>                    |          |         |
| citroma oral solution   | 1 or 1a* | \$0     |
| cvs magnesium citrate oral solution                               | 1 or 1a* | \$0     |
| cvs milk of magnesia oral suspension 1200 mg/15ml                 | 1 or 1b* | \$0     |
| dulcolax oral suspension  | 1 or 1b* | \$0     |
| eq magnesium citrate oral solution                                | 1 or 1a* | \$0     |
| eql magnesium citrate oral solution                               | 1 or 1a* | \$0     |
| <b>FRESKARO MAGNESIUM CITRATE ORAL SOLUTION</b>                   | 1 or 1a* | \$0     |
| ft magnesium citrate oral solution                                | 1 or 1a* | \$0     |
| ft milk of magnesia oral suspension                               | 1 or 1b* | \$0     |
| gentle laxative oral suspension                                   | 1 or 1b* | \$0     |
| gnp magnesium citrate oral solution                               | 1 or 1a* | \$0     |

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| gnp milk of magnesia oral suspension                 | 1 or 1b* | \$0    |
| goodsense magnesium citrate oral solution            | 1 or 1a* | \$0    |
| goodsense milk of magnesia oral suspension           | 1 or 1b* | \$0    |
| magnesium citrate oral solution 1.745 gm/30ml        | 1 or 1a* | \$0    |
| milk of magnesia oral suspension                     | 1 or 1b* | \$0    |
| <b>ONELAX MAGNESIUM CITRATE ORAL SOLUTION</b>        | 1 or 1a* | \$0    |
| phillips milk of magnesia oral suspension 400 mg/5ml | 1 or 1b* | \$0    |
| qc magnesium citrate oral solution                   | 1 or 1a* | \$0    |
| qc milk of magnesia oral suspension                  | 1 or 1b* | \$0    |
| sb magnesium citrate oral solution                   | 1 or 1a* | \$0    |
| sb milk of magnesia oral suspension                  | 1 or 1b* | \$0    |
| <b>*LAXATIVES - MISCELLANEOUS***</b>                 |          |        |
| clearlax oral powder                                 | 1 or 1b* | \$0    |
| constulose oral solution                             | 1 or 1b* |        |
| cvs purelax oral packet                              | 1 or 1b* | \$0    |
| cvs purelax oral powder                              | 1 or 1b* | \$0    |
| eq clearlax oral powder                              | 1 or 1b* | \$0    |
| eq laxative oral packet                              | 1 or 1b* | \$0    |
| eql clearlax oral powder                             | 1 or 1b* | \$0    |
| ft clearlax oral powder                              | 1 or 1b* | \$0    |
| gavilax oral powder                                  | 1 or 1b* | \$0    |
| glycolax oral powder                                 | 1 or 1b* | \$0    |
| gnp clearlax oral packet                             | 1 or 1b* | \$0    |
| gnp clearlax oral powder                             | 1 or 1b* | \$0    |
| goodsense clearlax oral powder                       | 1 or 1b* | \$0    |
| healthylax oral packet                               | 1 or 1b* | \$0    |
| kls laxaclear oral powder                            | 1 or 1b* | \$0    |
| <b>KRISTALOSE ORAL PACKET</b>                        | 1 or 1b* | ST; QL |
| <b>LACTULOSE ORAL PACKET 10 GM</b>                   | 1 or 1b* | ST; QL |
| lactulose oral packet 20 gm                          | 1 or 1b* | ST; QL |
| lactulose oral solution                              | 1 or 1b* |        |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes |
|--|----------|-------|
| laxative osmotic oral powder                             | 1 or 1b* | \$0   |
| mm clearlax oral powder                                  | 1 or 1b* | \$0   |
| peg 3350 oral packet                                     | 1 or 1b* | \$0   |
| peg 3350 oral powder                                     | 1 or 1b* | \$0   |
| polyethylene glycol 3350 oral packet 17 gm               | 1 or 1b* | \$0   |
| polyethylene glycol 3350 oral powder                     | 1 or 1b* | \$0   |
| sb polyethylene glycol 3350 oral powder                  | 1 or 1b* | \$0   |
| smooth lax oral packet                                   | 1 or 1b* | \$0   |
| smooth lax oral powder                                   | 1 or 1b* | \$0   |
| <b>*LUBRICANT LAXATIVES***</b>                           |          |       |
| mineral oil heavy oral oil                               | 3        |       |
| <b>*STIMULANT LAXATIVES***</b>                           |          |       |
| bisacodyl ec oral tablet delayed release                 | 1 or 1a* | \$0   |
| cvs c-lax laxative oral tablet delayed release           | 1 or 1a* | \$0   |
| cvs gentle laxative oral tablet delayed release          | 1 or 1a* | \$0   |
| cvs gentle laxative womens oral tablet delayed release   | 1 or 1a* | \$0   |
| eq gentle laxative oral tablet delayed release           | 1 or 1a* | \$0   |
| eql gentle laxative oral tablet delayed release          | 1 or 1a* | \$0   |
| eql laxative oral tablet delayed release                 | 1 or 1a* | \$0   |
| ex-lax ultra oral tablet delayed release                 | 1 or 1a* | \$0   |
| <b>FLEET STIMULANT ORAL TABLET DELAYED RELEASE</b>       |          |       |
| ft laxative oral tablet delayed release                  | 1 or 1a* | \$0   |
| gentle laxative oral tablet delayed release              | 1 or 1a* | \$0   |
| gnp gentle laxative oral tablet delayed release          | 1 or 1a* | \$0   |
| gnp womens gentle laxative oral tablet delayed release   | 1 or 1a* | \$0   |
| goodsense bisacodyl laxative oral tablet delayed release | 1 or 1a* | \$0   |
| kp bisacodyl oral tablet delayed release                 | 1 or 1a* | \$0   |

| Drug Name   | Tier     | Notes |
|---|----------|-------|
| qc gentle laxative oral tablet delayed release                                  | 1 or 1a* | \$0   |
| qc gentle laxative womens oral tablet delayed release                           | 1 or 1a* | \$0   |
| qc laxative oral tablet delayed release   | 1 or 1a* | \$0   |
| sb bisacodyl laxative ec oral tablet delayed release                            | 1 or 1a* | \$0   |
| sb gentle lax-women oral tablet delayed release                                 | 1 or 1a* | \$0   |
| womans laxative oral tablet delayed release                                     | 1 or 1a* | \$0   |
| womens laxative oral tablet delayed release                                     | 1 or 1a* | \$0   |
| <b>*LOCAL ANESTHETICS-PARENTERAL*</b>   |          |       |
| <b>*LOCAL ANESTHETIC &amp; SYMPATHOMIMETIC**</b>                                |          |       |
| *   |          |       |
| articadent dental injection solution cartridge 4 %-1:100000                     | 3        |       |
| bupivacaine-epinephrine (pf) injection solution 0.25% -1:200000, 0.5% -1:200000 | 1 or 1b* |       |
| lidocaine-epinephrine (pf) injection solution 1.5 %-1:200000, 2 %-1:200000      | 1 or 1b* |       |
| lidocaine-epinephrine injection solution 0.5 %-1:200000, 2 %-1:100000           | 1 or 1b* |       |
| <b>ORABLOC INJECTION SOLUTION CARTRIDGE 4 %-1:200000</b>                        |          |       |
| sensorcaine/epinephrine injection solution                                      | 1 or 1b* |       |
| sensorcaine-mpf/epinephrine injection solution 0.25% -1:200000                  | 1 or 1b* |       |
| sensorcaine-mpf/epinephrine injection solution 0.5% -1:200000                   | 3        |       |
| <b>SENSORCAINE-MPF/EPINEPHRINE INJECTION SOLUTION 0.75-1:200000 %</b>           |          |       |
| <b>XYLOCAINE-MPF/EPINEPHRINE INJECTION SOLUTION 1 %-1:200000</b>                |          |       |
|   | 3        |       |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes |
|--|----------|-------|
| <b>*LOCAL ANESTHETICS - AMIDES***</b>                              |          |       |
| <b>BUPIVACAINE FISIOPHARMA INJECTION SOLUTION 0.5 %, 2.5 MG/ML</b> | 3        |       |
| bupivacaine hcl (pf) injection solution                            | 1 or 1b* |       |
| lidocaine hcl (pf) injection solution                              | 1 or 1b* |       |
| lidocaine hcl injection solution 0.5 %                             | 1 or 1b* |       |
| <b>MONOJECT BONE MARROW BIOPSY INJECTION KIT</b>                   | 3        |       |
| polocaine injection solution                                       | 1 or 1b* |       |
| polocaine-mpf injection solution                                   | 1 or 1b* |       |
| ropivacaine hcl injection solution 10 mg/ml, 5 mg/ml, 7.5 mg/ml    | 1 or 1b* |       |
| <b>ROPIVACAINE HCL INJECTION SOLUTION 2 MG/ML</b>                  | 1 or 1b* |       |
| sensorcaine injection solution                                     | 1 or 1b* |       |
| sensorcaine-mpf injection solution                                 | 1 or 1b* |       |
| <b>*LOCAL ANESTHETICS - ESTERS***</b>                              |          |       |
| chloroprocaine hcl (pf) injection solution                         | 1 or 1b* |       |
| <b>NESACAINE INJECTION SOLUTION</b>                                | 3        |       |
| <b>*MACROLIDES*</b>  |          |       |
| <b>*AZITHROMYCIN***</b>  |          |       |
| azithromycin intravenous solution reconstituted 500 mg             | 1 or 1b* |       |
| azithromycin oral suspension reconstituted                         | 1 or 1b* |       |
| azithromycin oral tablet 250 mg, 500 mg, 600 mg                    | 1 or 1b* |       |
| <b>*CLARITHROMYCIN***</b>  |          |       |
| clarithromycin er oral tablet extended release 24 hour             | 1 or 1b* |       |
| clarithromycin oral suspension reconstituted                       | 1 or 1b* |       |
| clarithromycin oral tablet   | 1 or 1b* |       |

| Drug Name  | Tier     | Notes   |
|--|----------|---------|
| <b>*ERYTHROMYCINS***</b>                                     |          |         |
| e.e.s. 400 oral tablet                                       | 1 or 1b* |         |
| erythromycin base oral capsule delayed release particles     | 1 or 1b* |         |
| erythromycin base oral tablet                                | 1 or 1b* |         |
| erythromycin base oral tablet delayed release                | 1 or 1b* |         |
| erythromycin ethylsuccinate oral suspension reconstituted    | 1 or 1b* |         |
| erythromycin lactobionate intravenous solution reconstituted | 1 or 1b* |         |
| erythromycin oral tablet delayed release                     | 1 or 1b* |         |
| <b>*FIDAXOMICIN***</b>                                       |          |         |
| <b>DIFICID ORAL SUSPENSION RECONSTITUTED</b>                 | 3        | QL      |
| fidaxomicin oral tablet                                      | 1 or 1b* | QL      |
| <b>*MEDICAL DEVICES AND SUPPLIES*</b>                        |          |         |
| <b>*CERVICAL CAPS***</b>                                     |          |         |
| <b>FEMCAP VAGINAL DEVICE</b>                                 | 2        | \$0     |
| <b>*CONDOMS - FEMALE***</b>                                  |          |         |
| <b>FC2 FEMALE CONDOM</b>                                     | 2        | \$0; QL |
| <b>*CONDOMS - MALE***</b>                                    |          |         |
| aimsco lubricated  | 2        | \$0     |
| condoms  | 2        | \$0     |
| <b>DUREX EXTRA SENSITIVE THIN</b>                            | 2        | \$0     |
| <b>DUREX EXTRA SENSITIVE THIN DEVICE</b>                     | 2        | \$0     |
| <b>DUREX REALFEEL DEVICE</b>                                 | 2        | \$0     |
| <b>DUREX TROPICAL</b>  | 2        | \$0     |
| <b>FANTASY LUBRICATED</b>                                    | 2        | \$0     |
| <b>FANTASY LUBRICATED/SPERMIC IDE</b>                        | 2        | \$0     |
| <b>KAMELEON LUBRICATED</b>                                   | 2        | \$0     |
| kimono   | 2        | \$0     |
| <b>KIMONO COLORS DEVICE</b>                                  | 2        | \$0     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name                                    | Tier | Notes |
|--|------|-------|
| <b>KIMONO MAXX-LARGE FLARE</b>               | 2    | \$0   |
| kimono micro thin                            | 2    | \$0   |
| kimono micro thin plus                       | 2    | \$0   |
| kimono plus                                  | 2    | \$0   |
| kimono ps                                    | 2    | \$0   |
| kimono ps plus                               | 2    | \$0   |
| kimono sensation                             | 2    | \$0   |
| kimono sensation plus                        | 2    | \$0   |
| <b>KIMONO SPECIAL DEVICE</b>                 | 2    | \$0   |
| maxx   | 2    | \$0   |
| maxx plus                                    | 2    | \$0   |
| <b>REALITY LATEX CONDOMS</b>                 | 2    | \$0   |
| <b>REALITY LATEX/ULTRA TEXTURED DEVICE</b>   | 2    | \$0   |
| <b>REALITY LATEX/ULTRA THIN DEVICE</b>       | 2    | \$0   |
| <b>TROJAN BARESKIN DEVICE</b>                | 2    | \$0   |
| <b>TROJAN ENZ</b>                            | 2    | \$0   |
| <b>TROJAN MAGNUM</b>                         | 2    | \$0   |
| <b>TROJAN ULTRA RIBBED LUBRICATED DEVICE</b> | 2    | \$0   |
| <b>TROJAN ULTRA THIN</b>                     | 2    | \$0   |
| <b>TROJAN ULTRA THIN/SPERMICIDAL</b>         | 2    | \$0   |
| <b>TROJAN-ENZ LUBRICATED</b>                 | 2    | \$0   |
| <b>TROJAN-ENZ/SPERMICIDAL</b>                | 2    | \$0   |
| true cover device                            | 2    | \$0   |
| <b>TRUSTEX COLOR CONDOMS + LUBE</b>          | 2    | \$0   |
| <b>TRUSTEX LUB/RIBBED/STUDED</b>             | 2    | \$0   |
| <b>TRUSTEX LUB/SPERMICIDE EX ST</b>          | 2    | \$0   |
| <b>TRUSTEX LUB/SPERMICIDE XL</b>             | 2    | \$0   |
| <b>TRUSTEX LUBRICATED</b>                    | 2    | \$0   |
| <b>TRUSTEX LUBRICATED EX LARGE</b>           | 2    | \$0   |

| Drug Name                                       | Tier | Notes |
|---|------|-------|
| <b>TRUSTEX LUBRICATED EXTRA ST</b>              | 2    | \$0   |
| <b>TRUSTEX LUBRICATED/SPERMICIDE</b>            | 2    | \$0   |
| <b>TRUSTEX NATURAL CONDOMS + LUBE</b>           | 2    | \$0   |
| <b>TRUSTEX NON-LUBRICATED</b>                   | 2    | \$0   |
| <b>TRUSTEX RIA LUB/SPERMICIDE</b>               | 2    | \$0   |
| <b>TRUSTEX RIA LUBRICATED</b>                   | 2    | \$0   |
| <b>TRUSTEX RIA NON-LUBRICATED</b>               | 2    | \$0   |
| <b>TRUSTEX-NONOXYNOL-9/RIB/STUD</b>             | 2    | \$0   |
| <b>*DENTAL DESENSITIZING PRODUCTS***</b>        |      |       |
| <b>REMESENSE DENTAL</b>                         | 3    |       |
| <b>*DENTIFRICES***</b>                          |      |       |
| <b>MI PASTE DENTAL PASTE</b>                    | 3    |       |
| <b>MI PASTE PLUS DENTAL PASTE</b>               | 3    |       |
| <b>*DIAPHRAGMS***</b>                           |      |       |
| <b>CAYA VAGINAL DIAPHRAGM</b>                   | 2    | \$0   |
| <b>OMNIFLEX DIAPHRAGM VAGINAL DIAPHRAGM</b>     | 3    | \$0   |
| <b>WIDE-SEAL DIAPHRAGM 60 VAGINAL DIAPHRAGM</b> | 2    | \$0   |
| <b>WIDE-SEAL DIAPHRAGM 65 VAGINAL DIAPHRAGM</b> | 2    | \$0   |
| <b>WIDE-SEAL DIAPHRAGM 70 VAGINAL DIAPHRAGM</b> | 2    | \$0   |
| <b>WIDE-SEAL DIAPHRAGM 75 VAGINAL DIAPHRAGM</b> | 2    | \$0   |
| <b>WIDE-SEAL DIAPHRAGM 80 VAGINAL DIAPHRAGM</b> | 2    | \$0   |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier | Notes |
|---|------|-------|
| WIDE-SEAL<br>DIAPHRAGM 85<br>VAGINAL DIAPHRAGM      | 2    | \$0   |
| WIDE-SEAL<br>DIAPHRAGM 90<br>VAGINAL DIAPHRAGM      | 2    | \$0   |
| WIDE-SEAL<br>DIAPHRAGM 95<br>VAGINAL DIAPHRAGM      | 2    | \$0   |
| <b>*GLUCOSE<br/>MONITORING TEST<br/>SUPPLIES***</b> |      |       |
| ACCU-CHEK FASTCLIX<br>LANCET KIT                    | 2    |       |
| ACCU-CHEK FASTCLIX<br>LANCETS                       | 2    | QL    |
| ACCU-CHEK SAFE-T<br>PRO LANCETS                     | 2    | QL    |
| ACCU-CHEK SOFTCLIX<br>LANCET DEV KIT                | 2    |       |
| ACCU-CHEK SOFTCLIX<br>LANCETS                       | 2    | QL    |
| ACTI-LANCE 28G                                      | 2    | QL    |
| ACTI-LANCE LITE<br>LANCETS 28G                      | 2    | QL    |
| ACTI-LANCE SPECIAL<br>LANCETS 17G                   | 2    | QL    |
| ACTI-LANCE<br>UNIVERSAL 23G                         | 2    | QL    |
| adjustable lancing device                           | 2    |       |
| ADVANCED MOBILE<br>LANCET                           | 2    | QL    |
| advantage safety lancets 28g                        | 2    | QL    |
| ADVOCATE LANCETS                                    | 2    | QL    |
| ADVOCATE LANCETS<br>30G                             | 2    | QL    |
| ADVOCATE LANCING<br>DEVICE                          | 2    |       |
| ADVOCATE RAPID-<br>SAFE LANCING                     | 2    |       |
| ADVOCATE SAFETY<br>LANCETS                          | 2    | QL    |
| ADVOCATE SAFETY<br>LANCETS 21G                      | 2    | QL    |
| ADVOCATE SAFETY<br>LANCETS 23G                      | 2    | QL    |
| ADVOCATE SAFETY<br>LANCETS 26G                      | 2    | QL    |

| Drug Name                         | Tier | Notes |
|-----------------------------------|------|-------|
| ADVOCATE SAFETY<br>LANCETS 28G    | 2    | QL    |
| AGAMATRIX ULTRA-<br>THIN LANCETS  | 2    | QL    |
| AIMSCO TWIST<br>LANCETS 32G       | 2    | QL    |
| AIMSCO TWIST<br>LANCETS 33G       | 2    | QL    |
| AQUALANCE LANCETS<br>30G          | 2    | QL    |
| ASSURE COMFORT<br>LANCETS 28G     | 2    | QL    |
| ASSURE LANCE<br>LANCETS           | 2    | QL    |
| ASSURE LANCE<br>LANCETS 21G       | 2    | QL    |
| ASSURE LANCE PLUS<br>SAFETY 25G   | 2    | QL    |
| ASSURE LANCE PLUS<br>SAFETY 30G   | 2    | QL    |
| ASSURE LANCE SAFETY<br>LANCET 28G | 2    | QL    |
| AURORA LANCET<br>SUPER THIN 30G   | 2    | QL    |
| AURORA LANCET THIN<br>23G         | 2    | QL    |
| AUTO-LANCET                       | 2    |       |
| AUTO-LANCET MINI                  | 2    |       |
| AUTOLET II CLINISAFE<br>KIT       | 2    |       |
| AUTOLET LANCING<br>DEVICE         | 2    |       |
| AUTOLET LITE<br>CLINISAFE KIT     | 2    |       |
| AUTOLET LITE<br>LANCING DEVICE    | 2    |       |
| AUTOLET LITE<br>STARTER PACK KIT  | 2    |       |
| AUTOLET MINI                      | 2    |       |
| AUTOLET PLATFORMS                 | 2    |       |
| AUTOLET PLUS                      | 2    |       |
| BD MICROTAINER<br>LANCETS         | 2    | QL    |
| CARDIOCOM LANCING<br>DEVICE       | 2    |       |
| careone advanced lancing<br>dev   | 2    |       |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name                      | Tier | Notes |
|--------------------------------|------|-------|
| CAREONE LANCET SUPER THIN 30G  | 2    | QL    |
| CAREONE LANCET THIN 23G        | 2    | QL    |
| CARESENS LANCETS               | 2    | QL    |
| CARESENS LANCETS 30G           | 2    | QL    |
| CARETOUCH LANCING/EJECTOR      | 2    |       |
| CARETOUCH SAFETY LANCETS       | 2    | QL    |
| CARETOUCH SAFETY LANCETS 26G   | 2    | QL    |
| CARETOUCH TWIST LANCETS 28G    | 2    | QL    |
| CARETOUCH TWIST LANCETS 30G    | 2    | QL    |
| CARETOUCH TWIST LANCETS 33G    | 2    | QL    |
| CARETOUCH TWIST MC LANCETS 30G | 2    | QL    |
| CHOSEN LANCETS 30G             | 2    | QL    |
| CHOSEN LANCING DEVICE          | 2    |       |
| CHOSEN SAFETY LANCETS 28G      | 2    | QL    |
| CLEANLET LANCETS 28G           | 2    | QL    |
| CLEVER CHEK LANCETS            | 2    | QL    |
| CLEVER CHOICE COMFORT EZ       | 2    | QL    |
| CLEVER CHOICE LANCETS 21G      | 2    | QL    |
| CLEVER CHOICE LANCETS 23G      | 2    | QL    |
| CLEVER CHOICE LANCETS 28G      | 2    | QL    |
| COAGUCHEK LANCETS              | 2    | QL    |
| COMFORT ASSURED LANCETS 28G    | 2    | QL    |
| COMFORT ASSURED LANCETS 33G    | 2    | QL    |
| COMFORT TOUCH LANCETS 31G      | 2    | QL    |
| COMFORT TOUCH PLUS LANCETS 28G | 2    | QL    |
| COMFORT TOUCH PLUS LANCETS 30G | 2    | QL    |

| Drug Name                      | Tier | Notes  |
|--------------------------------|------|--------|
| COMFORT TOUCH TWIST LANCET 30G | 2    | QL     |
| CVS LANCETS ORIGINAL           | 2    | QL     |
| CVS LANCETS THIN 26G           | 2    | QL     |
| cvs lancing device             | 2    |        |
| CVS ULTRA THIN LANCETS         | 2    | QL     |
| DEXCOM G6 RECEIVER DEVICE      | 2    | PA; QL |
| DEXCOM G6 SENSOR               | 2    | PA; QL |
| DEXCOM G6 TRANSMITTER          | 2    | PA; QL |
| DEXCOM G7 15 DAY SENSOR        | 2    | PA; QL |
| DEXCOM G7 RECEIVER DEVICE      | 2    | PA; QL |
| DEXCOM G7 SENSOR               | 2    | PA; QL |
| DIATHRIVE LANCET ULTRA THIN 30 | 2    | QL     |
| DIATHRIVE LANCETS              | 2    | QL     |
| DIATHRIVE LANCING DEVICE       | 2    |        |
| DROPLET GENTEEL LANCING DEVICE | 2    |        |
| DROPLET LANCETS ULTRA THIN 30G | 2    | QL     |
| DROPLET LANCING DEVICE         | 2    |        |
| DROPLET PERSONAL LANCETS 30G   | 2    | QL     |
| DROPSAFE ACTI-LANCE 23G        | 2    | QL     |
| DROPSAFE MEDLANCE LANCET 30G   | 2    | QL     |
| DRUG MART ON-THE-GO LANCET 30G | 2    | QL     |
| DRUG MART UNILET LANCETS 28G   | 2    | QL     |
| DRUG MART UNILET LANCETS 30G   | 2    | QL     |
| DRUG MART UNILET LANCETS 33G   | 2    | QL     |
| EASY COMFORT LANCETS           | 2    | QL     |
| EASY COMFORT LANCETS TWIST TOP | 2    | QL     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name                             | Tier | Notes  |
|---------------------------------------|------|--------|
| easy mini eject lancing device        | 2    |        |
| easy mini lancing device              | 2    |        |
| <b>EASY TOUCH LANCETS 21G</b>         | 2    | QL     |
| <b>EASY TOUCH LANCETS 23G</b>         | 2    | QL     |
| <b>EASY TOUCH LANCETS 26G</b>         | 2    | QL     |
| <b>EASY TOUCH LANCETS 28G</b>         | 2    | QL     |
| <b>EASY TOUCH LANCETS 28G/TWIST</b>   | 2    | QL     |
| <b>EASY TOUCH LANCETS 30G</b>         | 2    | QL     |
| <b>EASY TOUCH LANCETS 30G/TWIST</b>   | 2    | QL     |
| <b>EASY TOUCH LANCETS 32G</b>         | 2    | QL     |
| <b>EASY TOUCH LANCETS 32G/TWIST</b>   | 2    | QL     |
| <b>EASY TOUCH LANCETS 33G/TWIST</b>   | 2    | QL     |
| <b>EASY TOUCH LANCING DEVICE</b>      | 2    |        |
| <b>EASY TOUCH SAFETY LANCETS 21G</b>  | 2    | QL     |
| <b>EASY TOUCH SAFETY LANCETS 23G</b>  | 2    | QL     |
| <b>EASY TOUCH SAFETY LANCETS 26G</b>  | 2    | QL     |
| <b>EASY TOUCH SAFETY LANCETS 28G</b>  | 2    | QL     |
| <b>EMBRACE LANCETS ULTRA THIN 30G</b> | 2    | QL     |
| embrace lancing device/ejector        | 2    |        |
| <b>EMBRACE PRESSURE ACTIVATED 21G</b> | 2    | QL     |
| <b>EMBRACE PRESSURE ACTIVATED 28G</b> | 2    | QL     |
| <b>ENLITE GLUCOSE SENSOR</b>          | 3    | PA; QL |
| <b>EVERSENSE 365 SENSOR/HOLDER</b>    | 3    | PA; QL |
| <b>EVERSENSE 365 SMART TRANSMIT</b>   | 3    | PA; QL |
| <b>EVERSENSE SENSOR/HOLDER</b>        | 3    | PA; QL |

| Drug Name                             | Tier | Notes  |
|---------------------------------------|------|--------|
| <b>EVERSENSE SMART TRANSMITTER</b>    | 3    | PA; QL |
| <b>FIFTY50 SAFETY SEAL LANCETS</b>    | 2    | QL     |
| <b>FIFTY50 UNILET LANCETS 33G</b>     | 2    | QL     |
| <b>FINGERSTIX LANCETS</b>             | 2    | QL     |
| fondcircle lancing device             | 2    |        |
| fondcircle single use lancets         | 2    | QL     |
| <b>FORA LANCETS</b>                   | 2    | QL     |
| <b>FORA LANCING DEVICE</b>            | 2    |        |
| <b>FREESTYLE LANCETS</b>              | 2    | QL     |
| <b>FREESTYLE UNISTICK II LANCETS</b>  | 2    | QL     |
| <b>GENTEEL BUTTERFLY TOUCH LANCET</b> | 2    | QL     |
| <b>GENTEEL CONTACT TIPS (BLUE)</b>    | 2    |        |
| <b>GENTEEL CONTACT TIPS (CLEAR)</b>   | 2    |        |
| <b>GENTEEL CONTACT TIPS (GREEN)</b>   | 2    |        |
| <b>GENTEEL CONTACT TIPS (ORANGE)</b>  | 2    |        |
| <b>GENTEEL CONTACT TIPS (RAINBOW)</b> | 2    |        |
| <b>GENTEEL CONTACT TIPS (VIOLET)</b>  | 2    |        |
| <b>GENTEEL CONTACT TIPS (YELLOW)</b>  | 2    |        |
| <b>GENTEEL LANCING KIT (BLUE) KIT</b> | 2    |        |
| <b>GENTEEL NOZZLES</b>                | 2    |        |
| <b>GENTEEL PLUS LANCING (BLACK)</b>   | 2    |        |
| <b>GENTEEL PLUS LANCING (PURPLE)</b>  | 2    |        |
| <b>GENTEEL PLUS LANCING (WHITE)</b>   | 2    |        |
| <b>GENTEEL PLUS LANCING DEV(BLUE)</b> | 2    |        |
| <b>GENTEEL PLUS LANCING DEV(PINK)</b> | 2    |        |
| <b>GLOBAL INJECT EASE LANCETS 28G</b> | 2    | QL     |
| <b>GLOBAL INJECT EASE LANCETS 30G</b> | 2    | QL     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name                      | Tier | Notes  |
|--------------------------------|------|--------|
| global lancing device          | 2    |        |
| GLUCOCOM LANCETS 28G           | 2    | QL     |
| GLUCOCOM LANCETS 30G           | 2    | QL     |
| GLUCOCOM LANCETS 33G           | 2    | QL     |
| GNP LANCING SYSTEM DEVICE      | 2    |        |
| GNP STERILE LANCETS 28G        | 2    | QL     |
| GNP STERILE LANCETS 30G        | 2    | QL     |
| GNP STERILE LANCETS 33G        | 2    | QL     |
| GOJJI LANCING DEVICE/CLEAR CAP | 2    |        |
| GOJJI STERILE LANCETS          | 2    | QL     |
| GUARDIAN 4 GLUCOSE SENSOR      | 3    | PA; QL |
| GUARDIAN 4 TRANSMITTER         | 3    | PA; QL |
| GUARDIAN LINK 3 TRANSMITTER    | 3    | PA; QL |
| GUARDIAN SENSOR (3)            | 3    | PA; QL |
| GUARDIAN SENSOR 3              | 3    | PA; QL |
| HAEMOLANCE                     | 2    | QL     |
| HAEMOLANCE LOW FLOW LANCETS    | 2    | QL     |
| HAEMOLANCE PLUS                | 2    | QL     |
| HAEMOLANCE PLUS HIGH FLOW      | 2    | QL     |
| HAEMOLANCE PLUS LOW FLOW       | 2    | QL     |
| HAEMOLANCE PLUS MAX FLOW       | 2    | QL     |
| HAEMOLANCE PLUS PEDIATRIC FLOW | 2    | QL     |
| h-e-b incontrol adv lancing    | 2    |        |
| H-E-B INCONTROL LANCETS 28G    | 2    | QL     |
| H-E-B INCONTROL LANCETS 30G    | 2    | QL     |
| H-E-B INCONTROL LANCETS 33G    | 2    | QL     |
| HYPOLANCE AST LANCING KIT      | 2    |        |

| Drug Name                      | Tier | Notes |
|--------------------------------|------|-------|
| HY-VEE LANCETS                 | 2    | QL    |
| HY-VEE THIN LANCETS            | 2    | QL    |
| IHEALTH LANCING DEVICE         | 2    |       |
| IN TOUCH LANCING DEVICE        | 2    |       |
| IN TOUCH STERILE LANCETS 30G   | 2    | QL    |
| KINNEY LANCETS                 | 2    | QL    |
| KINNEY THIN LANCETS            | 2    | QL    |
| KROGER AUTOLET LANCING DEVICE  | 2    |       |
| KROGER HEALTHPRO LANCET 26G    | 2    | QL    |
| KROGER LANCETS                 | 2    | QL    |
| KROGER LANCETS SUPER THIN      | 2    | QL    |
| KROGER LANCETS THIN            | 2    | QL    |
| lancet device                  | 2    |       |
| lancet device with ejector     | 2    |       |
| LANCETS                        | 2    | QL    |
| LANCETS 28G THIN               | 2    | QL    |
| LANCETS 30G                    | 2    | QL    |
| LANCETS 33G                    | 2    | QL    |
| LANCETS MICRO THIN 33G         | 2    | QL    |
| LANCETS SUPER THIN             | 2    | QL    |
| LANCETS SUPER THIN 28G         | 2    | QL    |
| LANCETS ULTRA THIN             | 2    | QL    |
| LANCETS ULTRA THIN 30G         | 2    | QL    |
| lancing device                 | 2    |       |
| LANZO                          | 2    |       |
| leader advanced lancing device | 2    |       |
| LIBERTY MEDICAL LANCETS        | 2    | QL    |
| LITE TOUCH LANCETS             | 2    | QL    |
| LITE TOUCH LANCING PEN         | 2    |       |
| LITETOUCH LANCETS              | 2    | QL    |
| LIVE BETTER LANCET SUPER THIN  | 2    | QL    |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name                      | Tier | Notes |
|--------------------------------|------|-------|
| MEDICHOICE SAFETY LANCET       | 2    | QL    |
| MEDICHOICE SAFETY LANCET EXTRA | 2    | QL    |
| MEDICHOICE SAFETY LANCET NORM  | 2    | QL    |
| MEDLANCE PLUS EXTRA 21G        | 2    | QL    |
| MEDLANCE PLUS LITE 25G         | 2    | QL    |
| MEDLANCE PLUS SPECIAL 0.8MM    | 2    | QL    |
| MEDLANCE PLUS SUPERLITE 30G    | 2    | QL    |
| MEDLANCE PLUS UNIVERSAL 21G    | 2    | QL    |
| MEIJER LANCETS                 | 2    | QL    |
| MEIJER LANCETS UNIVERSAL 21G   | 2    | QL    |
| MEIJER LANCETS UNIVERSAL 30G   | 2    | QL    |
| MEIJER LANCETS UNIVERSAL 33G   | 2    | QL    |
| MICROLET LANCETS               | 2    | QL    |
| MICROLET NEXT LANCING DEVICE   | 2    |       |
| mini lancing device            | 2    |       |
| MM LANCING DEVICE              | 2    |       |
| MM TWIST LANCETS               | 2    | QL    |
| mobile lancets 30g             | 2    | QL    |
| MONOLET LANCETS                | 2    | QL    |
| MONOLET OPD LANCETS            | 2    | QL    |
| MONOLETTOR SAFETY LANCETS      | 2    | QL    |
| multi-lancet device            | 2    |       |
| MULTI-LANCET DEVICE 2 KIT      | 2    |       |
| MYGLUCOHEALTH LANCETS 30G      | 2    | QL    |
| NOVA SAFETY LANCETS 23G        | 2    | QL    |
| NOVA SAFETY LANCETS 28G        | 2    | QL    |
| NOVA SUREFLEX LANCETS          | 2    | QL    |
| NOVA SUREFLEX LANCING DEVICE   | 2    |       |

| Drug Name                      | Tier | Notes |
|--------------------------------|------|-------|
| ONETOUCH DELICA PLUS LANCET30G | 2    | QL    |
| ONETOUCH DELICA PLUS LANCET33G | 2    | QL    |
| ONETOUCH DELICA PLUS LANCING   | 2    |       |
| ONETOUCH DELICA SAFETY LANCING | 2    | QL    |
| ONETOUCH ULTRASOFT 2 LANCETS   | 2    | QL    |
| PERFECT LANCETS 28G            | 2    | QL    |
| PERFECT LANCETS 30G            | 2    | QL    |
| PERFECT POINT SAFETY LANCETS   | 2    | QL    |
| PHARMACIST CHOICE LANCETS      | 2    | QL    |
| PIP LANCETS 28G                | 2    | QL    |
| PIP LANCETS 30G                | 2    | QL    |
| PRO COMFORT LANCETS 30G        | 2    | QL    |
| PRO COMFORT LANCETS 31G        | 2    | QL    |
| pro comfort safety lancets 30g | 2    | QL    |
| PRODIGY LANCETS 28G            | 2    | QL    |
| PRODIGY LANCING DEVICE         | 2    |       |
| PRODIGY SAFETY LANCETS 26G     | 2    | QL    |
| PRODIGY TWIST TOP LANCETS 28G  | 2    | QL    |
| PURE COMFORT LANCETS 30G       | 2    | QL    |
| pure comfort safety lancet 30g | 2    | QL    |
| px advanced lancing device     | 2    |       |
| PX LANCETS MICROTHIN 33G       | 2    | QL    |
| PX LANCETS ULTRA THIN 28G      | 2    | QL    |
| qc advanced lancing device     | 2    |       |
| QC LANCETS SUPER THIN 30G      | 2    | QL    |
| QC LANCETS ULTRA THIN          | 2    | QL    |
| QC UNILET LANCETS 28G          | 2    | QL    |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name                      | Tier | Notes |
|--------------------------------|------|-------|
| QC UNILET LANCETS MICRO THIN   | 2    | QL    |
| READYLANCANCE SAFETY LANCETS   | 2    | QL    |
| REALITY LANCETS                | 2    | QL    |
| REALITY TRIGGER LANCETS        | 2    | QL    |
| RELION LANCET DEVICES 30G      | 2    | QL    |
| RELION LANCETS                 | 2    | QL    |
| RELION LANCETS MICRO-THIN 33G  | 2    | QL    |
| RELION LANCETS THIN 26G        | 2    | QL    |
| RELION LANCETS ULTRA-THIN 30G  | 2    | QL    |
| RELION LANCING DEVICE          | 2    |       |
| RELION ULTRA THIN LANCETS 30G  | 2    | QL    |
| RIGHTEST ALTERNATE SITE ADAPT  | 2    |       |
| RIGHTEST GD500 LANCING DEVICE  | 2    |       |
| RIGHTEST GL300 LANCETS         | 2    | QL    |
| SAFETY LANCET 30G/PRESSURE ACT | 2    | QL    |
| SAFETY LANCETS                 | 2    | QL    |
| SAFETY LANCETS 21G             | 2    | QL    |
| SAFETY LANCETS 23G             | 2    | QL    |
| SAFETY LANCETS 28G             | 2    | QL    |
| saps health plus lancets       | 2    | QL    |
| SAPS HEALTH TWIST TOP LANCETS  | 2    | QL    |
| SAPS TWIST TOP LANCETS         | 2    | QL    |
| SAPSCARE TWIST TOP LANCETS     | 2    | QL    |
| SB LANCETS THIN                | 2    | QL    |
| SB LANCETS ULTRA THIN          | 2    | QL    |
| select-lite device/lancets kit | 2    |       |
| select-lite lancing device     | 2    |       |
| SENSILANCE SAFETY LANCETS 21G  | 2    | QL    |
| SENSILANCE SAFETY LANCETS 26G  | 2    | QL    |

| Drug Name                      | Tier | Notes |
|--------------------------------|------|-------|
| SENSILANCE SAFETY LANCETS 28G  | 2    | QL    |
| SIMPLE DIAGNOSTICS LANCING DEV | 2    |       |
| SINGLE-LET                     | 2    | QL    |
| SMART DIABETES VANTAGE LANCING | 2    |       |
| SMARTEST LANCETS 28G           | 2    | QL    |
| SOLUS V2 LANCETS 28G           | 2    | QL    |
| SOLUS V2 LANCING DEVICE        | 2    |       |
| SOLUS V2 TWIST LANCETS 30G     | 2    | QL    |
| STERILANCE TL                  | 2    | QL    |
| SUPER THIN LANCETS             | 2    | QL    |
| SURE COMFORT LANCETS 18G       | 2    | QL    |
| SURE COMFORT LANCETS 21G       | 2    | QL    |
| SURE COMFORT LANCETS 23G       | 2    | QL    |
| SURE COMFORT LANCETS 28G       | 2    | QL    |
| SURE COMFORT LANCETS 30G       | 2    | QL    |
| sure comfort lancing pen       | 2    |       |
| SURELITE LANCETS               | 2    | QL    |
| TECHLITE AST LANCETS           | 2    | QL    |
| TECHLITE LANCETS               | 2    | QL    |
| TECHLITE LANCETS 26G           | 2    | QL    |
| today's health lancing device  | 2    |       |
| TODAYS HEALTH THIN LANCETS 28G | 2    | QL    |
| TODAYS HEALTH THIN LANCETS 30G | 2    | QL    |
| TRAVEL LANCETS ADVANCED 28G    | 2    | QL    |
| true comfort safety lancets    | 2    | QL    |
| TRUE COMFORT TWIST TOP LANCETS | 2    | QL    |
| TRUEDRAW LANCING DEVICE        | 2    |       |
| TRUEPLUS LANCETS 26G           | 2    | QL    |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name                    | Tier | Notes |
|------------------------------|------|-------|
| TRUEPLUS LANCETS 28G         | 2    | QL    |
| TRUEPLUS LANCETS 30G         | 2    | QL    |
| TRUEPLUS LANCETS 33G         | 2    | QL    |
| TRUEPLUS SAFETY LANCETS 28G  | 2    | QL    |
| twist top lancets 30g        | 2    | QL    |
| ULTI-LANCE AUTOMATIC         | 2    |       |
| ULILET CLASSIC LANCETS       | 2    | QL    |
| ULILET LANCETS               | 2    | QL    |
| ULILET SAFETY LANCETS        | 2    | QL    |
| ULILET SAFETY LANCETS 23G    | 2    | QL    |
| ULTRA THIN LANCETS 31G       | 2    | QL    |
| ULTRA-CARE LANCETS 30G       | 2    | QL    |
| ULTRA-THIN II AUTO LANCET    | 2    | QL    |
| ULTRA-THIN II LANCETS        | 2    | QL    |
| UNILET COMFORTOUCH LANCET    | 2    | QL    |
| UNILET EXCELITE              | 2    | QL    |
| UNILET EXCELITE II           | 2    | QL    |
| UNILET G.P. LANCET           | 2    | QL    |
| UNILET G.P. SUPERLITE LANCET | 2    | QL    |
| UNILET GP 28 ULTRA THIN      | 2    | QL    |
| UNILET LANCET                | 2    | QL    |
| UNILET MICRO-THIN 33G        | 2    | QL    |
| UNILET SUPERLITE LANCET      | 2    | QL    |
| UNILET SUPER-THIN 30G        | 2    | QL    |
| UNILET ULTRA-THIN 28G        | 2    | QL    |
| UNISTIK 1                    | 2    | QL    |
| UNISTIK 2                    | 2    | QL    |
| UNISTIK 2 COMFORT            | 2    | QL    |

| Drug Name                      | Tier | Notes |
|--------------------------------|------|-------|
| UNISTIK 2 EXTRA                | 2    | QL    |
| UNISTIK 2 NEONATAL             | 2    | QL    |
| UNISTIK 2 NORMAL               | 2    | QL    |
| UNISTIK 2 SUPER                | 2    | QL    |
| UNISTIK 3                      | 2    | QL    |
| UNISTIK 3 COMFORT              | 2    | QL    |
| UNISTIK 3 EXTRA                | 2    | QL    |
| UNISTIK 3 GENTLE               | 2    | QL    |
| UNISTIK 3 NEONATAL             | 2    | QL    |
| UNISTIK 3 NORMAL               | 2    | QL    |
| UNISTIK CZT COMFORT            | 2    | QL    |
| UNISTIK CZT NORMAL             | 2    | QL    |
| UNISTIK NORMAL                 | 2    | QL    |
| UNISTIK PRO SAFETY LANCET      | 2    | QL    |
| UNISTIK SAFETY LANCETS 28G     | 2    | QL    |
| UNISTIK SAFETY LANCETS 30G     | 2    | QL    |
| UNISTIK TOUCH SAFETY LANC 21G  | 2    | QL    |
| UNISTIK TOUCH SAFETY LANC 23G  | 2    | QL    |
| UNISTIK TOUCH SAFETY LANC 28G  | 2    | QL    |
| UNISTIK TOUCH SAFETY LANC 30G  | 2    | QL    |
| VERIFINE SAFE LANCET MINI 21G  | 2    | QL    |
| VERIFINE SAFE LANCET MINI 23G  | 2    | QL    |
| VERIFINE SAFE LANCET MINI 28G  | 2    | QL    |
| VERIFINE SAFE LANCET MINI 30G  | 2    | QL    |
| VERIFINE UNIVERSAL LANCETS 28G | 2    | QL    |
| VERIFINE UNIVERSAL LANCETS 30G | 2    | QL    |
| VERIFINE UNIVERSAL LANCETS 33G | 2    | QL    |
| VIVAGUARD LANCETS              | 2    | QL    |
| VIVAGUARD LANCETS 30G          | 2    | QL    |
| VIVAGUARD LANCING DEVICE       | 2    |       |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name                                  | Tier | Notes  |
|--|------|--------|
| VIVAGUARD SAFETY LANCETS 28G               | 2    | QL     |
| ZEVX TWIST TOP LANCETS 30G                 | 2    | QL     |
| <b>*INSULIN ADMINISTRATION SUPPLIES***</b> |      |        |
| OMNIPOD 5 DEXG7G6 INTRO GEN 5 KIT          | 2    | PA; QL |
| OMNIPOD 5 DEXG7G6 PODS GEN 5               | 2    | PA; QL |
| OMNIPOD 5 LIBRE2 G6 INTRO GEN5 KIT         | 2    | PA; QL |
| OMNIPOD 5 LIBRE2 PLUS G6 PODS              | 2    | PA; QL |
| OMNIPOD DASH INTRO (GEN 4) KIT             | 2    | PA; QL |
| OMNIPOD DASH PDM (GEN 4) KIT               | 2    | PA; QL |
| OMNIPOD DASH PODS (GEN 4)                  | 2    | PA; QL |
| TWIST REFILL KIT KIT                       | 2    | PA; QL |
| TWIST REFILL KIT/INFUSION SET KIT          | 2    | PA; QL |
| TWIST STARTER KIT KIT                      | 2    | PA; QL |
| <b>*NEEDLES &amp; SYRINGES***</b>          |      |        |
| 1ST TIER UNIFINE PENTIPS                   | 3    | ST; QL |
| 1ST TIER UNIFINE PENTIPS PLUS              | 3    | ST; QL |
| ADVOCATE INSULIN PEN NEEDLE                | 3    | ST; QL |
| ADVOCATE INSULIN PEN NEEDLES               | 3    | ST; QL |
| ADVOCATE INSULIN SYRINGE                   | 3    | ST; QL |
| aq insulin syringe                         | 3    | ST; QL |
| aqinject pen needle                        | 3    | ST; QL |
| ASSURE ID DUO PRO PEN NEEDLES              | 3    | ST; QL |
| ASSURE ID PRO PEN NEEDLES                  | 3    | ST; QL |
| ASSURE ID SAFETY PEN NEEDLES 30G X 8 MM    | 3    | ST; QL |
| aum insulin safety pen needle              | 3    | ST; QL |
| AUM MINI INSULIN PEN NEEDLE                | 3    | ST; QL |

| Drug Name  | Tier | Notes  |
|--|------|--------|
| aum pen needle   | 3    | ST; QL |
| AUM READYGARD DUO PEN NEEDLE   | 3    | ST; QL |
| AUM SAFETY PEN NEEDLE  | 3    | ST; QL |
| AURORA PEN NEEDLES   | 3    | ST; QL |
| BD AUTOSHIELD DUO  | 2    | QL     |
| BD INS SYR ULTRAFINE 1/2UNIT   | 2    | QL     |
| BD INSULIN SYR ULTRAFINE II 31G X 5/16" 0.3 ML   | 2    | QL     |
| BD INSULIN SYRINGE 27.5G X 5/8" 2 ML, 27G X 1/2" 1 ML, 29G X 1/2" 0.3 ML, 29G X 1/2" 0.5 ML, 29G X 1/2" 1 ML, U-100 1 ML   | 2    | QL     |
| BD INSULIN SYRINGE HALF-UNIT   | 2    | QL     |
| BD INSULIN SYRINGE MICROFINE 27G X 5/8" 1 ML, 28G X 1/2" 0.5 ML, 28G X 1/2" 1 ML   | 2    | QL     |
| BD INSULIN SYRINGE U/F 30G X 1/2" 1 ML   | 2    | QL     |
| BD INSULIN SYRINGE U-500   | 2    | QL     |
| BD INSULIN SYRINGE ULTRAFINE 29G X 1/2" 0.3 ML, 29G X 1/2" 0.5 ML, 30G X 1/2" 0.3 ML, 30G X 1/2" 0.5 ML, 30G X 1/2" 1 ML, 31G X 5/16" 0.3 ML, 31G X 5/16" 0.5 ML, 31G X 5/16" 1 ML | 2    | QL     |
| BD PEN NEEDLE MICRO ULTRAFINE  | 2    | QL     |
| BD PEN NEEDLE MINI ULTRAFINE   | 2    | QL     |
| BD PEN NEEDLE NANO 2ND GEN   | 2    | QL     |
| BD PEN NEEDLE NANO ULTRAFINE   | 2    | QL     |
| BD PEN NEEDLE ORIG ULTRAFINE   | 2    | QL     |
| BD PEN NEEDLE SHORT ULTRAFINE  | 2    | QL     |
| BD SAFETYGLIDE INSULIN SYRINGE   | 2    | QL     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier | Notes  |
|--|------|--------|
| BD VEO INSULIN SYR U/F 1/2UNIT   | 2    | QL     |
| BD VEO INSULIN SYR ULTRAFINE   | 2    | QL     |
| CAREFINE PEN NEEDLES   | 3    | ST; QL |
| CAREONE INSULIN SYRINGE  | 3    | ST; QL |
| CAREONE UNIFINE PENTIPS PLUS   | 3    | ST; QL |
| CARETOUCH INSULIN SYRINGE  | 3    | ST; QL |
| CARETOUCH PEN NEEDLES  | 3    | ST; QL |
| CEQR SIMPLICITY INSERTER   | 2    | QL     |
| CLEVER CHOICE COMFORT EZ 29G X 12MM , 33G X 4 MM   | 3    | ST; QL |
| COMFORT EZ INSULIN SYRINGE   | 3    | ST; QL |
| COMFORT EZ MICRO PEN NEEDLES   | 3    | ST; QL |
| COMFORT EZ PEN NEEDLES   | 3    | ST; QL |
| COMFORT EZ PRO PEN NEEDLES   | 3    | ST; QL |
| COMFORT EZ SHORT PEN NEEDLES   | 3    | ST; QL |
| COMFORT TOUCH INSULIN PEN NEED   | 3    | ST; QL |
| DIATHRIVE PEN NEEDLE   | 3    | ST; QL |
| DROPLET INSULIN SYRINGE 29G X 1/2" 0.3 ML, 29G X 1/2" 0.5 ML, 29G X 1/2" 1 ML, 30G X 1/2" 0.3 ML, 30G X 1/2" 0.5 ML, 30G X 1/2" 1 ML, 30G X 15/64" 0.3 ML, 30G X 15/64" 0.5 ML, 30G X 15/64" 1 ML, 30G X 5/16" 0.3 ML, 30G X 5/16" 0.5 ML, 30G X 5/16" 1 ML, 31G X 15/64" 0.3 ML, 31G X 15/64" 0.5 ML, 31G X 15/64" 1 ML, 31G X 5/16" 0.3 ML, 31G X 5/16" 0.5 ML, 31G X 5/16" 1 ML | 3    | ST; QL |
| DROPLET MICRON   | 3    | ST; QL |

| Drug Name   | Tier | Notes  |
|---|------|--------|
| DROPLET PEN NEEDLES   | 3    | ST; QL |
| DROPSAFE AUTOPROTECT DUO  | 3    | ST; QL |
| DROPSAFE SAFETY PEN NEEDLES   | 3    | ST; QL |
| DROPSAFE SAFETY SYRINGE/NEEDLE  | 3    | ST; QL |
| DRUG MART UNIFINE PENTIPS 29G X 12MM , 31G X 6 MM , 31G X 8 MM  | 3    | ST; QL |
| DRUG MART UNIFINE PENTIPS PLUS  | 3    | ST; QL |
| easy comfort insulin syringe 29g x 5/16" 0.5 ml, 29g x 5/16" 1 ml, 31g x 1/2" 0.3 ml, 31g x 5/16" 0.3 ml  | 3    | ST; QL |
| EASY COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML, 30G X 1/2" 1 ML, 30G X 5/16" 0.5 ML, 30G X 5/16" 1 ML, 31G X 5/16" 0.5 ML, 31G X 5/16" 1 ML, 32G X 5/16" 0.5 ML, 32G X 5/16" 1 ML | 3    | ST; QL |
| easy comfort pen needles 29g x 4mm , 29g x 5mm  | 3    | ST; QL |
| EASY COMFORT PEN NEEDLES 31G X 5 MM , 31G X 6 MM , 31G X 8 MM , 32G X 4 MM , 33G X 4 MM , 33G X 5 MM , 33G X 6 MM   | 3    | ST; QL |
| EASY GLIDE PEN NEEDLES  | 3    | ST; QL |
| EASY TOUCH FLIPLOCK INSULIN SY  | 3    | ST; QL |
| EASY TOUCH INSULIN BARRELS  | 3    | ST; QL |
| EASY TOUCH INSULIN SAFETY SYR   | 3    | ST; QL |
| EASY TOUCH INSULIN SYRINGE  | 3    | ST; QL |
| EASY TOUCH PEN NEEDLES  | 3    | ST; QL |
| EASY TOUCH SAFETY PEN NEEDLES   | 3    | ST; QL |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier | Notes  |
|--|------|--------|
| EASY TOUCH SHEATHLOCK SYRINGE 29G X 1/2" 1 ML, 30G X 1/2" 1 ML, 30G X 5/16" 1 ML, 31G X 5/16" 1 ML | 3    | ST; QL |
| EMBECTA AUTOSHIELD DUO   | 2    | QL     |
| EMBECTA INS SYR U/F 1/2 UNIT   | 2    | QL     |
| EMBECTA INSULIN SYR ULTRAFINE  | 2    | QL     |
| EMBECTA INSULIN SYRINGE  | 2    | QL     |
| EMBECTA INSULIN SYRINGE U-100 27G X 5/8" 1 ML  | 2    | QL     |
| EMBECTA INSULIN SYRINGE U-500  | 2    | QL     |
| EMBECTA PEN NEEDLE NANO  | 2    | QL     |
| EMBECTA PEN NEEDLE NANO 2 GEN  | 2    | QL     |
| EMBECTA PEN NEEDLE ULTRAFINE   | 2    | QL     |
| EMBRACE PEN NEEDLES  | 3    | ST; QL |
| FIFTY50 PEN NEEDLES  | 3    | ST; QL |
| FIFTY50 SUPERIOR COMFORT SYR   | 3    | ST; QL |
| GLOBAL EASE INJECT PEN NEEDLES   | 3    | ST; QL |
| GLOBAL EASY GLIDE INSULIN SYR  | 3    | ST; QL |
| GLOBAL EASY GLIDE PEN NEEDLES  | 3    | ST; QL |
| GLOBAL INJECT EASE INSULIN SYR   | 3    | ST; QL |
| GLOBAL INSULIN SYRINGES  | 3    | ST; QL |
| GLUCOPRO INSULIN SYRINGE   | 3    | ST; QL |
| GNP INSULIN SYRINGE 31G X 5/16" 0.5 ML, 31G X 5/16" 1 ML   | 3    | ST; QL |
| GNP INSULIN SYRINGES   | 3    | ST; QL |
| GNP INSULIN SYRINGES 28GX1/2"  | 3    | ST; QL |
| GNP INSULIN SYRINGES 29GX1/2"  | 3    | ST; QL |

| Drug Name   | Tier | Notes  |
|---|------|--------|
| GNP INSULIN SYRINGES 30GX5/16"  | 3    | ST; QL |
| GNP INSULIN SYRINGES 31GX5/16"  | 3    | ST; QL |
| gnp pen needles   | 3    | ST; QL |
| GNP ULTICARE PEN NEEDLES  | 3    | ST; QL |
| GNP ULTIGUARD SAFEPACK NEEDLE   | 3    | ST; QL |
| GNP ULTRA COM INSULIN SYRINGE 28G X 1/2" 1 ML   | 3    | ST; QL |
| HEALTHWISE INSULIN SYR/NEEDLE   | 3    | ST; QL |
| HEALTHWISE MICRON PEN NEEDLES   | 3    | ST; QL |
| HEALTHWISE SHORT PEN NEEDLES  | 3    | ST; QL |
| H-E-B INCONTROL PEN NEEDLES   | 3    | ST; QL |
| H-E-B INCONTROL UNIFINE PENTIP  | 3    | ST; QL |
| HM ULTICARE INSULIN SYRINGE   | 3    | ST; QL |
| HM ULTICARE MINI PEN NEEDLES  | 3    | ST; QL |
| HM ULTICARE SHORT PEN NEEDLES   | 3    | ST; QL |
| INCONTROL ULTICARE PEN NEEDLES  | 3    | ST; QL |
| INSULIN SYRINGE 28G X 1/2" 0.5 ML, 29G X 1/2" 0.3 ML, 29G X 1/2" 1 ML, 30G X 5/16" 0.3 ML, 30G X 5/16" 0.5 ML, 30G X 5/16" 1 ML, 31G X 5/16" 0.3 ML, 31G X 5/16" 0.5 ML, 31G X 5/16" 1 ML | 3    | ST; QL |
| insulin syringe-needle u-100 27g x 1/2" 0.5 ml, 27g x 1/2" 1 ml, 28g x 1/2" 0.5 ml, 28g x 1/2" 1 ml, 30g x 1/2" 1 ml  | 3    | ST; QL |
| INSULIN SYRINGE-NEEDLE U-100 29G X 1/2" 0.5 ML, 29G X 1/2" 1 ML, 30G X 5/16" 0.3 ML, 30G X 5/16" 0.5 ML, 30G X 5/16" 1 ML, 31G X 5/16" 0.3 ML, 31G X 5/16" 0.5 ML, 31G X 5/16" 1 ML       | 3    | ST; QL |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier | Notes  |
|--|------|--------|
| INSUPEN PEN NEEDLES<br>29G X 12MM , 31G X 5<br>MM , 31G X 8 MM , 32G X<br>4 MM             | 3    | ST; QL |
| INSUPEN32G EXTR3ME   | 3    | ST; QL |
| KINRAY INSULIN<br>SYRINGE 29G X 1/2" 0.5<br>ML   | 3    | ST; QL |
| KROGER PEN NEEDLES<br>31G X 5 MM , 31G X 6<br>MM , 31G X 8 MM , 32G X<br>4 MM , 33G X 4 MM | 3    | ST; QL |
| LEADER UNIFINE<br>PENTIPS  | 3    | ST; QL |
| LEADER UNIFINE<br>PENTIPS PLUS   | 3    | ST; QL |
| LITETOUCH INSULIN<br>SYRINGE   | 3    | ST; QL |
| LITETOUCH PEN<br>NEEDLES   | 3    | ST; QL |
| MAGELLAN INSULIN<br>SAFETY SYR   | 3    | ST; QL |
| MARATHON MEDICAL<br>PENTIPS  | 3    | ST; QL |
| MAXICOMFORT II PEN<br>NEEDLE   | 3    | ST; QL |
| MAXI-COMFORT<br>INSULIN SYRINGE  | 3    | ST; QL |
| MAXI-COMFORT<br>SAFETY PEN NEEDLE  | 3    | ST; QL |
| MAXICOMFORT SYR<br>27G X 1/2"  | 3    | ST; QL |
| MEDIC INSULIN<br>SYRINGE   | 3    | ST; QL |
| MEDICINE SHOPPE PEN<br>NEEDLES 29G X 12MM ,<br>31G X 8 MM                                  | 3    | ST; QL |
| MEIJER PEN NEEDLES   | 3    | ST; QL |
| MICRODOT PEN<br>NEEDLE   | 3    | ST; QL |
| MM INSULIN<br>SYRINGE/NEEDLE   | 3    | ST; QL |
| MM PEN NEEDLES   | 3    | ST; QL |
| MONOJECT INSULIN<br>SYRINGE  | 3    | ST; QL |

| Drug Name  | Tier | Notes  |
|--|------|--------|
| MONOJECT ULTRA<br>COMFORT SYRINGE<br>28G X 1/2" 0.5 ML, 28G X<br>1/2" 1 ML, 29G X 1/2" 0.3<br>ML, 29G X 1/2" 0.5 ML,<br>29G X 1/2" 1 ML, 30G X<br>5/16" 0.3 ML, 30G X 5/16"<br>0.5 ML, 31G X 5/16" 0.3<br>ML, 31G X 5/16" 0.5 ML | 3    | ST; QL |
| NOVOFINE PEN<br>NEEDLE   | 3    | ST; QL |
| NOVOFINE PLUS PEN<br>NEEDLE  | 3    | ST; QL |
| PC UNIFINE PENTIPS<br>31G X 5 MM , 31G X 6<br>MM , 31G X 8 MM  | 3    | ST; QL |
| pen needle/5-bevel tip   | 3    | ST; QL |
| PEN NEEDLES  | 3    | ST; QL |
| PENTIPS 29G X 12MM ,<br>31G X 5 MM , 31G X 6<br>MM , 31G X 8 MM , 32G X<br>4 MM , 32G X 6 MM   | 3    | ST; QL |
| PENTIPS GENERIC PEN<br>NEEDLES   | 3    | ST; QL |
| pip pen needles 31g x 5mm  | 3    | ST; QL |
| pip pen needles 32g x 4mm  | 3    | ST; QL |
| PRECISION SURE-DOSE<br>SYRINGE 30G X 5/16" 0.3<br>ML   | 3    | ST; QL |
| PREFERRED PLUS<br>UNIFINE PENTIPS 29G X<br>12MM  | 3    | ST; QL |
| PREVENT DROPSAFE<br>PEN NEEDLES  | 3    | ST; QL |
| PREVENT SAFETY PEN<br>NEEDLES  | 3    | ST; QL |
| PRO COMFORT<br>INSULIN SYRINGE   | 3    | ST; QL |
| PRO COMFORT PEN<br>NEEDLES 32G X 4 MM ,<br>32G X 5 MM , 32G X 6<br>MM , 32G X 8 MM   | 3    | ST; QL |
| PRODIGY INSULIN<br>SYRINGE   | 3    | ST; QL |
| PURE COMFORT PEN<br>NEEDLE   | 3    | ST; QL |
| pure comfort safety pen<br>needle  | 3    | ST; QL |
| PX INSULIN SYRINGE<br>30G X 1/2" 0.5 ML  | 3    | ST; QL |
| PX MINI PEN NEEDLES  | 3    | ST; QL |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier | Notes  |
|---|------|--------|
| QC PEN NEEDLES  | 3    | ST; QL |
| QC UNIFINE PENTIPS  | 3    | ST; QL |
| QUICK TOUCH INSULIN PEN NEEDLE  | 3    | ST; QL |
| raya sure pen needle  | 3    | ST; QL |
| REALITY INSULIN SYRINGE   | 3    | ST; QL |
| RELION INSULIN SYRINGE 29G X 1/2" 0.5 ML, 31G X 15/64" 0.3 ML, 31G X 15/64" 0.5 ML, 31G X 15/64" 1 ML, 31G X 5/16" 0.3 ML, 31G X 5/16" 0.5 ML, 31G X 5/16" 1 ML | 3    | ST; QL |
| RELION PEN NEEDLES 31G X 6 MM , 31G X 8 MM , 32G X 4 MM   | 3    | ST; QL |
| safety pen needles  | 3    | ST; QL |
| SB INSULIN SYRINGE  | 3    | ST; QL |
| SECURESAFE INSULIN SYRINGE  | 3    | ST; QL |
| SECURESAFE SAFETY PEN NEEDLES   | 3    | ST; QL |
| SURE COMFORT INSULIN SYRINGE  | 3    | ST; QL |
| SURE COMFORT PEN NEEDLES 29G X 12.7MM , 30G X 8 MM , 31G X 5 MM , 31G X 8 MM , 32G X 4 MM , 32G X 6 MM  | 3    | ST; QL |
| sure comfort pen needles 31g x 6 mm   | 3    | ST; QL |
| TECHLITE INSULIN SYRINGE 30G X 1/2" 1 ML, 31G X 15/64" 0.3 ML, 31G X 15/64" 0.5 ML, 31G X 15/64" 1 ML, 31G X 5/16" 0.3 ML, 31G X 5/16" 0.5 ML, 31G X 5/16" 1 ML | 3    | ST; QL |
| TECHLITE PEN NEEDLES 29G X 12MM , 31G X 5 MM , 31G X 8 MM , 32G X 4 MM , 32G X 6 MM   | 3    | ST; QL |
| TECHLITE PLUS PEN NEEDLES   | 3    | ST; QL |
| TODAYS HEALTH PEN NEEDLES   | 3    | ST; QL |
| TODAYS HEALTH SHORT PEN NEEDLE  | 3    | ST; QL |

| Drug Name   | Tier | Notes  |
|---|------|--------|
| true comfort insulin syringe 30g x 1/2" 0.5 ml, 30g x 1/2" 1 ml, 30g x 5/16" 0.5 ml, 30g x 5/16" 1 ml, 32g x 5/16" 1 ml | 3    | ST; QL |
| TRUE COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML, 31G X 5/16" 1 ML   | 3    | ST; QL |
| TRUE COMFORT PEN NEEDLES  | 3    | ST; QL |
| TRUE COMFORT PRO INSULIN SYR  | 3    | ST; QL |
| TRUE COMFORT PRO PEN NEEDLES  | 3    | ST; QL |
| true comfort safety pen needle  | 3    | ST; QL |
| TRUEPLUS 5-BEVEL PEN NEEDLES  | 3    | ST; QL |
| TRUEPLUS INSULIN SYRINGE  | 3    | ST; QL |
| ULTICARE INSULIN SAFETY SYR   | 3    | ST; QL |
| ULTICARE INSULIN SYR 1/2 UNIT   | 3    | ST; QL |
| ULTICARE INSULIN SYRINGE  | 3    | ST; QL |
| ULTICARE MICRO PEN NEEDLES  | 3    | ST; QL |
| ULTICARE MINI PEN NEEDLES   | 3    | ST; QL |
| ULTICARE PEN NEEDLES 29G X 12.7MM , 31G X 5 MM  | 3    | ST; QL |
| ULTICARE SHORT PEN NEEDLES  | 3    | ST; QL |
| ULTIGUARD SAFEPAK PEN NEEDLE  | 3    | ST; QL |
| ULTIGUARD SAFEPAK SYR/NEEDLE  | 3    | ST; QL |
| ULTILET PEN NEEDLE  | 3    | ST; QL |
| ULTRA FLO INSULIN PEN NEEDLES   | 3    | ST; QL |
| ULTRA FLO INSULIN SYR 1/2 UNIT  | 3    | ST; QL |
| ULTRA FLO INSULIN SYRINGE   | 3    | ST; QL |
| ULTRA THIN PEN NEEDLES  | 3    | ST; QL |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier | Notes  |
|--|------|--------|
| ULTRACARE INSULIN SYRINGE  | 3    | ST; QL |
| ULTRACARE PEN NEEDLES  | 3    | ST; QL |
| ULTRA-THIN II INS SYR SHORT                                      | 3    | ST; QL |
| ULTRA-THIN II INSULIN SYRINGE 29G X 1/2" 0.5 ML, 29G X 1/2" 1 ML | 3    | ST; QL |
| ULTRA-THIN II MINI PEN NEEDLE                                    | 3    | ST; QL |
| ULTRA-THIN II PEN NEEDLE SHORT                                   | 3    | ST; QL |
| ULTRA-THIN II PEN NEEDLES  | 3    | ST; QL |
| UNIFINE OTC PEN NEEDLES  | 3    | ST; QL |
| UNIFINE PENTIPS  | 3    | ST; QL |
| UNIFINE PENTIPS PLUS   | 3    | ST; QL |
| UNIFINE PROTECT PEN NEEDLE                                       | 3    | ST; QL |
| UNIFINE SAFECONTROL PEN NEEDLE                                   | 3    | ST; QL |
| UNIFINE ULTRA PEN NEEDLE   | 3    | ST; QL |
| VANISHPOINT INSULIN SYRINGE                                      | 3    | ST; QL |
| VERIFINE INSULIN PEN NEEDLE                                      | 3    | ST; QL |
| VERIFINE INSULIN SYRINGE   | 3    | ST; QL |
| VERIFINE PLUS PEN NEEDLE   | 3    | ST; QL |
| WEGMANS UNIFINE PENTIPS PLUS                                     | 3    | ST; QL |
| ZEV RX INSULIN SYRINGE   | 3    | ST; QL |
| ZEV RX PEN NEEDLES   | 3    | ST; QL |
| <b>*MIGRAINE PRODUCTS*</b>                                       |      |        |
| <b>*CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAG (CGRP)***</b> |      |        |
| NURTEC ORAL TABLET DISPERSIBLE                                   | 2    | QL     |
| QULIPTA ORAL TABLET  | 2    | QL     |

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| UBRELVY ORAL TABLET  | 2        | QL     |
| <b>*CGRP RECEPTOR ANTAGONISTS - MONOCLONAL ANTIBODIES***</b>   |          |        |
| AIMOVIG SUBCUTANEOUS SOLUTION AUTO-INJECTOR                    | 3        | QL     |
| AJOVY SUBCUTANEOUS SOLUTION AUTO-INJECTOR                      | 3        | QL     |
| AJOVY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE                  | 3        | QL     |
| EMGALITY (300 MG DOSE) SUBCUTANEOUS SOLUTION PREFILLED SYRINGE | 3        | QL     |
| EMGALITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR                   | 3        | QL     |
| EMGALITY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE               | 3        | QL     |
| <b>*ERGOT COMBINATIONS***</b>                                  |          |        |
| ergotamine-caffeine oral tablet                                | 1 or 1b* |        |
| migergot rectal suppository                                    | 1 or 1b* |        |
| <b>*MIGRAINE PRODUCTS***</b>                                   |          |        |
| dihydroergotamine mesylate injection solution                  | 1 or 1b* | PA; QL |
| <b>*SELECTIVE SEROTONIN AGONISTS 5-HT(1)***</b>                |          |        |
| almotriptan malate oral tablet                                 | 1 or 1b* | QL     |
| eletriptan hydrobromide oral tablet                            | 1 or 1b* | QL     |
| frovatriptan succinate oral tablet                             | 1 or 1b* | ST; QL |
| naratriptan hcl oral tablet                                    | 1 or 1b* | QL     |
| rizatriptan benzoate oral tablet                               | 1 or 1b* | QL     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| rizatriptan benzoate oral tablet dispersible                               | 1 or 1b* | QL     |
| sumatriptan nasal solution   | 1 or 1b* | QL     |
| sumatriptan succinate oral tablet  | 1 or 1b* | QL     |
| sumatriptan succinate subcutaneous solution 6 mg/0.5ml                     | 1 or 1b* | QL     |
| sumatriptan succinate subcutaneous solution auto-injector 6 mg/0.5ml       | 1 or 1b* | QL     |
| zolmitriptan nasal solution  | 1 or 1b* | ST; QL |
| zolmitriptan oral tablet   | 1 or 1b* | QL     |
| zolmitriptan oral tablet dispersible                                       | 1 or 1b* | QL     |
| <b>*MINERALS &amp; ELECTROLYTES*</b>                                       |          |        |
| <b>*BICARBONATES***</b>  |          |        |
| sodium acetate intravenous solution 4 meq/ml                               | 1 or 1b* |        |
| sodium bicarbonate intravenous solution 4.2 %                              | 1 or 1b* |        |
| <b>*CALCIUM COMBINATIONS***</b>  |          |        |
| CALCIUM GLUCONATE-NACL INTRAVENOUS SOLUTION 1-0.8 GM/100ML-%               | 3        |        |
| <b>*ELECTROLYTES &amp; DEXTROSE***</b>                                     |          |        |
| DEXTROSE 5%/ELECTROLYTE #48 INTRAVENOUS SOLUTION                           | 3        |        |
| dextrose in lactated ringers intravenous solution                          | 1 or 1b* |        |
| dextrose-nacl intravenous solution 5-0.9 %                                 | 3        |        |
| DEXTROSE-SODIUM CHLORIDE INTRAVENOUS SOLUTION 10-0.2 %                     | 3        |        |
| dextrose-sodium chloride intravenous solution 10-0.45 %, 5-0.2 %, 5-0.33 % | 3        |        |
| IONOSOL-MB IN D5W INTRAVENOUS SOLUTION                                     | 3        |        |

| Drug Name   | Tier     | Notes |
|---|----------|-------|
| ISOLYTE-P IN D5W INTRAVENOUS SOLUTION   | 3        |       |
| kcl in dextrose-nacl intravenous solution 20-5-0.2 meq/l-%-%, 20-5-0.45 meq/l-%-%, 20-5-0.9 meq/l-%-% | 3        |       |
| KCL-LACTATED RINGERS-D5W INTRAVENOUS SOLUTION   | 3        |       |
| NORMOSOL-M IN D5W INTRAVENOUS SOLUTION  | 3        |       |
| NORMOSOL-R IN D5W INTRAVENOUS SOLUTION  | 3        |       |
| potassium cl in dextrose 5% intravenous solution 10 meq/l   | 1 or 1b* |       |
| <b>*ELECTROLYTES PARENTERAL***</b>  |          |       |
| ISOLYTE-S INTRAVENOUS SOLUTION  | 3        |       |
| ISOLYTE-S PH 7.4 INTRAVENOUS SOLUTION   | 3        |       |
| kcl (0.149%) in nacl intravenous solution   | 1 or 1b* |       |
| kcl (0.298%) in nacl intravenous solution   | 1 or 1b* |       |
| multiple electro type 1 ph 5.5 intravenous solution   | 1 or 1b* |       |
| multiple electro type 1 ph 7.4 intravenous solution   | 1 or 1b* |       |
| NORMOSOL-R INTRAVENOUS SOLUTION   | 3        |       |
| NORMOSOL-R PH 7.4 INTRAVENOUS SOLUTION  | 3        |       |
| PLASMA-LYTE 148 INTRAVENOUS SOLUTION  | 3        |       |
| ringers intravenous solution  | 1 or 1b* |       |
| TPN ELECTROLYTES INTRAVENOUS CONCENTRATE  | 3        |       |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes |
|---|----------|-------|
| <b>*FLUORIDE COMBINATIONS***</b>                                    |          |       |
| FLORIVA ORAL LIQUID   | 3        | ST    |
| <b>*FLUORIDE***</b>   |          |       |
| sodium fluoride oral solution 1.1 (0.5 f) mg/ml                     | 1 or 1a* | \$0   |
| sodium fluoride oral tablet   | 1 or 1a* | \$0   |
| sodium fluoride oral tablet chewable                                | 1 or 1a* | \$0   |
| <b>*MAGNESIUM***</b>  |          |       |
| magnesium sulfate intravenous solution 3 gm/100ml                   | 1 or 1b* |       |
| <b>*PHOSPHATE***</b>  |          |       |
| GLYCOPHOS INTRAVENOUS SOLUTION                                      | 3        |       |
| phosphorous oral tablet   | 1 or 1b* |       |
| phospho-trin 250 neutral oral tablet                                | 1 or 1b* |       |
| phospho-trin k500 oral tablet                                       | 1 or 1b* |       |
| potassium phosphates intravenous solution 45 mmole/15ml             | 1 or 1b* |       |
| potassium phosphates-nacl intravenous solution 15 mmol/100ml        | 3        |       |
| sodium phosphates intravenous solution 15 mmole/5ml, 150 mmole/50ml | 1 or 1b* |       |
| <b>*POTASSIUM***</b>  |          |       |
| klor-con 10 oral tablet extended release                            | 1 or 1b* |       |
| klor-con m10 oral tablet extended release                           | 1 or 1a* |       |
| klor-con m15 oral tablet extended release                           | 1 or 1a* |       |
| klor-con m20 oral tablet extended release                           | 1 or 1a* |       |
| klor-con oral packet 20 meq   | 1 or 1b* |       |
| potassium chloride crys er oral tablet extended release             | 1 or 1a* |       |
| potassium chloride er oral capsule extended release                 | 1 or 1b* |       |
| potassium chloride er oral tablet extended release                  | 1 or 1b* |       |

| Drug Name   | Tier     | Notes  |
|---|----------|--------|
| potassium chloride intravenous solution 2 meq/ml                            | 1 or 1b* |        |
| potassium chloride oral packet 20 meq                                       | 1 or 1b* |        |
| potassium chloride oral solution 10 %, 20 meq/15ml (10%), 40 meq/15ml (20%) | 1 or 1b* |        |
| <b>*SODIUM***</b>   |          |        |
| aquastat intravenous solution   | 1 or 1b* |        |
| AQUASTAT SFR INTRAVENOUS SOLUTION   | 3        |        |
| bd posiflush intravenous solution   | 1 or 1b* |        |
| BD POSIFLUSH SAFESCRUB INTRAVENOUS SOLUTION                                 | 3        |        |
| monoject flush syringe intravenous solution                                 | 3        |        |
| monoject sodium chloride flush intravenous solution                         | 3        |        |
| normal saline flush intravenous solution                                    | 1 or 1b* |        |
| saline flush intravenous solution   | 3        |        |
| sodium chloride (pf) injection solution                                     | 1 or 1b* |        |
| sodium chloride injection solution 2.5 meq/ml                               | 1 or 1b* |        |
| sodium chloride intravenous solution 0.45 %, 3 %, 5 %                       | 1 or 1b* |        |
| <b>*TRACE MINERAL COMBINATIONS***</b>                                       |          |        |
| MULTRYS INTRAVENOUS SOLUTION  | 3        |        |
| TRALEMENT INTRAVENOUS SOLUTION  | 3        |        |
| <b>*TRACE MINERALS***</b>   |          |        |
| SELENIOS ACID INTRAVENOUS SOLUTION 12 MCG/2ML, 60 MCG/ML                    | 3        |        |
| ZYCUBO SUBCUTANEOUS SOLUTION RECONSTITUTED                                  | 5        | PA; QL |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| <b>*ZINC***</b>   |          |                |
| GALZIN ORAL CAPSULE   | 3        |                |
| <b>*MISCELLANEOUS THERAPEUTIC CLASSES*</b>                          |          |                |
| <b>*ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME AGENT***</b> |          |                |
| JOENJA ORAL TABLET  | 5        | PA; LD; QL     |
| <b>*ANTILEPTOTICS***</b>  |          |                |
| THALOMID ORAL CAPSULE 100 MG, 50 MG                                 | 2        | PA; LD; QL; SP |
| <b>*B-LYMPHOCYTE STIMULATOR (BLYS)-SPECIFIC INHIBITORS***</b>       |          |                |
| BENLYSTA INTRAVENOUS SOLUTION RECONSTITUTED                         | 5        | PA; LD; SP     |
| BENLYSTA SUBCUTANEOUS SOLUTION AUTO-INJECTOR                        | 5        | PA; LD; QL; SP |
| BENLYSTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE                    | 5        | PA; LD; QL; SP |
| <b>*CHELATING AGENTS***</b>   |          |                |
| penicillamine oral tablet   | 1 or 1b* | PA; QL; SP     |
| trientine hcl oral capsule 250 mg                                   | 1 or 1b* | PA; QL; SP     |
| <b>*COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) ANTIBODIES**</b>  |          |                |
| NIKTIMVO INTRAVENOUS SOLUTION                                       | 3        | PA; LD         |
| <b>*CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) SOLUTIONS***</b>    |          |                |
| PHOXILLUM B22K4/0 EXTRACORPOREAL SOLUTION                           | 3        |                |

| Drug Name                                     | Tier     | Notes      |
|---|----------|------------|
| PHOXILLUM BK4/2.5 EXTRACORPOREAL SOLUTION     | 3        |            |
| PRISMASOL B22GK 4/0 EXTRACORPOREAL SOLUTION   | 3        |            |
| PRISMASOL BGK 0/2.5 EXTRACORPOREAL SOLUTION   | 3        |            |
| PRISMASOL BGK 2/0 EXTRACORPOREAL SOLUTION     | 3        |            |
| PRISMASOL BGK 2/3.5 EXTRACORPOREAL SOLUTION   | 3        |            |
| PRISMASOL BGK 4/0/1.2 EXTRACORPOREAL SOLUTION | 3        |            |
| PRISMASOL BGK 4/2.5 EXTRACORPOREAL SOLUTION   | 3        |            |
| PRISMASOL BK 0/0/1.2 EXTRACORPOREAL SOLUTION  | 3        |            |
| <b>*CYCLOSPORINE ANALOGS***</b>               |          |            |
| cyclosporine modified oral capsule            | 1 or 1b* |            |
| cyclosporine modified oral solution           | 1 or 1b* |            |
| cyclosporine oral capsule                     | 1 or 1b* |            |
| gengraf oral capsule 100 mg, 25 mg            | 1 or 1b* |            |
| LUPKYNIS ORAL CAPSULE                         | 5        | PA; LD; QL |
| <b>*ENZYMES***</b>                            |          |            |
| AMPHADASE INJECTION SOLUTION                  | 3        |            |
| HYLENEX INJECTION SOLUTION                    | 3        |            |
| XIAFLEX INJECTION SOLUTION RECONSTITUTED      | 5        | PA; LD; SP |
| <b>*FARNESYLTRANSFERASE INHIBITORS***</b>     |          |            |
| ZOKINVY ORAL CAPSULE                          | 5        | PA; LD; QL |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| <b>*IMMUNE GLOBULIN IMMUNOSUPPRESSANTS***</b>                |          |                |
| ATGAM INTRAVENOUS SOLUTION                                   | 3        | SP             |
| THYMOGLOBULIN INTRAVENOUS SOLUTION RECONSTITUTED             | 3        | SP             |
| <b>*IMMUNOMODULATORS - COMBINATIONS***</b>                   |          |                |
| VYVGART HYTRULO SUBCUTANEOUS SOLUTION                        | 5        | PA; LD; QL; SP |
| VYVGART HYTRULO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE      | 5        | PA; LD; QL; SP |
| <b>*IMMUNOMODULATORS FOR MYELODYSPLASTIC SYNDROMES***</b>    |          |                |
| lenalidomide oral capsule                                    | 1 or 1b* | PA; LD; QL; SP |
| <b>*INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITORS***</b>    |          |                |
| mycophenolate mofetil hcl intravenous solution reconstituted | 1 or 1b* | SP             |
| mycophenolate mofetil intravenous solution reconstituted     | 1 or 1b* | SP             |
| mycophenolate mofetil oral capsule                           | 1 or 1b* |                |
| mycophenolate mofetil oral suspension reconstituted          | 1 or 1b* |                |
| mycophenolate mofetil oral tablet                            | 1 or 1b* |                |
| mycophenolate sodium oral tablet delayed release             | 1 or 1b* |                |
| mycophenolic acid oral tablet delayed release 180 mg, 360 mg | 1 or 1b* |                |
| MYHIBBIN ORAL SUSPENSION                                     | 3        | ST             |

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| <b>*INTERLEUKIN-6 (IL-6) ANTAGONISTS***</b>           |          |                |
| SYLVANT INTRAVENOUS SOLUTION RECONSTITUTED            | 5        | LD; SP         |
| <b>*IRRIGATION SOLUTIONS***</b>                       |          |                |
| argyle sterile water irrigation solution              | 3        |                |
| lactated ringers irrigation solution                  | 1 or 1b* |                |
| physiolyte irrigation solution                        | 1 or 1b* |                |
| ringers irrigation irrigation solution                | 3        |                |
| sterile water for irrigation irrigation solution      | 1 or 1b* |                |
| water for irrigation, sterile irrigation solution     | 1 or 1b* |                |
| <b>*MACROLIDE IMMUNOSUPPRESSANTS***</b>               |          |                |
| ASTAGRAF XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR     | 3        |                |
| ENVARUS XR ORAL TABLET EXTENDED RELEASE 24 HOUR       | 3        |                |
| everolimus oral tablet 0.25 mg, 0.5 mg, 0.75 mg, 1 mg | 1 or 1b* |                |
| PROGRAF ORAL PACKET                                   | 3        |                |
| sirolimus oral solution                               | 1 or 1b* |                |
| sirolimus oral tablet                                 | 1 or 1b* |                |
| tacrolimus intravenous solution                       | 1 or 1b* | SP             |
| tacrolimus oral capsule                               | 1 or 1b* |                |
| <b>*MONOCLONAL ANTIBODIES***</b>                      |          |                |
| ENSPRYNG SUBCUTANEOUS SOLUTION PREFILLED SYRINGE      | 5        | PA; LD; QL; SP |
| GAMIFANT INTRAVENOUS SOLUTION                         | 3        | PA; LD; SP     |
| SIMULECT INTRAVENOUS SOLUTION RECONSTITUTED           | 3        |                |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| UPLIZNA INTRAVENOUS SOLUTION                                      | 5        | PA; LD; QL     |
| <b>*NEONATAL FC RECEPTOR (FCRN) ANTAGONISTS***</b>                |          |                |
| IMAAVY INTRAVENOUS SOLUTION 1200 MG/6.5ML                         | 5        | PA; LD; SP     |
| IMAAVY INTRAVENOUS SOLUTION 300 MG/1.62ML                         | 5        | PA; SP         |
| RYSTIGGO SUBCUTANEOUS SOLUTION                                    | 5        | PA; LD; QL; SP |
| VYVGART INTRAVENOUS SOLUTION                                      | 5        | PA; LD; QL; SP |
| <b>*PIK3CA-RELATED OVERGROWTH SPECTRUM AGENTS - PI3K INHIB***</b> |          |                |
| VIJOICE ORAL PACKET   | 5        | PA; LD; QL     |
| VIJOICE ORAL TABLET THERAPY PACK                                  | 5        | PA; LD; QL     |
| <b>*POTASSIUM REMOVING AGENTS***</b>                              |          |                |
| LOKELMA ORAL PACKET   | 3        | QL             |
| sodium polystyrene sulfonate oral powder                          | 1 or 1b* |                |
| sps (sodium polystyrene sulf) rectal suspension                   | 1 or 1b* |                |
| VELTASSA ORAL PACKET  | 3        | QL             |
| <b>*PURINE ANALOGS***</b>   |          |                |
| azasan oral tablet  | 1 or 1b* |                |
| azathioprine oral tablet  | 1 or 1b* |                |
| AZATHIOPRINE SODIUM INJECTION SOLUTION RECONSTITUTED              | 3        |                |
| <b>*ROCK INHIBITORS***</b>  |          |                |
| REZUROCK ORAL TABLET  | 3        | PA; LD; QL     |
| <b>*SCLEROSING AGENTS***</b>                                      |          |                |
| ASCLERA INTRAVENOUS SOLUTION                                      | 3        |                |

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| ETHAMOLIN INTRAVENOUS SOLUTION                          | 3        |                |
| sodium tetradecyl sulfate intravenous solution          | 1 or 1b* |                |
| SOTRADECOL INTRAVENOUS SOLUTION 1 %                     | 1 or 1b* |                |
| sotradecol intravenous solution 3 %                     | 1 or 1b* |                |
| VARITHENA INTRAVENOUS FOAM                              | 3        | LD             |
| <b>*SELECTIVE T-CELL COSTIMULATION BLOCKERS***</b>      |          |                |
| NULOJIX INTRAVENOUS SOLUTION RECONSTITUTED              | 3        | PA             |
| <b>*TYPE I INTERFERON (IFN) RECEPTOR ANTAGONISTS***</b> |          |                |
| SAPHNELO INTRAVENOUS SOLUTION                           | 5        | PA; LD; QL; SP |
| <b>*UREMIC PRURITUS AGENTS***</b>                       |          |                |
| KORSUVA INTRAVENOUS SOLUTION                            | 3        | PA             |
| <b>*MOUTH/THROAT/DENTAL AGENTS*</b>                     |          |                |
| <b>*ANESTHETICS TOPICAL ORAL***</b>                     |          |                |
| lidocaine hcl mouth/throat solution                     | 1 or 1a* | QL             |
| lidocaine viscous hcl mouth/throat solution             | 1 or 1a* | QL             |
| <b>*ANTI-INFECTIVES - THROAT***</b>                     |          |                |
| clotrimazole mouth/throat troche                        | 1 or 1b* | QL             |
| ORAVIG BUCCAL TABLET                                    | 3        |                |
| <b>*ANTISEPTICS - MOUTH/THROAT***</b>                   |          |                |
| chlorhexidine gluconate mouth/throat solution           | 1 or 1a* | QL             |
| perigard mouth/throat solution                          | 1 or 1a* | QL             |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes |
|--|----------|-------|
| <b>*DENTAL PRODUCTS - COMBINATIONS***</b>        |          |       |
| sodium fluoride 5000 enamel dental gel           | 1 or 1b* |       |
| sodium fluoride 5000 sensitive dental gel        | 1 or 1b* |       |
| <b>*FLUORIDE DENTAL PRODUCTS***</b>              |          |       |
| clinpro 5000 dental paste                        | 1 or 1b* | QL    |
| denta 5000 plus dental cream                     | 1 or 1b* | QL    |
| dentagel dental gel                              | 1 or 1a* | QL    |
| easygel dental gel                               | 3        |       |
| fluoridex daily renewal mouth/throat concentrate | 3        |       |
| fluoridex dental paste                           | 1 or 1b* | QL    |
| sf 5000 plus dental cream                        | 1 or 1b* | QL    |
| sf dental gel                                    | 1 or 1b* | QL    |
| sodium fluoride 5000 plus dental cream           | 1 or 1b* | QL    |
| sodium fluoride 5000 ppm dental gel              | 1 or 1b* | QL    |
| sodium fluoride 5000 ppm dental paste            | 1 or 1b* | QL    |
| sodium fluoride dental cream                     | 1 or 1b* | QL    |
| sodium fluoride mouth/throat solution            | 1 or 1a* |       |
| <b>*SALIVA STIMULANTS***</b>                     |          |       |
| cevimeline hcl oral capsule                      | 1 or 1b* |       |
| pilocarpine hcl oral tablet                      | 1 or 1b* | QL    |
| <b>*STEROIDS - MOUTH/THROAT/DENTAL***</b>        |          |       |
| <b>KOURZEQ MOUTH/THROAT PASTE</b>                | 1 or 1b* |       |
| oralone mouth/throat paste                       | 1 or 1b* |       |
| triamcinolone acetonide mouth/throat paste       | 1 or 1b* |       |
| <b>*MULTIVITAMINS*</b>                           |          |       |
| <b>*B-COMPLEX VITAMINS***</b>                    |          |       |
| b complex-b12 oral tablet                        | 1 or 1b* | \$0   |
| b-complex plus b-12 oral tablet                  | 1 or 1b* | \$0   |
| b-complex/b-12 oral tablet                       | 1 or 1b* | \$0   |
| vitamin b complex oral tablet                    | 1 or 1b* | \$0   |

| Drug Name                                    | Tier     | Notes |
|--|----------|-------|
| vitamin b complex w/b-12 oral tablet         | 1 or 1b* | \$0   |
| vitamin-b complex oral tablet                | 1 or 1b* | \$0   |
| <b>*B-COMPLEX W/ C &amp; CALCIUM***</b>      |          |       |
| gnp b-complex plus vitamin c oral tablet     | 1 or 1b* | \$0   |
| qc b-complex/vitamin c oral tablet           | 1 or 1b* | \$0   |
| <b>*B-COMPLEX W/ C &amp; FOLIC ACID***</b>   |          |       |
| b complex-c-folic acid oral tablet           | 1 or 1b* | \$0   |
| b-complex balanced oral tablet               | 1 or 1b* | \$0   |
| b-complex/vitamin c oral tablet              | 1 or 1b* | \$0   |
| b-complex-c (w/folic acid) oral tablet       | 1 or 1b* | \$0   |
| b-plex oral tablet                           | 3        | \$0   |
| dialyvite 800 oral tablet                    | 1 or 1b* | \$0   |
| eql super b complex/vitamin c oral tablet    | 1 or 1b* | \$0   |
| <b>FULL SPECTRUM B/VITAMIN C ORAL TABLET</b> | 1 or 1b* | \$0   |
| kp b complex-c oral tablet                   | 1 or 1b* | \$0   |
| nephro vitamins oral tablet                  | 1 or 1b* | \$0   |
| <b>NEPHRO-VITE ORAL TABLET</b>               | 1 or 1b* | \$0   |
| renal vitamin oral tablet                    | 1 or 1b* | \$0   |
| rena-vite oral tablet                        | 1 or 1b* | \$0   |
| stress formula (folic acid) oral tablet      | 1 or 1b* | \$0   |
| super b complex/fa/vit c oral tablet         | 1 or 1b* | \$0   |
| super b-complex/vit c/fa oral tablet         | 1 or 1b* | \$0   |
| <b>*B-COMPLEX W/ C***</b>                    |          |       |
| allbee/c oral tablet                         | 1 or 1b* | \$0   |
| b complex-c oral tablet                      | 1 or 1b* | \$0   |
| b-complex-c oral tablet                      | 1 or 1b* | \$0   |
| better b complex oral tablet                 | 1 or 1b* | \$0   |
| cvs b complex plus c oral tablet             | 1 or 1b* | \$0   |
| cvs super b complex/c oral tablet            | 1 or 1b* | \$0   |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes |
|---|----------|-------|
| ft b-complex plus vitamin c oral tablet             | 1 or 1b* | \$0   |
| super b complex/vitamin c oral tablet               | 1 or 1b* | \$0   |
| super b-complex + vitamin c oral tablet             | 1 or 1b* | \$0   |
| <b>*B-COMPLEX W/ C-BIOTIN-E &amp; FOLIC ACID***</b> |          |       |
| <b>B COMPLEX-C-BIOTIN-E-FA ORAL TABLET</b>          | 2        | \$0   |
| <b>*B-COMPLEX W/ C-D-E &amp; FOLIC ACID***</b>      |          |       |
| vitara oral capsule                                 | 3        |       |
| <b>*B-COMPLEX W/ FOLIC ACID***</b>                  |          |       |
| b complex formula 1 (w/ fa) oral tablet             | 1 or 1b* | \$0   |
| b-complex (folic acid) oral tablet                  | 1 or 1b* | \$0   |
| b-complex/electrolytes oral tablet                  | 1 or 1b* | \$0   |
| big 100 oral tablet                                 | 1 or 1b* | \$0   |
| kobee oral tablet                                   | 1 or 1b* | \$0   |
| <b>*B-COMPLEX W/BIOTIN &amp; FOLIC ACID***</b>      |          |       |
| b complex 100 tr oral tablet extended release       | 1 or 1b* | \$0   |
| b-100 b-complex oral tablet                         | 1 or 1b* | \$0   |
| b-100 complex cr oral tablet extended release       | 1 or 1b* | \$0   |
| b-100 tr oral tablet extended release               | 1 or 1b* | \$0   |
| b-50 complex oral tablet                            | 1 or 1b* | \$0   |
| balance b-50 oral tablet                            | 1 or 1b* | \$0   |
| balanced b complex oral tablet                      | 1 or 1b* | \$0   |
| balanced b-100 oral tablet                          | 1 or 1b* | \$0   |
| balanced b-100 oral tablet extended release         | 1 or 1b* | \$0   |
| balanced b-50/fa oral tablet                        | 1 or 1b* | \$0   |
| b-compleet-100 oral tablet                          | 1 or 1b* | \$0   |
| b-compleet-50 oral tablet                           | 1 or 1b* | \$0   |
| b-complex oral tablet                               | 1 or 1b* | \$0   |
| big 100 (biotin) oral tablet                        | 1 or 1b* | \$0   |
| complex b-100 oral tablet extended release          | 1 or 1b* | \$0   |

| Drug Name   | Tier     | Notes |
|---|----------|-------|
| complex b-50 prolonged release oral tablet extended release | 1 or 1b* | \$0   |
| endur-b oral tablet extended release                        | 1 or 1b* | \$0   |
| eql b complex 50 oral tablet                                | 1 or 1b* | \$0   |
| eql b-100 complex oral tablet extended release              | 1 or 1b* | \$0   |
| ft b-100 complex pr oral tablet extended release            | 1 or 1b* | \$0   |
| gnp b-100 complex oral tablet extended release              | 1 or 1b* | \$0   |
| gnp b-50 complex oral tablet extended release               | 1 or 1b* | \$0   |
| qc b50 prolonged release oral tablet extended release       | 1 or 1b* | \$0   |
| quin b strong b-25 oral tablet                              | 1 or 1b* | \$0   |
| super b-complex oral tablet                                 | 1 or 1b* | \$0   |
| super dec b-100 oral tablet                                 | 1 or 1b* | \$0   |
| super quints b-50 oral tablet                               | 1 or 1b* | \$0   |
| yl balanced b-100 oral tablet                               | 1 or 1b* | \$0   |
| <b>*MULTIPLE VITAMINS W/ IRON***</b>                        |          |       |
| daily vite multivitamin/iron oral tablet                    | 2        | \$0   |
| destress-iron oral tablet                                   | 2        | \$0   |
| <b>FLORAVITA MINI ORAL TABLET</b>                           |          |       |
| mini multi vitamins/iron oral tablet                        | 2        | \$0   |
| multiple vitamins/iron oral tablet                          | 2        | \$0   |
| multivitamin plus iron adult oral tablet                    | 2        | \$0   |
| multi-vitamin/iron oral tablet                              | 2        | \$0   |
| nat-rul daily-vite+iron oral tablet                         | 2        | \$0   |
| one daily multivitamin/iron oral tablet                     | 2        | \$0   |
| one-daily multi-vitamin/iron oral tablet                    | 2        | \$0   |
| one-daily/iron oral tablet                                  | 2        | \$0   |
| qc daily multivitamins/iron oral tablet                     | 2        | \$0   |
| stress b complex/iron oral tablet                           | 2        | \$0   |
| stress formula/iron oral tablet                             | 2        | \$0   |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier | Notes |
|---|------|-------|
| stress formula/iron/energy oral tablet                            | 2    | \$0   |
| tab-a-vite/iron oral tablet                                       | 2    | \$0   |
| <b>TAB-A-VITE/IRON/BETA CAROTENE ORAL TABLET</b>                  | 2    | \$0   |
| <b>*MULTIPLE VITAMINS W/ MINERALS &amp; CALCIUM-FOLIC ACID***</b> |      |       |
| <b>FOLGARD OS ORAL TABLET</b>                                     | 3    |       |
| <b>*MULTIPLE VITAMINS W/ MINERALS***</b>                          |      |       |
| <b>DEPLINPRO MOOD HEALTH ORAL CAPSULE</b>                         | 3    |       |
| <b>FLORRAXYL ORAL TABLET</b>                                      | 3    |       |
| <b>*MULTIVITAMINS***</b>  |      |       |
| anti-oxidant oral tablet  | 2    | \$0   |
| <b>CENTRUM MENOPAUSE MIND/MOOD ORAL TABLET</b>                    | 2    | \$0   |
| daily multiple vitamins oral tablet                               | 2    | \$0   |
| daily value multivitamin oral tablet                              | 2    | \$0   |
| daily vitamins oral tablet  | 2    | \$0   |
| daily vite oral tablet  | 2    | \$0   |
| daily vites oral tablet   | 2    | \$0   |
| daily-vite multivitamin oral tablet                               | 2    | \$0   |
| daily-vite oral tablet  | 2    | \$0   |
| <b>ESTROFACTORS ORAL TABLET</b>                                   | 2    | \$0   |
| gnp essential one daily oral tablet                               | 2    | \$0   |
| healthy hair/skin/nails oral tablet                               | 2    | \$0   |
| <b>INFUVITE ADULT INTRAVENOUS SOLUTION</b>                        | 3    |       |
| multi vitamin oral tablet   | 2    | \$0   |
| <b>MULTI VITAMIN W/D-3 ORAL TABLET</b>                            | 2    | \$0   |
| multiple vitamin-folic acid oral tablet                           | 2    | \$0   |
| multiple vitamins oral tablet                                     | 2    | \$0   |

| Drug Name                                      | Tier | Notes |
|--|------|-------|
| multivitamin adult oral tablet                 | 2    | \$0   |
| multivitamin iron-free oral tablet             | 2    | \$0   |
| <b>MULTIVITAMIN ORAL TABLET</b>                | 2    | \$0   |
| multi-vitamin oral tablet                      | 2    | \$0   |
| <b>NEOMULTIVITE ORAL TABLET</b>                | 2    | \$0   |
| <b>NEWVITE ORAL TABLET</b>                     | 2    | \$0   |
| novite oral capsule                            | 3    |       |
| <b>OMNICAP ORAL TABLET</b>                     | 2    | \$0   |
| once daily oral tablet                         | 2    | \$0   |
| one daily essential oral tablet                | 2    | \$0   |
| one daily essentials oral tablet               | 2    | \$0   |
| one daily multivitamin adult oral tablet       | 2    | \$0   |
| one daily oral tablet                          | 2    | \$0   |
| <b>ONE VITE DAILY MULTIVITAMIN ORAL TABLET</b> | 2    | \$0   |
| one-daily multi vitamins oral tablet           | 2    | \$0   |
| one-daily multi-vitamin oral tablet            | 2    | \$0   |
| qc essentials oral tablet                      | 2    | \$0   |
| <b>QUINTABS ORAL TABLET</b>                    | 2    | \$0   |
| stress formula oral tablet                     | 2    | \$0   |
| stress formula/zinc/energy oral tablet         | 2    | \$0   |
| stresstabs energy oral tablet                  | 2    | \$0   |
| tab-a-vite oral tablet                         | 2    | \$0   |
| tab-a-vite/beta carotene oral tablet           | 2    | \$0   |
| <b>THERA ORAL TABLET</b>                       | 2    | \$0   |
| thera-tabs oral tablet                         | 2    | \$0   |
| <b>THEREMS ORAL TABLET</b>                     | 2    | \$0   |
| tm-daily vite oral tablet                      | 2    | \$0   |
| true daily vite oral tablet                    | 2    | \$0   |
| true multivitamin oral tablet                  | 2    | \$0   |
| <b>VIREXA ORAL TABLET</b>                      | 3    |       |
| vit e-vit c-beta carotene oral tablet          | 2    | \$0   |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes |
|--|----------|-------|
| vitalee oral tablet  | 2        | \$0   |
| <b>VITLIPID N ADULT INTRAVENOUS EMULSION</b>                     | 3        |       |
| vitrax oral tablet   | 3        |       |
| <b>*PED MULTI VITAMINS W/FL &amp; FE***</b>                      |          |       |
| multi-vitamin/fluoride/iron oral solution                        | 1 or 1b* |       |
| <b>POLY-VI-FLOR/IRON ORAL TABLET CHEWABLE</b>                    | 3        | ST    |
| <b>*PED MV W/ FLUORIDE***</b>                                    |          |       |
| <b>DAVIMET-FLUORIDE ORAL TABLET CHEWABLE</b>                     | 3        | ST    |
| <b>FLORIVA PLUS ORAL SOLUTION</b>                                | 3        | ST    |
| <b>FLOTREX ORAL TABLET CHEWABLE</b>                              | 3        |       |
| multivitamin w/fluoride oral tablet chewable                     | 1 or 1b* | \$0   |
| multi-vitamin/fluoride oral solution                             | 1 or 1b* | \$0   |
| multivitamin/fluoride oral suspension                            | 3        | ST    |
| multivitamin/fluoride oral tablet chewable 0.25 mg, 0.5 mg, 1 mg | 1 or 1b* | \$0   |
| <b>MULTI-VIT-FLOR ORAL TABLET CHEWABLE</b>                       | 3        | ST    |
| <b>POLY-VI-FLOR ORAL SUSPENSION</b>                              | 3        | ST    |
| <b>POLY-VI-FLOR ORAL TABLET CHEWABLE</b>                         | 3        | ST    |
| <b>TRI-VI-FLOR ORAL SUSPENSION 0.25 MG/ML</b>                    | 3        | ST    |
| tri-vitamin with fluoride oral suspension                        | 3        | ST    |
| <b>*PED VITAMINS ACD &amp; FA W/ FLUORIDE***</b>                 |          |       |
| <b>TRI-VI-FLORO ORAL SUSPENSION</b>                              | 3        | ST    |
| <b>*PED VITAMINS ACD W/ FLUORIDE***</b>                          |          |       |
| tri-vite/fluoride oral solution                                  | 1 or 1b* | \$0   |

| Drug Name   | Tier     | Notes   |
|---|----------|---------|
| <b>*PEDIATRIC MULTIPLE VITAMINS &amp; MINERALS W/ FLUORIDE***</b> |          |         |
| <b>FLORIVA ORAL TABLET CHEWABLE</b>                               | 3        | ST      |
| <b>*PEDIATRIC MULTIPLE VITAMINS***</b>                            |          |         |
| <b>INFUVITE PEDIATRIC INTRAVENOUS SOLUTION</b>                    | 3        |         |
| <b>VITALIPID N INFANT INTRAVENOUS EMULSION</b>                    | 3        |         |
| <b>VITLIPID N INFANT INTRAVENOUS EMULSION</b>                     | 3        |         |
| <b>*PRENATAL MV &amp; MIN W/FE-FA ***</b>                         |          |         |
| <b>ATABEX EC ORAL TABLET DELAYED RELEASE</b>                      | 2        | QL      |
| <b>AZESCO ORAL TABLET</b>   | 3        | ST; QL  |
| <b>CLASSIC PRENATAL ORAL TABLET</b>                               | 2        | \$0; QL |
| <b>C-NATE DHA ORAL CAPSULE</b>                                    | 2        | QL      |
| <b>COMPLETENATE ORAL TABLET CHEWABLE</b>                          | 2        | QL      |
| <b>CO-NATAL FA ORAL TABLET</b>                                    | 2        | QL      |
| <b>CONCEPT DHA ORAL CAPSULE</b>                                   | 2        | QL      |
| <b>CONCEPT OB ORAL CAPSULE</b>                                    | 2        | QL      |
| <b>CVS PRENATAL ORAL TABLET 27-0.8 MG</b>                         | 2        | \$0; QL |
| <b>DERMACINRX PRETRATE ORAL TABLET</b>                            | 3        | QL      |
| elite-ob oral tablet  | 1 or 1b* | QL      |
| <b>EMBRIVA ORAL TABLET</b>  | 3        | QL      |
| <b>ENBRACE HR ORAL CAPSULE</b>                                    | 3        | ST; QL  |
| <b>EQL PRENATAL FORMULA ORAL TABLET</b>                           | 2        | \$0; QL |
| folatexcel oral tablet 20-1 mg                                    | 3        | QL      |
| <b>FOLIVANE-OB ORAL CAPSULE 85-1 MG</b>                           | 2        | QL      |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name                                      | Tier     | Notes   |
|--|----------|---------|
| ft prenatal oral tablet                        | 2        | \$0; QL |
| <b>GESTYRA ORAL TABLET</b>                     | 3        | QL      |
| <b>GNP PRENATAL ORAL TABLET</b>                | 2        | \$0; QL |
| gnp prenatal/folic acid oral tablet            | 2        | \$0; QL |
| inatal gt oral tablet                          | 1 or 1b* | QL      |
| <b>JENLIVA PRENATAL/POSTNATAL ORAL CAPSULE</b> | 3        | ST; QL  |
| <b>KOSHER PRENATAL PLUS IRON ORAL TABLET</b>   | 3        | ST; QL  |
| <b>KP PRENATAL MULTIVITAMINS ORAL TABLET</b>   | 2        | \$0; QL |
| <b>KPN PRENATAL ORAL TABLET</b>                | 2        | \$0; QL |
| <b>MASONATAL ORAL TABLET</b>                   | 2        | \$0; QL |
| <b>MATERNACEL ORAL TABLET</b>                  | 3        | ST; QL  |
| <b>M-NATAL PLUS ORAL TABLET</b>                | 2        | QL      |
| <b>MULTI PRENATAL ORAL TABLET</b>              | 2        | \$0; QL |
| natal pnv oral tablet                          | 3        | ST; QL  |
| <b>NEEVO DHA ORAL CAPSULE 27-1.13 MG</b>       | 3        | ST; QL  |
| neomaterna oral tablet 20-1 mg                 | 3        | QL      |
| <b>NEONATAL COMPLETE ORAL TABLET 27-1 MG</b>   | 3        | ST; QL  |
| <b>NEONATAL PLUS ORAL TABLET</b>               | 3        | ST; QL  |
| neonatal prenatal oral tablet                  | 2        | \$0; QL |
| <b>NEONATAL VITAMIN ORAL TABLET</b>            | 2        | \$0; QL |
| neo-vital rx oral tablet                       | 3        | ST; QL  |
| <b>NESTABS DHA ORAL</b>                        | 3        | ST; QL  |
| <b>NESTABS ORAL TABLET</b>                     | 3        | ST; QL  |
| <b>NIVA-PLUS ORAL TABLET</b>                   | 2        | QL      |
| <b>OB COMPLETE ONE ORAL CAPSULE</b>            | 3        | ST; QL  |
| <b>OB COMPLETE ORAL TABLET</b>                 | 3        | ST; QL  |

| Drug Name   | Tier     | Notes   |
|---|----------|---------|
| <b>OB COMPLETE PETITE ORAL CAPSULE</b>            | 3        | ST; QL  |
| <b>OB COMPLETE PREMIER ORAL TABLET</b>            | 3        | ST; QL  |
| <b>OB COMPLETE/DHA ORAL CAPSULE</b>               | 3        | ST; QL  |
| <b>ONE VITE WOMENS ORAL TABLET</b>                | 2        | \$0; QL |
| <b>ONE VITE WOMENS PLUS ORAL TABLET</b>           | 2        | QL      |
| <b>ONENATAL RX ORAL TABLET</b>                    | 3        | ST; QL  |
| pnv 27-ca/fe/fa oral tablet                       | 2        | QL      |
| pnv prenatal plus multivit+dha oral               | 2        | QL      |
| <b>PNV TABS 20-1 ORAL TABLET</b>                  | 3        | ST; QL  |
| <b>PNV-OMEGA ORAL CAPSULE</b>                     | 3        | ST; QL  |
| pnv-select oral tablet                            | 1 or 1b* | QL      |
| <b>PREGENNA ORAL TABLET</b>                       | 3        | ST; QL  |
| <b>PRENA1 PEARL ORAL CAPSULE EXTENDED RELEASE</b> | 3        | ST; QL  |
| <b>PRENATAL (W/IRON &amp; FA) ORAL TABLET</b>     | 2        | \$0; QL |
| <b>PRENATAL 19 ORAL TABLET 29-1 MG</b>            | 2        | QL      |
| prenatal 19 oral tablet chewable                  | 1 or 1a* | QL      |
| <b>PRENATAL 19 ORAL TABLET CHEWABLE 29-1 MG</b>   | 2        | QL      |
| <b>PRENATAL COMPLETE ORAL TABLET</b>              | 2        | \$0; QL |
| <b>PRENATAL FORTE ORAL TABLET</b>                 | 2        | \$0; QL |
| prenatal multivit plus folate oral tablet         | 2        | \$0; QL |
| <b>PRENATAL ONE DAILY ORAL TABLET</b>             | 2        | \$0; QL |
| <b>PRENATAL ORAL TABLET 27-0.8 MG, 28-0.8 MG</b>  | 2        | \$0; QL |
| <b>PRENATAL ORAL TABLET 27-1 MG</b>               | 2        | QL      |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name                                    | Tier     | Notes   |
|--|----------|---------|
| PRENATAL PLUS ORAL TABLET                    | 2        | QL      |
| PRENATAL PLUS VITAMIN/MINERAL ORAL TABLET    | 2        | QL      |
| PRENATAL VITAMIN AND MINERAL ORAL TABLET     | 2        | \$0; QL |
| prenatal vitamins oral tablet 27-0.8 mg      | 2        | \$0; QL |
| PRENATAL VITAMINS ORAL TABLET 28-0.8 MG      | 2        | \$0; QL |
| PRENATAL/IRON ORAL TABLET                    | 2        | \$0; QL |
| PRENATAL-U ORAL CAPSULE                      | 2        | QL      |
| PRENATE ELITE ORAL TABLET 20-0.6-0.4 MG      | 3        | ST; QL  |
| PRENATRIX ORAL TABLET                        | 3        | ST; QL  |
| PRENATRYL ORAL TABLET                        | 3        | ST; QL  |
| PROVIDA OB ORAL CAPSULE                      | 2        | QL      |
| QC PRENATAL ORAL TABLET                      | 2        | \$0; QL |
| RELEVIA ORAL TABLET                          | 3        | QL      |
| RELNATE DHA ORAL CAPSULE                     | 3        | ST; QL  |
| SELECT-OB ORAL TABLET CHEWABLE 29-0.6-0.4 MG | 3        | ST; QL  |
| SELECT-OB ORAL TABLET CHEWABLE 29-1 MG       | 2        | QL      |
| SE-NATAL 19 ORAL TABLET                      | 2        | QL      |
| SE-NATAL 19 ORAL TABLET CHEWABLE             | 2        | QL      |
| TARON-C DHA ORAL CAPSULE 35-1 MG             | 2        | QL      |
| THRIVITE RX ORAL TABLET                      | 2        | QL      |
| TRINATAL RX 1 ORAL TABLET                    | 2        | QL      |
| trinate oral tablet                          | 1 or 1a* | QL      |
| VINATE DHA RF ORAL CAPSULE                   | 3        | ST; QL  |

| Drug Name  | Tier     | Notes   |
|--|----------|---------|
| VITAFOL GUMMIES ORAL TABLET CHEWABLE                         | 2        | QL      |
| VITAFOL-OB ORAL TABLET                                       | 3        | ST; QL  |
| vitalara oral tablet   | 3        | ST; QL  |
| VITATHELY WITH GINGER ORAL TABLET                            | 3        | ST; QL  |
| WESTAB PLUS ORAL TABLET                                      | 2        | QL      |
| ZALVIT ORAL TABLET   | 3        | ST; QL  |
| ZIPHEX ORAL TABLET   | 3        | ST; QL  |
| <b>*PRENATAL MV &amp; MIN W/FE-FA-CA-OMEGA 3 FISH OIL***</b> |          |         |
| COMPLETE NATAL DHA ORAL 29-1-200 & 200 MG                    | 2        | QL      |
| wesnatal dha complete oral                                   | 2        | QL      |
| <b>*PRENATAL MV &amp; MIN W/FE-FA-DHA***</b>                 |          |         |
| CITRANATAL 90 DHA ORAL 90-1 & 300 MG                         | 3        | ST; QL  |
| CITRANATAL ASSURE ORAL 35-1 & 300 MG                         | 3        | ST; QL  |
| ENFAMIL EXPECTA ORAL   | 2        | \$0; QL |
| NESTABS ONE ORAL CAPSULE                                     | 3        | ST; QL  |
| pnv-dha oral capsule   | 1 or 1b* | QL      |
| PNV-DHA+DOCUSATE ORAL CAPSULE                                | 3        | ST; QL  |
| PREGEN DHA ORAL CAPSULE                                      | 3        | ST; QL  |
| prena 1 true oral  | 2        | QL      |
| PRENATAL MULTIVITAMIN + DHA ORAL                             | 2        | \$0; QL |
| PRENATE DHA ORAL CAPSULE 18-0.6-0.4-300 MG                   | 3        | ST; QL  |
| PRENATE ENHANCE ORAL CAPSULE                                 | 3        | ST; QL  |
| PRENATE ESSENTIAL ORAL CAPSULE 18-0.6-0.4-300 MG             | 3        | ST; QL  |
| PRENATE MINI ORAL CAPSULE 18-0.6-0.4-350 MG                  | 3        | ST; QL  |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes  |
|---|----------|--------|
| PRENATE PIXIE ORAL CAPSULE                              | 3        | ST; QL |
| PRENATE RESTORE ORAL CAPSULE                            | 3        | ST; QL |
| SELECT-OB+DHA ORAL                                      | 3        | ST; QL |
| TRISTART DHA ORAL CAPSULE                               | 3        | ST; QL |
| VITAFOL FE+ ORAL CAPSULE                                | 3        | ST; QL |
| VITAFOL ULTRA ORAL CAPSULE                              | 3        | ST; QL |
| VITAFOL-OB+DHA ORAL                                     | 3        | ST; QL |
| VITAFOL-ONE ORAL CAPSULE                                | 3        | ST; QL |
| WESTGEL DHA ORAL CAPSULE                                | 3        | ST; QL |
| <b>*PRENATAL MV &amp; MINERALS W/FA WITHOUT IRON***</b> |          |        |
| PRENATE ORAL TABLET CHEWABLE                            | 3        | ST; QL |
| <b>*PRENATAL VITAMINS***</b>                            |          |        |
| PREMESISRX ORAL TABLET                                  | 3        | ST; QL |
| prena1 oral tablet chewable                             | 3        | ST; QL |
| PRENATE AM ORAL TABLET                                  | 3        | ST; QL |
| <b>*VITAMINS W/ LIPOTROPICS***</b>                      |          |        |
| ACTIFLOVIT EAR HEALTH ORAL TABLET                       | 1 or 1b* | \$0    |
| b complex (lipotropics) oral tablet                     | 1 or 1b* | \$0    |
| b complex formula 1 (lipotrop) oral tablet              | 1 or 1b* | \$0    |
| balanced b-50 complex oral tablet                       | 1 or 1b* | \$0    |
| COMPLEX B-100-INOSITOL ORAL TABLET EXTENDED RELEASE     | 2        | \$0    |
| cvs balanced b50 oral tablet                            | 1 or 1b* | \$0    |
| cvs inner ear plus oral tablet                          | 1 or 1b* | \$0    |
| ear health formula oral tablet                          | 1 or 1b* | \$0    |
| ear health plus oral tablet                             | 1 or 1b* | \$0    |
| lipo flavonoid plus oral tablet                         | 1 or 1b* | \$0    |

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| LIPOTRIAD ORAL TABLET  | 1 or 1b* | \$0    |
| mega multiple/chelated mineral oral tablet                   | 1 or 1b* | \$0    |
| nat-rul b-50 oral tablet                                     | 1 or 1b* | \$0    |
| risanoid plus oral tablet                                    | 1 or 1b* | \$0    |
| ultra b-100 complex oral tablet                              | 1 or 1b* | \$0    |
| <b>*MUSCULOSKELETAL THERAPY AGENTS*</b>                      |          |        |
| <b>*CENTRAL MUSCLE RELAXANTS***</b>                          |          |        |
| baclofen oral tablet 10 mg, 20 mg, 5 mg                      | 1 or 1b* | QL     |
| carisoprodol oral tablet                                     | 1 or 1b* | QL     |
| chlorzoxazone oral tablet 375 mg, 750 mg                     | 1 or 1b* | ST; QL |
| chlorzoxazone oral tablet 500 mg                             | 1 or 1b* | QL     |
| cyclobenzaprine hcl oral tablet 10 mg, 5 mg                  | 1 or 1b* | QL     |
| methocarbamol injection solution 1000 mg/10ml                | 1 or 1b* |        |
| methocarbamol oral tablet 500 mg, 750 mg                     | 1 or 1b* | QL     |
| orphenadrine citrate er oral tablet extended release 12 hour | 1 or 1b* | QL     |
| orphenadrine citrate injection solution                      | 1 or 1b* |        |
| tizanidine hcl oral capsule 6 mg                             | 1 or 1b* | QL     |
| tizanidine hcl oral tablet                                   | 1 or 1b* | QL     |
| <b>*DIRECT MUSCLE RELAXANTS***</b>                           |          |        |
| dantrolene sodium intravenous solution reconstituted         | 1 or 1b* |        |
| dantrolene sodium oral capsule                               | 1 or 1b* |        |
| revonto intravenous solution reconstituted                   | 1 or 1b* |        |
| <b>RYANODEX INTRAVENOUS SUSPENSION RECONSTITUTED</b>         | 3        |        |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| <b>*MUSCLE RELAXANT COMBINATIONS***</b>                       |          |                |
| <b>NORGESIC FORTE ORAL TABLET</b>                             | 1 or 1b* | ST; QL         |
| norgesic oral tablet  | 1 or 1b* | ST; QL         |
| <b>ORPHENADRINE-ASPIRIN-CAFFEINE ORAL TABLET 25-385-30 MG</b> | 1 or 1b* | ST; QL         |
| orphengesic forte oral tablet 50-770-60 mg                    | 1 or 1b* | ST; QL         |
| <b>*RETINOIC ACID RECEPTOR GAMMA SELECTIVE AGONISTS***</b>    |          |                |
| <b>SOHONOS ORAL CAPSULE</b>                                   | 5        | PA; LD; QL; SP |
| <b>*NASAL AGENTS - SYSTEMIC AND TOPICAL*</b>                  |          |                |
| <b>*ANTIHIAMINE-STERIOD***</b>                                |          |                |
| azelastine-fluticasone nasal suspension                       | 3        | QL             |
| <b>*NASAL ANESTHETICS***</b>                                  |          |                |
| <b>COCAINE HCL NASAL SOLUTION</b>                             | 3        |                |
| <b>NUMBRINO NASAL SOLUTION</b>                                | 3        |                |
| <b>*NASAL ANTICHOLINERGICS***</b>                             |          |                |
| ipratropium bromide nasal solution                            | 1 or 1b* | QL             |
| <b>*NASAL ANTIHIAMINES***</b>                                 |          |                |
| azelastine hcl nasal solution 0.1 %, 137 mcg/spray            | 1 or 1b* | QL             |
| olopatadine hcl nasal solution                                | 1 or 1b* | QL             |
| <b>*NASAL STEROIDS***</b>                                     |          |                |
| flunisolide nasal solution 25 mcg/act (0.025%)                | 3        | ST; QL         |
| fluticasone propionate nasal suspension                       | 1 or 1a* | BE; QL         |
| mometasone furoate nasal suspension                           | 3        | ST; BE; QL     |
| <b>PROPEL CONTOUR NASAL IMPLANT</b>                           | 3        |                |

| Drug Name  | Tier | Notes          |
|--|------|----------------|
| <b>PROPEL MINI NASAL IMPLANT</b>                               | 3    |                |
| <b>PROPEL MINI SDS NASAL IMPLANT</b>                           | 3    |                |
| <b>PROPEL NASAL IMPLANT</b>                                    | 3    |                |
| <b>XHANCE NASAL EXHALER SUSPENSION</b>                         | 3    | PA; QL         |
| <b>*NEUROMUSCULAR AGENTS*</b>                                  |      |                |
| <b>*ALS AGENTS - MISCELLANEOUS***</b>                          |      |                |
| <b>RADICAVA ORS ORAL SUSPENSION</b>                            | 5    | PA; LD; QL; SP |
| <b>RADICAVA ORS STARTER KIT ORAL SUSPENSION</b>                | 5    | PA; LD; QL; SP |
| <b>*BENZATHIAZOLES***</b>                                      |      |                |
| riluzole oral tablet   | 4    | PA; QL; SP     |
| <b>TEGLUTIK ORAL SUSPENSION</b>                                | 5    | PA; LD; QL     |
| <b>TIGLUTIK ORAL SUSPENSION</b>                                | 5    | PA; LD; QL     |
| <b>*DEPOLARIZING MUSCLE RELAXANTS***</b>                       |      |                |
| <b>ANECTINE INJECTION SOLUTION</b>                             | 3    |                |
| succinylcholine cl +rfid injection solution prefilled syringe  | 3    |                |
| <b>*FRIEDRICH'S ATAXIA AGENTS - NRF2 PATHWAY ACTIVATORS***</b> |      |                |
| <b>SKYCLARYS ORAL CAPSULE</b>                                  | 5    | PA; LD; QL     |
| <b>*MUSCULAR DYSTROPHY - GENE THERAPY AGENTS***</b>            |      |                |
| <b>AMONDYS 45 INTRAVENOUS SOLUTION</b>                         | 5    | PA; LD         |
| <b>EXONDYS 51 INTRAVENOUS SOLUTION</b>                         | 5    | PA; LD         |
| <b>VILTEPSO INTRAVENOUS SOLUTION</b>                           | 5    | PA; LD         |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| VYONDYS 53 INTRAVENOUS SOLUTION                                 | 5        | PA; LD     |
| <b>*MUSCULAR DYSTROPHY - HISTONE DEACETYLASE INHIBITORS**</b>   |          |            |
| DUVYZAT ORAL SUSPENSION   | 5        | PA; LD; QL |
| <b>*NEUROMUSCULAR BLOCKING AGENT - NEUROTOXINS***</b>           |          |            |
| BOTOX INJECTION SOLUTION RECONSTITUTED                          | 5        | PA         |
| DAXXIFY INTRAMUSCULAR SOLUTION RECONSTITUTED                    | 5        | PA; LD     |
| DYSPO RT INTRAMUSCULAR SOLUTION RECONSTITUTED 300 UNIT          | 5        | PA         |
| DYSPO RT INTRAMUSCULAR SOLUTION RECONSTITUTED 500 UNIT          | 5        | PA; SP     |
| MYOBLOC INTRAMUSCULAR SOLUTION 10000 UNIT/2ML, 5000 UNIT/ML     | 5        | PA; SP     |
| MYOBLOC INTRAMUSCULAR SOLUTION 2500 UNIT/0.5ML                  | 5        | PA         |
| XEOMIN INTRAMUSCULAR SOLUTION RECONSTITUTED                     | 5        | PA; LD     |
| <b>*NONDEPOLARIZING MUSCLE RELAXANTS***</b>                     |          |            |
| atracurium besylate intravenous solution 100 mg/10ml, 50 mg/5ml | 1 or 1b* |            |
| cisatracurium besylate (pf) intravenous solution                | 1 or 1b* |            |
| cisatracurium besylate intravenous solution 20 mg/10ml          | 1 or 1b* |            |

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| rocuronium bromide +rfid intravenous solution                       | 3        |            |
| rocuronium bromide intravenous solution 10 mg/ml                    | 1 or 1b* |            |
| rocuronium bromide intravenous solution 100 mg/10ml, 50 mg/5ml      | 3        |            |
| vecuronium bromide intravenous solution reconstituted               | 1 or 1b* |            |
| <b>*RETT SYNDROME AGENTS - GLYCINE-PROLINE-GLUTAMATE ANALOGS***</b> |          |            |
| DAYBUE ORAL SOLUTION  | 5        | PA; LD; QL |
| DAYBUE STIX ORAL PACKET   | 5        | PA; QL     |
| <b>*SPINAL MUSCULAR ATROPHY-SMN2 SPLICING MODIFIERS***</b>          |          |            |
| EVRYSDI ORAL SOLUTION RECONSTITUTED                                 | 5        | PA; LD; QL |
| EVRYSDI ORAL TABLET   | 5        | PA; LD; QL |
| <b>*NUTRIENTS*</b>  |          |            |
| <b>*AMINO ACID MIXTURES***</b>                                      |          |            |
| AMINOSYN II INTRAVENOUS SOLUTION 10 %                               | 3        |            |
| aminosyn ii intravenous solution 15 %                               | 1 or 1b* |            |
| AMINOSYN-PF 7% INTRAVENOUS SOLUTION                                 | 3        |            |
| AMINOSYN-PF INTRAVENOUS SOLUTION 10 %                               | 3        |            |
| CLINIMIX E/DEXTROSE (2.75/5) INTRAVENOUS SOLUTION                   | 3        |            |
| CLINIMIX E/DEXTROSE (4.25/10) INTRAVENOUS SOLUTION                  | 3        |            |
| CLINIMIX E/DEXTROSE (4.25/5) INTRAVENOUS SOLUTION                   | 3        |            |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026





| Drug Name   | Tier     | Notes |
|---|----------|-------|
| bacitracin ophthalmic ointment                                    | 1 or 1b* | QL    |
| besifloxacin hcl ophthalmic suspension                            | 1 or 1b* | QL    |
| <b>CILOXAN OPTHALMIC OINTMENT</b>                                 | 3        | QL    |
| ciprofloxacin hcl ophthalmic solution                             | 1 or 1a* | QL    |
| erythromycin ophthalmic ointment                                  | 3        | QL    |
| gatifloxacin ophthalmic solution                                  | 1 or 1b* | QL    |
| gentamicin sulfate ophthalmic solution                            | 1 or 1a* | QL    |
| levofloxacin ophthalmic solution                                  | 1 or 1b* | QL    |
| <b>MITOSOL OPTHALMIC KIT</b>                                      | 3        |       |
| moxifloxacin hcl (2x day) ophthalmic solution                     | 1 or 1b* | QL    |
| moxifloxacin hcl ophthalmic solution                              | 1 or 1b* | QL    |
| ofloxacin ophthalmic solution                                     | 1 or 1a* | QL    |
| tobramycin ophthalmic solution                                    | 1 or 1a* | QL    |
| <b>TOBREX OPTHALMIC OINTMENT</b>                                  | 3        | QL    |
| <b>*OPHTHALMIC ANTIFUNGAL***</b>                                  |          |       |
| <b>NATACYN OPTHALMIC SUSPENSION</b>                               | 3        | QL    |
| <b>*OPHTHALMIC ANTI-INFECTIVE COMBINATIONS***</b>                 |          |       |
| bacitracin-polymyxin b ophthalmic ointment 500-10000 unit/gm      | 1 or 1a* | QL    |
| neomycin-bacitracin zn-polymyx ophthalmic ointment 5-400-10000    | 1 or 1b* | QL    |
| neomycin-polymyxin-gramicidin ophthalmic solution 1.75-10000-.025 | 1 or 1b* | QL    |
| polymyxin b-trimethoprim ophthalmic solution                      | 1 or 1a* | QL    |

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| <b>*OPHTHALMIC ANTISEPTICS***</b>                       |          |            |
| <b>BETADINE OPTHALMIC PREP OPTHALMIC SOLUTION</b>       | 3        |            |
| <b>*OPHTHALMIC ANTIVIRALS***</b>                        |          |            |
| trifluridine ophthalmic solution                        | 1 or 1b* | QL         |
| <b>ZIRGAN OPTHALMIC GEL</b>                             | 3        | QL         |
| <b>*OPHTHALMIC CARBONIC ANHYDRASE INHIBITORS***</b>     |          |            |
| brinzolamide ophthalmic suspension                      | 1 or 1b* | QL         |
| dorzolamide hcl ophthalmic solution                     | 1 or 1b* | QL         |
| <b>*OPHTHALMIC COMPLEMENT C3 INHIBITORS***</b>          |          |            |
| <b>SYFOVRE INTRAVITREAL SOLUTION</b>                    | 5        | PA; LD     |
| <b>*OPHTHALMIC COMPLEMENT C5 INHIBITORS***</b>          |          |            |
| <b>IZERVAY INTRAVITREAL SOLUTION</b>                    | 5        | PA; LD; SP |
| <b>*OPHTHALMIC DIAGNOSTIC PRODUCTS***</b>               |          |            |
| ak-fluor intravenous solution 10 %                      | 1 or 1b* |            |
| altafluor benox ophthalmic solution                     | 3        |            |
| fluorescein intravenous solution                        | 1 or 1b* |            |
| fluorescein sodium intravenous solution                 | 1 or 1b* |            |
| <b>FLUORESCEIN SODIUM/BENOXINATE OPTHALMIC SOLUTION</b> | 3        |            |
| fluorescein-benoxinate ophthalmic solution              | 3        |            |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes      |
|--|----------|------------|
| FLURA-SAFE OPTHALMIC SOLUTION                          | 3        |            |
| <b>*OPHTHALMIC ECTOPARASITICIDE**</b>                  |          |            |
| XDEMVIY OPTHALMIC SOLUTION                             | 3        | PA; LD; QL |
| <b>*OPHTHALMIC IMMUNOMODULATORS ***</b>                |          |            |
| RESTASIS MULTIDOSE OPTHALMIC EMULSION 0.05 %           | 2        | QL         |
| RESTASIS OPTHALMIC EMULSION                            | 1 or 1b* | QL         |
| VERKAZIA OPTHALMIC EMULSION                            | 3        | PA; QL     |
| <b>*OPHTHALMIC IRRIGATION SOLUTIONS***</b>             |          |            |
| BSS INTRAOCULAR SOLUTION                               | 3        |            |
| BSS PLUS INTRAOCULAR SOLUTION                          | 3        |            |
| <b>*OPHTHALMIC KINASE INHIBITORS - COMBINATIONS***</b> |          |            |
| ROCKLATAN OPTHALMIC SOLUTION                           | 3        | QL         |
| <b>*OPHTHALMIC LOCAL ANESTHETIC - COMBINATIONS***</b>  |          |            |
| lido-phen intraocular solution                         | 3        |            |
| <b>*OPHTHALMIC LOCAL ANESTHETICS***</b>                |          |            |
| AKTEN OPTHALMIC GEL                                    | 3        |            |
| IHEEZO OPTHALMIC GEL                                   | 3        |            |
| proparacaine hcl ophthalmic solution                   | 1 or 1b* |            |
| <b>*OPHTHALMIC NERVE GROWTH FACTORS***</b>             |          |            |
| OXERVATE OPTHALMIC SOLUTION                            | 5        | PA; LD; QL |

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| <b>*OPHTHALMIC NONSTEROIDAL ANTI-INFLAMMATORY AGENTS***</b> |          |            |
| ACUVAIL OPTHALMIC SOLUTION                                  | 3        | QL         |
| bromfenac sodium (once-daily) ophthalmic solution           | 1 or 1b* | QL         |
| bromfenac sodium ophthalmic solution 0.07 %, 0.075 %        | 1 or 1b* | QL         |
| diclofenac sodium ophthalmic solution                       | 1 or 1b* | QL         |
| flurbiprofen sodium ophthalmic solution                     | 1 or 1b* | QL         |
| ILEVRO OPTHALMIC SUSPENSION                                 | 2        | QL         |
| ketorolac tromethamine ophthalmic solution                  | 1 or 1b* | QL         |
| NEVANAC OPTHALMIC SUSPENSION                                | 3        | QL         |
| <b>*OPHTHALMIC PHOTODYNAMIC THERAPY AGENTS***</b>           |          |            |
| VISUDYNE INTRAVENOUS SOLUTION RECONSTITUTED                 | 5        | LD; QL; SP |
| <b>*OPHTHALMIC RHO KINASE INHIBITORS***</b>                 |          |            |
| RHOPRESSA OPTHALMIC SOLUTION                                | 3        | QL         |
| <b>*OPHTHALMIC SELECTIVE ALPHA ADRENERGIC AGONISTS***</b>   |          |            |
| apraclonidine hcl ophthalmic solution                       | 1 or 1b* |            |
| brimonidine tartrate ophthalmic solution                    | 1 or 1b* | QL         |
| IOPIDINE OPTHALMIC SOLUTION 1 %                             | 3        |            |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| <b>*OPHTHALMIC STEROID COMBINATIONS***</b>              |          |            |
| bacitra-neomycin-polymyxin-hc ophthalmic ointment       | 1 or 1b* | QL         |
| loteprednol-tobramycin ophthalmic suspension            | 1 or 1b* | QL         |
| neomycin-polymyxin-dexameth ophthalmic ointment         | 1 or 1a* | QL         |
| neomycin-polymyxin-dexameth ophthalmic suspension       | 1 or 1a* | QL         |
| neomycin-polymyxin-hc ophthalmic suspension 3.5-10000-1 | 1 or 1b* |            |
| sulfacetamide-prednisolone ophthalmic solution          | 1 or 1a* | QL         |
| <b>TOBRADEX OPTHALMIC OINTMENT</b>                      | 2        |            |
| tobramycin-dexamethasone ophthalmic suspension          | 1 or 1b* | QL         |
| <b>*OPHTHALMIC STEROIDS***</b>                          |          |            |
| dexamethasone sodium phosphate ophthalmic solution      | 1 or 1b* |            |
| <b>DEXTENZA OPTHALMIC INSERT</b>                        | 3        |            |
| <b>DEXYCU INTRAOCULAR SUSPENSION</b>                    | 3        |            |
| difluprednate ophthalmic emulsion                       | 1 or 1b* | QL         |
| <b>FLAREX OPTHALMIC SUSPENSION</b>                      | 3        |            |
| fluorometholone ophthalmic suspension                   | 1 or 1b* |            |
| <b>FML FORTE OPTHALMIC SUSPENSION</b>                   | 3        |            |
| <b>ILUVIEN INTRAVITREAL IMPLANT</b>                     | 5        | PA; LD; SP |
| <b>INVELTYS OPTHALMIC SUSPENSION</b>                    | 3        | QL         |

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| <b>LOTEMAX OPTHALMIC OINTMENT</b>                       | 3        | QL         |
| <b>LOTEMAX SM OPTHALMIC GEL</b>                         | 3        | QL         |
| loteprednol etabonate ophthalmic gel                    | 1 or 1b* | QL         |
| loteprednol etabonate ophthalmic suspension 0.5 %       | 1 or 1b* | QL         |
| <b>MAXIDEX OPTHALMIC SUSPENSION</b>                     | 3        |            |
| <b>OZURDEX INTRAVITREAL IMPLANT</b>                     | 3        | PA; LD; SP |
| <b>PRED MILD OPTHALMIC SUSPENSION</b>                   | 3        |            |
| prednisolone acetate ophthalmic suspension              | 1 or 1b* | QL         |
| <b>PREDNISOLONE SODIUM PHOSPHATE OPTHALMIC SOLUTION</b> | 3        | QL         |
| <b>RETISERT INTRAVITREAL IMPLANT</b>                    | 3        | PA; LD; SP |
| <b>TRIESENCE INTRAOCULAR SUSPENSION</b>                 | 3        |            |
| <b>XIPERE INTRAOCULAR SUSPENSION</b>                    | 5        | PA; LD     |
| <b>YUTIQ INTRAVITREAL IMPLANT</b>                       | 3        | PA; LD; SP |
| <b>*OPHTHALMIC SULFONAMIDES***</b>                      |          |            |
| sulfacetamide sodium ophthalmic solution                | 1 or 1b* | QL         |
| <b>*OPHTHALMIC SURGICAL AIDS - COMBINATIONS***</b>      |          |            |
| <b>DISCOVISC INTRAOCULAR SOLUTION</b>                   | 3        |            |
| <b>DUOVISC INTRAOCULAR KIT 0.4-0.35 ML, 0.55-0.5 ML</b> | 3        |            |
| <b>OMIDRIA INTRAOCULAR SOLUTION</b>                     | 3        |            |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier | Notes |
|--|------|-------|
| VISCOAT INTRAOCULAR SOLUTION PREFILLED SYRINGE         | 3    |       |
| <b>*OPHTHALMIC SURGICAL AIDS***</b>                    |      |       |
| AMVISC INTRAOCULAR SOLUTION PREFILLED SYRINGE          | 5    |       |
| AMVISC PLUS INTRAOCULAR SOLUTION PREFILLED SYRINGE     | 5    |       |
| CELLUGEL INTRAOCULAR SOLUTION                          | 3    |       |
| CLEARVISC INTRAOCULAR SOLUTION PREFILLED SYRINGE       | 5    |       |
| HEALON DUET PRO INTRAOCULAR SOLUTION PREFILLED SYRINGE | 5    |       |
| HEALON GV PRO INTRAOCULAR SOLUTION PREFILLED SYRINGE   | 5    |       |
| HEALON PRO INTRAOCULAR SOLUTION PREFILLED SYRINGE      | 5    |       |
| HEALON5 PRO INTRAOCULAR SOLUTION PREFILLED SYRINGE     | 5    |       |
| PROVISC INTRAOCULAR SOLUTION PREFILLED SYRINGE         | 5    |       |
| TISSUEBLUE INTRAOCULAR SOLUTION PREFILLED SYRINGE      | 3    |       |
| TOTALVISC INTRAOCULAR SOLUTION PREFILLED SYRINGE       | 3    |       |
| VISIONBLUE INTRAOCULAR SOLUTION PREFILLED SYRINGE      | 3    |       |

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| <b>*OPHTHALMICS - BLEPHAROPTOSIS AGENTS**</b>                    |          |                |
| UPNEEQ OPHTHALMIC SOLUTION                                       | 3        | PA; QL         |
| <b>*OPHTHALMICS - CYSTINOSIS AGENTS**</b>                        |          |                |
| CYSTADROPS OPHTHALMIC SOLUTION                                   | 3        | PA; LD; QL     |
| CYSTARAN OPHTHALMIC SOLUTION                                     | 4        | PA; LD; QL     |
| <b>*OPHTHALMICS MISC. - OTHER***</b>                             |          |                |
| MIEBO OPHTHALMIC SOLUTION  | 2        | QL             |
| <b>*PROSTAGLANDINS - OPHTHALMIC***</b>                           |          |                |
| bimatoprost ophthalmic solution 0.03 %                           | 1 or 1b* |                |
| DURYSTA INTRAOCULAR IMPLANT                                      | 5        | PA; LD; QL; SP |
| latanoprost ophthalmic solution                                  | 1 or 1b* | QL             |
| LUMIGAN OPHTHALMIC SOLUTION 0.01 %                               | 2        | QL             |
| tafluprost (pf) ophthalmic solution                              | 1 or 1b* | QL             |
| travoprost (bak free) ophthalmic solution                        | 1 or 1b* | QL             |
| <b>*VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ANTAGONISTS***</b> |          |                |
| BEOVU INTRAVITREAL SOLUTION PREFILLED SYRINGE                    | 5        | PA; LD; SP     |
| BYOOVIZ INTRAVITREAL SOLUTION                                    | 4        | PA; SP         |
| CIMERLI INTRAVITREAL SOLUTION                                    | 4        | PA; LD; SP     |
| EYLEA HD INTRAVITREAL SOLUTION                                   | 4        | PA; LD; SP     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| EYLEA INTRAVITREAL SOLUTION                         | 4        | PA; LD; SP |
| EYLEA INTRAVITREAL SOLUTION PREFILLED SYRINGE       | 4        | PA; LD; SP |
| LUCENTIS INTRAVITREAL SOLUTION PREFILLED SYRINGE    | 4        | PA; LD; SP |
| PAVBLU INTRAVITREAL SOLUTION                        | 5        | PA         |
| PAVBLU INTRAVITREAL SOLUTION PREFILLED SYRINGE      | 5        | PA         |
| SUSVIMO (IMPLANT 1ST FILL) INTRAVITREAL SOLUTION    | 5        | LD; SP     |
| SUSVIMO (IMPLANT REFILL) INTRAVITREAL SOLUTION      | 5        | LD; SP     |
| <b>*OTIC AGENTS*</b>                                |          |            |
| <b>*OTIC AGENTS - MISCELLANEOUS***</b>              |          |            |
| acetic acid otic solution                           | 1 or 1b* |            |
| <b>*OTIC ANALGESIC COMBINATIONS***</b>              |          |            |
| PRAMOTIC OTIC LIQUID                                | 3        |            |
| <b>*OTIC ANTI-INFECTIVES***</b>                     |          |            |
| ciprofloxacin hcl otic solution                     | 1 or 1b* | QL         |
| ofloxacin otic solution                             | 1 or 1b* | QL         |
| <b>*OTIC STEROID-ANTI-INFECTIVE COMBINATIONS***</b> |          |            |
| ciprofloxacin-dexamethasone otic suspension         | 1 or 1b* | QL         |
| ciprofloxacin-fluocinolone pf otic solution         | 1 or 1b* | QL         |
| CORTISPORIN-TC OTIC SUSPENSION                      | 3        |            |
| neomycin-polymyxin-hc otic solution                 | 1 or 1b* |            |
| neomycin-polymyxin-hc otic suspension               | 1 or 1b* | QL         |

| Drug Name  | Tier     | Notes |
|--|----------|-------|
| <b>*OTIC STEROIDS***</b>   |          |       |
| fluocinolone acetonide otic oil                                  | 1 or 1b* |       |
| hydrocortisone-acetic acid otic solution                         | 1 or 1b* | QL    |
| <b>*OXYTOCICS*</b>   |          |       |
| <b>*ABORTIFACIENTS/CERVICAL RIPENING - PROSTAGLANDINS***</b>     |          |       |
| carboprost tromethamine intramuscular solution                   | 1 or 1b* |       |
| carboprost tromethamine intramuscular solution prefilled syringe | 3        |       |
| CERVIDIL VAGINAL INSERT  | 3        |       |
| PREPIDIL VAGINAL GEL   | 3        |       |
| <b>*OXYTOCICS***</b>   |          |       |
| methergine oral tablet   | 1 or 1b* |       |
| methylergonovine maleate injection solution                      | 1 or 1b* |       |
| methylergonovine maleate oral tablet                             | 1 or 1b* |       |
| oxytocin +rfid injection solution                                | 1 or 1b* |       |
| <b>*PASSIVE IMMUNIZING AND TREATMENT AGENTS*</b>                 |          |       |
| <b>*ANTITOXINS-ANTIVENINS***</b>                                 |          |       |
| ANASCORP INTRAVENOUS SOLUTION RECONSTITUTED                      | 3        |       |
| ANAVIP INTRAVENOUS SOLUTION RECONSTITUTED                        | 3        |       |
| ANTIVENIN LATRODECTUS MACTANS INJECTION KIT                      | 3        |       |
| ANTIVENIN MICRURUS FULVIUS INTRAVENOUS SOLUTION RECONSTITUTED    | 3        |       |
| CROFAB INTRAVENOUS SOLUTION RECONSTITUTED                        | 3        |       |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier | Notes       |
|---|------|-------------|
| <b>*ANTIVIRAL MONOCLONAL ANTIBODIES***</b>                                |      |             |
| BEYFORTUS INTRAMUSCULAR SOLUTION PREFILLED SYRINGE                        | 5    | PA; \$0; QL |
| ENFLONIA INTRAMUSCULAR SOLUTION PREFILLED SYRINGE                         | 5    | PA; \$0; QL |
| PEMGARDA INTRAVENOUS SOLUTION   | 3    |             |
| <b>*BACTERIAL MONOCLONAL ANTIBODIES***</b>                                |      |             |
| ZINPLAVA INTRAVENOUS SOLUTION   | 3    | PA          |
| <b>*IMMUNE SERUMS***</b>  |      |             |
| BABYBIG INTRAVENOUS SOLUTION RECONSTITUTED                                | 3    |             |
| CNJ-016 INTRAVENOUS SOLUTION 50000 UNIT/VIAL                              | 3    |             |
| CUTAQUIG SUBCUTANEOUS SOLUTION  | 4    | PA; LD; SP  |
| CYTOGAM INTRAVENOUS SOLUTION  | 5    | SP          |
| GAMASTAN INTRAMUSCULAR SOLUTION   | 5    | PA; LD; SP  |
| GAMUNEX-C INJECTION SOLUTION  | 4    | PA; LD; SP  |
| HEPAGAM B INJECTION SOLUTION 312 UNIT/ML                                  | 5    | SP          |
| HIZENTRA SUBCUTANEOUS SOLUTION 1 GM/5ML, 10 GM/50ML, 2 GM/10ML, 4 GM/20ML | 4    | PA; LD; SP  |
| HIZENTRA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE                          | 4    | PA; LD; SP  |

| Drug Name   | Tier | Notes      |
|---|------|------------|
| HYPERHEP B INTRAMUSCULAR SOLUTION 220 UNIT/ML   | 5    | LD; SP     |
| HYPERHEP B INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 110 UNIT/0.5ML  | 5    | LD; SP     |
| HYPERRAB INJECTION SOLUTION   | 5    | SP         |
| HYPERRHO INTRAMUSCULAR SOLUTION PREFILLED SYRINGE   | 5    | LD; QL; SP |
| HYPERRHO MINI-DOSE INTRAMUSCULAR SOLUTION PREFILLED SYRINGE   | 5    | LD; QL; SP |
| HYPERTET INTRAMUSCULAR SOLUTION PREFILLED SYRINGE   | 3    |            |
| KEDRAB INJECTION SOLUTION   | 5    | SP         |
| NABI-HB INTRAMUSCULAR SOLUTION 312 UNIT/ML  | 5    | LD; SP     |
| OCTAGAM INTRAVENOUS SOLUTION 1 GM/20ML, 10 GM/100ML, 10 GM/200ML, 2 GM/20ML, 2.5 GM/50ML, 20 GM/200ML, 30 GM/300ML, 5 GM/100ML, 5 GM/50ML | 4    | PA; LD; SP |
| RHOGAM ULTRA-FILTERED PLUS INTRAMUSCULAR SOLUTION PREFILLED SYRINGE   | 5    | QL; SP     |
| RHOPHYLAC INJECTION SOLUTION PREFILLED SYRINGE  | 5    | LD; QL; SP |
| VARIZIG INTRAMUSCULAR SOLUTION  | 3    |            |
| WINRHO SDF INJECTION SOLUTION 1500 UNIT/1.3ML, 2500 UNIT/2.2ML  | 5    | QL; SP     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| <b>XEMBIFY<br/>SUBCUTANEOUS<br/>SOLUTION</b>  | 4        | PA; LD; SP |
| <b>*PENICILLINS*</b>  |          |            |
| <b>*AMINOPENICILLINS**</b>  |          |            |
| *   |          |            |
| amoxicillin oral capsule  | 1 or 1a* |            |
| amoxicillin oral suspension reconstituted   | 1 or 1a* |            |
| amoxicillin oral tablet   | 1 or 1a* |            |
| amoxicillin oral tablet chewable 125 mg, 250 mg   | 1 or 1a* |            |
| ampicillin oral capsule 500 mg  | 1 or 1a* |            |
| ampicillin sodium injection solution reconstituted 1 gm, 2 gm, 250 mg, 500 mg                             | 1 or 1b* |            |
| ampicillin sodium intravenous solution reconstituted  | 1 or 1b* |            |
| <b>*NATURAL<br/>PENICILLINS***</b>  |          |            |
| <b>BICILLIN L-A<br/>INTRAMUSCULAR<br/>SUSPENSION<br/>PREFILLED SYRINGE</b>                                | 3        |            |
| <b>LENTOCILIN<br/>INTRAMUSCULAR<br/>SUSPENSION<br/>RECONSTITUTED</b>                                      | 3        |            |
| <b>PENICILLIN G POT IN<br/>DEXTROSE<br/>INTRAVENOUS<br/>SOLUTION 40000<br/>UNIT/ML, 60000<br/>UNIT/ML</b> | 3        |            |
| penicillin g potassium injection solution reconstituted   | 1 or 1b* |            |
| penicillin g sodium injection solution reconstituted  | 1 or 1b* |            |
| penicillin v potassium oral solution reconstituted  | 1 or 1b* |            |
| penicillin v potassium oral tablet  | 1 or 1b* |            |
| pfizerpen injection solution reconstituted  | 1 or 1b* |            |

| Drug Name  | Tier     | Notes |
|--|----------|-------|
| <b>*PENICILLIN<br/>COMBINATIONS***</b>   |          |       |
| amoxicillin-pot clavulanate er oral tablet extended release 12 hour  | 1 or 1b* |       |
| amoxicillin-pot clavulanate oral suspension reconstituted  | 1 or 1b* |       |
| amoxicillin-pot clavulanate oral tablet  | 1 or 1b* |       |
| ampicillin-sulbactam sodium injection solution reconstituted 1.5 (1-0.5) gm, 3 (2-1) gm  | 1 or 1b* |       |
| ampicillin-sulbactam sodium intravenous solution reconstituted   | 1 or 1b* |       |
| <b>AUGMENTIN ORAL<br/>SUSPENSION<br/>RECONSTITUTED 125-<br/>31.25 MG/5ML</b>   | 2        |       |
| <b>BICILLIN C-R 900/300<br/>INTRAMUSCULAR<br/>SUSPENSION</b>   | 3        |       |
| <b>BICILLIN C-R<br/>INTRAMUSCULAR<br/>SUSPENSION</b>   | 3        |       |
| piperacillin sod-tazobactam so intravenous solution reconstituted 13.5 (12-1.5) gm, 2.25 (2-0.25) gm, 3-0.375 gm, 3.375 (3-0.375) gm, 4.5 (4-0.5) gm, 40.5 (36-4.5) gm | 1 or 1b* |       |
| piperacillin-tazobactam-nacl intravenous solution reconstituted  | 3        |       |
| <b>ZOSYN INTRAVENOUS<br/>SOLUTION</b>  | 3        |       |
| <b>*PENICILLINASE-<br/>RESISTANT<br/>PENICILLINS***</b>  |          |       |
| dicloxacillin sodium oral capsule  | 1 or 1b* |       |
| <b>NAFCILLIN SODIUM IN<br/>DEXTROSE<br/>INTRAVENOUS<br/>SOLUTION 2 GM/100ML</b>  | 3        |       |
| nafcillin sodium injection solution reconstituted 1 gm, 2 gm   | 1 or 1b* |       |
| nafcillin sodium intravenous solution reconstituted 10 gm  | 1 or 1b* |       |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes      |
|--|----------|------------|
| <b>OXACILLIN SODIUM IN DEXTROSE INTRAVENOUS SOLUTION 2 GM/50ML</b> | 3        |            |
| oxacillin sodium injection solution reconstituted 1 gm, 2 gm       | 1 or 1b* |            |
| oxacillin sodium intravenous solution reconstituted                | 1 or 1b* |            |
| <b>*PROGESTINS*</b>  |          |            |
| <b>*PROGESTINS***</b>  |          |            |
| <b>GALLIFREY ORAL TABLET</b>                                       | 1 or 1b* |            |
| medroxyprogesterone acetate oral tablet                            | 1 or 1a* |            |
| megestrol acetate oral suspension 625 mg/5ml                       | 1 or 1b* |            |
| norethindrone acetate oral tablet                                  | 1 or 1b* |            |
| progesterone intramuscular oil                                     | 1 or 1b* |            |
| progesterone oral capsule  | 1 or 1b* |            |
| <b>*PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.*</b>         |          |            |
| <b>*AGENTS FOR OPIOID WITHDRAWAL***</b>                            |          |            |
| lofexidine hcl oral tablet   | 1 or 1b* | QL         |
| <b>*ALCOHOL DETERRENTS***</b>                                      |          |            |
| acamprosate calcium oral tablet delayed release                    | 1 or 1b* | QL         |
| disulfiram oral tablet   | 1 or 1b* |            |
| <b>*ALZHEIMER'S TREATMENT - ANTI-AMYLOID ANTIBODIES***</b>         |          |            |
| <b>LEQEMBI IQLIK SUBCUTANEOUS SOLUTION AUTO-INJECTOR</b>           | 5        | PA; LD; QL |
| <b>*ANTI-CATAPLECTIC AGENTS***</b>                                 |          |            |
| sodium oxybate oral solution                                       | 4        | PA; LD; QL |
| <b>*ANTI-CATAPLECTIC COMBINATIONS***</b>                           |          |            |
| <b>XYWAV ORAL SOLUTION</b>   | 4        | PA; LD; QL |

| Drug Name  | Tier     | Notes      |
|--|----------|------------|
| <b>*ANTIDEMENTIA AGENT COMBINATIONS***</b>                                     |          |            |
| memantine hcl-donepezil hcl er oral capsule extended release 24 hour           | 1 or 1b* | QL         |
| <b>NAMZARIC ORAL CAPSULE EXTENDED RELEASE 24 HOUR 7-10 MG</b>                  | 2        | QL         |
| <b>*ANTISENSE OLIGONUCLEOTIDE (ASO) INHIBITOR AGENTS***</b>                    |          |            |
| <b>WAINUA SUBCUTANEOUS SOLUTION AUTO-INJECTOR</b>                              | 5        | PA; LD; QL |
| <b>*BENZODIAZEPINES &amp; TRICYCLIC AGENTS***</b>                              |          |            |
| chlordiazepoxide-amitriptyline oral tablet                                     | 1 or 1b* |            |
| <b>*CHOLINOMIMETICS - ACHE INHIBITORS***</b>                                   |          |            |
| donepezil hcl oral tablet 10 mg, 23 mg   | 1 or 1b* | QL         |
| donepezil hcl oral tablet 5 mg   | 1 or 1b* | DO         |
| donepezil hcl oral tablet dispersible  | 1 or 1b* | QL         |
| galantamine hydrobromide er oral capsule extended release 24 hour 16 mg, 24 mg | 1 or 1b* | QL         |
| galantamine hydrobromide er oral capsule extended release 24 hour 8 mg         | 1 or 1b* | DO         |
| galantamine hydrobromide oral solution   | 1 or 1b* | QL         |
| galantamine hydrobromide oral tablet 12 mg, 8 mg                               | 1 or 1b* | QL         |
| galantamine hydrobromide oral tablet 4 mg                                      | 1 or 1b* | DO         |
| rivastigmine tartrate oral capsule 1.5 mg, 3 mg                                | 1 or 1b* | DO         |
| rivastigmine tartrate oral capsule 4.5 mg, 6 mg                                | 1 or 1b* | QL         |
| rivastigmine transdermal patch 24 hour   | 1 or 1b* | QL         |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| <b>*FIBROMYALGIA AGENT - SNRIS***</b>   |          |                |
| SAVELLA ORAL TABLET   | 2        | QL             |
| SAVELLA TITRATION PACK ORAL   | 2        | QL             |
| <b>*MELANOCORTIN RECEPTOR AGONISTS***</b>   |          |                |
| VYLEESI SUBCUTANEOUS SOLUTION AUTO-INJECTOR   | 3        | PA; LD; QL     |
| <b>*MOVEMENT DISORDER DRUG THERAPY***</b>   |          |                |
| AUSTEDO ORAL TABLET 12 MG, 9 MG   | 4        | PA; QL; SP     |
| AUSTEDO ORAL TABLET 6 MG  | 4        | PA; DO; SP     |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR   | 4        | PA; QL; SP     |
| AUSTEDO XR PATIENT TITRATION ORAL TABLET EXTENDED RELEASE THERAPY PACK 12 & 18 & 24 & 30 MG | 4        | PA; QL; SP     |
| INGREZZA ORAL CAPSULE 40 MG   | 4        | PA; LD; DO; SP |
| INGREZZA ORAL CAPSULE 60 MG, 80 MG  | 4        | PA; LD; QL; SP |
| INGREZZA ORAL CAPSULE SPRINKLE 40 MG  | 4        | PA; LD; DO; SP |
| INGREZZA ORAL CAPSULE SPRINKLE 60 MG, 80 MG   | 4        | PA; LD; QL; SP |
| INGREZZA ORAL CAPSULE THERAPY PACK  | 4        | PA; LD; QL; SP |
| tetrabenazine oral tablet   | 1 or 1b* | PA; QL; SP     |
| <b>*MS AGENTS - PYRIMIDINE SYNTHESIS INHIBITORS***</b>                                      |          |                |
| teriflunomide oral tablet   | 4        | PA; QL; SP     |

| Drug Name   | Tier | Notes          |
|---|------|----------------|
| <b>*MULTIPLE SCLEROSIS AGENTS - ANTIMETABOLITES***</b>        |      |                |
| cladribine (10 tabs) oral tablet therapy pack                 | 4    | PA; QL; SP     |
| cladribine (4 tabs) oral tablet therapy pack                  | 4    | PA; QL; SP     |
| cladribine (5 tabs) oral tablet therapy pack                  | 4    | PA; QL; SP     |
| cladribine (6 tabs) oral tablet therapy pack                  | 4    | PA; QL; SP     |
| cladribine (7 tabs) oral tablet therapy pack                  | 4    | PA; QL; SP     |
| cladribine (8 tabs) oral tablet therapy pack                  | 4    | PA; QL; SP     |
| cladribine (9 tabs) oral tablet therapy pack                  | 4    | PA; QL; SP     |
| <b>*MULTIPLE SCLEROSIS AGENTS - INTERFERONS***</b>            |      |                |
| AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT                    | 4    | PA; QL; SP     |
| AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT          | 4    | PA; QL; SP     |
| BETASERON SUBCUTANEOUS KIT                                    | 4    | PA; QL; SP     |
| PLEGRIDY INTRAMUSCULAR SOLUTION PREFILLED SYRINGE             | 4    | PA; LD; QL; SP |
| PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR     | 4    | PA; LD; QL; SP |
| PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE | 4    | PA; LD; QL; SP |
| PLEGRIDY SUBCUTANEOUS SOLUTION AUTO-INJECTOR                  | 4    | PA; LD; QL; SP |
| PLEGRIDY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE              | 4    | PA; LD; QL; SP |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| <b>REBIF REBIDOSE SUBCUTANEOUS SOLUTION AUTO-INJECTOR</b>                | 4        | PA; QL; SP     |
| <b>REBIF REBIDOSE TITRATION PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR</b> | 4        | PA; QL; SP     |
| <b>REBIF SUBCUTANEOUS SOLUTION PREFILLED SYRINGE</b>                     | 4        | PA; QL; SP     |
| <b>REBIF TITRATION PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE</b>      | 4        | PA; QL; SP     |
| <b>*MULTIPLE SCLEROSIS AGENTS - MONOCLONAL ANTIBODIES***</b>             |          |                |
| <b>KESIMPTA SUBCUTANEOUS SOLUTION AUTO-INJECTOR</b>                      | 5        | PA; LD; QL; SP |
| <b>LEMTRADA INTRAVENOUS SOLUTION</b>                                     | 5        | PA; LD; QL; SP |
| <b>TYSABRI INTRAVENOUS CONCENTRATE</b>                                   | 5        | PA; LD; QL; SP |
| <b>*MULTIPLE SCLEROSIS AGENTS - NRF2 PATHWAY ACTIVATORS***</b>           |          |                |
| dimethyl fumarate oral capsule delayed release                           | 1 or 1b* | PA; QL; SP     |
| dimethyl fumarate starter pack oral capsule delayed release therapy pack | 1 or 1b* | PA; QL; SP     |
| <b>VUMERITY ORAL CAPSULE DELAYED RELEASE</b>                             | 4        | PA; LD; QL; SP |
| <b>*MULTIPLE SCLEROSIS AGENTS - POTASSIUM CHANNEL BLOCKERS***</b>        |          |                |
| dalfampridine er oral tablet extended release 12 hour                    | 4        | PA; QL; SP     |
| <b>*MULTIPLE SCLEROSIS AGENTS***</b>                                     |          |                |
| glatiramer acetate subcutaneous solution prefilled syringe               | 4        | PA; QL; SP     |

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| glatopa subcutaneous solution prefilled syringe                     | 4        | PA; QL; SP |
| <b>*N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTAGONISTS***</b>         |          |            |
| memantine hcl er oral capsule extended release 24 hour 14 mg, 7 mg  | 1 or 1b* | DO         |
| memantine hcl er oral capsule extended release 24 hour 21 mg, 28 mg | 1 or 1b* | QL         |
| memantine hcl oral solution   | 1 or 1b* | QL         |
| memantine hcl oral tablet 10 mg, 28 x 5 mg & 21 x 10 mg             | 1 or 1b* | QL         |
| memantine hcl oral tablet 5 mg                                      | 1 or 1b* | DO         |
| <b>*PHENOTHIAZINES &amp; TRICYCLIC AGENTS***</b>                    |          |            |
| perphenazine-amitriptyline oral tablet                              | 1 or 1b* | AL         |
| <b>*POSTHERPETIC NEURALGIA (PHN)/NEUROPATHIC PAIN AGENTS***</b>     |          |            |
| gabapentin (once-daily) oral tablet 300 mg, 450 mg, 600 mg          | 1 or 1b* | PA; DO     |
| gabapentin (once-daily) oral tablet 750 mg, 900 mg                  | 1 or 1b* | PA; QL     |
| <b>GRALISE ORAL TABLET 300 MG</b>                                   | 3        | PA; DO     |
| <b>GRALISE ORAL TABLET 450 MG</b>                                   | 2        | PA; DO     |
| <b>GRALISE ORAL TABLET 600 MG</b>                                   | 3        | PA; QL     |
| <b>GRALISE ORAL TABLET 750 MG, 900 MG</b>                           | 2        | PA; QL     |
| pregabalin er oral tablet extended release 24 hour 165 mg, 82.5 mg  | 1 or 1b* | PA; DO     |
| pregabalin er oral tablet extended release 24 hour 330 mg           | 1 or 1b* | PA; QL     |
| <b>*PREMENSTRUAL DYSPHORIC DISORDER (PMDD) AGENTS - SSRIS***</b>    |          |            |
| fluoxetine hcl (pmdd) oral tablet 10 mg                             | 1 or 1b* | DO         |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes          |
|---|----------|----------------|
| fluoxetine hcl (pmdd) oral tablet 20 mg                             | 1 or 1b* | QL             |
| <b>*PSEUDOBULBAR AFFECT AGENT COMBINATIONS***</b>                   |          |                |
| NUDEXTA ORAL CAPSULE  | 3        | QL             |
| <b>*PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC.***</b>        |          |                |
| AQNEURSA ORAL PACKET  | 5        | PA; LD; QL     |
| MIPLYFFA ORAL CAPSULE   | 5        | PA; LD; QL     |
| pimozide oral tablet  | 1 or 1b* | AL; QL         |
| <b>*SEROTONIN 1A RECEPT AGONIST/SEROTONIN 2A RECEPT ANTAG***</b>    |          |                |
| ADDYI ORAL TABLET   | 3        | PA; QL         |
| <b>*SMALL INTERFERING RIBONUCLEIC ACID (SIRNA) AGENTS***</b>        |          |                |
| AMVUTTRA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE                    | 5        | PA; LD; QL; SP |
| ONPATRO INTRAVENOUS SOLUTION  | 5        | PA; LD; QL; SP |
| <b>*SMOKING DETERRENTS***</b>                                       |          |                |
| bupropion hcl er (smoking det) oral tablet extended release 12 hour | 1 or 1b* | \$0; QL        |
| cvs nicotine mouth/throat gum                                       | 1 or 1b* | \$0            |
| cvs nicotine mouth/throat lozenge                                   | 1 or 1b* | \$0            |
| cvs nicotine polacrilex mouth/throat gum                            | 1 or 1b* | \$0            |
| cvs nicotine polacrilex mouth/throat lozenge                        | 1 or 1b* | \$0            |
| cvs nicotine transdermal patch 24 hour                              | 1 or 1b* | \$0            |
| eq nicotine mouth/throat lozenge                                    | 1 or 1b* | \$0            |
| eq nicotine polacrilex mouth/throat gum                             | 1 or 1b* | \$0            |

| Drug Name  | Tier     | Notes |
|--|----------|-------|
| eq nicotine polacrilex mouth/throat lozenge                  | 1 or 1b* | \$0   |
| eq nicotine step 3 transdermal patch 24 hour                 | 1 or 1b* | \$0   |
| eq nicotine transdermal patch 24 hour 14 mg/24hr, 21 mg/24hr | 1 or 1b* | \$0   |
| ft nicotine mini mouth/throat lozenge                        | 1 or 1b* | \$0   |
| ft nicotine mouth/throat gum                                 | 1 or 1b* | \$0   |
| ft nicotine mouth/throat lozenge                             | 1 or 1b* | \$0   |
| ft nicotine transdermal patch 24 hour                        | 1 or 1b* | \$0   |
| gnp nicotine mini mouth/throat lozenge                       | 1 or 1b* | \$0   |
| gnp nicotine mouth/throat gum                                | 1 or 1b* | \$0   |
| gnp nicotine polacrilex mouth/throat gum                     | 1 or 1b* | \$0   |
| gnp nicotine polacrilex mouth/throat lozenge                 | 1 or 1b* | \$0   |
| gnp nicotine transdermal patch 24 hour                       | 1 or 1b* | \$0   |
| goodsense nicotine mouth/throat gum                          | 1 or 1b* | \$0   |
| goodsense nicotine mouth/throat lozenge                      | 1 or 1b* | \$0   |
| goodsense nicotine polacrilex mouth/throat gum               | 1 or 1b* | \$0   |
| habitrol transdermal patch 24 hour                           | 1 or 1b* | \$0   |
| kls quit2 mouth/throat gum                                   | 1 or 1b* | \$0   |
| kls quit2 mouth/throat lozenge                               | 1 or 1b* | \$0   |
| kls quit4 mouth/throat gum                                   | 1 or 1b* | \$0   |
| kls quit4 mouth/throat lozenge                               | 1 or 1b* | \$0   |
| <b>NICODERM CQ TRANSDERMAL PATCH 24 HOUR</b>                 | 1 or 1b* | \$0   |
| <b>NICORETTE MINI MOUTH/THROAT LOZENGE</b>                   | 1 or 1b* | \$0   |
| <b>NICORETTE MOUTH/THROAT GUM</b>                            | 1 or 1b* | \$0   |
| <b>NICORETTE MOUTH/THROAT LOZENGE</b>                        | 1 or 1b* | \$0   |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| <b>NICORETTE STARTER KIT MOUTH/THROAT GUM</b>                | 1 or 1b* | \$0            |
| nicotine mini mouth/throat lozenge                           | 1 or 1b* | \$0            |
| nicotine polacrilex mini mouth/throat lozenge                | 1 or 1b* | \$0            |
| nicotine polacrilex mouth/throat gum                         | 1 or 1b* | \$0            |
| nicotine polacrilex mouth/throat lozenge                     | 1 or 1b* | \$0            |
| nicotine step 1 transdermal patch 24 hour                    | 1 or 1b* | \$0            |
| nicotine step 2 transdermal patch 24 hour                    | 1 or 1b* | \$0            |
| nicotine step 3 transdermal patch 24 hour                    | 1 or 1b* | \$0            |
| <b>NICOTINE TRANSDERMAL KIT</b>                              | 2        | \$0            |
| nicotine transdermal patch 24 hour                           | 1 or 1b* | \$0            |
| <b>NICOTROL NS NASAL SOLUTION</b>                            | 3        | \$0; QL        |
| qc nicotine transdermal system transdermal patch 24 hour     | 1 or 1b* | \$0            |
| thrive mouth/throat gum 2 mg                                 | 1 or 1b* | \$0            |
| varenicline tartrate (starter) oral tablet therapy pack      | 1 or 1b* | \$0; QL        |
| varenicline tartrate oral tablet 0.5 mg, 1 mg                | 1 or 1b* | \$0; QL        |
| varenicline tartrate(continue) oral tablet                   | 1 or 1b* | \$0; QL        |
| <b>*SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS***</b> |          |                |
| fingolimod hcl oral capsule                                  | 4        | PA; QL; SP     |
| <b>GILENYA ORAL CAPSULE 0.25 MG</b>                          | 5        | PA; QL; SP     |
| <b>MAYZENT ORAL TABLET</b>                                   | 4        | PA; LD; QL; SP |
| <b>MAYZENT STARTER PACK ORAL TABLET THERAPY PACK</b>         | 4        | PA; LD; QL; SP |
| <b>PONVORY ORAL TABLET</b>                                   | 5        | PA; LD; QL; SP |

| Drug Name  | Tier     | Notes          |
|--|----------|----------------|
| <b>PONVORY STARTER PACK ORAL TABLET THERAPY PACK</b>                               | 5        | PA; LD; QL; SP |
| <b>ZEPOSIA 7-DAY STARTER PACK ORAL CAPSULE THERAPY PACK</b>                        | 4        | PA; LD; QL; SP |
| <b>ZEPOSIA ORAL CAPSULE</b>  | 4        | PA; LD; QL; SP |
| <b>ZEPOSIA STARTER KIT ORAL CAPSULE THERAPY PACK 0.23MG &amp;0.46MG 0.92MG(21)</b> | 4        | PA; LD; QL; SP |
| <b>*THIENBENZODIAZEPINES &amp; OPIOID ANTAGONISTS***</b>                           |          |                |
| <b>LYBALVI ORAL TABLET</b>   | 3        | ST; QL         |
| <b>*THIENBENZODIAZEPINES &amp; SSRIS***</b>  |          |                |
| olanzapine-fluoxetine hcl oral capsule 12-25 mg, 12-50 mg, 6-50 mg                 | 1 or 1b* | AL; QL         |
| olanzapine-fluoxetine hcl oral capsule 3-25 mg, 6-25 mg                            | 1 or 1b* | DO; AL         |
| <b>*VASOMOTOR SYMPTOM AGENTS - SSRIS***</b>  |          |                |
| paroxetine mesylate oral capsule   | 1 or 1b* |                |
| <b>*RESPIRATORY AGENTS - MISC.*</b>  |          |                |
| <b>*ALPHA-PROTEINASE INHIBITOR (HUMAN)***</b>                                      |          |                |
| <b>ARALAST NP INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG, 500 MG</b>               | 5        | PA; LD; SP     |
| <b>GLASSIA INTRAVENOUS SOLUTION</b>  | 5        | PA; LD; SP     |
| <b>PROLASTIN-C INTRAVENOUS SOLUTION</b>  | 5        | PA; LD         |
| <b>ZEMAIRA INTRAVENOUS SOLUTION RECONSTITUTED</b>                                  | 5        | PA; LD; SP     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier | Notes          |
|--|------|----------------|
| <b>*CFTR POTENTIATORS***</b>                             |      |                |
| KALYDECO ORAL PACKET                                     | 5    | PA; LD; QL; SP |
| KALYDECO ORAL TABLET                                     | 5    | PA; LD; QL; SP |
| <b>*CYSTIC FIBROSIS AGENT - COMBINATIONS***</b>          |      |                |
| ALYFTREK ORAL TABLET                                     | 5    | PA; LD; QL     |
| ORKAMBI ORAL PACKET                                      | 5    | PA; LD; QL; SP |
| ORKAMBI ORAL TABLET                                      | 5    | PA; LD; QL; SP |
| SYMDEKO ORAL TABLET THERAPY PACK                         | 5    | PA; LD; QL; SP |
| TRIKAFTA ORAL TABLET THERAPY PACK                        | 5    | PA; LD; QL; SP |
| TRIKAFTA ORAL THERAPY PACK                               | 5    | PA; LD; QL; SP |
| <b>*CYSTIC FIBROSIS AGENTS - MISCELLANEOUS***</b>        |      |                |
| BRONCHITOL INHALATION CAPSULE                            | 5    | PA; LD; QL; SP |
| BRONCHITOL TOLERANCE TEST INHALATION CAPSULE             | 5    | PA; LD; QL; SP |
| <b>*DIPEPTIDYL PEPTIDASE 1 (DPP1) INHIBITORS***</b>      |      |                |
| BRINSUPRI ORAL TABLET                                    | 5    | PA; LD; QL     |
| <b>*HYDROLYTIC ENZYMES***</b>                            |      |                |
| PULMOZYME INHALATION SOLUTION 2.5 MG/2.5ML               | 5    | PA; LD; QL; SP |
| <b>*PULMONARY FIBROSIS AGENTS - KINASE INHIBITORS***</b> |      |                |
| OFEV ORAL CAPSULE  | 5    | PA; LD; QL; SP |
| <b>*PULMONARY FIBROSIS AGENTS***</b>                     |      |                |
| pirfenidone oral capsule                                 | 4    | PA; QL; SP     |
| pirfenidone oral tablet 267 mg, 801 mg                   | 4    | PA; QL; SP     |

| Drug Name   | Tier     | Notes      |
|---|----------|------------|
| pirfenidone oral tablet 534 mg                            | 4        | PA; QL     |
| <b>*SULFONAMIDES*</b>                                     |          |            |
| <b>*SULFONAMIDES***</b>                                   |          |            |
| sulfadiazine oral tablet                                  | 1 or 1b* |            |
| <b>*TETRACYCLINES*</b>                                    |          |            |
| <b>*AMINOMETHYLCYCLOPENTANES***</b>                       |          |            |
| NUZYRA INTRAVENOUS SOLUTION RECONSTITUTED                 | 3        | LD         |
| NUZYRA ORAL TABLET 150 MG                                 | 3        | PA; LD; QL |
| <b>*FLUOROCYCLINES***</b>                                 |          |            |
| XERAVA INTRAVENOUS SOLUTION RECONSTITUTED                 | 3        |            |
| <b>*GLYCYLCYCLINES***</b>                                 |          |            |
| TIGECYCLINE INTRAVENOUS SOLUTION RECONSTITUTED            | 3        |            |
| <b>*TETRACYCLINES***</b>                                  |          |            |
| demeclocycline hcl oral tablet                            | 1 or 1b* |            |
| doxy 100 intravenous solution reconstituted               | 1 or 1b* | QL         |
| doxycycline hyclate intravenous solution reconstituted    | 1 or 1b* | QL         |
| doxycycline hyclate oral capsule                          | 1 or 1b* | QL         |
| doxycycline hyclate oral tablet 100 mg, 20 mg             | 1 or 1b* | QL         |
| doxycycline monohydrate oral capsule 100 mg, 50 mg, 75 mg | 1 or 1b* | QL         |
| doxycycline monohydrate oral capsule 150 mg               | 3        | ST; QL     |
| doxycycline monohydrate oral suspension reconstituted     | 1 or 1b* | QL         |
| doxycycline monohydrate oral tablet                       | 1 or 1b* | QL         |
| MINOCIN INTRAVENOUS SOLUTION RECONSTITUTED                | 3        |            |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier     | Notes |
|---|----------|-------|
| minocycline hcl oral capsule  | 1 or 1b* | QL    |
| minocycline hcl oral tablet   | 1 or 1b* | QL    |
| mondoxyne nl oral capsule 100 mg  | 1 or 1b* | QL    |
| tetracycline hcl oral capsule   | 1 or 1b* | QL    |
| <b>*THYROID AGENTS*</b>   |          |       |
| <b>*ANTITHYROID AGENTS - RADIOPHARMACEUTICALS***</b>                            |          |       |
| SODIUM IODIDE I-131 ORAL SOLUTION   | 3        |       |
| <b>*ANTITHYROID AGENTS***</b>   |          |       |
| methimazole oral tablet   | 1 or 1a* |       |
| propylthiouracil oral tablet  | 1 or 1b* |       |
| <b>*THYROID HORMONES***</b>   |          |       |
| levo-t oral tablet  | 1 or 1b* |       |
| LEVOTHYROXINE SODIUM INTRAVENOUS SOLUTION 100 MCG/5ML, 200 MCG/5ML, 500 MCG/5ML | 3        |       |
| levothyroxine sodium intravenous solution 100 mcg/ml                            | 3        |       |
| levothyroxine sodium oral capsule   | 1 or 1b* |       |
| levothyroxine sodium oral tablet  | 1 or 1a* |       |
| levoxyl oral tablet   | 1 or 1a* |       |
| LIOMNY ORAL TABLET  | 1 or 1b* |       |
| liothyronine sodium intravenous solution  | 1 or 1b* |       |
| liothyronine sodium oral tablet   | 1 or 1b* |       |
| THYQUIDITY ORAL SOLUTION  | 3        |       |
| TIROSINT-SOL ORAL SOLUTION  | 3        |       |
| unithroid oral tablet   | 1 or 1a* |       |

| Drug Name  | Tier | Notes |
|--|------|-------|
| <b>*TOXOIDS*</b>                                     |      |       |
| <b>*TOXOID COMBINATIONS***</b>                       |      |       |
| ADACEL INTRAMUSCULAR SUSPENSION 5-2-15.5 LF-MCG/0.5  | 3    | \$0   |
| ADACEL INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE    | 3    | \$0   |
| BOOSTRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE  | 3    | \$0   |
| DAPTACEL INTRAMUSCULAR SUSPENSION 23-15-5            | 3    | \$0   |
| INFANRIX INTRAMUSCULAR SUSPENSION                    | 3    | \$0   |
| KINRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE    | 3    | \$0   |
| PEDIARIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE  | 3    | \$0   |
| PENTACEL INTRAMUSCULAR SUSPENSION RECONSTITUTED      | 3    | \$0   |
| QUADRACEL INTRAMUSCULAR SUSPENSION                   | 3    | \$0   |
| QUADRACEL INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 3    | \$0   |
| TENIVAC INTRAMUSCULAR SUSPENSION                     | 3    | \$0   |
| VAXELIS INTRAMUSCULAR SUSPENSION                     | 3    |       |
| VAXELIS INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE   | 3    |       |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes |
|--|----------|-------|
| <b>*ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS*</b>                     |          |       |
| <b>*ANTICHOLINERGIC COMBINATIONS***</b>                                  |          |       |
| chlordiazepoxide-clidinium oral capsule                                  | 1 or 1b* |       |
| <b>*ANTISPASMODICS***</b>  |          |       |
| dicyclomine hcl intramuscular solution                                   | 1 or 1b* |       |
| dicyclomine hcl oral capsule   | 1 or 1a* |       |
| dicyclomine hcl oral solution 10 mg/5ml                                  | 1 or 1a* |       |
| dicyclomine hcl oral tablet 20 mg  | 1 or 1a* |       |
| <b>*BELLADONNA ALKALOIDS***</b>  |          |       |
| <b>ATROPINE SULFATE INJECTION SOLUTION PREFILLED SYRINGE 0.25 MG/5ML</b> | 3        |       |
| <b>ATROPINE SULFATE INJECTION SOLUTION PREFILLED SYRINGE 0.5 MG/5ML</b>  | 1 or 1b* |       |
| <b>ATROPINE SULFATE INTRAVENOUS SOLUTION</b>                             | 1 or 1b* |       |
| <b>*H-2 ANTAGONISTS***</b>   |          |       |
| cimetidine hcl oral solution 300 mg/5ml                                  | 1 or 1b* |       |
| cimetidine oral tablet   | 1 or 1b* |       |
| famotidine (pf) intravenous solution                                     | 1 or 1b* |       |
| famotidine intravenous solution 200 mg/20ml, 40 mg/4ml                   | 1 or 1b* |       |
| famotidine oral suspension reconstituted                                 | 1 or 1b* |       |
| famotidine oral tablet 20 mg, 40 mg                                      | 1 or 1b* |       |
| famotidine premixed intravenous solution                                 | 1 or 1b* |       |
| nizatidine oral capsule  | 1 or 1b* |       |
| ranitidine hcl oral tablet 150 mg, 300 mg                                | 1 or 1b* |       |
| <b>*MISC. ANTI-ULCER***</b>  |          |       |
| sucralfate oral suspension   | 1 or 1b* |       |

| Drug Name   | Tier     | Notes |
|---|----------|-------|
| sucralfate oral tablet  | 1 or 1b* |       |
| <b>*PROTON PUMP INHIBITORS***</b>   |          |       |
| esomeprazole magnesium oral capsule delayed release                           | 1 or 1b* |       |
| esomeprazole magnesium oral packet  | 1 or 1b* |       |
| esomeprazole sodium intravenous solution reconstituted 40 mg                  | 1 or 1b* |       |
| lansoprazole oral capsule delayed release 15 mg                               | 1 or 1b* | BE    |
| lansoprazole oral capsule delayed release 30 mg                               | 1 or 1b* |       |
| omeprazole oral capsule delayed release                                       | 1 or 1b* |       |
| pantoprazole sodium intravenous solution reconstituted                        | 3        |       |
| pantoprazole sodium oral tablet delayed release                               | 1 or 1b* |       |
| pantoprazole sodium-nacl intravenous solution                                 | 3        |       |
| <b>PROTONIX INTRAVENOUS SOLUTION RECONSTITUTED</b>                            |          |       |
| rabeprazole sodium oral tablet delayed release                                | 1 or 1b* |       |
| <b>*QUATERNARY ANTICHOLINERGICS***</b>  |          |       |
| <b>GLYCATE ORAL TABLET</b>  | 3        | PA    |
| glycopyrrolate injection solution   | 1 or 1b* |       |
| glycopyrrolate oral solution  | 1 or 1b* |       |
| glycopyrrolate oral tablet 1 mg, 2 mg   | 1 or 1b* |       |
| <b>GLYCOPYRROLATE ORAL TABLET 1.5 MG</b>                                      | 3        | PA    |
| <b>GLYCOPYRROLATE PF +RFID INJECTION SOLUTION PREFILLED SYRINGE 0.2 MG/ML</b> | 1 or 1b* |       |
| glycopyrrolate pf +rfid injection solution prefilled syringe 0.4 mg/2ml       | 1 or 1b* |       |
| glycopyrrolate pf injection solution prefilled syringe 0.6 mg/3ml             | 3        |       |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes                                       |
|--|----------|---|
| GLYRX-PF INJECTION SOLUTION  | 3        |   |
| GLYRX-PF INJECTION SOLUTION PREFILLED SYRINGE 1 MG/5ML             | 3        |   |
| methscopolamine bromide oral tablet                                | 1 or 1b* |   |
| <b>*ULCER ANTI-INFECTIVE W/ BISMUTH COMBINATIONS***</b>            |          |   |
| bis subcit-metronid-tetracyc oral capsule                          | 1 or 1b* | ST; QL                                      |
| bismuth/metronidaz/tetracycl in oral capsule                       | 1 or 1b* | ST; QL                                      |
| <b>*ULCER ANTI-INFECTIVE W/ PROTON PUMP INHIBITORS***</b>          |          |   |
| amoxicill-clarithro-lansopraz oral therapy pack                    | 1 or 1b* | ST; QL                                      |
| TALICIA ORAL CAPSULE DELAYED RELEASE                               | 3        | ST; QL                                      |
| <b>*ULCER DRUGS - PROSTAGLANDINS***</b>                            |          |   |
| misoprostol oral tablet  | 1 or 1a* | \$0 for Fully insured members in California |
| <b>*URINARY ANTISPASMODICS*</b>                                    |          |   |
| <b>*URINARY ANTISPASMODIC - ANTIMUSCARINIC (ANTICHOLINERGIC)**</b> |          |   |
| *  |          |   |
| darifenacin hydrobromide er oral tablet extended release 24 hour   | 1 or 1b* | QL  |
| fesoterodine fumarate er oral tablet extended release 24 hour      | 1 or 1b* | QL  |
| oxybutynin chloride er oral tablet extended release 24 hour        | 1 or 1b* | QL  |
| oxybutynin chloride oral solution                                  | 1 or 1b* | QL  |
| oxybutynin chloride oral tablet                                    | 1 or 1b* | QL  |
| solifenacin succinate oral tablet                                  | 1 or 1b* | QL  |

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| tolterodine tartrate er oral capsule extended release 24 hour  | 1 or 1b* | QL     |
| tolterodine tartrate oral tablet                               | 1 or 1b* | QL     |
| tropium chloride er oral capsule extended release 24 hour      | 1 or 1b* | QL     |
| tropium chloride oral tablet                                   | 1 or 1b* | QL     |
| <b>*URINARY ANTISPASMODICS - BETA-3 ADRENERGIC AGONISTS***</b> |          |        |
| GEMTESA ORAL TABLET  | 3        | QL     |
| mirabegron er oral tablet extended release 24 hour             | 1 or 1b* | QL     |
| MYRBETRIQ ORAL SUSPENSION RECONSTITUTED ER                     | 3        | PA; QL |
| <b>*URINARY ANTISPASMODICS - CHOLINERGIC AGONISTS***</b>       |          |        |
| bethanechol chloride oral tablet                               | 1 or 1b* |        |
| <b>*URINARY ANTISPASMODICS - DIRECT MUSCLE RELAXANTS***</b>    |          |        |
| flavoxate hcl oral tablet                                      | 1 or 1b* |        |
| <b>*VACCINES*</b>  |          |        |
| <b>*BACTERIAL VACCINES***</b>                                  |          |        |
| ACTHIB INTRAMUSCULAR SOLUTION RECONSTITUTED                    | 3        | \$0    |
| BCG VACCINE INJECTION SOLUTION RECONSTITUTED                   | 3        | \$0    |
| BEXSERO INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE             | 3        | \$0    |
| CAPVAXIVE INTRAMUSCULAR SOLUTION PREFILLED SYRINGE             | 3        | \$0    |
| HIBERIX INJECTION SOLUTION RECONSTITUTED                       | 3        | \$0    |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier | Notes |
|--|------|-------|
| MENQUADFI INTRAMUSCULAR SOLUTION                       | 3    | \$0   |
| MENVEO INTRAMUSCULAR SOLUTION                          | 3    | \$0   |
| MENVEO INTRAMUSCULAR SOLUTION RECONSTITUTED            | 3    | \$0   |
| PEDVAX HIB INTRAMUSCULAR SUSPENSION                    | 3    | \$0   |
| PENBRAYA INTRAMUSCULAR SUSPENSION RECONSTITUTED        | 3    | \$0   |
| penmenvy intramuscular suspension reconstituted        | 3    | \$0   |
| PNEUMOVAX 23 INJECTION SOLUTION PREFILLED SYRINGE      | 2    | \$0   |
| PREVNAR 20 INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE  | 2    | \$0   |
| TRUMENBA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE    | 3    | \$0   |
| TYPHIM VI INTRAMUSCULAR SOLUTION PREFILLED SYRINGE     | 3    |       |
| VAXCHORA ORAL SUSPENSION RECONSTITUTED                 | 3    |       |
| VAXNEUVANCE INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 2    | \$0   |
| VIVOTIF ORAL CAPSULE DELAYED RELEASE                   | 2    |       |
| <b>*VIRAL VACCINE COMBINATIONS***</b>                  |      |       |
| M-M-R II INJECTION SOLUTION RECONSTITUTED              | 3    | \$0   |
| PRIORIX SUBCUTANEOUS SUSPENSION RECONSTITUTED          | 3    | \$0   |

| Drug Name  | Tier | Notes           |
|--|------|-----------------|
| PROQUAD SUBCUTANEOUS SUSPENSION RECONSTITUTED                        | 3    | \$0             |
| TWINRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE                   | 3    | \$0             |
| <b>*VIRAL VACCINES***</b>  |      |                 |
| ABRYSVO INTRAMUSCULAR SOLUTION RECONSTITUTED                         | 3    | \$0; QL         |
| ACAM2000 INJECTION SOLUTION RECONSTITUTED                            | 3    | \$0             |
| AFLURIA INTRAMUSCULAR SUSPENSION                                     | 2    | \$0; QL         |
| AFLURIA PRESERVATIVE FREE INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 2    | \$0; QL         |
| AREXVY INTRAMUSCULAR SUSPENSION RECONSTITUTED                        | 3    | PA; AL; \$0; QL |
| AUDENZ INTRAMUSCULAR EMULSION  | 2    | \$0             |
| AUDENZ INTRAMUSCULAR PREFILLED SYRINGE                               | 2    | \$0             |
| COMIRNATY 5-11 YEARS INTRAMUSCULAR SUSPENSION                        | 2    | \$0             |
| COMIRNATY INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE                 | 2    | \$0             |
| DENGVAXIA SUBCUTANEOUS SUSPENSION RECONSTITUTED                      | 3    |                 |
| ENGERIX-B INJECTION SUSPENSION 20 MCG/ML                             | 3    | \$0             |
| ENGERIX-B INJECTION SUSPENSION PREFILLED SYRINGE                     | 3    | \$0             |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name   | Tier | Notes   |
|---|------|---------|
| ERVEBO<br>INTRAMUSCULAR<br>SUSPENSION                                 | 3    |         |
| FLUAD<br>INTRAMUSCULAR<br>SUSPENSION<br>PREFILLED SYRINGE             | 2    | \$0; QL |
| FLUARIX<br>INTRAMUSCULAR<br>SUSPENSION<br>PREFILLED SYRINGE           | 2    | \$0; QL |
| FLUBLOK<br>INTRAMUSCULAR<br>SOLUTION PREFILLED<br>SYRINGE             | 2    | \$0; QL |
| FLUCELVAX<br>INTRAMUSCULAR<br>SUSPENSION                              | 2    | \$0; QL |
| FLUCELVAX<br>INTRAMUSCULAR<br>SUSPENSION<br>PREFILLED SYRINGE         | 2    | \$0; QL |
| FLULAVAL<br>INTRAMUSCULAR<br>SUSPENSION<br>PREFILLED SYRINGE          | 2    | \$0; QL |
| FLUMIST NASAL<br>LIQUID   | 2    | \$0; QL |
| FLUZONE HIGH-DOSE<br>INTRAMUSCULAR<br>SUSPENSION<br>PREFILLED SYRINGE | 2    | \$0; QL |
| FLUZONE<br>INTRAMUSCULAR<br>SUSPENSION                                | 2    | \$0; QL |
| FLUZONE<br>INTRAMUSCULAR<br>SUSPENSION<br>PREFILLED SYRINGE           | 2    | \$0; QL |
| GARDASIL 9<br>INTRAMUSCULAR<br>SUSPENSION                             | 2    | \$0     |
| GARDASIL 9<br>INTRAMUSCULAR<br>SUSPENSION<br>PREFILLED SYRINGE        | 2    | \$0     |
| HAVRIX<br>INTRAMUSCULAR<br>SUSPENSION<br>PREFILLED SYRINGE            | 3    | \$0     |

| Drug Name  | Tier | Notes       |
|--|------|-------------|
| HEPLISAV-B<br>INTRAMUSCULAR<br>SOLUTION PREFILLED<br>SYRINGE                     | 3    | \$0         |
| IMOVAX RABIES<br>INTRAMUSCULAR<br>SUSPENSION<br>RECONSTITUTED                    | 3    |             |
| IPOL INJECTION<br>SUSPENSION   | 3    | \$0         |
| IXIARO<br>INTRAMUSCULAR<br>SUSPENSION  | 3    |             |
| JYNNEOS<br>SUBCUTANEOUS<br>SUSPENSION  | 3    | \$0         |
| MNEXSPIKE<br>INTRAMUSCULAR<br>SUSPENSION<br>PREFILLED SYRINGE                    | 2    | \$0         |
| MRESVIA<br>INTRAMUSCULAR<br>SUSPENSION<br>PREFILLED SYRINGE                      | 3    | AL; \$0; QL |
| nuvaxovid covid-19 vaccine<br>intramuscular suspension<br>prefilled syringe      | 2    | \$0         |
| RABAVERT<br>INTRAMUSCULAR<br>SUSPENSION<br>RECONSTITUTED                         | 3    |             |
| RECOMBIVAX HB<br>INJECTION<br>SUSPENSION 10<br>MCG/ML, 40 MCG/ML, 5<br>MCG/0.5ML | 3    | \$0         |
| RECOMBIVAX HB<br>INJECTION<br>SUSPENSION<br>PREFILLED SYRINGE                    | 3    | \$0         |
| ROTARIX ORAL<br>SUSPENSION   | 3    | \$0         |
| ROTATEQ ORAL<br>SOLUTION   | 3    | \$0         |
| SHINGRIX<br>INTRAMUSCULAR<br>SUSPENSION<br>PREFILLED SYRINGE                     | 3    | \$0         |
| SHINGRIX<br>INTRAMUSCULAR<br>SUSPENSION<br>RECONSTITUTED 50<br>MCG/0.5ML         | 3    | \$0         |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| SPIKEVAX 6M-11Y INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 2        | \$0    |
| SPIKEVAX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE        | 2        | \$0    |
| TICOVAC INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE         | 3        |        |
| VAQTA INTRAMUSCULAR SUSPENSION 25 UNIT/0.5ML, 50 UNIT/ML   | 3        | \$0    |
| VAQTA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE           | 3        | \$0    |
| VARIVAX INJECTION SUSPENSION RECONSTITUTED                 | 3        | \$0    |
| VIMKUNYA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE        | 3        |        |
| YF-VAX SUBCUTANEOUS SUSPENSION RECONSTITUTED               | 3        |        |
| <b>*VAGINAL AND RELATED PRODUCTS*</b>                      |          |        |
| <b>*IMIDAZOLE-RELATED ANTIFUNGALS***</b>                   |          |        |
| GYNAZOLE-1 VAGINAL CREAM                                   | 3        |        |
| miconazole 3 vaginal suppository                           | 1 or 1b* |        |
| terconazole vaginal cream                                  | 1 or 1b* | QL     |
| terconazole vaginal suppository                            | 1 or 1b* | QL     |
| <b>*MISCELLANEOUS VAGINAL PRODUCTS***</b>                  |          |        |
| INTRAROSA VAGINAL INSERT                                   | 3        | ST; QL |
| <b>*SPERMICIDES***</b>                                     |          |        |
| ENCARE VAGINAL SUPPOSITORY                                 | 2        | \$0    |

| Drug Name  | Tier     | Notes  |
|--|----------|--------|
| OPTIONS GYNOL II CONTRACEPTIVE VAGINAL GEL                   | 2        | \$0    |
| TODAY SPONGE VAGINAL   | 2        | \$0    |
| VCF VAGINAL CONTRACEPTIVE VAGINAL FILM                       | 2        | \$0    |
| VCF VAGINAL CONTRACEPTIVE VAGINAL GEL                        | 2        | \$0    |
| <b>*VAGINAL ANTI-INFECTIVES***</b>                           |          |        |
| CLEOCIN VAGINAL SUPPOSITORY                                  | 2        |        |
| clindamycin phosphate vaginal cream                          | 1 or 1b* |        |
| CLINDESSE VAGINAL CREAM                                      | 3        |        |
| metronidazole vaginal gel                                    | 1 or 1b* |        |
| NUVESSA VAGINAL GEL  | 3        |        |
| VANDAZOLE VAGINAL GEL  | 1 or 1b* |        |
| XACIATO VAGINAL GEL  | 3        | PA; QL |
| <b>*VAGINAL CONTRACEPTIVE PH MODULATOR - COMBINATIONS***</b> |          |        |
| PHEXX VAGINAL GEL  | 3        |        |
| <b>*VAGINAL ESTROGENS***</b>                                 |          |        |
| estradiol vaginal cream 0.01 %                               | 1 or 1b* | QL     |
| estradiol vaginal tablet                                     | 1 or 1b* | QL     |
| PREMARIN VAGINAL CREAM                                       | 2        | QL     |
| yuvafem vaginal tablet                                       | 1 or 1b* | QL     |
| <b>*VAGINAL PROGESTINS***</b>                                |          |        |
| CRINONE VAGINAL GEL 4 %                                      | 5        |        |
| CRINONE VAGINAL GEL 8 %                                      | 5        | PA; QL |
| progesterone vaginal insert                                  | 1 or 1b* | PA     |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

| Drug Name  | Tier     | Notes      |
|--|----------|------------|
| <b>*VASOPRESSORS*</b>  |          |            |
| <b>*ANAPHYLAXIS THERAPY AGENTS***</b>  |          |            |
| <b>AUVI-Q INJECTION SOLUTION AUTO-INJECTOR</b>                                 | 2        | QL         |
| epinephrine (anaphylaxis) injection solution                                   | 1 or 1b* |            |
| epinephrine injection solution auto-injector                                   | 1 or 1b* | QL         |
| <b>EPINEPHRINESNAP INJECTION KIT</b>   | 3        |            |
| <b>*NEUROGENIC ORTHOSTATIC HYPOTENSION (NOH) - AGENTS***</b>                   |          |            |
| droxidopa oral capsule   | 1 or 1b* | PA; QL; SP |
| <b>*VASOPRESSORS***</b>  |          |            |
| <b>ADRENALIN INTRAVENOUS SOLUTION</b>  | 3        |            |
| <b>ADRENALIN-NACL INTRAVENOUS SOLUTION</b>                                     | 3        |            |
| <b>EMERPHED INTRAVENOUS SOLUTION</b>   | 3        |            |
| <b>EMERPHED INTRAVENOUS SOLUTION PREFILLED SYRINGE</b>                         | 3        |            |
| <b>EPHEDRINE SULFATE (PRESSORS) INTRAVENOUS SOLUTION</b>                       | 3        |            |
| ephedrine sulfate (pressors) intravenous solution prefilled syringe 50 mg/10ml | 1 or 1b* |            |
| epinephrine bitartrate-nacl intravenous solution                               | 3        |            |
| <b>EPINEPHRINE INTRAVENOUS SOLUTION PREFILLED SYRINGE 1 MG/10ML</b>            | 3        |            |
| <b>GIAPREZA INTRAVENOUS SOLUTION</b>   | 3        |            |
| <b>IMMPHENTIV INTRAVENOUS SOLUTION</b>   | 3        |            |
| midodrine hcl oral tablet  | 1 or 1b* |            |

| Drug Name  | Tier     | Notes |
|--|----------|-------|
| phenylephrine hcl (pf) intravenous solution                | 1 or 1b* |       |
| <b>*VITAMINS*</b>  |          |       |
| <b>*VITAMIN A***</b>                                       |          |       |
| <b>AQUASOL A INTRAMUSCULAR SOLUTION 50000 UNIT/ML</b>      | 3        |       |
| <b>*VITAMIN B-1***</b>                                     |          |       |
| thiamine hcl injection solution                            | 1 or 1b* |       |
| <b>*VITAMIN C***</b>                                       |          |       |
| <b>ASCOR INTRAVENOUS SOLUTION</b>                          | 3        |       |
| ascorbic acid intravenous solution 25000 mg/50ml           | 1 or 1b* |       |
| <b>*VITAMIN D***</b>                                       |          |       |
| ergocalciferol oral capsule                                | 1 or 1a* |       |
| vitamin d (ergocalciferol) oral capsule 1.25 mg (50000 ut) | 1 or 1a* |       |
| <b>*VITAMIN K***</b>                                       |          |       |
| phytonadione injection solution 1 mg/0.5ml, 10 mg/ml       | 1 or 1b* |       |
| phytonadione oral tablet                                   | 1 or 1b* |       |
| vitamin k1 injection solution 1 mg/0.5ml, 10 mg/ml         | 1 or 1b* |       |

\*Your plan may include Tiers 1a/1b. Refer to your pharmacy benefit summary for more information.

Effective 04/01/2026

Most plans include our home delivery program at no extra cost to you. Find out more by going online to [anthem.com](http://anthem.com) or call 866-281-4279.

**For information about your pharmacy benefit, log in at [anthem.com](http://anthem.com).**

You'll find the most up-to-date drug list and details about your benefits. If you still have questions, we're here. Just call the Member Services number on your ID card.

Speech and hearing impaired (TDD/TTY) users  
Call 1-800-221-6915, Monday through Friday, 8:30 a.m. to 5 p.m.ET.



Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans of Virginia. Anthem Blue Cross and Blue Shield, and its affiliate Healthkeepers, Inc., serving all of Virginia except for the City of Fairfax, the Town of Vienna, and the area east of State Route 123, are independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

# Get help in your language

Curious to know what all this says? We would be too. Here's the English version:

You have the right to get this information and help in your language for free. Call the Member Services number on your ID card for help. (TTY/TDD: 711)

Separate from our language assistance program, we make documents available in alternate formats for members with visual impairments. If you need a copy of this document in an alternate format, please call the customer service telephone number on the back of your ID card.

## Spanish

Tiene el derecho de obtener esta información y ayuda en su idioma en forma gratuita. Llame al número de Servicios para Miembros que figura en su tarjeta de identificación para obtener ayuda. (TTY/TDD: 711)

## Chinese

您有權使用您的語言免費獲得該資訊和協助。請撥打您的 ID 卡上的成員服務號碼尋求協助。(TTY/TDD: 711)

## Vietnamese

Quý vị có quyền nhận miễn phí thông tin này và sự trợ giúp bằng ngôn ngữ của quý vị. Hãy gọi cho số Dịch Vụ Thành Viên trên thẻ ID của quý vị để được giúp đỡ. (TTY/TDD: 711)

## Korean

귀하에게는 무료로 이 정보를 얻고 귀하의 언어로 도움을 받을 권리가 있습니다. 도움을 얻으려면 귀하의 ID 카드에 있는 회원 서비스 번호로 전화하십시오. (TTY/TDD: 711)

## Tagalog

May karapatan kayong makuha ang impormasyon at tulong na ito sa ginagamit ninyong wika nang walang bayad. Tumawag sa numero ng Member Services na nasa inyong ID card para sa tulong. (TTY/TDD: 711)

## Russian

Вы имеете право получить данную информацию и помощь на вашем языке бесплатно. Для получения помощи звоните в отдел обслуживания участников по номеру, указанному на вашей идентификационной карте. (TTY/TDD: 711)

## Arabic

يحق لك الحصول على هذه المعلومات والمساعدة بلغتك مجاناً. اتصل برقم خدمات الأعضاء الموجود على بطاقة التعريف الخاصة بك للمساعدة. (TTY/TDD: 711)

## Armenian

Ձեր իրավունք ունեք Ձեր լեզվով անվճար ստանալ այս տեղեկատվությունը և ցանկացած օգնություն: Օգնություն ստանալու համար զանգահարեք Անդամների սպասարկման կենտրոն՝ Ձեր ID քարտի վրա նշված համարով: (TTY/TDD: 711)

## Farsi

شما این حق را دارید که این اطلاعات و کمکها را به صورت رایگان به زبان خودتان دریافت کنید. برای دریافت کمک به شماره مرکز خدمات اعضاء که بر روی کارت شناساییتان درج شده است، تماس بگیرید. (TTY/TDD: 711)

## French

Vous avez le droit d'accéder gratuitement à ces informations et à une aide dans votre langue. Pour cela, veuillez appeler le numéro des Services destinés aux membres qui figure sur votre carte d'identification. (TTY/TDD: 711)

#### Japanese

この情報と支援を希望する言語で無料で受けることができます。支援を受けるには、IDカードに記載されているメンバーサービス番号に電話してください。(TTY/TDD: 711)

#### Haitian

Ou gen dwa pou resevwa enfòmasyon sa a ak asistans nan lang ou pou gratis. Rele nimewo Manm Sèvis la ki sou kat idantifikasyon ou a pou jwenn èd. (TTY/TDD: 711)

#### Italian

Ha il diritto di ricevere queste informazioni ed eventuale assistenza nella sua lingua senza alcun costo aggiuntivo. Per assistenza, chiami il numero dedicato ai Servizi per i membri riportato sul suo libretto. (TTY/TDD: 711)

#### Polish

Masz prawo do bezpłatnego otrzymania niniejszych informacji oraz uzyskania pomocy w swoim języku. W tym celu skontaktuj się z Działem Obsługi Klienta pod numerem telefonu podanym na karcie identyfikacyjnej. (TTY/TDD: 711)

#### Punjabi

ਤੁਹਾਨੂੰ ਆਪਣੀ ਭਾਸ਼ਾ ਵਿੱਚ ਇਹ ਜਾਣਕਾਰੀ ਅਤੇ ਮਦਦ ਮੁਫਤ ਵਿੱਚ ਪ੍ਰਾਪਤ ਕਰਨ ਦਾ ਅਧਿਕਾਰ ਹੈ। ਮਦਦ ਲਈ ਆਪਣੇ ਆਈਡੀ ਕਾਰਡ ਉੱਤੇ ਮੈਂਬਰ ਸਰਵਿਸਜ਼ ਨੰਬਰ ਤੇ ਕਾਲ ਕਰੋ। (TTY/TDD: 711)

#### Navajo

Bee ná ahoót'í t'áá ni nizaad k'ehjí níká a'doowó t'áá jík'e. Naaltsoos bee atah nilínígíí bee nécho'dólzingo nanitínígíí béésh bee hane'í bikáá' áá jì' hodiílnih. Naaltsoos bee atah nilínígíí bee nécho'dólzingo nanitínígíí béésh bee hane'í bikáá' áá jì' hodiílnih. (TTY/TDD: 711)

#### It's important we treat you fairly

That's why we follow federal civil rights laws in our health programs and activities. We don't discriminate, exclude people, or treat them differently on the basis of race, color, national origin, sex, age or disability. For people with disabilities, we offer free aids and services. For people whose primary language isn't English, we offer free language assistance services through interpreters and other written languages. Interested in these services? Call the Member Services number on your ID card for help (TTY/TDD: 711). If you think we failed to offer these services or discriminated based on race, color, national origin, age, disability, or sex, you can file a complaint, also known as a grievance. You can file a complaint with our Compliance Coordinator in writing to Compliance Coordinator, P.O. Box 27401, Mail Drop VA2002-N160, Richmond, VA 23279. Or you can file a complaint with the U.S. Department of Health and Human Services, Office for Civil Rights at 200 Independence Avenue, SW; Room 509F, HHH Building; Washington, D.C. 20201 or by calling 1-800-368-1019 (TDD: 1-800-537-7697) or online at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>. Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.